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Zusammenfassung 
 
Während der mitotischen Phase des Zellzyklus’ verteilen Zellen ihre Chromsomen auf die 
zwei neu entstehenden Zellen. Dieser Prozess ist begleitet von immensen morphologischen 
Veränderungen wie zum Beispiel dem Abbau der Kernhülle, der Verdichtung der 
Chromosomen, dem Aufbau der mitotischen Spindel, der Chromosomenaufteilung und 
schließlich der Zytokinese. Die biochemischen Mechanismen, die diesen Prozessen zugrunde 
liegen und diese regulieren sind bisher erst wenig verstanden. 
 
Einige Proteinkomplexe wurden als die wichtigsten Regulatoren der Mitose identifiziert. Die 
Aktivität der Cyclin-dependent Kinase 1 im Komplex mit Cyclin B 1 (CDK1/CCNB1) ist 
essentiell für den Eintritt in die Mitose und frühe mitotische Vorgänge, während der 
Anaphase-promoting Complex (APC/C) die Anaphase und das Ende der Mitose einleitet. 
Einige andere mitotische Proteinkomplexe wurden identifiziert, doch für die meisten Proteine, 
die wichtig für den Verlauf der Mitose sind, sind nur wenige oder gar keine 
Interaktionspartner bekannt. Um die biochemischen Mechanismen der Mitose besser zu 
verstehen, ist es nötig, ein umfassenderes Bild der Proteinkomplexe, die für die Regulation 
der Mitose wichtig sind, zu bekommen. Die kürzlich etablierte BAC TransgeneOmics pipeline 
ermöglichte die Herstellung einer großen Anzahl von menschlichen Zellen, die „localisation 
and affinity purification“ (LAP) getaggte Mausgene von ihrem endogenen Promoter 
exprimieren. Aus diesen Zellen konnten wir erfolgreich 175 mitotische Proteine aufreinigen 
und 787 spezifisch-interagierende Proteine mittels Massenspektrometrie identifizieren. Die 
weitere Analyse dieser Daten mit Hilfe bioinformatischer Methoden ergab 130 potentielle 
Proteinkomplexe, von denen bis dahin 71 unbekannt waren. Eine weitergehende 
Untersuchung einiger dieser Komplexe bestätigte einen neuen Komplex, der möglicherweise 
bei der Funktion des Zentrosoms eine Rolle spielt, sowie zwei neue Interaktionspartner des 
γ-tubulin ring complex (γ-TuRC) und eine neue APC/C Untereinheit. Unsere Ergebnisse sind 
der erste Schritt, um die Organisation der mitotischen Proteinkomplexe gründlicher zu 
verstehen. Weitergehende Untersuchungen dieser identifizierten Proteinkomplexe werden 
unser Verständnis der molekularen Basis der mitotischen Regulation weiter voranbringen.  
 
Einige der wichtigsten Regulatoren, die den Eintritt und den Verlauf der Mitose kontrollieren 
sind mitotische Proteinkinasen. Die Phosphorylierung einer unbekannten Anzahl von 
Substraten wirkt wahrscheinlich wie ein Schalter, der die Aktivität, Stabilität und 
Lokalisierung dieser Substrate verändert. Dies löst die drastischen morphologischen 
Veränderungen aus, die nötig sind, damit Zellen zuverlässig durch die Mitose gehen und die 
mitotische Teilung vollziehen. CDK1/CCNB1 war das erste Mitglied der Familie der 
mitotischen Kinasen von der einige weitere identifiziert worden sind. Die Polo-like kinase 1 
(PLK1) ist essentiell für die Mitose und ist an der Regulation vieler mitotischer Ereignisse 
beteiligt. Der Kontakt von PLK1 mit Substraten wird wahrscheinlich durch die 
Substratphosphorylierung von CDK1, aber vielleicht auch von PLK1 selbst kontrolliert. Aurora 
kinase B (AURKB) ist eine weitere essentielle mitotische Kinase, die, abgesehen von anderen 
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Funktionen, essentiell für den „spindle assembly checkpoint“ ist, indem sie inkorrekte 
Mikrotubuli-Kinetochore Verbindungen korrigiert. PLK1 und AURKB sind nur in der Mitose 
aktiv und ihre Lokalisierung ist streng reguliert. Das lässt vermuten, dass PLK1 und AURKB 
Substrate nur zu einer bestimmten Zeit und an einem bestimmten Ort phosphoryliert werden 
dürfen um ihre Funktion zu erfüllen. Versuche zum Detektieren von Kinase Substraten sind 
bisher allerdings meist in vitro durchgeführt worden, also in der Abwesenheit jeglicher 
zellulärer Kontrollmechanismen. Wir haben deshalb eine Zell-basierte Methode entwickelt, 
um neue PLK1 und AURKB Substrate zu finden. Mit Inhibitoren aus kleinen Molekülen gegen 
PLK1 und AURKB in Kombination mit LAP-Aufreinigung und Massenspektrometrie konnten wir 
Kinase-abhängige Phosphorylierungsstellen auf 16 potentiellen Substratkomplexen 
detektieren. Insgesamt haben wir 470 Phosphorylierungsstellen gefunden, von denen 41 
PLK1- und 20 AURKB-abhängig waren. Wir haben einen Teil dieser Phosphorylierungsstellen 
mit Phospho-spezifischen Antikörpern validiert und 17 neue potentielle PLK1 Substrate sowie 
18 neue potentielle AURKB Substrate gefunden. 
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Abstract 
During the mitotic phase of the cell cycle cells equally distribute their chromosomes into 
two daughter cells. This process is accompanied by immense morphological changes 
such as breakdown of the nuclear envelope, chromosome condensation, mitotic spindle 
assembly, chromosome segregation and finally cytokinesis. The underlying biochemical 
mechanisms regulating these processes are only beginning to be understood.  
 
A number of protein complexes have been identified as the major mitotic regulators. 
The activity of cyclin-dependent kinase 1 bound to cyclin B (CDK1/CCNB1) is essential 
for entry into mitosis and early mitotic events while the activity of the anaphase-
promoting complex (APC/C) initiates anaphase onset and mitotic exit. Some other 
mitotic protein complexes have been identified but for most proteins involved in mitotic 
progression only few or no binding partners are known. To better understand the 
biochemical mechanisms that govern mitosis, a more comprehensive picture of the 
protein complexes involved in mitotic regulation is necessary. The recently established 
BAC TransgeneOmics pipeline allowed the generation of a large set of human cells 
expressing localisation and affinity purification (LAP)-tagged mouse genes from their 
endogenous promoter. Using these cells we successfully purified 175 mitotic bait 
proteins and identified 787 specific interaction partners by mass spectrometry (MS). 
Further analysis of this dataset using computational methods predicted 130 protein 
complexes of which 71 were previously unknown. Some of those complexes and 
interacting partners were tested further to confirm one novel protein complex 
potentially involved in centrosome function, two novel interaction partners of the γ-
tubulin ring complex (γ-TuRC) and one novel APC/C subunit. Our study provides the 
first step towards more comprehensively understanding mitotic protein complex 
organisation. Further studies of these identified protein complexes will advance our 
understanding of the molecular basis of mitotic regulation. 
 
One of the key regulators that control entry and progression through mitosis are mitotic 
protein kinases. Phosphorylation of an unknown number of substrates is thought to act 
like a switch that changes activity, stability and localisation of these substrates. This 
triggers the drastic morphological changes that are necessary for cells to faithfully 
progress through and complete a mitotic division. CDK1/CCNB1 was the first member of 
the mitotic protein kinase family but several more have been identified. The Polo-like 
kinase 1 (PLK1) is essential for mitosis and has been implicated in the regulation of 
many events during mitosis. Targeting of PLK1 to its substrates is thought to be 
controlled by priming phosphorylation by CDK1 but might, for some substrates, also be 
regulated through PLK1’s own activity. Aurora kinase B (AURKB) is another essential 
mitotic kinase which, apart from other functions, is essential for spindle assembly 
checkpoint function by correcting improper microtubule kinetochore attachments. The 
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activity of PLK1 and AURKB is limited to mitosis and their localisation is tightly 
regulated. This suggests that PLK1 and AURKB substrates must only be phosphorylated 
at a specific time and place to fulfil their function. Assays to detect kinase substrates 
have been, however, largely carried out in vitro, without any cellular regulatory systems 
in place. We have therefore set out to develop a cellular assay to find novel PLK1 and 
AURKB substrates. Using small molecule inhibitors against PLK1 and AURKB in 
combination with LAP purification and MS we could detect kinase-dependent 
phosphorylation sites on 16 candidate substrate complexes. In total we found 470 
phosphorylation sites, 41 of which were PLK1-dependent and 20 of which were AURKB-
dependent. We validated a subset of these sites with phospho-specific antibodies and 
detected 17 novel potential PLK1 substrates and 18 novel potential AURKB substrates.   
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1 Introduction 
1.1 The cell cycle 
The cell cycle is the ordered sequence of cell growth, DNA replication and cell division 
that leads to propagation of unicellular organisms and growth and differentiation of 
multicellular organisms. Cells progress from the first gap-phase (G1) into synthesis-
phase (S) during which the genetic material is duplicated, through the second gap-
phase (G2) into mitosis (M). Mitosis consists of six phases called pro-, prometa-, meta-, 
ana-, telophase and cytokinesis. Chromosomes are condensed and congress to the cell 
equator from pro- to metaphase. In anaphase chromosomes are then segregated to the 
two poles, decondense in telophase and the cells divide in cytokinesis.  
 
The length of G1, S, G2 and M varies between organisms but also between 
developmental stages and cell types. During the gap-phases cells grow dependent on 
nutrient availability and, in multicellular organisms, dependent on extracellular signals. 
Cells can also exit the cell cycle from G1 into G0 to remain in a quiescent state if 
conditions are not suitable for division or if the cell terminally differentiates within a 
tissue. Early embryonic cell cycles, e.g. of the D. melanogaster and X. laevis embryo, 
are very short, consisting of only S- and M-phases. Unicellular organisms like S. 
cerevisiae and S. pombe run through cell cycles of a few h with only a G1- or a very 
short G1- and long G2-phase, respectively; while higher vertebrates have cell cycles of 
about 24 h. The order of S- and M-phase is the same in all organisms (Morgan, 2007).  
 
S-phase must precede M-phase to ensure genome stability over cell generations. This 
irreversible sequence of events is determined by an autonomous biochemical oscillator. 
The oscillator consists of the cycling kinase activity of CDKs and high or low levels of 
proteolytic activity which are regulated by the ubiquitin ligase activity of the APC/C 
(Figure 1.1-1). CDK activity is turned on in late G1-phase, remains high during S-phase 
and until the anaphase of mitosis. During all this time, APC/C activity is low and only 
activated at the meta- to anaphase transition. This activation is mediated by CDK1 
phosphorylation and leads to destruction of the CDK1 activating subunit Cyclin B1 
(CCNB1) and decline of CDK activity. APC/C activity remains high in G1 which keeps 
CDK activity low. Thus, CDK and APC/C activity are interdependent. CDKs, APC/C and 
inhibitors and activators of CDKs not mentioned here form a bistable system. This 
bistable system oscillates between high states of either CDK or APC/C activity without 
any external input. Within this system each transition point (G1/S, G2/M and meta- to 
anaphase) behaves like a switch that generates an irreversible transition (Morgan, 
2007).  
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Figure 1.1-1: The autonomuos oscillator and its main components CDKs, cyclins 
(CCN) and APC/C together with the regulatory checkpoints. 
The graph shows the activity of the different cell cycle phase-specific cyclin-CDK 
complexes and the APC/C activity during the cell cycle. The scheme below shows the 
different CDK-cyclin complexes involved (CCND1: Cyclin D1, CCNE1: Cyclin E1, CCNA1: 
Cyclin A1, CCNB1: Cyclin B1) and the points where cell cyle checkpoints can modulate the 
phase transitions. Activating and inhibitory arrows do not necessarily indicate direct 
interactions. Additional CDK and APC/C inhibitors and activators are omitted for clarity.  
 
The key property of a bistable switch is that after a certain level of input stimulation it 
switches to full activation and remains activated even if the input stimulus is removed. 
To achieve this irreversible transition using reversible biochemical reactions positive 
feedback loops are necessary. It is assumed that every of the key cell cycle transitions 
are regulated by bistable switches. The basic mechanisms for the G2/M transition are 
fairly well understood from studies in cycling Xenopus laevis egg extracts and are 
assumed to be similar in other organisms (Figure 1.1-2). CDK1 is kept inactive in G2-
phase by inhibitory phosphorylations on T14 and Y15. The kinase Wee1 generates Y15 
while Myt1 phosphorylates both T14 and Y15. The first step in CDK1 activation is 
binding to its activating subunit CCNB1 whose expression levels rise during G2. Further, 
CDK7 phosphorylates T160 once CCNB1 is bound and the phosphatases CDC25A, B and 
10 
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C remove the inhibitory phosphorylations on T14 and Y15. Positive and double negative 
feedback loops turn this activation pathway into a bistable system. CDK1 
phosphorylates CDC25A, B and C which prevents CDC25A degradation by SCF and 
enhances CDC25C phosphatase activity. In addition, CDK1 phosphorylation of MYT1 and 
WEE1 leads to their inactivation and in the case of WEE1 also to its degradation. CDK1 
thus activates its own activator and inhibits its own inhibitor leading to rapid activation 
of CDK1. Additional positive feedback might be generated by PLK1 which can be 
activated by CDK1 and is assumed to further activate CDC25 and inhibit MYT1/WEE1 by 
phosphorylation (Morgan, 2007). 
 
 
 
Figure 1.1-2: Positive and double negative feedback loops at the G2/M transition. 
Scheme showing the double negative feedback loop through WEE1, MYT1 and possibly 
PLK1 that leads to CDK1-CCNB1 activation as well as the positive feedback loop via CDC25 
and possibly PLK1. CDC25 isoforms are omitted for clarity. Phosphates, indicated as P, do 
not reflect the actual number of phosphorylation sites on each protein, for CDK1 only the 
inhibitory phosphorylation is shown.  
 
 
1.2 Mechanisms of cell cycle control 
The transitions between cell cycle phases are controlled by so-called checkpoints at the 
G1/S, G2/M and at the metaphase to anaphase transition. The checkpoints ensure that 
cells contain all necessary metabolites to grow before entering into S-phase (G1/S 
checkpoint), that the genetic material has been copied and is intact before onset of 
mitosis (G2/M checkpoint) and that the genetic material can be equally segregated into 
the daughter cells before initiation of cell division (spindle assembly checkpoint (SAC)). 
The cell cycle is either halted at each checkpoint or it progresses to the next stage but it 
never reverses. This directionality is provided by the autonomous oscillator and its 
underlying switch like behaviour as described above (Morgan, 2007). 
11 
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Transition of the cell cycle from G0 into G1/S-phase depends on CDK4 activity in 
complex with D-type cyclins (CCND1 in Figure 1.1-1). CDK4 phosphorylates pRB family 
proteins which activate the expression of G1/S genes. Inhibition of the E- and A-type 
cyclins in complex with CDK2 is released by CDK4-mediated sequestration of their 
inhibitor CDKN1B (also known as p27 or Kip1). CDK4/D-type cyclin activity is largely 
regulated by mitogenic signals which can for example arise from nutrient-dependent 
intracellular signals or from extracellular signals in multicellular organisms. The G1/S 
transition is mediated by the E- and A-type cyclins (CCNE1 and CCNA1, respectively in 
Figure 1.1-1) in complex with CDK2. They induce the formation of the preinitiation 
complex on replication origins and the subsequent initiation of DNA synthesis by the 
replication machinery. As S-phase progresses and the replication forks have moved 
away from their replication origin, repeated firing of the origins has to be inhibited to 
avoid rereplication of DNA. Continued high activity of CDK2/CCNE1 in combination with 
geminin (GMNN) prevents formation of the prereplication complex (preRC). In late 
mitosis CDK activity is reduced and APC/C activity is high. APC/C targets geminin for 
destruction by the proteasome, enabling preRC formation, also called origin licensing, to 
set the stage for another round of DNA replication (Morgan, 2007). 
 
The G2/M transition depends on the activation of CDK1/CCNB1 which drives many early 
mitotic processes like nuclear envelope breakdown, spindle assembly and chromosome 
condensation. To regulate the bistable switch at this transition described in 1.1 several 
of the described feedback loops for CDK1 activation are targeted. Signals inhibiting the 
G2/M transition are generated by the DNA damage response which is active upon stalled 
replication forks within S-phase or DNA damage within S- or G2-phase. The effector 
kinases of the DNA damage response, CHK1 and CHK2 (CHECK1 and CHECK2), 
phosphorylate the CDC25 phosphatases which leads to their increased degradation (A 
isoform), inactivation (B isoform) or inactivation and nuclear export (C isoform), 
altogether resulting in reduced activation of CDK1/CCNB1. A long term DNA-damage 
induced arrest is mediated by the activation of the p53 pathway which ultimately leads 
to expression of the CDK/CCNB1 inhibitor CDKN1A (p21) (Morgan, 2007). 
 
Anaphase onset depends on the activation of the APC/C. APC/C mediated degradation of 
Securin (PTTG1) leads to cohesin cleavage by the protease separase (ESPL1) to allow 
sister chromatid separation. APC/C mediated CCNB1 degradation in anaphase initiates 
mitotic exit. APC/C is activated by phosphorylation of CDK1/CCNB1 and PLK1 in early 
mitosis but remains inhibited by the spindle assembly checkpoint (SAC) until sister 
chromatids are biooriented and spindle microtubules are properly attached to the 
kinetochores. The mitotic checkpoint complex (MCC) directly translates unattached 
kinetochores into APC/C inhibition. Once the SAC is silenced APC/C in conjunction with 
its coactivator CDC20 initiates cohesin cleavage and anaphase onset as well as initial 
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CCNB1 degradation. This leads to a reduction of CCNB1 activity allowing the second 
APC/C coactivator FZR1 to become dephosphorylated and active which leads to 
complete CCNB1 degradation and thus a drop in CDK1 activity (Morgan, 2007). Exit 
from mitosis requires many mitotic phosphoproteins to be dephosphorylated. In budding 
yeast this is accomplished by activation of the Cdc14 phosphatase. Whether mammalian 
cells also require increased phosphatase activity or whether CCNB1 degradation is 
sufficient, remains under discussion (Potapova et al., 2006; Skoufias et al., 2007).  
 
1.3 Sister chromatid cohesion 
The main role of the SAC is to ensure that sister chromatids become biooriented in 
metaphase and are equally segregated to opposite poles in anaphase. In addition to the 
APC/C, the cohesin complex plays a crucial role in this process. The cohesin complex 
holds replicated sister chromatids together from S-phase until the meta- to anaphase 
transition. The physical connection of sisters is thought to be required for their 
biorientation on the metaphase spindle. Cohesin is cleaved at anaphase onset to allow 
equal segregation of sister chromatids to daughter cells. In telophase cohesin is loaded 
back onto chromosomes by the Scc2-Scc4 complex (Watrin et al., 2006). Cohesion 
between sister chromatids is established in S-phase by a process requiring replication 
which is not fully understood. In yeast, members of the replication fork have been 
implicated in this process (Skibbens, 2005). During prophase, most of cohesin is 
removed from chromosome arms in mammals but not in yeast (Waizenegger et al., 
2000). The remaining cohesin at the centromere is cleaved by the protease separase at 
the meta- to anaphase transition once all sister chromatids are bioriented and the 
spindle assembly checkpoint has been silenced. 
 
The cohesin core complex consists of a heterodimer of SMC1A and SMC3 which connects 
to RAD21 to form a trimeric ring. RAD21 in addition interacts with STAG1 or STAG2, 
defining two cohesin isoforms (Strom and Sjogren, 2007). PDS5A and B, homologs of 
yeast Pds5p, bind cohesin throughout the cell cycle but their function is not well 
understood (Losada et al., 2005; Sumara et al., 2000). Yeast Pds5p is required for 
cohesion establishment in S-phase and maintenance in a prolonged G2 arrest (Hartman 
et al., 2000; Panizza et al., 2000). Human PDS5A and PDS5B are about 70% identical in 
their sequence and interact with cohesin exclusive of each other (Losada et al., 2005). 
Depletion of PDS5A or PDS5B by siRNA in HeLa cells leads to a very mild loss of 
cohesion phenotype in metaphase while depletion of both isoforms from X. laevis egg 
extracts lead to an increase of cohesin on mitotic chromosomes (Losada et al., 2005). 
The relatively weak phenotypes of PDS5A or B depletion might reflect a partial 
redundant function. However, another cohesin interactor and regulator called WAPAL 
preferentially interacts with PDS5A but not PDS5B (Kueng et al., 2006), suggesting a 
distinct role of PDS5A in association with WAPAL. Depletion of WAPAL by siRNA blocks 
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the removal of cohesin in prophase, placing it as a regulator of the so-called prophase 
pathway (Gandhi et al., 2006; Kueng et al., 2006). It has not been determined so far if 
the PDS5A-WAPAL interaction is required for WAPAL’s function or whether the 
interaction is direct. Even though PDS5A and B are highly identical in their N-terminal 
part, their C-terminal shares little sequence similarity.  
 
 
1.4 Protein complexes in mitotic progression 
The APC/C and the cohesin complex are two protein complexes important for proper 
mitotic progression. That proteins can be organised into discrete protein complexes 
became clear with the discovery of macromolecular machines like the ribosome, the 
spliceosome or the proteasome (Alberts, 1998). Association of proteins into complexes 
enables grouping of sequential chemical reactions that would otherwise not happen at 
random in the protein-crowded intracellular space. Every molecular process studied so 
far involves a number of complexes that often form a physical and functional interaction 
network to carry out a specific function. Functional and structural characterisations of 
some of those complexes have shown that interactions within a complex are often 
mediated by protein domains and can be dynamically regulated, suggesting that protein 
complexes are not rigid structures but interchangeable and dynamic protein assemblies. 
This is exemplified in cell cycle complexes which are often composed of modules that 
bind via distinct domains in a cell cycle-dependent manner.  
 
One good example of a cell cycle-dependent complex is the binary complex of the CDKs 
and their activating cyclin subunits. CDK/cyclin complexes exist in varying combinations 
in different phases of the cell cycle. Different cyclins bind to the same region in CDKs 
which results in a structural arrangement within CDK to allow activation. Specific cyclins 
can then direct the CDKs to distinct substrates, leading to phosphorylation of cell cycle-
specific CDK substrates (Morgan, 2007, see also 1.1). Also the CDK antagonist within 
the cell cycle oscillator, the APC/C (see 1.1), interacts with varying coactivators and 
inhibitors. While the coactivator CDC20 enables the APC/C to ubiquitinate early mitotic 
substrates, the coactivator FZR1 targets the APC/C to late mitotic and G1-specific 
substrates (Peters, 2006).  
 
Not only the composition of protein complexes can be cell cycle-dependent, they can 
also localise to different subcellular structures. Localisation can depend on different 
complex subunits. A recent very detailed structure function and localisation study has 
focussed on one such example: the chromosomal passenger complex or CPC. It consists 
of Aurora B kinase (AURKB), INCENP, Borealin (CDC8A) and Survivin (BIRC5) and is 
central to the regulation of the meta- to anaphase transition (Ruchaud et al., 2007). It 
localises to chromosomes in G2 and prophase, is then enriched at centromeres until 
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metaphase to finally travel via the anaphase central spindle to the midbody in 
cytokinesis. The enymatic part of the complex, AURKB, is thought to function at the 
centromere from prophase to prometaphase and its activity is required to correct 
incorrect microtubule kinetochore attachments (Ruchaud et al., 2007). AURKB 
localisation and activity is dependent on INCENP (Sessa et al., 2005), which in turn 
binds to the remaining CPC members, where BIRC5 is the subunit targeting the whole 
complex to the centromere in pro- and prometaphase (Ruchaud et al., 2007). The 
mechanisms responsible for CPC localisation after metaphase are not well understood. A 
recent structural analysis followed by cell biological experiments suggests that a surface 
generated by INCENP and CDC8A is required for central spindle/midbody localisation 
and CPC cytokinesis function (Jeyaprakash et al., 2007). In this study, the interacting 
domains of BIRC5, CDC8A and INCENP have been crystallised to understand intra CPC 
binding as well as CPC movement throughout mitosis. This revealed that INCENP, 
Borealin and Survivin form a three-helical bundle with their interaction domains. Point 
mutations within these helices selectively disturb interactions within the complex and 
also the late mitotic localisation, implicating the helical bundle as the core of the 
chromosomal passenger complex. The core interactions ensure accurate localisation of 
the CPC and are directly coupled to AURKB localisation through INCENP, nicely 
illustrating how different members of a protein complex cooperate to build its function 
(Jeyaprakash et al., 2007). How the complex interacts with partners on the 
chromosome, the centromere, the central spindle and the midbody remains to be seen. 
A systematic analysis of mitotic protein-protein interactions might reveal such additional 
interaction partners and further advance our understanding of the CPC and other, albeit 
to date less characterised, mitotic protein complexes.  
 
1.4.1 How to detect protein complexes? 
The basic building block of a protein complex consists of pair wise protein interactions. 
Thus, a protein complex could be viewed as a set of overlapping pair wise interactions 
between a number of proteins. To determine a protein complex from the bottom up, i.e. 
by first identifying pair wise interactions and then search for a set of overlapping pairs, 
the most commonly used assays are in vitro binding assays or yeast two hybrid  assays 
(Y2H). Yeast two hybrid assays are amenable to very high throughput and have been 
used extensively to map pair wise interactions in whole genomes of various organisms 
from yeast to human (Parrish et al., 2006). An interaction is detected by fusing the 
cDNA of a bait to the DNA binding domain of a transcription factor and a library of prey 
proteins to the transactivation domain of the transcription factor. Positive hits transcribe 
the target gene, usually a selection marker, as a reporter of the interaction. The 
detected set of binary interactions can be used to draw an interaction graph and highly 
connected components might represent protein complexes (e.g. Wong et al., 2007). In 
vivo validation by immunopurification of the candidate is essential to confirm the 
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interaction since a high false positive rate is common (Parrish et al., 2006). Since Y2H 
assays are limited to the number of available and expressable cDNA clones, they often 
miss in vivo interactions by not testing them. In addition, cooperative effects in complex 
formation are neglected, making it very difficult to systematically infer protein 
complexes from Y2H data.  
 
To identify protein interactions in vivo, candidate proteins, either affinity-tagged or 
endogenous proteins, are analysed by affinity purification experiments. Purified complex 
members are separated by SDS-PAGE and detected by western blotting for candidate 
proteins or by silver staining followed by MS analysis. Importantly, co-immunopurifying 
proteins do not necessarily interact directly but might be connected through other 
components. Also, affinity purification coupled to MS (AP-MS) approaches do not just 
identify distinct protein complexes but also more transient and substoichiometric 
interactions. To confirm complex membership of a given protein, further biochemical 
characterisation is necessary. For example, cell extracts can be centrifuged through a 
density gradient to separate protein complexes by their S-value. Co-sedimentation of 
candidate complex members, detectable by western blotting or silver staining, confirms 
complex membership and allows an estimate of the complex size. Candidate complex 
members of which only a small fraction co-sediment with the complex can not be 
considered as complex members. They might represent substrates or regulators of the 
given protein complex but might also be members of complex isoforms that are present 
at a lower stoichiometry than the members of the main isoform. One example for 
different complex isoforms is the cohesin complex further described in 1.3. The core 
complex of SMC1, SMC3 and RAD21 associates mutually exclusive with either STAG1 or 
STAG2 resulting in either STAG1-cohesin or STAG2-cohesin (Losada et al., 2000; 
Sumara et al., 2000). These two isoforms in turn associate mutually exclusive with 
PDS5A or PDS5B resulting in four isoforms of cohesin (Losada et al., 2005). AP-MS can 
not necessarily differentiate complex isoforms like this. Proteins identified by AP-MS of a 
given bait represent a set of interacting proteins of which some might form a distinct 
protein complex. 
 
To better define a protein complex by AP-MS, different potential complex members can 
be purified to test for their reciprocal interaction. The set of proteins that interacts 
reciprocally most likely represents the major isoform of the given complex. By using 
many baits in a systematic AP-MS analysis, protein complexes can thus be inferred from 
the overlaps between different bait purifications. This has been applied to the yeast S. 
cerevisiae where about 60% of the expressed proteome were identified in purification of 
about 2000 unique baits (Gavin et al., 2006; Krogan et al., 2006). A similar approach 
targeting disease related proteins in human cells identified 2235 proteins from 
purifications of 338 baits. Protein complexes were not inferred from the data set, 
presumably because of low overlap between the interacting proteins (Ewing et al., 
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2007). To obtain a high confidence set of protein complexes it is essential to construct a 
dense, partially overlapping set of baits. This allows many complexes to be probed more 
than once, allowing confident complex identification. It is important to note, however, 
that the described high-throughput interaction studies solely rely on clustering methods 
to describe protein complexes. These computationally inferred clusters might overlap to 
some degree with the actual protein complex but might miss some complex members, 
isoforms or subcomplexes.  
 
1.5 Mitotic protein kinases  
Since the discovery that the key mitotic regulator Cdc2 is a kinase (Simanis and Nurse, 
1986) a number of other mitotic kinases essential for mitotic progression have been 
identified and characterised. The key biochemical and morphological changes in mitosis 
are all dependent on kinase activity: mitotic entry, chromosome condensation, nuclear 
envelope breakdown, mitotic spindle assembly, spindle assembly checkpoint, APC/C 
activation and cytokinesis. How these changes are brought about by kinase activity is, 
however, not well understood. The key feature of protein phosphorylation is that it 
allows to transiently change the properties of the modified protein. A phosphorylation 
can lead to overall biochemical and structural changes or to creation or abolition of 
sequence-specific binding sites. A few kinase substrate relationships in mitosis have 
been well-characterised and include example where phosphorylation leads to the 
disintegration of subcellular structure, the generation of a degradation signal or the 
generation protein-protein interactions. These examples will be described in the 
following paragraphs. 
 
One early mitotic event is nuclear envelope breakdown. It takes place in late prophase 
and results in the complete disintegration of the nucelar membrane and its underlying 
cytoskeletal support, the nuclear lamina. The nuclear lamina is a network of 
intermediate filaments constructed by the so-called lamins. The lamins were some of 
the first identified CDK1 substrates. Their phosphorylation causes the lamin network to 
disintegrate which is essential for nuclear envelope disassembly (Heald and McKeon, 
1990; Peter et al., 1990; Ward and Kirschner, 1990). Phosphorylation inhibits the 
longitudinal association of B-type lamin in vitro and might thus cause a structural 
change of the entire lamin network that results in its disassembly (Peter et al., 1991). 
Similar mechanisms are the basis of the restructuring of the Golgi apparatus during 
mitotis. CDK1 and PLK1 mediate the disintegration of the Golgi stacks into vesicles 
which are localised around the spindle pole during mitosis and are consequenctly 
reassembled in telophase (Morgan, 2007). 
 
Phosphorylation can generate or inhibit degradation signals. WEE1 kinase generates the 
inhibitory Y15 phosphorylation on CDK1 and needs to be inactivated to allow full CDK1 
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activation and mitotic entry. Its stability is negatively regulated by CDK1 and PLK1 
phosphorylation sites which generate a so-called phospho-degron. This degron is 
recognised by SCF, an ubiquitin ligase, bound to βTrCP (SCFβTrCP) which mediates 
ubiquitination and subsequent degradation (Asano et al., 2005; Watanabe et al., 2005; 
Watanabe et al., 2004). Conversely, phosphorylation can also inhibit degradation and 
thus stabilise proteins. This has been suggested for another component of the CDK1 
regulatory system CDC25A which is stabilised upon CDK1 phosphorylation (Mailand et 
al., 2002). Since there are also a few APC/C substrates which have been shown to be 
protected from degradation through phosphorylation, this mechanism might be a more 
universal one to control protein stability in mitosis (Peters, 2006). 
 
Phosphorylation can directly generate or abolish a protein binding site. This concept has 
been intensively studied in tyrosine phosphorylation cascades where SH2- and SH3-
domain containing proteins specifically bind to phospho-tryosine residues (Koch et al., 
1991). In mitotic regulation only few examples have so far been characterised. One is 
the polo box of PLK1 which binds phospho-serine or phospho-threonine residues (Elia et 
al., 2003b). The polo box is essential for correct localisation of PLK1 to many of its 
target sites (Hanisch et al., 2006). Conversely, CBX5 (also known as HP1alpha) binding 
to H3 has been shown to be negatively regulated by phosphorylation. It binds H3 in 
interphase via trimethylated lysine 9 and dissociates upon serine 10 phosphorylation by 
AURKB (Fischle et al., 2005; Hirota et al., 2005). 
 
A few other kinase substrates relationships have been well studied and advanced our 
understanding of kinase function in mitosis. However, only few kinase substrates have 
been detected so far, mainly because efficient methods to identify kinase substrates 
have been lacking. To begin to understand the intricate steps of the various mitotic 
phospho-regulatory networks a systematic approach to kinase substrate detection 
needs to be established that allows finding kinase substrates in a cellular assay. 
1.5.1 How to find mitotic kinases substrates? 
Different methods have been used to identify mitotic kinase substrates and their 
respective phosphorylation sites. Early studies relied on comparing P32-labelled 
phosphopeptide maps from in vitro kinase assays using the candidate substrate and in 
vivo labelling of immunoprecipitated candidate substrate. Phosphorylation sites were 
identified by phospho-peptide mapping using 2D electrophoresis and Edman 
degradation (Morgan et al., 1989; Shenoy et al., 1989). The most commonly used 
method today relies on in vitro phosphorylation and radioactive labelling of recombinant 
candidate substrate, targeted mutation of potential phosphorylation sites and reanalysis 
in the kinase assay. The function of the detected phosphorylation sites can then be 
validated in vivo by using phospho-specific antibodies and the function tested by 
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expressing the phospho-mutants. By using the following different variations of this 
workflow most mitotic kinase substrates known to date have been detected ( 
Figure 1.5-1). 
 
 
 
Figure 1.5-1: Overview of different in vitro kinase assay variations commonly 
used to identify kinase substrates. 
The general workflow of kinase substrate detection is outlined using arrows, different 
variations for each step are given. Various combinations of these have been used, see text 
for examples (ID: identification, wt: wild type, as: analogue-sensitive, p-antibody: 
phospho-specific antibody). 
 
A high throughput variation, which has often been applied, uses a λ-phage cDNA 
expression library and purified kinase to identify expressed clones that are P32-labelled 
(Fukunaga and Hunter, 1997). This allows screening for the entire genome but has the 
drawback of missing a number of candidates that are not properly expressed or are not 
encoded within the cDNA library. Cell extracts can be used to test phosphorylation of all 
possible substrates present in the cell. The major challenge is to then identify the 
phosphorylated endogenous proteins. To circumvent this problem an elegant assay 
using a library of yeast strains in which each strain contains one tagged protein has 
been combined with an analog- sensitive kinase (as-kinase) in an in vitro kinase assay 
(Ubersax et al., 2003). The as-kinases are generated by mutating the gate keeper 
residue of the kinase domain to allow a bulky ATP-analog to be used instead of ATP 
(Shah and Shokat, 2002; Witucki et al., 2002). Using a radiolabelled bulky analogue 
such as N6-(benzyl) ATP, only those proteins are labelled that are direct substrates of 
the as-kinase. To identify labelled substrates, candidate tagged substrates are purified 
via the generic tag and the incorporation of radiolabel is measured. While this method 
allows rather high throughput and establishes a kinase substrate connection under close 
to in vivo conditions, it still requires lengthy follow up mutational analysis to identify the 
relevant phosphorylation sites.  
 
To directly identify the sites phosphorylated within kinase substrates without the need 
for mutational analysis, a conventional in vitro kinase assay with purified candidate 
substrates and recombinant kinases has been combined with MS based phospho-site 
mapping (Kraft et al., 2003). Comparison of the in vitro data with phosphorylation sites 
mapped on the same candidate substrates in vivo (APC/C subunits in this case) allowed 
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partial validation of the substrates identified in vitro. A further improvement to the as-
kinase method which allows in vitro phosphorylation in extracts and at the same time 
substrate and phosphorylation site identification was recently reported. The ATP 
analogue was modified to contain sulphur instead of oxygen in the γ-phosphate of the 
ATP (N6-(benzyl) ATP-γ-S). Proteins can be specifically labelled with the sulphur 
containing phosphate in an in vitro kinase assay using the as-kinase. Subsequently, 
proteins are digested and the thiophosphate peptides can be specifically enriched using 
iodoacetyl-agarose. Analysis of the thiophosphate peptides by MS then allows 
identification of the substrate and the phosphorylation site of the direct as-kinase target 
(Blethrow et al., 2008). A complementary approach allows to detect or enrich the 
thiophosphate using a monoclonal antibody (Allen et al., 2005).  
 
Given the high importance of spatio- and temporal regulation of mitotic kinases the 
ideal assay would detect substrates in an in vivo setting. One possibility is to use 
specific kinase inhibitors that allow precise temporal control of a given kinase’s activity 
in the cell and also permit large scale biochemical analysis. This approach has been 
taken using an as-Cdc5 allele and an as-kinase-specific inhibitor to identify potential 
substrates of Cdc5, the yeast PLK1 homolog (Snead et al., 2007).  
 
The most challenging task in substrate identification still is the validation of the kinase 
substrate relationship in vivo and its subsequent functional characterisation. Current 
assays for substrate validation have used phospho-specific antibodies which can 
specifically detect the phosphorylated residue in fixed cells or in cell extracts and 
compared cells with or without the kinase activity present (e.g. Elowe et al., 2007). 
Even though this is the best validation that a given substrate is an in vivo substrate, 
this experiment has two drawbacks. First: it requires the complete elimination of kinase 
activity which is difficult to achieve. Second: it can not rule out that loss of the kinase 
activity has indirect effects which lead to the abrogation of the phosphorylation site. 
This problem can partially be addressed by using small molecule inhibitors since they 
can fully inactivate the kinase. Also, since inhibitors act immediately, they can be 
applied within a short time window, reducing the chance of indirect effects. 
Nevertheless the ideal method for detecting direct in vivo phosphorylation sites is not 
yet available. 
 
 
 
1.6 Aim of this study 
This study is divided into three parts. The first two parts are contained within the results 
section as manuscripts in preparation. An additional introduction to the questions posed 
in the manuscripts can be found in section 1.4 Protein complexes in mitotic progression 
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and in section 1.5 Mitotic protein kinases. An extended discussion of the results 
described within the manuscripts can be found in section 3.1 Protein interaction 
mapping and in section 3.2 Phosphorylation site mapping of the discussion.  
 
The aim of the first two parts of this study was to more systematically understand the 
regulation of mitosis. While some general elements regulating entry and progression 
through mitosis have been identified, the molecular mechanisms underlying their 
function are not understood. Especially, the protein complex composition of many 
proteins known to be involved in mitosis is not or only partially understood. Further, 
many kinases that regulate various aspects of mitotic progression have been identified. 
Through which substrates these kinases exert their function is, however, poorly 
understood. As part of the EU-funded MitoCheck project we focussed on two aspects of 
mitotic regulation in human cells: the composition of mitotic protein complexes as well 
as the identification of mitotic phosphorylation sites on a subset of these complexes and 
the identification of substrates of the two mitotic kinases PLK1 and AURKB.  
 
To understand the composition of mitotic protein complexes we wanted to establish a 
method allowing systematic analysis of a large set of protein complexes. To do this we 
wanted to adapt the tandem affinity purification protocol for localisation and affinity 
purification (LAP)-tagged proteins to purify LAP-tagged proteins expressed from 
bacterial artificial chromosomes (BACs). The tandem affinity purification would allow 
specific purification of LAP-tagged proteins and their interactions partners which could 
then be analysed with high sensitivity by MS (LAP-MS). At the same time, the generic 
purification protocol would allow analysis of a large number of diverse protein 
complexes, resulting in a more comprehensive set of protein interactions in mitosis. To 
analyse this large dataset of protein interactions, we wanted to set up a bioinformatic 
analysis pipeline that would allow detecting purified known and potential novel protein 
complexes within the dataset. Potential novel protein complexes could then be further 
analysed by follow up biochemical and functional characterisation. 
 
To identify phosphorylation sites on mitotic protein complexes and to identify substrates 
of the two mitotic kinases PLK1 and AURKB we wanted to use a combination of LAP-MS 
and small molecule kinase inhibitors. Purified candidate protein complexes from cells in 
interphase, mitosis or mitosis in the presence of a kinase inhibitor specific for PLK1 or 
AURKB could be analysed by MS to identify the phosphorylation pattern specific for each 
cellular state. Phosphorylation sites present in mitotic cells and absent in mitotic cells 
treated with a kinase inhibitor would be identified as kinase-dependent phosphorylation 
sites, the corresponding protein would be identified as a potential kinase substrate. This 
method would allow identifying potential kinase substrates in a cellular assay. In 
addition, by using the LAP-MS method established in the first part of the study, we 
21 
1 Introduction 
 
would be able to more systematically identify potential kinase substrates, thus creating 
a resource for further functional characterisation of PLK1 and AURKB substrates. 
 
The third part of this study concerns the generation and development of stable cell lines 
that allow the functional analysis of the cohesin interactors PDS5A and PDS5B. The 
yeast homologue of human PDS5A and PDS5B, called Pds5p, has been implicated in the 
establishment of cohesion in S-phase and the maintenance of cohesion in G2 and M-
phase. The role of PDS5A and PDS5B in human cohesion is not well understood. Since 
PDS5A and PDS5B bind the cohesin complex exclusive of each other and PDS5A but not 
PDS5B forms a subcomplex with the cohesin regulator WAPAL, it is conceivable that the 
function of PDS5A and PDS5B can be explained by their specific interaction partners. In 
a first step to understand the role of PDS5A and PDS5B I wanted to generate cell lines 
inducibly expressing MYC-tagged versions of PDS5A and PDS5B. These cell lines would 
allow studying the localisation and specific interaction partners of PDS5A and PDS5B. 
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2 Results 
The results part contains two manuscripts in preparation and additional results obtained 
to generate cell lines stably expressing MYC-tagged versions of PDS5A and PDS5B. The 
contributions to each of these parts are listed at the end of the results section (2.4). 
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2.1.1 Abstract 
Regulation of mitotis depends on a number of mitotic protein complexes. The activity of 
cyclin-dependent kinase 1 bound to CyclinB (CDK1/CCNB1) is essential for entry into 
mitosis and early mitotic events while the activity of the anaphase-promoting complex 
(APC/C) initiates anaphase onset and mitotic exit.  A number of other mitotic protein 
complexes have been identified that are important for early mitotic events like spindle 
assembly, chromosome condensation, kinetochore structure and the spindle assembly 
checkpoint. It has become clear that in many cases complex formation is essential for 
protein function. However, for many proteins known to be involved in mitosis only few 
or no interaction partners are known. To better understand the function of mitotic 
proteins it is essential to identify their interactions partners and define the protein 
complexes in which they might function. Protein tandem affinity purification has proven 
to be a valuable tool to systematically identify protein interaction partners and to detect 
novel protein complexes in yeast. The recently established BAC TransgeneOmics 
pipeline allowed the generation of a large set of human cells expressing localisation and 
affinity purification (LAP)-tagged mouse genes from their endogenous promoter. Using 
these cells we successfully purified 175 baits and identified 787 specific interaction 
partners by mass spectrometry (MS). Computational analysis defined 130 potential 
protein complexes, 71 of which contained no known protein interactions. Comparison of 
our dataset to siRNA screens carried out to identify mitotic genes showed that 58 of the 
novel complexes contained one or more members required for mitosis. Further 
characterisation confirmed one novel protein complex potentially involved in centrosome 
function during mitosis. In addition we could confirm two novel interaction partners of 
the γ-tubulin ring complex (γ-TuRC) and one novel APC/C complex member. Our study 
provides the first step towards more comprehensively understanding mitotic protein 
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complex organisation. Further studies of these identified protein complexes will advance 
our understanding of the molecular basis of mitotic regulation. 
 
2.1.2 Introduction 
Entry into and progression through mitosis in eukaryotic cells requires the timely 
assembly and often activation of several mitosis-specific protein complexes. Some of 
these protein complexes, their localisation and their involvement in key mitotic 
processes have been characterised in some detail.  
 
The master regulators of the cell cycle are the CDKs, which phosphorylate multiple 
target proteins controlling mitotic processes such as chromosome condensation, nuclear 
envelope breakdown and spindle assembly. The catalytic subunits of CDKs require 
heterodimerisation with a cyclin subunit for activation and are often also bound to a Cks 
protein (orthologue of S.pombe p13Suc1) and may be negatively regulated by being 
complexed by an inhibitory protein such as p21Cip1/Waf1 or p27Kip1 (Morgan, 1997). 
 
Another mitotic protein kinase, Aurora B (AURKB), requires association with INCENP for 
catalytic activity, and with Survivin (BIRC5) and Borealin (CDCA8) to form a functional 
complex (Andrews et al., 2003; Vagnarelli and Earnshaw, 2001). Together, these 
proteins display a dynamic localisation (termed chromosomal passenger) behaviour 
during mitosis; the complex first associates with chromosomes in prophase, then moves 
onto the inner centromere in prometa- and metaphase, where its action is believed to 
promote sister chromatid biorientation by destabilising incorrect spindle-kinetochore 
attachments (Hauf et al., 2003; Tanaka et al., 2002). In anaphase the complex then 
undergoes a dramatic relocalisation, first to the central spindle, then in late mitosis to 
the midbody (Ruchaud et al., 2007). 
 
One class of protein complex has vital roles in organising chromosomes during mitosis: 
the condensins and cohesins both contain a heterodimer of Smc-family proteins, with a 
linker in the form of a kleisin protein (Hirano, 2006; Nasmyth and Haering, 2005; 
Schleiffer et al., 2003), plus at least two additional regulatory proteins. The condensin 
complexes I and II associate with chromatin and act to maintain the duplicated 
chromosomes in a condensed state during mitosis (Hirano, 2005). Cohesin complexes in 
contrast are thought to form stable tripartite ring-like structures, which in association 
with other regulatory subunits topologically entrap sister chromatids to ensure that the 
latter are held together until specific cleavage of cohesin allows anaphase to begin 
(Nasmyth and Haering, 2005). 
 
The APC/C is a multi-subunit E3 ubiquitin ligase, which when activated targets specific 
substrate proteins for degradation, thereby triggering anaphase onset and mitotic exit 
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(Peters, 2006). The activity of the APC/C is tightly regulated by the action of the spindle 
assembly checkpoint (SAC), whose effector, the mitotic checkpoint complex (MCC), 
inhibits the activity of the APC/C towards key substrates when one or more unattached 
kinetochores are present in the cell (Musacchio and Salmon, 2007). 
 
On the centrosomes, the gamma-tubulin ring complex (γ-TuRC) serves as the point of 
initiation of microtubule polymerisation, which by contacting mitotic chromatids via their 
kinetochores ultimately leads to formation of the mitotic spindle (Wiese and Zheng, 
2006). The kinetochores build the interphase between spindle microtubules and the 
centromeric regions on the mitotic chromosomes. While the inner kinetochore 
complexes remain associated with the centromere throughout the cell cycle, the outer 
kinetochore components are sequentially assembled in mitosis (Cheeseman and Desai, 
2008). The complex composition at the kinetochore has been analysed to some detail 
and considerably advanced our understanding of kinetochore function (Cheeseman et 
al., 2006; Cheeseman et al., 2008; Cheeseman et al., 2004). These detailed studies by 
Cheeseman and colleagues have nicely shown that the understanding of complex 
composition forms the basis for understanding the regulatory mechanisms of a complex 
structure like the kinetochore.  
 
A first step to understand the mechanisms underlying mitotic regulation is thus the 
identification of mitotic protein complexes. Although some protein complexes required 
for mitosis have been well characterised, the interaction partners for many mitotic 
proteins have not been identified. The identification of uncharacterised protein-protein 
interactions involved in mitosis in a thorough manner requires a systematic approach. 
The two principal techniques that are often employed to identify protein-protein 
interactions are yeast two-hybrid assays (Y2H), and affinity purification coupled to MS 
(AP-MS). Y2H has been employed in a large-scale survey of interactions in human cells 
(Stelzl et al., 2005) and has the advantage of great sensitivity, with even very 
transiently interacting proteins being identifiable. However, this technique can suffer 
from the drawbacks of generating a high rate of false positive hits, requiring extensive 
post-screening validation, and the limitation that only binary interactions can be 
detected (Parrish et al., 2006). AP-MS, by contrast, purifies a set of interacting proteins, 
irrespective of protein stoichiometry, that might be part of one or more protien 
complexes. The great sensitivity and accuracy of modern tandem MS means that the 
predominant co-purifying proteins can be identified with high confidence (Kocher and 
Superti-Furga, 2007; Steen and Mann, 2004). However, in contrast to Y2H AP-MS can 
not be used to identify binary interaction. Previous genome-wide proteomic studies have 
demonstrated the feasibility of AP-MS for the characterisation of protein complexes in 
yeast (Gavin et al., 2006; Krogan et al., 2006). Although AP-MS has been used to 
detect interaction partners of various disease-related proteins overexpressed in human 
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cells (Ewing et al., 2007), a study systematically identifying protein complexes in 
human is lacking. 
 
In this study, we have used an AP-MS approach to isolate protein complexes from 
mitotic human cells, and to characterise their composition by MS. The affinity-tagged 
baits in our AP-MS experiments are proteins known to be required for mitosis, whose 
inclusion derives from several sources: from the biomedical literature relating to 
mitosis, from a previous screen to identify genes required for cell division (Kittler et al., 
2007), from a proteomics screen to identify components of the centrosome (Andersen 
et al., 2003) and from a genome-wide RNAi screen to identify genes required for mitosis 
in human cells (Neumann et al., in preparation). By expressing LAP-tagged mitotic 
genes from bacterial artificial chromosomes (BACs) in cultured human cells (Cheeseman 
and Desai, 2005; Poser et al., 2008), followed by tandem affinity purification procedure 
from extracts of mitotic cells under native-like conditions, we were able to isolate 
protein complexes corresponding to 175 distinct mitotic baits. LAP-MS was used to 
identify mitotic bait and associated proteins from these preparations with a very high 
success rate. Several previously-known mitotic complexes were identified in their 
entirety and in some cases previously unreported interacting proteins could be 
identified. Bioinformatics clustering of our LAP-MS dataset allowed the mitotic protein-
interaction network to be resolved into discrete potential protein complexes, whose 
existence in the cell could then be validated by biochemical and functional studies. This 
study represents the first step towards generating a comprehensive picture of the 
protein complexes within a human cell that are required for mitosis, and should serve as 
a basis for functional investigations to understand the mechanisms of mitotic regulation. 
2.1.3 Results 
2.1.3.1 Bait selection 
In order to set up an interaction screen that would enable us to systematically identify 
novel mitotic protein complexes, we first selected a number of baits that had previously 
been described as members of well characterised protein complexes. We defined 18 
protein complexes consisting of 88 proteins which have been implicated in diverse 
functions essential for mitotic progression such as chromosome structure (Cohesin, 
SMC5/6), spindle organisation (γ-TuRC, Dynactin), kinetochore microtubule interaction 
(NDC80, MIS12) and the mitotic checkpoint (APC/C, mitotic checkpoint complex (MCC)) 
(Supplemental table 2.1-1 and references therein). Within the reference complex set we 
selected 39 baits. We further chose baits implicated to function in the areas described 
above but where clear information on complex membership was missing. In addition we 
selected baits that have been detected in a screen for centrosomal proteins (Andersen 
et al., 2003) or detected in screens for mitotic genes (Kittler et al., 2007; Neumann et 
al., in preparation). Annotation of these baits with Gene Ontology functional terms 
(Ashburner et al., 2000) showed that about half of the baits are associated with mitotic 
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or mitosis-related functions (Figure 2.1-2). In total 193 stable cell pools expressing 
mostly C-terminally tagged baits were generated following the transgeneomics pipeline 
as described in Poser et al. 2008. Importantly most of the analysed baits were mouse 
homologues of the human target genes. This facilitates the follow up analysis of each 
cell line by RNAi rescue experiments since the expression of the mouse gene will not be 
affected by the siRNA targeting the endogenous mouse gene for depletion. Throughout 
this manuscript, mouse proteins are named with their mouse genome informatics (MGI) 
symbol and human proteins are named with their human genome projecct genome 
nomenclature committee (HGNC) symbol, e.g. Bub1b (Mus musculus), BUB1B (Homo 
sapiens) which corresponds to the common human protein synonym BubR1. A list of all 
used gene names and their most common synonyms is given in the abbreviations 
section (6.). 
 
2.1.3.2 Purification and LC-MS/MS analysis 
To identify interaction partners of the selected baits, we grew cell pools of every bait to 
around 70% confluency, arrested the cells in nocodazole for 18 h and harvested about 
3.2 x 108 cells per pool. Cells were extracted to obtain a high speed extract supernatant 
of about 50 mg and tandem affinity purified using an adapted version of the LAP-
protocol (Cheeseman and Desai, 2005) as outlined in Poser et al. 2008. The purified 
protein complexes were eluted with glycine, 20% of the eluate was separated by SDS-
PAGE and visualised using silver staining. Of the remaining sample, 40% to 80%, 
depending on the intensity of the silver stained bands detected by SDS-PAGE, were 
digested in solution using trypsin, analysed by nano liquid chromatography coupled to 
fourier transform ion cyclotron (FT-ICR) or orbi trap (OT) MS (LC-MS/MS). Peptides 
were identified using the  Mascot software to search a custom made version of the 
knowledge based management system (KBMS) database (187752 sequence entries, 
Applied Biosystems) containing all human sequence and all sequences of the mouse 
baits.  
 
The SDS-PAGE silver stain result of a typical analysis of a set of ten different LAP-
tagged baits is shown in Figure 2.1-1 B. While there are no bands visible for FGFR1OP 
(a human bait), 2810046L04Rik, Azi1 and Ogg1 (mouse); weak bands are visible for the 
purifications of Bach1 and Cep72 (not at the expected size) and strong bands are visible 
in the remaining purifications (in lanes Cep290, Cep55 and Cdc2 bands corresponding to 
the expected molecular weight are visible). Even though the amount of used starting 
material was similar, it is obvious that the amounts of purified complex varied strongly. 
It has been shown by Poser et al (2008) that the expression levels of transgenes in 
BAC-transfected cell pools is close to those of the endogenous gene so that differential 
expression of distinct genes is presumably due to endogenous regulation of expression 
levels.  
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In the illustrated set, the LC-MS/MS and Mascot analysis identified all ten bait proteins. 
Common contaminant proteins were removed (see below) to obtain a short list of 
identified proteins (72 for all ten baits). Each bait was identified with a sequence 
coverage between 2 and 89% (average 45%) and a Mascot score between 30 and 4863 
(average 1448). A summary of the sequence coverage, Mascot score, molecular weight 
and number of identified copurifying proteins is shown in Figure 2.1-1 C. This result is 
representative of the whole dataset in which we could identify 175 of the 193 purified 
baits (success rate 91%). The reproducibility of our purification method was assessed 
by comparing 17 independent purifications of Cdc2-LAP which we used in every 
purification set as the positive control (Figure 2.1-1 D). In 17 purifications we always 
detected the bait, Cdc2. In 15 out of 17 cases we identified the main interaction 
partners expected for Cdc2 in prometaphase, CCNB1 and CCNB2. The two small 
substrate targeting subunits CKS1B and CKS2 were detected in 12 out of 17 cases, 
while the S/M-phase cyclin CCNA2 and its activator SKP2 were only detected 10 out of 
17 times. This shows that most of the interaction partners can be reproducibly detected, 
even though, given a single purification, some might be missed. 
 
As a first validation step of our mitotic protein complex mapping strategy we tested 
whether we could purify intact protein complexes. To asses this, we compared the 
interaction partners identified for the 39 baits of the reference complex set with the 
interaction partners expected from the literature. All but one reference complex was 
sampled at least once, more than half were sampled two or more times. Of the 88 
reference complex members, 90% were detected at least once. We could retrieve all 
known complex members for 13 out of the 17 sampled reference complexes; all 17 
complexes were at least partially retrieved. For two (5%) of 39 baits we only detected 
the bait itself, indicating that the largest fraction of baits interacted with most of their 
known complex members. By comparing expression levels of the baits on western blots 
and silver stained bands on SDS-PAGE gels it is likely that those baits which purify only 
a fraction of known complex members are either low abundant or interact with the 
endogenous complex members at substoichiometric levels (data not shown). 
 
2.1.3.3 Complex detection 
To infer distinct protein complexes from the 175 unique bait purifications, we set up an 
analysis pipeline to map the peptides identified by Mascot onto Ensembl genes, to 
identify and remove contaminants and then to detect potential protein complexes by 
grouping copurifying proteins into distinct clusters using a computational approach. 
These clusters were then used to predict complex membership of each purified protein. 
 
29 
2.1 Protein interaction mapping manuscript 
 
Peptides in the LC-MS/MS analysis of proteolytic digests were identified using the 
Mascot search algorithm which assigns a confidence score to each identified peptide. 
These peptides were then mapped to a minimal list of proteins annotated in the 
Ensembl database following the parsimony principle (described in Nesvizhskii and 
Aebersold, 2005). Only proteins identified by two or more peptides with a Mascot score 
of at least 30 were included. The identified proteins were related back to their 
corresponding genes, which were then used in the further analysis. For mouse genes 
the human orthologue was identified using Treefam (Li et al., 2006) and this human 
orthologue was used in the subsequent analysis.  
 
It is essential to identify and remove copurifying contaminant hits from each purification 
prior to complex inference by clustering since these unspecific interaction partners are 
present in many purifications and would thus link many proteins into a large cluster. To 
define contaminants we first established a gene list of empirically determined 
contaminants by comparing a number of blank purifications (i.e. purifications from cell 
extracts not containing any tagged bait). This gene list comprised mostly cytoskeletal 
and ribosomal genes and was extended to include the entire gene family of an identified 
contaminant gene. In addition we removed prey that interacted with a large number of 
baits, assuming that unspecific interactors would co-purify with many baits. To 
determine how many bait-prey interactions would specify an unspecific interactor, we 
varied the number of bait-prey interactions allowed to be included into the dataset and 
tested the performance of the clustering algorithm (described below) on the dataset. 
Inclusion of prey interacting with ten or more baits increased the cluster size and 
connected known distinct complexes into larger clusters. We thus only included prey 
interacting with nine or less baits (5% of all baits). This is similar to how contaminants 
were removed in a large scale yeast interactome study (threshold of 3% Krogan et al., 
2006) and in a human protein interactions screen (threshold of 5% Ewing et al., 2007). 
Thus, the proteins remaining in every bait purification after contaminant removal can be 
considered as specific interactors for two reasons: they were not identified in blank 
purifications and they only interact with few or none of the other baits in the dataset. 
After removing contaminants the 175 purifications contained 893 unique genes, 
involved in 1551 bait prey interactions. A comparison to human protein interactions 
recorded in different public databases (IntAct (Kerrien et al., 2007), HPRD (Peri et al., 
2003), MINT (Chatr-aryamontri et al., 2007), MIPS (Mewes et al., 2002) and Reactome 
(Mewes et al., 2002)) showed that we recover 143 known bait - prey interactions and 
591 prey-prey interactions (Figure 2.1-2 B). 
 
To predict potential protein complexes we needed to detect copurifying proteins within 
the large purification data set. In previous AP-MS studies in yeast, different clustering 
algorithms have been used to group interacting proteins into clusters that were 
interpreted to represent protein complexes (Gavin et al., 2006; Krogan et al., 2006). 
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However, it was later pointed out that the clusters did fully recover the organisation of 
several known complexes into isoforms and can thus not always be directly interpreted 
as protein complexes (Gingras et al., 2007). To asses how well a determined cluster 
corresponds to a protein complex, we first needed to define the characteristics of a 
protein complex. In general, a protein complex can be defined as an assembly of two or 
more proteins at similar stoichiometry which is biochemically stable and forms a 
structural and functional unit. In the framework of this study we can not determine 
functionality of complexes so we needed to have a complex definition based on AP-MS 
data. An AP-MS purification identifies a set of interacting proteins, irrespective of 
protein stoichiometry, that stably interact at the given purification conditions. If some of 
these interacting proteins form a complex, the purification of a second complex member 
should identify a similar set of proteins. Proteins that are present in both purifications 
most likely represent complex members. As a minimal definition of a protein complex 
we will thus consider a set of proteins copurifying with two independent baits. 
Computationally derived clusters that fulfil this definition will be called complexes; all 
other clusters will be named clusters or potential protein complexes.  
 
To obtain clusters that best represent potential protein complexes, we wanted to use a 
method that does not depend on pre-set parameters. Specifically, we wanted to use a 
clustering method for complex inference that allows proteins to be members of more 
than one cluster and does not require predefining the cluster granularity, i.e. the 
number and size of clusters. Currently, Markov Clustering (MCL) seems to be the most 
robust clustering method for interaction graphs (Brohee and van Helden, 2006). 
However, MCL requires parameters that determine cluster granularity and MCL does not 
allow proteins to belong to multiple complexes. A spectral algorithm (Meila and Shi, 
2001; Shi and Malik, 2000) is similar to MCL but allows determining of the number of 
clusters by the data-dependent eigengap heuristic. It further allows proteins to belong 
to more than one complex since the last step of the spectral clustering algorithm uses 
the fuzzy c-means algorithm (see materials and methods for details). We decided to use 
a combination of the spectral algorithm and the fuzzy c-means algorithm (SFCM) for 
data analysis since this best matched our requirements described above. 
 
The main connected component as defined by the interaction graph constructed from 
the affinity purification data contained 787 genes. A set of 31 small connected 
components contained 106 genes (the largest small connected component contained 16 
members, 17 connected components contained only one member). The small connected 
components were not subjected to clustering since, by definition, they do not interact 
with any other complex in the dataset. For these 31 components, the complexes were 
determined by the copurifying proteins of every bait. The main network was subjected 
to spectral fuzzy c-means clustering which produced 116 clusters. The complexes of the 
small connected components containing at least two members were added to the SFCM 
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clusters, to obtain 130 clusters that vary in size from 1 to 38 proteins. Of these 130 
clusters 7 contain 21 to 38 members, 11 clusters contain 11 to 20 members, 111 
clusters contain 2-10 members and one cluster contains only a single member (Figure 
2.1-2 C, see appendix 5.4 for entire table including the small connected components).  
 
In order to evaluate our computational approach, we tested how well the detected 
clusters corresponded to the reference complex set had we defined in the bait selection 
procedure (Supplemental table 2.1-1 and references therein). We detected 75% of the 
members of the reference complex set in the clusters. To determine whether the cluster 
size also corresponds to the size of the reference complexes, we calculated the 
accuracy, i.e. how many members of a cluster equal the reference complex members. 
The accuracy of our data in comparison to the reference complex set was 51%. This is 
in part due to the fact that some of the mitotic checkpoint and kinetochore complexes 
are highly interconnected and thus are grouped into larger clusters that contain two 
complexes as defined by the reference set. Additionally, some clusters contain potential 
novel members of the reference complexes (see 2.1.3.4) and thus also reduced the 
calculated accuracy. 
 
To test to what extent we recovered novel interactions and novel complexes we used 
the matrix model to allow each cluster member to interact with all other cluster 
members and compared these binary interactions to the interactions recorded in public 
interactions databases as described above. In 130 clusters 368 interactions are known 
(107 are bait-prey interactions). A total of 58 clusters contain one or more known 
interaction, defining 71 clusters as potential novel complexes (Figure 2.1-2 B). 
 
We wanted to know which of the potential novel complexes might play a role in mitosis. 
We compared the members of all clusters with data of various screens that have been 
performed recently to identify genes essential for mitosis (Goshima et al., 2007; Kittler 
et al., 2007; Rines et al., 2008; Sonnichsen et al., 2005). In addition we also annotated 
all clusters with the phenotypes detected in the genome wide siRNA screen carried out 
within the MitoCheck project. This screen combined siRNA knockdown with live cell 
imaging for all siRNA knockdowns and thus allowed a detailed description of the mitotic 
phenotypes (Neumann et al., in preparation). Application of this filter showed that 111 
out of 130 clusters contained at leastonemember with a mitotic phenotype in one of the 
screens. Out of the 71 potential novel complexes, 58 showed at least one mitotic 
phenotype (Figure 2.1-2B and Supplemental table 2.1-3). The most striking example is 
a cluster containing the baits FAM29A and CEP27 (cluster 79, Supplemental table 
2.1-3). It consists of six other members (NP_219485.1, UCHL5IP, C14orf94, CCDC5, 
C4orf15 and KIAA0841) that all copurify with the baits in the original purifications. Out 
of these eight potential complex members, six have been detected as a hit in one or 
more of the genome wide screens for mitotic genes (Figure 2.1-3 D, Supplemental table 
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2.1-3). Only one member, CCDC5, has been previously described, where it was called 
HEI-C (Einarson et al., 2004). CCDC5 localises to centrosomes in interphase and to the 
mitotic spindle. Depletion of CCDC5 leads to mitotic spindle defects, prolonged 
metaphase arrest and apoptosis, consistent with the phenotype observed in the 
MitoCheck screen (Neumann et al., in preparation). To further elucidate and confirm the 
complex composition we tagged C14orf94, CCDC5 and C4orf15 for further purification 
experiments (see below). 
 
Manual inspection of all clusters showed that, apart from the many potentially novel 
complexes, some well known complexes contained additional interaction partners that 
had not been previously described (Supplemental table 2.1-3). We will focus on a few 
interesting examples. The cluster containing the centralspindlin complex (cluster 93, 
Supplemental table 2.1-3), known to be composed of RACGAP1 and KIF23 and required 
for cytokinesis (D'Avino et al., 2005), contains a number of additional members: 
MICAL3, CD2AP, CCAR1 and TRAF3IP1. Interestingly, MICAL3 and CCAR1 also scored as 
a mitotic hit in the MitoCheck screen (Neumann et al., in preparation). Movies recorded 
from H2B-GFP-expressing HeLa cells after siRNA depletion of MICAL3 or CCAR1 show 
that loss of either protein leads to metaphase delay and multinucleated cells, suggesting 
that MICAL3 and CCAR are required during early mitosis or cytokinesis.  
 
The γ-Tubulin ring complex (γ-TuRC) consists of the six subunits TUBG1 and TUBGCP2-
6 (Raynaud-Messina and Merdes, 2007). Two clusters contain members of the γ-TuRC: 
39 (TUBG1, TUBGCP4, 5 & 6) and 71 (TUBG1/2 and TUBGCP2 & 3). NEDD1, a known 
interactor of γ-TuRC (Luders et al., 2006), is located in cluster 39 while two previously 
unknown members are present either in cluster 39 (Q5VXS7_HUMAN) or in cluster 71 
(FAM128B). Both clusters are connected through the TUBG1 subunit (Figure 2.1-2 D).  
FAM128B and Q5VXS7_HUMAN might, nonetheless, represent novel interactions 
partners of γ-TuRC. Most surprisingly was the finding that the APC/C, which has been 
affinity purified and analysed by MS in various organisms repeated times (Peters, 2006) 
also showed one previously unknown interaction partner, which is the gene product of 
c10orf104 (Figure 2.1-2 D).  
 
To further test some of the predicted protein complexes, we tagged 29 genes within 17 
predicted complexes. Analysis of this dataset is still ongoing, some preliminary results 
are summarised in the next section. 
 
2.1.3.4 Characterisation of novel complexes 
Of the 29 genes within the predicted complexes, we have so far analysed 14 by MS. Out 
of those 14 purifications, the bait was detected in 13 cases. Eight baits copurified at 
least one other interacting protein and four baits purified one or more of the members 
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of the predicted complex. In the following, five example are discussed which have so far 
only been analysed by SDS-PAGE and silver staining (the MS analysis has not yet been 
performed) and one example is discussed for which also the MS analysis has been 
carried out. 
 
We first tested whether the two potential interactors of the γ-TuRC, FAM128B and 
Q5VXS7_HUMAN, also copurify components of γ-TuRC. We prepared mitotic protein 
extracts from the three tagged cell pools used in the initial experiments (containing 
LAP-tagged TUBG1, TUBGCP2 and TUBGCP3) as well as mitotic protein extracts from 
TUBGCP6-LAP, FAM128B and Q5VXS7-LAP cell pools. We performed LAP purifications in 
parallel as described above and analysed 20% of the eluate by SDS-PAGE and silver 
staining (Figure 2.1-3 A). Bands were annotated based on the expected electrophoretic 
mobility of the γ-TuRC subunits as indicated in the table in Figure 2.1-3 A. The band 
pattern observed for TUBG1 and TUBGCP3 was identical to the one observed in the 
previous purification (data not shown), also for the TUBGCP2 we previously did not 
detect any bands. As expected, TUBGCP6 (also a γ-TuRC subunit) produced an identical 
band pattern. Importantly, the band pattern of FAM128B was identical to the γ-TuRC 
pattern apart from a band between 20 and 30 kDa which might correspond to the S-
peptide-tagged form of FAM128B. The purification of Q5VXS7_HUMAN-LAP resulted in 
weak bands at the sizes expected for TUBGCP5, 3, 2 and 4. MS analysis has not been 
carried out yet. The similarity of the band patterns for both predicted γ-TuRC interactors 
with the known γ-TuRC subunits however suggests, that FAM128B and Q5VXS7_HUMAN 
are indeed novel members of the γ-TuRC. Analysis of TUBG1 purifications from 
interphase and mitosis indicate that both proteins are also present in the interphase 
form of the γ-TuRC (see phospho-mapping manuscript). Further functional analysis of 
these two novel members will help understand their role in γ-TuRC function. 
 
Further we analysed the novel FAM29A complex. We prepared mitotic protein extracts 
of cell pools containing the LAP-tagged versions of the two founding members of the 
complex FAM29A and CEP27, as well as of cell pools containing LAP-tagged C4ORF15, 
C14ORF94 and CCDC5. Eluates of parallel LAP purifications were analysed by SDS-PAGE 
and silver staining (Figure 2.1-3 B). Bands were annotated based on the expected 
electrophoretic mobility of the potential FAM29A subunits as indicated in the table in 
Figure 2.1-3 B. The purification of FAM29A produced only a few weak bands which were, 
however, identical to the bands detected in the CEP27 purification. MS analysis of 
previous purifications of FAM29A and CEP27 showed that all eight potential FAM29A 
complex members copurified with both baits. While the C4ORF15 purification only 
yielded one band corresponding to its own size (slightly shifted due to the S-peptide-
tag) the purification of C14ORF94 and CCDC5 yielded a number of bands identical with 
the CEP27 bands. The MS analysis of these purifications has not been carried out so far 
but the partially identical band patterns suggest that FAM29A, CEP27, C4ORF15, 
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C14ORF94 and CCDC5 are part of the same complex. Unique bands detected in the 
C14ORF94 purification might indicate the presence of additional interacting partners 
specific to C14ORF94. Further functional analysis of this complex will show if the whole 
complex is involved in mitotic spindle integrity as suggested by the study on CCDC5 
(Einarson et al., 2004) or if it serves other functions.  
 
2.1.3.5 Identification of ANAPC16 as a novel subunit of human APC/C 
One interesting finding of our complex analysis was the identification of a novel 
potential subunit of the APC/C. Previous work in yeast, Xenopus and human has 
identified the APC/C as the major regulator of the metaphase to anaphase transition 
(Peters, 2006). This 1.5 MDa complex, which consists of twelve subunits in human, is a 
ubiquitin ligase that ubiquitinates substrates to target them for proteasomal 
degradation. It was thus quite surprising for us to find a 11.7 kDa protein encoded by 
the c10orf104 gene as a potential additional subunit of the APC/C. This subunit was 
found in purifications with the mouse LAP-tagged subunits Anapc1, Anapc5, Cdc16, 
Anapc8 and Cdc26 (Figure 2.1-3 C) but also in purifications using an antibody against 
endogenous CDC27 (data not shown). To confirm this interaction we generated a cell 
pool expressing N-terminally tagged C10orf104. We used a variation of the LAP-tag 
called MitoTag which, in addition to the LAP-tag also contains a FLAG epitope. We 
purified C10orf104 from these cells using the standard LAP purification protocol as 
described above and analysed 20% of the eluate by SDS-PAGE and silver staining (data 
not shown) and 80% of the eluate by LC-MS/MS. We could detect the mouse bait 
C10orf104 as well as eight out of twelve APC/C subunits and three members of the 
mitotic checkpoint complex (Figure 2.1-3 C), confirming that LAP-tagged C10orf104 can 
interact with the APC/C. 
 
To further characterise the interaction of endogenous C10orf104 with the APC we 
generated three polyclonal antibodies directed against three peptides located at the N-
terminus (2185), the central region (2186) and the C-terminus of the protein (2184, 
Supplemental figure 2.1-1). We tested the antibodies by depleting C10orf104 from HeLa 
cells, preparing cell extracts 24, 48 and 72 h after transfection and probing them with 
the three different affinity purified antibodies. A specific antibody should recognise a 
band at about 12 kDa which should be reduced or absent in the C10orf104 depleted 
extracts. While the antibody raised against peptide 2185 did not recognise any specific 
bands, antibodies 2184 and 2186 did recognise a band at approximately 15 kDa in HeLa 
protein exctracts that was absent (2186) or strongly reduced (2184) at 24, 48 and 72 h 
after siRNA transfection (Supplemental figure 2.1-1). We continued to use antibody 
2184 (named C10orf104 hereafter) for detection of C10orf104 in western blots. 
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We also tested whether the 2186 antibody could immunoprecipitate C10orf104 and, 
more importantly whether it would also immunoprecipitate APC subunits. To do this we 
used 2186 antibody bound to Affiprep beads and CDC27 antibody (Gieffers et al., 1999) 
crosslinked to Affiprep beads and incubated them separately with HeLa extract from 
logarithmically growing cells. Precipitated proteins were eluted with glycine and 
analysed by SDS-PAGE followed by Western blotting with C10orf104 and APC2 
antibodies. The 2186 antibody could immunopurify (IP) C10orf104 and APC2 in similar 
amounts as the CDC27 antibody (Figure 2.1-4 A), confirming our initial finding with six 
different LAP-tagged APC subunits that C10orf104 interacts with the APC (Figure 2.1-3 
C). In a further immunoprecipitation experiment we wanted to test whether C10orf104 
interacted with all APC/C subunits in different cell cycle stages. To do this we incubated 
2186 antibody crosslinked to Affiprep bead as well as crosslinked CDC27 antibody with 
HeLa cell extracts from logarithmically growing cells, from cells arrested in S-phase by 
hydroxyurea and from cell extracts of cells arrested in prometaphase by nocodazole. 
Precipitated protein was glycine eluted and analysed by SDS-PAGE followed by silver 
staining. The resulting band pattern of the C10orf104 IP from all three cell cycle stages 
was indistinguishable from the CDC27 IPs (Figure 2.1-4 C); strongly suggesting that 
C10orf104 interacts with the whole APC/C complex.  
 
To test whether C10orf104 is mainly present as an APC/C complex member we 
fractionated cell extract from logarithmically grown HeLa cells in a 10 to 30 % sucrose 
gradient and analysed the single fractions by SDS-PAGE and western blotting using 
antibodies against the APC/C subunits CDC16, APC10 and against C10orf104. Figure 
2.1-4 B shows that the largest fraction of C10orf104 indeed co-sedimented with the 
APC/C while a minor fraction sedimented in fractions 6, 7 and 8. Since C10orf104 would 
have been expected not to enter the gradient due to its low molecular weight, this peak 
at fractions 6-8 suggests that C10orf104 either oligomerises, is a member of a smaller 
complex or partially dissociates from APC/C in the sucrose gradient.  
 
The observation that C10orf104 interacts with APC/C was further confirmed in APC/C 
activity assays. We purified APC/C form interphase HeLa extracts using either the 2186 
antibody directed against C10orf104 or the CDC27 antibody bound to beads. The 
purified complex was then incubated with all components of a ubiquination assay to test 
if it can in vitro ubiquitinate a recombinant, 125I – labelled CCNB1 (Cyclin B1) fragment. 
The reaction was stopped at different time points and analysed by SDS-PAGE and 
phosphorimaging (Figure 2.1-4 D) to show that APC/C purified via the C10orf104 
protein is equally efficient in ubiquitination as the APC/C purified via the CDC27 
antibody. 
 
To analyse whether the expression of C10orf104 was regulated in a cell cycle-dependent 
manner we synchronised HeLa cells with a double thymidine block release and analysed 
36 
                                                                 2.1 Protein interaction mapping manuscript 
 
extracts prepared at different time points after S-phase release by SDS-PAGE and 
western blotting for C10orf104, CCNB1 and TUBA1B (Figure 2.1-4 E). As indicated by 
the TUBA1B signal the overall protein levels are similar between the different time 
points. The sharp drop of CCNB1 levels between 9 and 10.5 h after the S-phase release 
mark the metaphase- to anaphase-transition. The levels of C10orf104 seem to remain 
equally high throughout the cell cycle. A small reduction of its levels at the 15 and 16.5 
h time point needs to be further analysed to determine whether they are due to small 
loading differences not discernible in the TUBA1B control or due to some degradation of 
C10orf104 prior to S-phase in G1. 
 
We next wanted to test the function of C10orf104 as an APC/C subunit. If it was 
essential for APC/C’s catalytic function we expected that depletion of C10orf104 would 
arrest cells at the meta- to anaphase transition or would abolish APC/C’s activity in G1-
phase. We first tested the former possibility by depleting C10orf104 by siRNA 
transfection for 48 h and testing whether cells accumulated in mitosis by counting the 
mitotic index of fixed cells and by analysing CCNB1 levels. Accumulation of cells in 
mitosis would lead to higher CCNB1 levels and an increased mitotic index. However, the 
contrary was the case. We observed a reduction of CCNB1 levels and a decrease of the 
mitotic index from 3.2% to 1.6% (Figure 2.1-1 F). To further investigate this 
observation in a synchronised cell population we depleted C10orf104 by RNAi and 
arrested cells in thymidine to block them in early S-phase. Six h after release from 
thymidine we added taxol to activate the spindle checkpoint and let cells accumulate in 
mitosis for three h. To confirm the C10orf104 depletion and G2/M cell cycle state we 
made cell extracts and analysed them by SDS-PAGE and western blotting using the 
indicated antibodies (Figure 2.1-4 G). CCNB1 levels were similar in control cells and 
cells treated with siRNA while the levels of C10orf10 were strongly reduced. Analysis of 
the cells before and after taxol treatment by immunofluorescence microscopy using 
CCNB1 and BUB1B antibodies showed that in control conditions about 90% of cells were 
in S- or G2-phase six h after thymidine release (Figure 2.1-4 H). These cells were 
positive for BUB1B and CCNB1 in the cytosol and the DAPI staining showed the 
chromatin to be in a decondensed state. After three h of taxol treatment 50% of control 
cells were in a prometaphase state with BUB1B staining the kinetochores, condensed 
chromatin and cytoplasmic staining of CCNB1. Cells depleted of C10orf104, however, 
did not accumulate in mitosis. Most cells retained cytosolic BUB1B and CCNB1 staining 
indicative of a G2 or S-phase state. There were no cells that passed metaphase which 
would have been CCNB1 negative. This indicates that cells lacking C10orf104 delay their 
progression through S and G2 or delay mitotic entry.  
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2.1.4 Discussion 
To systematically map protein-protein interactions in mitosis we adapted the LAP-
protocol (Cheeseman and Desai, 2005) into a fast, robust and clean tandem affinity 
purification procedure for bacterial artificial chromosome expressed transgenes (Poser 
et al., 2008). In combination with very sensitive FT or OT MS we were able to 
successfully identify 175 out of 193 (91%) purified baits, 718 additional unique proteins 
which involved in 1551 bait-prey interactions. Validation of 39 unique bait purifications 
by comparison to a reference complex set showed that 90% of expected complex 
members could be recovered and only 5% of the baits did not purify any of the 
expected complex members. Our approach thus enabled us to systematically identify 
mitotic protein complexes in HeLa cells with a high confidence.  
 
The stringent tandem-affinity purification procedure strongly reduced the number of 
unspecific interactions usually detected when using antibodies against endogenous 
proteins. After removing common contaminants a typical purification resulted in a list 
containing tens of proteins instead of hundreds of proteins usually detected in single 
step antibody purifications. Nonetheless, in a few cases we were able to detect a 
number of rather transient or weak interactions like the APC/C substrate NEK2 or a 
number of Cdc2a substrates (ANAPC1, CDC25C).  
 
A low number of unspecific interactors was key to allow for a clustering analysis of the 
purification data set. We used spectral fuzzy c-means (SFCM) clustering (Meila and Shi, 
2001) which is based on the Normalised Cut algorithm (Shi and Malik, 2000) to obtain a 
largely unbiased analysis of the data set. Clustering was performed on 787 genes from 
the main connected component and resulted in 116 interaction clusters in addition to 14 
complexes from small connected components. The large interaction graph of 787 genes 
reflects the overlapping set of protein interactions we analysed. The recent AP-MS 
studies in yeast covered over two thirds of the expressed genome and obtained a very 
densely connected set of interactions from most functional pathways (Gavin et al., 
2006; Krogan et al., 2006). Since a whole genome analysis of protein-protein 
interactions in human is still far beyond the scope of currently available techniques, we 
focussed our analysis on a small subset of protein interactions, targeting proteins 
involved in cell cycle regulation. It was important to select baits from defined 
localisations within the cell to recover a dense protein interaction network with our data. 
Sparse complex coverage would have resulted in low overlap between copurifying 
protein so that complex inference would not have been possible. 
 
It is important to note that, based on the definition of a protein complex as two baits 
and their overlap of copurifying proteins, the clusters obtained computationally do not 
always reflect true protein complexes. The overlap of cluster components (coverage) 
and cluster size (accuracy) with a set of well defined complexes can be used to assess 
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how well clusters reflect actual protein complexes. The clusters determined from our 
purification data have a coverage of 75% and an accuracy of 51%. In comparison to the 
coverage determined by Gavin et al. (78%) and the accuracy determined by Gavin et al. 
(78%) and Krogan et al. (72%) for their yeast interactome dataset, our coverage is 
similar but the accuracy is much lower. This is most likely due to the fact that both 
studies used clustering algorithms which have been trained (Krogan et al., 2006) or 
their parameters adjusted (Gavin et al., 2006) to best match a set of reference 
complexes. This introduced a bias towards the characteristics of the reference 
complexes and might not best reflect the original purification data. We avoided any bias 
in our data analysis by using SFCM clustering which does not require preset parameters 
to determine cluster number and cluster size. The comparison of our computationally 
defined clusters with our set of reference complexes indicate that most known complex 
members have been identified within the clusters but the cluster size is quite different 
from the expected complex size in the reference set.  
 
This discrepancy can be explained in two ways. One reason could be that we detected a 
number of novel complex members, suggesting that the set of reference complexes is 
not very accurate. The other reason would be that the clustering procedure either fuses 
highly connected protein complexes into one cluster or splits one protein complex into 
two or more subclusters. While we could not yet test occurrence of the first explanation, 
we find several cases of the second in our data set. For example: a fusion of two 
complexes into one cluster was observed for the MIS12 and NDC80 complexes 
(reference complexes 11 and 12 in Supplemental table 2.1-1; cluster 67 in 
Supplemental table 2.1-3). Both complexes are highly connected at the outer 
kinetochore in mitosis (Cheeseman and Desai, 2008) and it is thus not surprising that 
purification of MIS12 and NDC80 finds mostly overlapping prey which confirms earlier 
findings (Cheeseman et al., 2004). Still, while the coverage for both complexes is 
100%, the accuracy is 27% for the NDC80 complex and 45% for the MIS12 complex. 
Other examples for complex fusions into one cluster or splitting into several clusters 
exist, suggesting that this was a common phenomenon in our clustering procedure. In 
conclusion, the clusters serve as indicators for a potential complex but do not 
necessarily represent a protein complex.  
 
Another common feature of protein complexes, their modularity, can not be easily 
assessed using a clustering approach. Many complexes are known to exist in isoforms 
with different subunit composition. This is exemplified in the complex regulation and 
targeting of the PP2A phosphatase where regulatory, catalytic and structural subunits 
combine mutually exclusive of each other to control PP2A’s localisation and activity 
(Janssens et al., 2005). Gavin et al. attempted to resolve complex isoforms in their 
yeast interactome study by using iterative, slightly varied runs of their clustering 
procedure to define complex cores and modules. But as outlined in a recent review on 
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protein complex analysis by AP-MS, this approach did not allow detection of validated 
complex isoforms (Gingras et al., 2007). We also did not resolve this issue in our data 
analysis. The cohesin complex serves as one example. It is known to exist in four 
mutually exclusive isoforms in human (Losada et al., 2005; Sumara et al., 2000) but 
falls into one common cluster in our dataset (Supplemental table 2.1-3, Cluster 43). To 
determine mutually exclusive interactions or subcomplexes, many more baits per 
complex are required. Large scale analysis in addition would require that not just 
positive interactions are considered for complex inference but also the absence of 
interactions as outlined in (Collins et al., 2007). 
 
To better assess the quality of the protein complex predictions made by the cluster 
analysis, we carried out a number of follow up experiments. We could show that two 
potential novel interaction partners of γ-TuRC (Q5VXS7_HUMAN and FAM128B)  are 
indeed complex members (Figure 2.1-3 A), that one potential novel interaction partner 
(C10orf104) of the previously well characterised APC/C (Peters, 2006) does indeed 
interact with APC/C subunits (Figure 2.1-3 C) and that the completely novel FAM29A 
complex, potentially involved in spindle organisation during mitosis (Einarson et al., 
2004), does consist of at least five of the eight members predicted by our initial AP-MS 
and cluster analysis (Figure 2.1-3 B). 
 
We further went on to investigate the biological significance of the interaction of 
C10orf104 with the APC/C. By purifiying the endogenous protein via polyclonal 
antibodies, by density gradient centrifugation and ubiquitination activity assays we 
could clearly show that C10orf104 is a novel complex member of APC/C which we 
propose to name ANAPC16. We hypothesized that ANAPC16 could be required for APC/C 
activity at the meta- to anaphase transition similar to APC2, which, if knocked out, leads 
to a metaphase arrest in mouse hepatocytes (Wirth et al., 2004). Surprisingly, depletion 
of ANAPC16 did not lead to accumulation of cells in mitosis but rather delayed cells in S- 
or G2-phase. This was supported by the observation that CCNB1 levels and mitotic 
index were reduced after ANAPC16 depletion in asynchronously growing cells. Since 
S/G2 is the part of the cell cycle where APC/C is not active, this is a surprising finding. 
It is conceivable that instead of being necessary for APC/C activity, ANAPC16 could be 
involved in keeping APC/C inactive in S and G2. An APC/C lacking ANAPC16 could thus 
be, at least partially, active and delay the ordered progression of S, G2 and timely entry 
into mitosis by premature degradation of its mitotic substrates. Likewise, the origin 
licensing inhibitor geminin (GMNN), which is a target of APC/C bound to its coactivator 
FZR1 in late mitosis and early G1 could be prematurely degraded by APC/C- FZR1 that 
has not been inactivated at the G1/S transition. A similar role has recently been 
implicated for Emi1 (FBXO5), which is required for the stabilisation of GMNN and for the 
accumulation of CCNA1 and CCNB1 (Di Fiore and Pines, 2007). Further experiments as 
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to where exactly cells are delayed and how APC/C activity is changed when it is lacking 
ANAPC16 will help to understand the function of ANAPC16 as an APC/C subunit. 
 
We have, for the first time, generated a comprehensive map of a subset of human 
mitotic protein complexes. The focus on proteins involved in mitosis defined 71 novel 
potential complexes and additional novel potential interactions partners for 58 other 
partially or well known protein complexes. This dataset, in combination with the results 
of a genome wide live cell imaging siRNA screen (Neumann et al., in preparation) and a 
comprehensive subcellular localisation screen carried out using the same cell pools as 
used in our study (Toyoda and Hyman, in preparation) will greatly enhance our 
understanding of human mitosis. More importantly, the accessibility of all data through 
a common website (www.mitocheck.org) will facilitate a large number of validation and 
follow up experiments within the cell cycle field that will lead to a more comprehensive 
understanding of the events leading to entry into and progression through mitosis. 
 
2.1.5 Materials and methods 
2.1.5.1 Cell culture and siRNA depletion 
HeLa cells were grown on Nunc cell culture dishes in DMEM supplemented with 10% 
FCS, 0.2 mM L-glutamine, 100 U/ml penicillin, and 100 µg/ml streptomycin. For 
transfected cell lines the medium was supplemented with 500 µg/ml G418. Mitotic cells 
were arrested for 18 h using 100 ng/µl nocodazole, harvested by scraping, washed 
twice with PBS, frozen in liquid nitrogen and stored at -80°C until analysis. For a 
standard purification 3 x 108 cells were grown on five 25x25 cm dishes. For cell cycle 
synchronisation cells were arrested at 50% confluency with 2 mM thymidine for 16 h. 
Cells were then released into fresh medium for eight h, then arrested a second time 
with 2 mM thymidine for 16 h and again released into fresh medium. Samples were 
collected at 1.5 h spaced time points for 18 h. To obtain S-phase arrested cells, 2 mM 
hydroxyurea was incubated with cells for 16 h prior to harvest. RNAi depletions were 
performed as previously described (Hirota et al., 2004) using a preannealed siRNA oligo 
targeting C10orf104 (Ambion): 5’-CGCUUAAACAGGUGAAACAtt-3’ (database ID: 117, 
Ambion ID: 129750). 
 
 
2.1.5.2 Protein extraction, purification and MS 
LAP-purification was carried out as described (Poser et al., 2008) using about 50 mg of 
high speed extract supernatant as input. Purified proteins were eluted from beads using 
0.1 M glycine pH 2.0 and the eluate neutralised with 1/10 volume 1.5 M Tris pH 9.2. Of 
the eluate 20% was analysed by SDS-PAGE and silver staining, the remaining 80% of 
the eluate was subjected to in-solution digest using trypsin as described previously 
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(Kraft et al., 2003). Depending on protein abundance in the eluate, 50% or 100% of the 
sample were analysed by MS. 
 
MS analysis 
Equipment - All nano HPLC separations were performed using UltiMate 3000 Nano-LC 
system (Dionex Benelux, Amsterdam, The Netherlands) equipped with a  trap column 
(PepMap C18, 300 μm ID x 5mm length, 3 μm particle size, 100 Å pore size, Dionex 
Benelux) for sample desalting and concentration and an analytical column (PepMap C18, 
75 μm ID x 150 mm length, 3 μm particle size, 100 Å pore size, Dionex Benelux) for the 
chromatographic separation. Loading buffer used contains 0.1% trifluoroacetic acid 
(Pierce). For chromatographic separation mobile phase A contains 5% acetonitrile 
(Merck, Darmstadt, Germany) and 0.1% formic acid (Merck) and mobile phase B 80% 
acetonitrile and 0.08% formic acid. 
Mass spectrometric analyses were conducted either on a hybrid linear ion trap/Fourier 
transform ion cyclotron resonance (FTICR) mass spectrometer with a 7-Tesla 
superconducting magnet (LTQ-FT Ultra) or on a hybrid linear ion trap/Orbitrap mass 
spectrometer (both ThermoElectron, Bremen, Germany). The mass spectrometer was 
equipped with a nano-electrospray ionization source (Proxeon Biosystems, Odense, 
Denmark). Metal coated nano ESI needles were used (New Objective, Woburn, MA, 
USA).  
 
LC separation - Samples were loaded onto the trap column at a flow rate of 20 µL/min 
loading buffer and were washed for ten minutes. Afterwards the sample was eluted from 
the trap column and separated on the separation column with a gradient from 0% to 
35% mobile phase B in 85 minutes followed by 35% to 60% in 5 minutes at a flow rate 
of 300 nL/min. 
 
MS detection – Eluting peptides were ionized with a spray voltage set to 1.5 kV. Fullscan 
(400-1800 Th.) was conducted in the ICR or OT cell yielding a survey scan with 
resolution of 100.000 and a typical mass accuracy < 2ppm (rms). CAD fragmentation 
and spectra acquisition were carried out in the linear ion trap using a multi stage 
activation (MSA) method. The target values of the automatic gain control (AGC) were 
set to 10,000 for CAD in the ion trap, and to 500,000 for FT-ICR fullscan spectra. In the 
applied MS method fragmentation was performed on the five most intense signals of the 
survey scan using MSA of the neutral loss of phosphoric acid. Singly charged ions were 
excluded for precursor selection and precursors of MS² spectra acquired in previous 
scans were excluded for further fragmentation for a period of 3 min whereas the 
exclusion mass tolerance was set to 5 ppm.  
 
Database search – Acquired data (Xcalibur RAWfile) were converted into Mascot generic 
files using Mascot Daemon (Matrix Science, London, UK).  For peptide identification a 
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database search against a custom database containing the human KBMS database 
(5.0.20050304, 187752 sequence entries, Applied Biosystems) and all relevant mouse 
bait sequences was carried out using Mascot (Matrix Science, London, UK; version 
2.2.0). The following parameters were used for the database search: 
carboxymethylation (+58.0055 u) of cystein was set as fixed and oxidation (+ 15.9949 
u) of methionine as variable modification; enzymatic cleavage was specified for trypsin 
and mass tolerances of the parent ion and the fragments were set to 10 ppm and 0.80 
Da, respectively. Proteins with two peptide hits, each having a Mascot score of 30 or 
higher, were kept as hits. Mascot results were exported into xml-files and converted to 
text files for further data processing. 
 
2.1.5.3 Sucrose density gradients 
Sucrose density gradients were prepared in ultra-clear centrifuge tubes (19 x 95 mm, 
Beckman) by mixing two sucrose solutions using a GradientMaster (Biocomp). Cell 
extracts supernatants were centrifuged at 42 000 rpm (TLA45 rotor) for 15 min in an 
Optima MAX ultracentrifuge (Beckman Coulter). Supernatant containing 2.5 mg protein 
was layered on a 10-30% sucrose gradient in TBS-Tween (0.01%). Gradients were 
centrifuged at 34 000 rpm for 18 h at 4°C in a Beckman SW40 rotor in a Beckman 
Optima MAX ultracentrifuge (Beckman Coulter). Gradients were fractionated into 400 µl 
aliquots using an ISCO fractionator at a flow rate of 1 ml/min. 
 
2.1.5.4 Ubiquitination assay 
Five µl of either C10orf104 or CDC27 immunopurified from interphase extracts on 
antibody beads was incubated in 7 – 10 µl XB buffer (20 mM Tris-HCl pH 7.5, 150 mM 
NaCl, 0.02% Tween 20) containing 10 µg ubiquitin, ATP regenerating system (7.5 mM 
creatine phosphate, 1 mM ATP, 1 mM MgCl2, 0.1 mM EGTA, 30 U/ml rabbit creatine 
phosphokinase type I (Sigma)), 0.25 µg His6-E1, 1 µg of E2 (His6-UbcH10 or a mixture 
of His6-UbcH10 and His6-Ubc4) and 0.2 µg purified FZR1 (as indicated). An iodinated 
fragment of human CCNB1 (amino acids 1-84, 3 µg) was used as a substrate. Reactions 
were incubated in a thermomixer (1400 rpm, 37°C) for the times indicated and the 
reaction was stopped by the addition of SDS-sample buffer. Samples were analyzed by 
SDS-PAGE and phosphorimaging. 
2.1.5.5 Data processing and clustering analysis 
Identification of interacting proteins - To map peptides to Ensembl proteins, we looked 
for proteins that perfectly match the peptides first in Ensembl then in Uniprot entries. 
Ensembl proteins corresponding to Uniprot matches were retrieved using Ensembl's 
mapping of Uniprot entries, then the peptide positions were identified by Smith-
Waterman alignment. For each bait, interactors were determined using the parsimony 
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principle (Nesvizhskii and Aebersold, 2005). Proteins identified by only one peptide were 
discarded. In addition, proteins found in a list of common contaminants or recovered 
with more than 5% of the baits were considered contaminants and also discarded. 
 
Complex inference - Complexes were defined as sets of densely connected proteins in 
the interaction graph. To identify them, we use the normalised cut spectral clustering 
algorithm (Meila and Shi, 2001; Shi and Malik, 2000).  First, we formed a binary 
experiment matrix E by setting Ei,j to 1 if protein j is an interactor of bait i or 0 
otherwise. From E, we derive the adjacency matrix A = ETE and the corresponding 
normalised graph Laplacian L= I-D-1A where D is the degree matrix of A and I is the 
identity matrix. A good approximation to the normalised cut is obtained by solving the 
eigenproblem Lz = λDz where the eigenvectors z are complex membership indicators. 
Complexes are identified by applying a clustering step to the proteins projected in the 
space defined by the eigenvectors z corresponding to the first k eigenvalues where k is 
the number of complexes determined from the data using the eigengap heuristic. To 
allow proteins to belong to multiple complexes, we perform the final clustering step 
using the fuzzy c-means algorithm. This algorithm associates each protein to all 
complexes through a membership value between 0 and 1 with values close to 1 
indicating strong association. As m tends to infinity, memberships tend to 1/k (ref ?). 
Thus this value represents a weak association and we assign proteins to complexes 
where they have membership >1/k. The fuzziness parameter m is determined by 
plotting the number of complexes per protein for different values of m. We observe a 
sharp transition between m=1 where each protein belongs to one complex and m=1.1 
where each protein belongs to many complexes. We set m to a value in the lower part 
of the transition region to reflect our belief that proteins are unlikely to belong to many 
complexes. In this work, m= 1.04. 
We run the fuzzy c-means algorithm at least 10 times and keep the complexes 
recovered in at least 70 % of the runs. 
 
2.1.5.6 Antibodies 
Antibodies against C10orf104 were raised in rabbits against three different synthetic 
peptides covering different regions of the protein sequence (supp fig2). Further 
antibodies used in immunopurification, western blotting and immnunopurification were: 
rabbit α-CDC27 (Gieffers et al., 1999), mouse α-CCNB1 (GNS1, Santa Cruz 
Biotechnology), rabbit α-BUB1B (gift from Gregor Kohlmaier), rabbit phospho-S10-H3 
(05-499, Upstate), goat α-GFP (Poser et al., 2008) and mouse α-GFP (11814460001, 
Roche), rabbit α-ANAPC10 (Herzog et al., in preparation), mouse α-ANAPC2 (Gieffers et 
al., 1999). 
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2.1.5.7 Immunofluorescence microscopy 
Cells were grown on 18 mm coverslips in 12 well plates and fixed with 4% PFA. 
Antibodies were used at a concentration of 2 µg/ml in 3% BSA and detected using Alexa 
488 and Alexa 568 labeled secondary antibodies (Invitrogen). DNA was counterstained 
with Hoechst 33342 and slides were mounted using Vectashield Mounting Medium 
(H1000, Vector Laboratories). Image acquisition was performed as described 
(Waizenegger et al., 2000). 
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2.1.6 Figure legend 
2.1.6.1 Figure 2.1-1 
Identification of bait and interacting proteins by LAP-MS 
A) The scheme shows the analysis workflow from selecting candidate baits, tagging 
mouse homologs of candidate genes with a LAP-tag in BACs (Poser et al 2008), 
purifying proteins expressed from BACs in nocodazole (noc) arrested stable cell pools by 
tandem affinity purification, analysing the glycine eluted and in solution digested protein 
complexes by LC-MS/MS, followed by Mascot database searches and finally dataset wide 
contaminant removal followed by SFCM clustering to resolve the interactions data into 
discrete potential complexes. 
B) Ten LAP-tagged proteins (FGFR1OP is a human gene, the remaining nine genes are 
mouse) were tandem affinity purified from nocodazole-arrested HeLa cells, glycine 
eluted and 20% of the eluate analysed by SDS-PAGE and silver staining. LAP-tagged 
Cdc2 (Cdc2) was used as a positive control and wild type HeLa cell extract (wt) was 
used as a negative control. 
C) Of the protein complexes purified as described in B), 80% were digested in solution 
and analysed by LC-MS/MS followed by Mascot database searching. The percent 
sequence coverage (%SC), Mascot score (M-Sc) and molecular weight in kDa of the bait 
proteins are summarised. The number of proteins detected in the purifications after 
contaminant removal is shown in the last column (#prey). 
D) Cdc2 was included with each set of LAP purifications performed so that Cdc2 was 
purified in 17 independent experiments. The reproducibility of co-purifiying proteins (i.e. 
times and percentage found per 17 repeats) is indicated. 
 
 
2.1.6.2 Figure 2.1-2 
Summary graphics of whole dataset 
A) Ontology of bait proteins was annotated sequentially to a set of gene ontology (GO) 
biological process terms (Ashburner et al., 2000) in a non-redundant fashion (i.e. if a 
bait gene is associated with M-phase, it falls into this category and other GO terms for 
the same bait are disregarded). 
B) The number of purified baits, detected bait-prey interactions and known interactions 
for the purification data (MS) as well as the number of total clusters with two or more 
members obtained, the number of clusters with known interactions, with no known 
interaction (novel potential complexes) and the number of novel potential complexes 
with at least one hit in one of the four siRNA screens 
C) Complex size distribution 
The number of interaction clusters with 1 member, 2-10 members, 11-20 members, 21-
30 members and 31-38 members. 
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D) Examples of interaction clusters determined by sFCM clustering are shown in the 
spoke model representing bait-prey interactions present in the cluster. Baits are shaded 
in brown, prey are shaded in yellow, genes which show a mitotic phenotype in any of 
four genome wide screens are marked with an asterisk (Goshima et al., 2007; Kittler et 
al., 2007; Neumann et al., in preparation; Sonnichsen et al., 2005). The APC has been 
sampled with four different baits which all interact with a potential novel subunit 
C10orf104. The γ-TuRC has been sampled by three of its known components (TUBG1, 
TUBCP2 and TUBGCP3), one known interactor NEDD1 and is predicted to have two 
additional subunits (FAM128B and Q5VXS7_HUMAN). Nevertheless, the γ-TuRC 
components fall into two different clusters, which are connected through TUBG1. The 
completely novel FAM29A complex has been predicted from the interactions of the LAP-
tagged baits FAM29A and CEP27. 
 
2.1.6.3 Figure 2.1-3 
Analysis of selected novel interactors and complexes 
A) Mouse LAP-tagged versions of the known γ-TuRC members TUBG1, TUBGCP2, 
TUBGCP3 and TUBGCP6 were LAP purified and analysed by SDS-PAGE and silver 
staining alongside LAP purifications of two predicted novel γ-TuRC members FAM128B 
and Q5VXS7_HUMAN. Bands were putatively annotated based on the expected protein 
size.  
B) Mouse LAP-tagged versions of FAM29A and CEP27 that defined the novel FAM29A 
complex were LAP purified and analysed by SDS-PAGE and silver staining alongside LAP 
purifications of three predicted complex members C4ORF15, C14ORF94 and CCDC5. 
Bands were putatively annotated based on the expected protein size.  
C) Comparison of the interaction partners of five mouse LAP-tagged APC/C subunits and 
the newly identified APC/C subunit  C10orf104  shows a large overlap, suggesting that 
C10orf104 is indeed a new APC/C subunit. The number of unique peptides (Mascot 
score ≥30) for each interaction partner is shown. In addition to all APC/C subunits, also 
the members of the mitotic checkpoint complex (shaded in grey) and other APC/C-
related proteins are shown. 
 
2.1.6.4 Figure 2.1-4 
C10orf104 is an APC/C subunit that might be involved in S- and/or G2-phase 
progression. 
A) Protein extracts from logarithmically growing HeLa cells were prepared and incubated 
with Affiprep beads bound to C10orf104 antibody or crosslinked to IgG or CDC27 
antibody. Precipitated complexes were glycine eluted, separated by SDS PAGE and 
analysed by western blotting using the indicated antibodies. 
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B) Logarithmically growing HeLa cells were extracted and subjected to sucrose density 
gradient centrifugation through a 10% - 30% gradient. After centrifugation 28 fractions 
were collected and analysed by immunoblotting with the indicated antibodies. * marks 
an unspecific band recognised by the APC10 antibody. 
C) Protein extracts from logarithmically growing (L), hydroxyurea (HU) or nocodazole 
(N) arrested HeLa cells were prepared and incubated with Affiprep beads crosslinked to 
C10orf104 antibody or to CDC27 antibody. Precipitated complexes were glycine eluted, 
separated by SDS PAGE and visualised by silver staining. APC/C subunits were 
annotated according to their known electrophoretic mobility. 
D) CDC27 or C10orf104 immunoprecipitates from logarithmically growing HeLa cells 
were incubated with E1 and E2 enzymes, recombinant FZR1, [125I]-labelled human 
CCNB1 fragment (amino acids 1 to 84) as substrate, ubiquitin and ATP for the times (in 
min) indicated and analysed by SDS-PAGE and phosphorimaging. CON indicates empty 
protein A beads and a condensin complex antibody (from left to right).* marks a 
contaminating band present in the substrate preparation. 
E) HeLa cells were synchronised by a double thymidine block, released into fresh 
medium and samples collected at indicated times after release. Cell pellets were lysed in 
SDS-sample buffer and by sonication, separated on SDS-PAGE and probed with the 
indicated antibodies. 
F) C10orf104 depletion by siRNA leads to a decrease in CCNB1 levels. 
Cells were transfected with c10orf104 siRNA for four h and afterwards split onto 
coverslips and tissue culture plates. Cells on coverslips were PFA-fixed and stained with 
DAPI and H3S10ph to count the mitotic index 48 h after transfection. Remaining cells 
were harvested 48 h after transfection, extracted, separated by SDS-PAGE and 
transferred to a membrane and probed with the indicated antibodies. 
G+H) Cells were transfected with C10orf104 siRNA for twelve h, afterwards split onto 
coverslips and tissue culture plates, treated with 2 mM thymidine for 24 h, then 
released into fresh medium and six h later (TP1) treated with 10 µM taxol (T) or 100 
ng/ml nocodazole (N) for three h (TP2). For immunoblot analysis (G) cells were 
harvested at time point 2, extracted, separated by SDS-PAGE, transferred to a 
membrane and probed with the indicated antibodies. For immunofluorescence 
microscopy cells were fixed at TP1 and TP2. Fixed cells were stained with BUB1B 
antibody, CCNB1 antibody and DAPI. More than 200 cells were counted at each time 
point and scored as either being in interphase (BUB1B/CCNB1 negative nuclei), 
prophase (CCNB1 positive nuclei before nuclear envelope breakdown) or prometa- and 
metaphase cells (BUB1B positive kinetochores and condensed chromosome 
morphology). 
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2.1.6.5 Supplemental table 2.1-1 
Table summarising the reference complex set giving the number of known complex 
members (SU), the number of baits selected for each complex (baits) and the number 
of baits retrieving either all members of the reference complex (full com.) or only a 
fraction of the complex (part. com.). The latest research paper or review describing 
each complex is given in the last column. 
 
2.1.6.6 Supplemental table 2.1-2 (See appendix 5.3) 
Table summarising all 175 unique bait purifications plus all Cdc2 purifications after 
contaminant removal annotated with sequence coverage and the sum of the Mascot 
score for all identified peptides. Since the table is very long, it can be found in the 
appendix (5.3). 
 
2.1.6.7 Supplemental table 2.1-3 (See appendix 5.4) 
Table summarising all identified clusters, annotated with complex number, baits within 
these clusters, known interactions of the bait within the cluster, total known interactions 
within the cluster, probability of observing the given number of interactions with each 
cluster at random, summary of mitotic screen hits per cluster, screen hits (fly: Goshima 
et al., 2007; human esiRNA: Kittler et al., 2007; human siRNA: Neumann et al., in 
preparation; worm: Sonnichsen et al., 2005). Since the table is very long, it can be 
found in the appendix (5.4). 
 
2.1.6.8 Supplemental figure 2.1-1 
Characterisation of three polyclonal antibodies raised against C10orf104/ANAPC16 
A: C10orf104 protein sequence with peptides used for antibody generation underlined 
and labelled with the peptide and antibody number in superscript. 
B: Generation of rabbit polyclonal antibodies against C10orf104 
Cells were transfected with siRNA against C10orf104 (siRNA) or water (CON) and 
protein extracts prepared at 24h, 48h or 72h after transfection. Extracts were separated 
by SDS-PAGE, transferred to a membrane and probed with the indicated antibodies. 
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Figure 2.1-2 
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Figure 2.1-3 
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Figure 2.1-4 
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Supplemental table 2.1-2 
See Appendix 5.3. 
 
 
Supplemental table 2.1-3 
See Appendix 5.4. 
 
 
Supplemental figure 2.1-1 
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2.2.1 Abstract 
Entry and progression through mitosis depends on the activity of a number of mitotic 
protein kinases. The Polo-like kinase 1 (PLK1) is essential for mitosis and has been 
implicated in the regulation of mitotic entry, bipolar spindle formation and maintenance, 
mitotic checkpoint function as well as cytokinesis. Targeting of PLK1 to its substrates is 
thought to be controlled by priming phosphorylation by the cyclin-dependent kinase 1 
(CDK1) but might for some substrates also be regulated through PLK1’s own activity. 
Aurora kinase B (AURKB) is another essential mitotic kinase which, apart from other 
functions, is essential for spindle assembly checkpoint function by correcting improper 
microtubule kinetochore attachments. Its localisation is tightly regulated by the so-
called chromosomal passenger complex which moves from chromosome arms in G2-
phase to centromeres in early mitosis to then travel via the central spindle in anaphase 
to the midbody in cytokinesis. The key functions of both kinases are mediated through 
their kinase activity since inhibition using small molecule inhibitors phenocopies siRNA 
depletion. Identification of PLK1 and AURKB substrates is therefore essential to 
understand how PLK1 and AURKB function. The tight spatio-temporal regulation of PLK1 
and AURKB during mitotic progression suggests that their substrates must only be 
phosphorylated at a specific time and place to fulfil their function. Assays to detect 
kinase substrates have been, however, largely carried out in vitro, without any cellular 
regulatory systems in place. We have therefore set out to develop a cellular assay to 
find novel PLK1 and AURKB substrates. Using small molecule inhibitors against PLK1 
and AURKB in combination with tandem affinity purification and mass spectrometry 
(MS) we could detect kinase-dependent phosphorylation sites on 16 candidate substrate 
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complexes. In total we found 470 phosphorylation sites, 41 of which were PLK1-
dependent and 20 of which were AURKB-dependent. We validated a subset of these 
sites with phospho-specific antibodies and detected 17 novel potential PLK1 substrates 
and 18 novel potential AURKB substrates.   
 
 
2.2.2 Introduction 
Entry into mitosis depends on the activity of CDK1, originally termed maturation 
promoting factor or later M-phase promoting factor (MPF). Early work revealed that 
activity of MPF in Xenopus laevis eggs and its effects at the G2/M transition are 
independent of protein synthesis (Wasserman and Masui, 1975), implying that MPF acts 
through post-translational mechanisms to allow mitotic entry. Later observations 
showed that MPF activity is accompanied by a burst of protein phosphorylation (Maller 
et al., 1977) which generates distinct phosphoproteins reoccurring with every mitotic 
phase (Karsenti et al., 1987). This set the stage for the realisation that Cdc2 in S. 
pombe and Cdc28 in S. cerevisiae are the same as MPF and that Cdc2 (later called 
CDK1) is a kinase (Simanis and Nurse, 1986) regulated by the cycling levels of cyclins 
(Felix et al., 1989; Labbe et al., 1989) and phosphorylation (Morla et al., 1989). Since 
then, efforts have been underway to understand the function of CDK1 by searching for 
its substrates (Morgan et al., 1989; Shenoy et al., 1989). This was mainly conducted by 
either in vitro kinase assays with candidate substrates or by predicting candidate 
substrates using the soon-emerged CDK1 consensus phosphorylation motif [ST]-P-X-
[KR] (Peter et al., 1990), followed by testing these substrates in vivo using 
phosphorylation site mutants. In parallel it became clear that CDK1 is not the only 
kinase specifically activated in mitosis. A number of other other proteins have 
subsequently been identified as kinases essential for mitotic progression: NIMA (Osmani 
et al., 1991), Wee1 (Piwnica-Worms et al., 1991), Polo (Llamazares et al., 1991), 
Aurora (Chan and Botstein, 1993; Francisco and Chan, 1994) and Myt1 (Mueller et al., 
1995). These kinases were initially identified in various model organisms and later found 
to be conserved in most species. Loss of function experiments using genetic tools in 
yeasts and flies, antibody injection or depletion experiments in vertebrates as well as 
siRNA-mediated knockdowns have revealed the involvement of these mitotic kinases in 
many aspects of cell division. This led to the understanding that phosphorylation, along 
with proteasome-mediated proteolysis (Glotzer et al., 1991), is one of the main 
regulatory switches for cells entering and progressing through mitosis. However, how 
these kinases exert their effects has remained elusive; mainly because only few 
substrates have been identified to date.  
 
Polo-like kinase 1 (PLK1) has been identified in Drosophila (where it is named polo) as a 
gene essential for mitosis and bipolar spindle formation (Llamazares et al., 1991). It has 
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further been detected and characterised as a protein specifically expressed in G2- and 
M-phase in human (Golsteyn et al., 1994), confirming a conserved function in mitosis. 
Further functional studies of PLK1 by antibody depletion or siRNA mediated knockdown 
have revealed that PLK1’s function is intimately linked to its localisation. Early studies 
showed that PLK1 is required for centrosome maturation (Lane and Nigg, 1996) and is 
localised to the centrosome (Arnaud et al., 1998). This is consistent with PLK1’s role in 
centrosome separation, mitotic spindle formation (Sumara et al., 2004; van Vugt et al., 
2004) and maintenance (Lenart et al., 2007). Centrosomal localisation might also be 
required for PLK1’s proposed role in mitotic entry where it phosphorylates CCNB1 
(Jackman et al., 2003). More recent data suggest however, that PLK1 might rather be 
involved in timely prophase progression into prometaphase (Lenart et al., 2007) than in 
entry into mitosis. During prophase PLK1 enters the nucleus and is involved in the 
removal of the bulk of the cohesin complex from chromosome arms, the so-called 
prophase pathway (Hauf et al., 2005). PLK1 then localises to kinetochores until 
prometaphase where it contributes to spindle checkpoint protein accumulation (Ahonen 
et al., 2005; Kang et al., 2006; Wong and Fang, 2005). During cytokinesis PLK1 
phosphorylation allows the interaction of the two central spindle proteins RACGAP1 and 
ECT2 to initiate cleavage furrow ingression (Burkard et al., 2007; Petronczki et al., 
2007). PLK1 is inactivated by APC/C-FZR1-dependent proteolysis in late mitosis to allow 
proper mitotic exit (Lindon and Pines, 2004). 
 
The main mechanism of targeting PLK1 to its substrates is thought to function through 
its phospho binding domain called the polo box domain, PBD (Elia et al., 2003a). The 
two polo boxes of PLK1 that comprise the PBD sandwich the target phosphopeptide and 
bind it with very high affinity (Elia et al., 2003a). By using the PBD in pull down assays 
combined with MS a large number of potential substrates has been detected (Lowery et 
al., 2007). Furthermore several studies have successfully used mutations of the PBD 
binding motif (S-[pSpT]-[PX]) to understand the role of PLK1 phosphorylation for the 
function of certain substrates (Baumann et al., 2007; Elowe et al., 2007; Neef et al., 
2007). This binding motif fits the consensus sequence of CDK1 and it has been 
speculated that CDK1 could be the main priming kinase for PLK1 binding. On the other 
hand recent studies using small molecule inhibitors have shown that PLK1 activity alone 
regulates its localistion (Lenart et al., 2007; Santamaria et al., 2007) supporting the 
idea that PLK1 can also generate its own binding sites (Neef et al., 2007). In addition, it 
has been shown that the PBD is not required for PLK1 function at the centrosome 
(Hanisch et al., 2006), indicating that PLK1 localisation might in addition be regulated 
by a mechanism other than polo box binding. 
 
The first member of the Aurora kinase family was identified as Ipl1 (increase in ploidy) 
in budding yeast (Chan and Botstein, 1993) and later identified in Drosophila as aurora 
(later named Aurora A) where the mutant fails to separate centrosomes and does not 
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form a bipolar spindle (Glover et al., 1995). Vertebrates contain three orthologs of 
Aurora: Aurora kinases A, B and C. Vertebrate Aurora kinase B (AURKB) was first 
identified in rat cells (Terada et al., 1998) and was later found to be an integral 
component of the chromosomal passenger complex, CPC (Adams et al., 2000), that 
localises to chromosome until prometaphase, moves to centromeres in metaphase only 
to later travel via the spindle midzone in anaphase to the midbody in telophase and 
cytokinesis. This well described localisation change is thought to govern the function of 
AURKB during mitosis. While initial observations indicated that AURKB only functions in 
cytokinesis (Terada et al., 1998), it was subsequently shown that it functions 
throughout mitosis with its earliest sign of activity appearing in late G2/early M where it 
phosphorylates serine 10 on Histone H3 (Crosio et al., 2002). During prophase AURKB 
promotes the binding of the condensin I complex, which is thought to regulate mitotic 
chromosome structure, to chromatin (Takemoto et al., 2007) by phosphorylation of 
some of its subunits. It is however not involved in chromosome condensation mediated 
by condensin II (Lipp et al., 2007). A further role of AURKB in chromosome structure is 
to promote cohesin removal in prophase via the prophase pathway (Losada et al., 
2002). Whether this is facilitated through direct phosphorylation of cohesin subunits or 
indirectly by delocalisation of SGOL1 and subsequent protection of cohesin 
phosphorylation by PLK1 is not clear (Dai et al., 2006; Kitajima et al., 2005). In 
prometaphase AURKB concentrates at centromeres where it is essential for ensuring 
correct, amphitelic, attachment of microtubules to kinetochores. It is thought that 
INCENP and Survivin of the CPC sense the tension applied across the kinetochore by 
microtubules and keep AURKB active in the absence of tension (Cheeseman et al., 
2006; DeLuca et al., 2006; Sandall et al., 2006). Phosphorylation of the kinetochore 
component NDC80 by AURKB decreases its affinity to microtubules, allowing syntelically 
attached microtubules to detach until fully bi-oriented kinetochores under tension are 
generated (Cheeseman et al., 2006). This inactivates AURKB at the kinetochore which 
leads to silencing of the mitotic spindle assembly checkpoint (Ditchfield et al., 2003; 
Hauf et al., 2003; Morrow et al., 2005) and allows anaphase onset. While it is clear that 
AURKB is essential for cytokinesis (Terada et al., 1998), the underlying mechanism is 
not yet fully understood. Possibly, phosphorylation of the centralspindlin complex 
(RACGAP1 and KIF23) by AURKB is the key function in the regulation of cytokinesis by 
AURKB (Guse et al., 2005). 
 
It is known that AURKB is targeted to its substrates through interaction with and 
localisation by the chromosomal passenger complex proteins (Adams et al., 2000). At 
the same time, interaction with INCENP is also essential for AURKB activation (Bishop 
and Schumacher, 2002). A recent study has further shown that full activity, at least 
against some substrates, requires a priming phosphorylation and microtubules 
(Rosasco-Nitcher et al., 2008). This indicates that, similar to the situation observed for 
PLK1, the function of AURKB is not only dependent on phosphorylating the right 
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substrate but more importantly on phosphorylating the right substrates at the right 
place and the right time. This implies that in order to understand PLK1 and AURKB 
function through their substrates; substrates need to be identified at the sites of PLK1 
and AURKB function in cells. However, substrate identification has to date largely relied 
on in vitro kinase assays because of the lack of tools to specifically identify kinase 
substrates in cells. An approach to study kinase function in cells has recently been 
demonstrated using analogue-sensitive kinases (as-kinases). As-kinases are engineered 
kinases that accept a bulky ATP analogue in their ATP binding pocket (Shah and Shokat, 
2002; Witucki et al., 2002). This bulky ATP-analogue can be used to inhibit the as-
kinase. Cell lines expressing an as-PLK1 in a background lacking wild type PLK1 have 
been employed in combination with a bulky ATP-analogue inhibitor to understand PLK1’s 
function in cytokinesis (Burkard et al., 2007). To inhibit the endogenous kinase in wild 
type cell lines, specific small molecule inhibitors can be used. The availability of the 
small molecule inhibitor Hesperadin for AURKB (Hauf et al., 2003) and BI2536 for PLK1 
(Lenart et al., 2007; Steegmaier et al., 2007) allows creating a loss of function situation 
for these kinases in large cell populations. In combination with a highly robust tandem 
affinity purification protocol (Poser et al., 2008) and high mass accuracy MS we have 
set up a method to detect kinase-dependent phosphorylation sites on candidate 
substrates. We have used this method to screen 16 candidate substrate complexes of 
PLK1 and AURKB for mitotic phosphorylation sites that are sensitive to kinase inhibitor 
treatment. This resulted in a collection of 470 phosphorylation sites on 99 unique 
proteins and the detection of 17 novel potential PLK1 substrates and 18 novel potential 
AURKB substrates, almost doubling the number of substrates previously known. 
 
2.2.3 Results 
Given that additional factors control the targeting and activity of PLK1 and AURKB to its 
substrates, we set up a cellular assay to detect their substrates. Using a combination of 
kinase inhibitors, candidate substrate affinity purification and phosphorylation site 
mapping by MS we wanted to identify phosphorylation sites that are sensitive to 
treatment with either the small molecule inhibitor Hesperadin (Hauf et al., 2003) or the 
PLK1 inhibitors BI2536 (Lenart et al., 2007; Steegmaier et al., 2007) or BI4834 (see 
below). These inhibitors have been thoroughly studied and it was shown that they 
recapitulate the phenotypes previously described for siRNA or antibody mediated 
depletion in various mammalian systems (Taylor and Peters, 2008).  
 
2.2.3.1 Characterisation of the BI2536-related inhibitor BI4834  
 
To inhibit PLK1 we used a structural relative of the recently described BI2536 inhibitor 
(Lenart et al., 2007; Steegmaier et al., 2007). To fully test BI4834’s effect on HeLa cells 
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we used a number of cellular assays already described in Lenart et al. (2007) to 
determine the concentration at which PLK1 is fully inhibited. Penetrance of the 
monopolar spindle phenotype was tested by treating HeLa cells, synchronised with a 
double thymidine arrest release, for three h with concentrations ranging from 10 to 
2500 nM of BI4834 before fixation and staining with TUBA1B antibodies as well DAPI. 
Using 250 nM BI4834 was sufficient to obtain 90% of cells that arrested in mitosis with 
a monopolar spindle (Supplemental figure 2.2-1 B and C) which is identical to the 
strongest PLK1 RNAi phenotype in human cells (Sumara et al., 2004). Cells treated as 
described above were also stained with TUBG1 antibodies to test at which concentration 
BI4834 fully inhibits centrosome maturation. Full inhibition was reached at a 
concentration range of  250 nM and 500 nM (Supplemental figure 2.2-1 D). To confirm 
that BI4834 could also prevent dissociation of cohesin from chromosomes in early 
mitosis we treated cells stably expressing RAD21-9x MYC (Hauf et al., 2005) with 250 
nM BI4834, prepared cytospins and stained with MYC antibodies to visualise cohesin. 
Cohesin was strongly enriched on chromosomes in prometaphase (Supplemental figure 
2.2-1 F), confirming the results obtained using 100 nM of BI2536 (Lenart et al., 2007). 
We further tested whether BI4834 would also abolish the electrophoretic mobility shift 
of BUB1B seen after depletion of PLK1 (Elowe et al., 2007; Matsumura et al., 2007) or 
inhibition of PLK1 with BI2536 (Lenart et al., 2007). Cells synchronised using a double 
thymidine block were released into nocodazole only or into nocodazole containing either 
100 nM of BI2536 or 250 nM of BI4834. Supplemental figure 2.2-1 G shows that 250 
nM BI4834 inhibit the phosphorylation of BUB1B equally well as 100 nM BI2536. In 
conclusion, treatment of HeLa cells with 250 nM of BI4834 induces a phenotype 
indistinguishable from treatment with 100 nM BI2536 (Lenart et al., 2007). We thus 
decided to use 250 nM final concentration of BI4834 in our phosphorylation mapping 
experiments. 
 
2.2.3.2 Bait selection, affinity purification and mass spectrometric analysis 
In order to detect PLK1- and AURKB-dependent sites in a cellular assay we first selected 
a number of candidate protein complexes that localise to subcellular mitotic structures 
where PLK1 and AURKB are known to act. We focussed on groups of baits that are 
components of the kinetochore, the mitotic checkpoint complex, chromosomes, the 
spindle or the centrosome (Figure 2.2-1 A).  
 
The 16 baits and their interaction partners were either tandem affinity-purified using the 
LAP-tag (Poser et al., 2008) or immunoprecipitated using antibodies against the 
endogenous proteins (Figure 2.2-4 A for details) from cultured HeLa cells. Most LAP-
tagged baits used were the mouse homologues of the candidate human genes. This is 
possible since most LAP-tagged mouse proteins expressed in HeLa cells tested so far 
localise and function as expected from the human homologue (Poser et al., 2008). 
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Throughout this manuscript, mouse proteins are named with their MGI symbol, human 
proteins are named with their HGNC symbol, i.e. Bub1b (Mus musculus) or BUB1B 
(Homo sapiens), which corresponds to the commonly used human synonym BubR1. A 
list of all used gene names and their most common synonyms is given in the 
abbreviations section (6.).  
 
To identify mitosis-specific and inhibitor-sensitive phosphorylation sites proteins were 
purified from HeLa cells growing exponentially (L), arrested in mitosis using nocodazole 
(N) or nocodazole arrested cells treated for two h with either 250 nM of BI4834 (NB) or 
100 nM Hesperadin in combination with 10 µM MG132 (NHM). Addition of MG132 was 
necessary to prevent cells from exiting mitosis due to a spindle assembly checkpoint 
override that results from AURKB inactivation (Ditchfield et al., 2003; Hauf et al., 
2003). A 5% fraction of the purified protein complex was analysed by SDS-PAGE and 
silver staining while the remaining sample was digested in parallel in solution using 
either trypsin or chymotrypsin or subtilisin. The resulting peptide mixtures were 
analysed using a nanoHPLC-FT-ICR or nanoHPLC-OT-ICR mass spectrometer. Using 
Mascot in combination with the knowledge based management system (KBMS) database 
(187752 sequence entries, Applied Biosystems) supplemented with the mouse bait 
sequences, peptides were identified. Detected phospho-peptide spectra were manually 
validated and assigned a confidence score from 0 to 3 (0 being low confidence, 3 high – 
only phospho-peptides with score 1-3 were kept). Figure 2.2-1 B and C shows a typical 
purification result of one bait purification, mouse Bub1b, including sequence coverage of 
selected interaction partners and their total number of identified phosphorylation sites. 
Bands are labelled according to the molecular weight of most abundant proteins 
identified in in solution digests. Sequence coverage was calculated by combining 
detected peptides from all three proteolytic digests with a Mascot score of 20 and 
higher. The same purifications have been carried out for a total of 16 protein complexes 
(Figure 2.2-1 A). We will first describe the detailed analysis of a LAP purification of the 
mitotic checkpoint protein Bub1b from HeLa cells and the immunoprecipitation of the 
cohesin interactor WAPAL before we summarise the results obtained from the whole 
data set. 
 
2.2.3.3 Phospho-site analysis of LAP-tagged mouse Bub1b and endogenous 
WAPAL  
 
To validate that mouse Bub1b interacts with the complex partners expected for human 
BUB1B, we compared the proteins identified by Mascot with the literature. The database 
search of mitotic samples (N, NB, NHM) resulted in a sequence coverage of 74% to 80% 
for Bub1b and sequence coverage from 15% to 89% for the three other members of the 
mitotic checkpoint complex, BUB3, CDC20 and MAD2L1 (Sudakin et al., 2001) as well 
62 
                                                               2.2 Phosphorylation site mapping manuscript 
  
as for most members of the APC/C (Peters, 2006), the recently described Bub1b 
interactor and outer kinetochore component CASC5 (Cheeseman et al., 2008; Kiyomitsu 
et al., 2007) as well as components of the kinetochore complexes MIS12 and NDC80 
(Cheeseman et al., 2006) ( 
 
Supplemental table 2.2-2). Unexpectedly, the ubiquitin ligase UBR5 was also found to 
interact with mouse Bub1b, showing a sequence coverage of 16% to 30%. UBR5, also 
known as EDD, might be involved in regulating the DNA damage checkpoints at G1/S, 
intra S-phase and G2/M (Henderson et al., 2006; Munoz et al., 2007; Ohshima et al., 
2007) but has not been reported to interact with mitotic checkpoint or kinetochore 
components. It also interacts with mouse Bub1 ( 
 
Supplemental table 2.2-2), but in the reciprocal purification of UBR5 we did not detect 
BUB1 or BUB1B, suggesting that UBR5 might be an unspecific interactor (data not 
shown). 
 
To evaluate the approximate stoichiometry of the most abundant interaction partners 
we compared the staining intensity of the most prominent silver stained bands. It is 
apparent that the Bub1b – BUB3 interaction exists in interphase and mitosis while 
CDC20 and CASC5 binding to Bub1b is strongly reduced in interphase. This change in 
complex composition is also partially reflected in the relative sequence coverage 
difference between the four different cellular states for CDC20 and CASC5 but also for 
the APC/C subunits and BUB1. This is consistent with earlier findings that the BUB1B 
checkpoint complex only interacts with APC/C and the kinetochore in mitosis (Chan et 
al., 1999; Jablonski et al., 1998). 
 
To confirm that the Bub1b complex composition changes between interphase and 
mitosis we tested whether changes in the levels of interacting proteins could be 
monitored by integrating the intensities of peptides in the MS1 chromatogram. A similar 
approach has been successfully taken to compare the complex composition of the 
transcription factor Fox03A before and after serum starvation (Rinner et al., 2007). 
However, we did not perform mixing experiments as described by Rinner et al. to 
minimise variations between chromatographic runs. So in order to normalise the levels 
between different runs and to also control for the different absolute peptide amounts 
present in each of the four different purifications (L, N, NB and NHM) we quantified six 
unmodified peptides of Bub1b in each run and calculated their change relative to Bub1b 
levels in condition N. This showed that Bub1b levels exhibit a relative change of 0.9 to 
1.6 fold in the tryptic digests with a relative standard deviation of 17% to 32% (Figure 
2.2-2 A). Thus, the observed variations between peptides of Bub1b in a single MS run 
are rather large so that for a relative change of an interactor to be significant it should 
be at least three fold. 
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We went on to quantify six peptides each for UBR5, BUB3, CASC5, CDC20, CDC27 and 
BUB1 in each tryptic digest of purifications from L, N, NB and NHM. The extent of 
variation between peptides of a single protein were similar to that detected for Bub1b 
and are indicated with the error bars (Figure 2.2-2 B). To assess the change of each 
protein relative to Bub1b we normalised the change to the N value and to Bub1b level 
changes and plotted it (Figure 2.2-2 B). It is apparent that while level changes of UBR5 
and BUB3 relative to Bub1b remain aroundonein all four samples, the levels of the other 
four interactors relative to Bub1b drop 4- to 5-fold in interphase (L) compared to all 
mitotic samples. Since this result is in line with the previous findings discussed earlier, 
this suggests that we can use quantitative information of detected peptides to monitor 
changes of interacting protein level relative to bait protein level.  
 
To further confirm this finding we carried out the same procedure on data obtained for 
immunopurified APC/C (Gieffers et al., 1999). The levels of CDC27 in all four runs were 
quantified and normalised to the amount of peptides in condition N and then compared 
to the normalised levels of BUB1B (Figure 2.2-2 C). BUB1B levels relative to CDC27 are 
reduced threefold in interphase compared to the mitotic samples. This is just outside of 
the standard deviation and thus confirms the validity of this approach to assess relative 
complex composition changes. Importantly, using this method we could semi-
quantitatively detect changes for interaction partners that were not visible on the silver 
stained gels and thus obtain comprehensive results for most of the identified interaction 
partners.  
 
We will employ a software tool called Superhirn (Mueller et al., 2007) which allows for 
automatic comparison of peptide levels between different chromatographic runs on FT 
and OT-MS instruments. Using Superhirn we plan to carry out quantitative analysis on 
the whole dataset. Given the well connected bait-prey networks (see below) we expect 
to obtain a comprehensive dataset of cell-cycle-dependent and possibly kinase inhibitor-
sensitive protein protein interactions. 
 
2.2.3.4 Phosphorylation site analysis of 16 complex purifications 
 
To determine the cell cycle-dependent phosphorylation pattern of each protein we 
followed a qualitative strategy. We compared the identified phosphorylation sites from 
samples L, N, NB and NHM and classified each site as either being present in log-phase 
cells only (I), in log and mitotic phase (I/M) or only in the mitotic phase (M). For a 
phospho-site to be classified as an interphase site a phospho-peptide had to be present 
in interphase and an unphosphorylated peptide corresponding to the region of the 
phosphorylation site had to be present in mitosis or vice versa for mitosis-specific 
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phospho-sites. To classify a phosphorylation site as sensitive to treatment with either 
BI4834 or Hesperadin a phospho-peptide had to be present in interphase and/or 
mitosis, absent in the inhibitor treated sample and an unphosphorylated peptide 
corresponding to the region of the phosphorylation site had to be present in the 
inhibitor treated sample. Where the phospho-peptide was absent from the BI4834-
treated sample we classified this site as sensitive to BI4834 (BI-sensitive), and where 
the phospho-peptide was absent from the Hesperadin-treated sample we classified this 
site as sensitive to Hesperadin (Hes-sensitive). Sites could also be sensitive to both 
inhibitor treatments (BI+Hes-sensitive). Finally, phospho-peptides could also be present 
in either or both of the inhibitor treated samples while an unphosphorylated peptide 
corresponding to the region of the phosphorylation site was present in all other 
samples. In this case the phosphorylation site was classified as inhibitor induced (BI-, 
Hes- or BI+Hes-induced).  
 
The purification of Bub1b yielded 46 identified phosphorylation sites in total. 
Purifications of other baits yielded from four up to 106 phosphorylation sites, depending 
mainly on the number of proteins per complex and protein size. In total we identified 
470 phosphorylation sites on 115 proteins (Figure 2.2-4 A; 99 unique proteins, 16 
proteins are present two to five times in different bait purifications). Of these 470 sites, 
15 were present exclusively in interphase, 125 were present in interphase and mitosis 
and 187 were present only in mitosis. A total of 143 sites could not be clearly assigned 
to one of these categories (ca. 66% of 143) or were induced by one or both of the 
kinase inhibitors (ca. 33% of 143). Of the mitotic phosphorylation sites, 41 were 
sensitive to the PLK1 inhibitor, 20 sites were sensitive to Hesperadin and 24 were 
sensitive to both inhibitors.  
 
Of the 327 sites that could be classified, almost 38% were present in interphase and 
mitosis (I/M). This was surprising as we assumed a much larger difference of total 
phosphorylation sites in interphase compared to mitosis. To determine whether this 
small difference represented the true distribution of phosphorylation between interphase 
and mitosis, we took a  closer look at phosphorylation sites we mapped on the APC/C 
and compared them to sites identified and characterised with phospho-specific 
antibodies previously (Kraft et al., 2003). Of the five mitotic phosphorylation sites 
validated with phospho-specific antibodies by Kraft et al., we identified four as being 
present in interphase and mitosis on the basis of our MS data. This indicated that at 
least a fraction of the I/M sites could actually be sites highly phosphorylated in mitosis 
and only phosphorylated at a basal level in interphase. Alternatively, contamination of 
interphase cells with mitotic cells may have led to detection of the phospho-peptides in 
the interphase sample. 
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Since we identified more than twice as many phosphorylation sites on the APC/C than 
Kraft et al. (106 as compared to 51), we assumed that this discrepancy is due to higher 
sensitivity of the FT-ICR mass spectrometer we used. However, this finding indicates 
that the qualitative method we use for phospho-site classification might produce a 
number of false negative hits, i.e. we might miss sites that are cell-cycle-dependent or 
inhibitor-sensitive because their fold change is within the dynamic range of the FT-ICR 
MS machine we are using. This finding prompted us to evaluate whether we could also 
analyse our phosphorylation site data semi-quantitatively to detect variations of 
phosphorylation levels in our protein purifications. 
 
2.2.3.5 Identification and validation of WAPAL and Bub1b phosphorylation 
sites 
 
We first applied the semi-quantitative peptide analysis to the cohesin regulator and 
interactor WAPAL (Kueng et al., 2006). WAPAL was immunoprecipitated using a 
polyclonal rabbit antibody (Kueng et al., 2006) from L, N, NB and NHM cells and its 
phosphorylation sites mapped and classified. Semi-quantification was done by 
measuring the levels of six WAPAL peptides in all three proteolytic digests (Figure 2.2-2 
E; trypsin (Try), chymotrypsin (ChT) and subtilisin (Sub)). Subsequently, all detected 
phospho-peptides for a single phosphorylation site in all three digests were also 
quantified and their level change, normalised to N and relative to WAPAL, was 
calculated. In total 19 phosphorylation sites were detected throughout the WAPAL 
protein. To quantitate and classify them we had to test which fold change would 
represent a biologically significant difference in phosphorylation level. Since there is 
usually only one distinct peptide detected for each phosphorylation site per digest, it is 
not possible to assess the standard deviation of the fold change as was done for the 
relative complex stoichiometry analysis above. So in order to determine which fold 
change in phospho-peptide levels would correspond to a significant and biologically 
informative phosphorylation change, we independently validated the results obtained by 
semi-quantitation on the peptide level with phospho-specific antibodies. For three 
phospho-peptides we could quantitate distinct peptides in each of the three digests. 
Figure 2.2-2 E shows the levels relative to WAPAL for the sites on S465, S528 and 
S1154 change from N to NHM between 1.25 and 0.5 fold (0.25 for the Sub digest of the 
S1154 peptide). The level change relative to WAPAL from N to L and N to NB was much 
more pronounced, between 0.2 and 0.05 fold, i.e. there was a 5 to 20 fold reduction of 
the quantified phospho-peptides. This change was largely consistent for three distinct 
peptides per phospho-site quantified in the three different proteolytic digests. 
 
To test if these five- to twenty-fold changes were significant we generated three 
phospho-specific polyclonal peptide antibodies (pWAPAL_S465, pWAPAL_S528 and 
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pWAPAL_S1154). These antibodies were tested on WAPAL immunoprecipitated from 
HeLa cell extracts of L, N, NB or NHM, separated on SDS-PAGE and transferred to a 
membrane for western blotting. All three of the tested antibodies confirmed the results 
obtained by MS and semi-quantitation (Figure 2.2-3 A and C, Supplemental figure 2.2-2 
B and data not shown). This led us to conclude that relative changes of at least five fold 
are needed to confidently classify a phosphorylation site as absent in a given sample.  
Consequently we classified the 19 phosphorylation sites of WAPAL (Figure 2.2-2 E) and 
obtained six sites present in interphase and mitosis, ten sites present only in mitosis 
and three sites that could not be classified. Of the ten mitotic sites seven were BI-
sensitive and one BI- and Hes-sensitive. In comparison to the qualitative analysis we 
performed on the WAPAL phosphorylation sites we could retrieve a more complete 
picture of the cell-cycle and kinase-dependent phosphorylation changes. Of the 19 total 
sites, two that had not been classified were now classified and three sites which had 
been classified as I/M were now classified as M (Figure 2.2-2 E, e.g. S465). 
 
Using this semi-quantitative method we could now further investigate the 
phosphorylation sites identified on Bub1b. The levels of six Bub1b peptides were 
quantified in all three proteolytic digests and the phospho-peptide level change 
normalised to N was calculated relative to the Bub1B level changes. Based on these 
quantifications the phospho-sites for Bub1b were classified and summarised in a 
schematic representation of Bub1b (Supplemental figure 2.2-2 E). In total four sites 
were present in interphase and mitosis, seven were mitosis-specific, one of the mitotic 
sites was BI-sensitive and three sites could not be clearly classified. These three 
phosphorylation sites were reduced by approximately four fold compared to N only in L 
(S360) or in L and NHM (T601 and T613/S620/S621). Since this is close to the 
borderline for classifying these sites as absent in the given cellular states they were 
marked as unclassified. Despite this relatively large standard deviation between 
peptides, we could achieve a more comprehensive data set for the Bub1b 
phosphorylation sites. Three sites that had not been classified or were only present in a 
single state were now classified over all four states and three sites which had been 
classified as I/M were now classified as M. 
 
In summary the semi-quantitative analysis of phosphorylation sites yielded a more 
complete set of data and abolished a number of previously false negative assignments 
(i.e. mitosis-specific sites had been classified as being present in interphase and 
mitosis). However, further testing of the label free quantification method is necessary to 
achieve more accurate classification of the phosphorylation sites. In particular automatic 
analysis using the Superhirn software described above will allow more sophisticated 
statistical analysis to better define the confidence threshold. In addition, control 
experiments to estimate the run to run variation and dynamic range of the nano HPLC 
and FT-MS instruments will improve the data confidence. 
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2.2.3.6 MS data validation using phospho-specific antibodies 
To better estimate the reliability of our data we generated a panel of phospho-specific 
polyclonal peptide antibodies against phosphorylation sites that were classified as either 
I/M, M, M and BI-sensitive as well as M and Hes-sensitive. The phospho-antibodies were 
then tested on either cell extracts from L, N, NB and NHM samples or on proteins that 
were immunoprecipitated from these samples. Figure 2.2-3 A shows results obtained 
with four of these antibodies. When tested on PDSBB immunoprecipitates the antibody 
pPDS5B_S1388 recognised PDS5B in all four states, as was predicted from the MS 
results. This phosphorylation site has also been detected in two independent large scale 
phosphoproteomics studies, however, without any information regarding the cell cycle 
dependence (Beausoleil et al., 2004; Olsen et al., 2006). The pPDS5B_S1417 antibodies 
gave similar results (Supplemental figure 2.2-2 A). An antibody recognising pS1237 on 
immunoprecipitated PDS5A confirmed that this phosphorylation site is only present on 
mitotic PDS5A and is not sensitive to the PLK1 inihibitor nor to Hesperadin.  
 
We generated seven antibodies against phosphorylation sites classified as PLK1-
inhibitor-sensitive sites (of a total of 41 sites) on the cohesin subunits RAD21, STAG2, 
WAPAL and PDS5A (Figure 2.2-3 C). Two sites on RAD21 were classified as present in 
I/M and BI-sensitive. These two sites (pS153 and pS175) were detected in previous 
phosphorylation site mapping experiments comparing S-phase and miotic HeLa cells 
(Hauf et al., 2005). It was shown that pS175 was present in S-phase and mitosis while 
pS153 was only found in mitosis. The two phospho-antibodies we generated 
(pRAD21_S175 and p RAD21_S153) showed that these sites were present in mitosis, 
confirming earlier results by Hauf et al. and confirmed our MS data that both sites were 
BI-sensitive (Supplemental figure 2.2-2 B). The three WAPAL phospho-antibodies 
confirmed the results obtained by qualitative and quantitative MS-analysis as described 
earlier (Figure 2.2-3 A and C, Supplemental figure 2.2-2 B and data not shown). The 
phospho-PDS5A antibody directed against a mitotic and BI-sensitive site recognised 
immunoprecipitated PDS5A equally well in N, NB and NHM but not in interphase, 
contradicting our finding that this site was BI-sensitive but confirming its mitosis-
specificity (Supplemental figure 2.2-2 B).  
 
In total 20 sites were classified as Hesperadin-sensitive. We tested four of them by 
generating phospho-specific antibodies. The Hesperadin-sensitive site on INCENP 
(S446) and the site on NUP85 (T91) could be confirmed by phospho-specific antibodies 
(Figure 2.2-3 A and C and Supplemental figure 2.2-2 C), while the site on NCAPH T1388 
or T1389 could only be confirmed as a mitotic site but not as Hes-sensitive. 
 
To summarise, using phospho-antibodies we have tested four sites classified as I/M of 
which two were I/M and two were M. Of the nine tested M sites, nine were confirmed by 
antibodies to be mitosis-specific. We could further show that six out of the seven sites 
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classified as BI-sensitive were correct and two out of the three Hesperadin-sensitive 
sites could be confirmed by phospho-specific antibodies. These results suggest that our 
MS-based method is an approach which identifies cell cycle- or kinase-regulated 
phosphorylation sites with reasonable accuracy. It is important to note that some sites 
we classified as present in interphase and mitosis are actually mitosis specific (e.g. 
S465 on WAPAL, comparison to Kraft et al 2005). This indicates that we might miss 
sites whose levels change within the dynamic range of the FT-ICR-MS between states. 
The number of kinase inhibitor and mitosis-specific sites we find might therefore be an 
underestimate. 
 
It was previously shown that nocodazole arrest is a valid method to identify 
phosphorylation sites that are also present in unperturbed mitosis (Kraft et al., 2003) 
and that have a functional significance in prometaphase phosphoregulation (Hauf et al., 
2005). We nevertheless wanted to address whether the phosphorylation sites we 
identified from nocodazole arrested cells were only generated in cells arrested for a long 
time in prometaphase. We tested some of the generated phospho-antibodies on western 
blots prepared from cell extracts of cells synchronised without long nocodazole 
treatment. Using a double thymdine arrest we blocked cells in early S-phase and 
released them into fresh medium to allow progression into G2-phase. Cells were 
harvested four h after release (G2), ten h after release by mitotic shake off (SO) or 
were first treated with nocodazole seven h after release and harvested three h later 
(sN) or nocodazole treated cells were treated for the last two h of the three h mitotic 
arrest with either BI4834 (sNB) or Hesperadin and MG132 (sNHM). Cell extracts were 
prepared, separated by SDS-PAGE and analysed by western blotting using antibodies 
against Cyclin B (CCNB1), phosphorylated S10 on Histone H3 (H3S10ph), Histone H3 
(H3) and the APC/C subunit CDC27 to control for the cell cycle stage (Figure 2.2-3 B). 
CCNB1 levels were similar in all conditions, indicating that cells were in G2/M. Serine 10 
phosphorylation on Histone 3 was high in SO cells but much higher in sN and sNB, 
indicating that mitotic cells were enriched in SO but mitotic phosphorylation much 
higher in sN and sNB. Judging by the phosphorylation shift of CDC27 (Kraft et al., 2003; 
Peters et al., 1996) all cells in sN, sNB and sNHM were mitotic.  Probing these extracts 
with the phospho-specific antibody pSTAG2-S1224 (Kueng et al., 2006) showed that 
this phosphorylation site was also present in cells isolated by mitotic shake off. A similar 
result was obtained using the antibody pRAD21_S175 (Supplemental figure 2.2-2 D) 
and two other phospho-specific antibodies (pRAD21_S153 and pWAPAL_S465, data not 
shown). In agreement with earlier studies (Hauf et al., 2005; Kraft et al., 2003) these 
results indicate that the phosphorylation pattern detected in prolonged nocodazole 
arrests resembles the situation of cells in an unperturbed mitosis. We can not exclude, 
however, that the relative level of phosphorylation is much higher in prolonged 
nocodazole arrests. 
 
69 
2.2 Phosphorylation site mapping manuscript 
Our analysis of phosphorylation sites that are sensitive to treatments with PLK1 or 
AURKB inhbitors might detect indirect phosphorylation changes on proteins that are 
substrates of a kinase downstream of PLK1 or AURKB. Since it is not possible to 
measure direct phosphorylation events in living cells we tested whether two of the 
detected BI-sensitive phosphorylation sites could also be generated directly by PLK1 in 
an in vitro kinase assay. We purified STAG2 or WAPAL by immunoprecipitation from 
interphase cells and incubated it with recombinant PLK1, ATP and PLK1 inhibitor as 
indicated (Figure 2.2-3 D). The phosphorylation site S1224 on STAG2 as well as the 
phosphorylation site S465 on WAPAL are phosphorylated by PLK1 directly, suggesting 
that these sites might be direct phosphorylation sites also in vivo. 
 
We further tested whether the phospho-specific antibodies could recognise their 
epitopes in immunofluorescence microscopy (IF) of HeLa cells. To do this we treated 
HeLa cells grown on coverslips for 30 minutes with PLK1-inhibitor prior to fixation and 
stained them with the phospho-antibody and an antibody against the unphosphorylated 
protein. So far, only the STAG2_pS1224 antibodies were of sufficient specificity to be 
useful for IF experiments. These antibodies stain chromatin associated STAG2 in early 
prophase and soluble cohesin in prometa- and metaphase while the signal is reduced in 
telophase and not present in cytokinesis, interphase and S-phase (Figure 2.2-3 E). The 
antibody also stains two structures specifically in mitosis which might represent the 
centrosomes. Since control staining with STAG2 antibodies did not stain these two 
structures, we assume that this signal of STAG2_pS1224 antibodies results from a cross 
reaction. Most importantly, the signal is completely abolished after treating the cells for 
30 minutes with the PLK1 inhibitor (Figure 2.2-3 E) or after 24 siRNA depletion of PLK1. 
This shows also in immunofluorescence that the phosphorylation site on S1224 of 
STAG2 is dependent on PLK1. Whether loss of this phosphorylation site is responsible 
for the cohesin enrichment on mitotic chromatin after PLK1 inhibition (Hauf et al., 2005) 
remains to be seen. Phospho-mutants of STAG2 suggested that all phosphorylation sites 
need to be mutated to cause a similar cohesin enrichment phenotype as is seen with 
PLK1 inhibition. However, mutants of only S1224 or S1224 together with the second BI-
sensitive site on STAG2 (S1091) have not been tested. 
 
In conclusion, we have shown that a large fraction of the phosphorylation sites we 
analysed by phospho-specific antibodies confirmed our MS results. In addition, the 
phosphorylation sites mapped in prolonged nocodazole arrest are not likely to be 
different from the phosphorylation sites generated during an unperturbed mitosis and at 
least two of the BI-sensitive sites can be directly generated by PLK1 in vitro. We are 
thus confident that our experimental approach finds true mitotic phosphorylation sites 
and true PLK1 and AURKB-dependent phosphorylation sites.  This allows us to use our 
data to define novel potential substrates of PLK1 and AURKB which might help us to 
understand the essential roles of these two kinases in mitosis. 
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2.2.3.7 Potential novel PLK1 and AURKB substrates 
 
We identified in total 39 BI-sensitive phosphorylation sites on 25 proteins, 23 Hes-
sensitive phosphorylation sites on 21 proteins and 26 sites that are sensitive to both 
inhibitors on a total of 13 proteins (Figure 2.2-4 B and C). We also find ten proteins that 
have both, PLK1 inhibitor-sensitive sites and Hesperadin-sensitive sites. Of the 25 
potential PLK1 substrates, eight have been described previously, of the 21 potential 
AURKB substrates, four have been described previously.  
 
Compared to the previously known PLK1 substrates that were included in our data set 
we also found ANAPC1 (Kraft et al., 2003), Bub1 (Qi et al., 2006), Bub1b (Elowe et al., 
2007), CDC27 (Kraft et al., 2003), Kif23 (Liu et al., 2004), PLK1 (Kelm et al., 2002), 
RAD21 and STAG2 (Sumara et al., 2002) but not ANAPC4, ANAPC7 (Kraft et al., 2003) 
and CyclinB (Jackman et al., 2003; Toyoshima-Morimoto et al., 2001). Most of these 
known substrates, with the exception of BUB1B, have been found using in vitro kinase 
assays with recombinant kinases or mitotic extracts of HeLa cells or Xenopus eggs. In 
few cases the actual phosphorylation sites were mapped using amino acid substitution 
or MS.  
 
We found that the cohesin subunit RAD21 is phosphorylated in vivo by PLK1 on four 
sites (S134/S138, S175, S153 and S545) and another cohesin subunit, STAG2, is 
phosphorylated on two sites (S1091, S1224). This is consistent with earlier findings that 
phosphorylation of RAD21 by PLK1 enhances its cleavage by separase (Hauf et al., 
2005) and that STAG2 phosphorylation, presumably by PLK1, is required for the bulk of 
cohesin to dissociate from chromatin in early mitosis (Hauf et al., 2005). This latter 
effect, the so-called prophase pathway (Waizenegger et al., 2000), can only be partially 
inhibited by making STAG2 unphosphorylatable or by inhibiting PLK1 activity. A full 
block in this pathway is observed when the cohesin interaction partner WAPAL is 
depleted. We could now show that WAPAL is highly phosphorylated in mitosis, that 
seven out of its nine mitotic phosphorylation sites are sensitive to Plk-inhibitor 
treatment (Figure 2.2-2 E) and that at least one of these inhibitor-sensitive sites can be 
directly generated by PLK1 (Figure 2.2-3 D). This is the only protein we found where the 
majority of mitotic phosphorylation sites is dependent on PLK1. In the future it will be 
interesting to test if WAPAL phosphorylation by PLK1 has a role in the prophase 
pathway of cohesion dissociation from chromatin. 
 
Of the known AURKB substrates we find AURKB (Yasui et al., 2004), INCENP (Honda et 
al., 2003), NCAPD2 (Lipp et al., 2007) but not NDC80 (Cheeseman et al., 2006; DeLuca 
et al., 2006). Interestingly, we find a Hesperadin-sensitive site on BUB1B in purification 
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of MAD2L1 since it has been speculated previously that BUB1B might be an AURKB 
substrate. Data from AURKB inhibition experiments using the small molecule inhibitor 
ZM447439 showed that BUB1B hyperphosphorylation is abolished when AURKB is 
inhibited already before mitosis (Ditchfield et al., 2003) but not when it is inhibited 
during mitosis (Morrow et al., 2005). We could now find that at least one site, T354, on 
human BUB1B is dependent on AURKB during mitosis. Experiments in yeast show that 
phosphorylation of the BUB1B homolog Mad3 by Ipl1p – the AURKB homolog – is 
required for the spindle checkpoint response to the lack of tension (King et al., 2007). 
We are planning to mutate the identified site in LAP-tagged BUB1B to test if this 
function is conserved in human. 
 
In summary, we have detected 17 novel potential PLK1 and 18 novel potential AURKB 
substrates at the kinetochore, the chromosome, the centrosome and the mitotic spindle.  
Further investigation by mutational analysis will reveal the function of these potential 
substrates and might help advance our understanding of the role of PLK1 at these 
mitotic structures. 
 
2.2.3.8 Initial bioinformatic analysis of PLK1-dependent phosphorylation 
sites 
Our approach of mapping PLK1- and AURKB-dependent phosphorylation sites in cells 
lead to detection of potential physiological substrates of these kinases, two of which we 
could show to be direct substrates in vitro. The consensus sequence for PLK1 has been 
determined in an in vitro kinase assay using peptides as model substrates (Nakajima et 
al., 2003). Some, but not all of the identified PLK1 phosphorylation sites on its 
substrates match this proposed consensus [DE]-X-[ST]-Φ-X-[DE] (Φ = hydrophobic 
amino acid). Several of those sites have been determined in vitro (Supplemental table 
2.2-1, (Barr et al., 2004)). Since our data represents the first systematic identification 
of potential PLK1 phosphorylation sites in cells, we wanted to test to what extent these 
sites correspond to the proposed consensus sequence.  
 
Initial sequence analysis surrounding the PLK1 inhibitor-sensitive phosphorylation sites 
was done as follows: the occurrence of Glutamate (E) and Aspartate (E) at the position 
-3, -2 or -1 relative to the phosphorylation site was counted and compared to the 
expected occurrence at random (11%). At the +1 and +2 positions the occurrences of 
hydrophobic residues (Φ = I, L, V, M, F, C) was counted and compared to the expected 
occurrence at random (26%). The only enrichment detectable was that of D and E at 
the -2 position (3.8 fold enrichment) which is partially consistent with the consensus 
sequence [DE]-X-[ST]-Φ-X-[DE] (as determined by in vitro kinase assays (Nakajima et 
al., 2003). More detailed analysis might show whether this weak correlation is due to a 
more relaxed consensus sequence in vivo, i.e. conserved residues could be distributed 
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over several positions, or whether our data set contains phosphorylation sites that are 
not direct targets of PLK1. In addition it will also be interesting to test whether these 
proteins that carry PLK1 inhibitor-sensitive phosphorylation sites also contain a potential 
PBD binding site and, if yes, whether this is also phosphorylated. 
 
2.2.4 Discussion 
The key mitotic roles of PLK1 and AURKB are reasonably well understood, but the 
search for their substrates and ultimately their substrate’s function still lags behind. In 
an effort to develop a systematic assay for the detection of PLK1 and AURKB substrates, 
we established a protocol to purify candidate substrate complexes from HeLa cell and 
detected kinase-dependent phosphorylation sites by combining small molecule inhibitors 
of PLK1 (Lenart et al., 2007; Steegmaier et al., 2007) and AURKB (Hauf et al., 2003) 
and MS. We could show that this protocol successfully detects known PLK1 substrates 
like RAD21 (Hauf et al., 2005) and known AURKB substrates like INCENP (Honda et al., 
2003). At the same time we could identify additional phosphorylation sites dependent 
on AURKB on INCENP and finally pinpoint the phosphorylation sites on RAD21 that are 
PLK1-dependent. In addition we could confirm two PLK1 substrates, the cohesin 
complex members STAG2 and WAPAL, and one novel AURKB substrate, NUP85, with 
phospho-specific antibodies. This finally led to the identification of 17 novel potential 
substrates each for PLK1 and AURKB, approximately doubling the number of substrates 
that are known for these two kinases. In addition we have identified the 
phosphorylation sites on each substrate that are dependent on PLK1 or AURKB, which 
has not been the case for most of previously identified substrates. In particular, only 
one in vivo PLK1 site had been previously established within the eight known PLK1 
substrates we tested (BUB1B S676 (Elowe et al., 2007)). Considering the usual 
workflow of mutational analysis, in vitro kinase assays and finally generation of a 
phospho-specific antibody to show that a single phosphorylation site is kinase-
dependent in vivo, our approach yields results faster and can be applied on a more 
systematic level. With the availability of a high throughput pipeline for BAC tagging 
(Poser et al, 2008) a large collection of candidate complexes is available for further 
analysis. 
 
We could show that the analysis of phospho-mapping as well as interaction mapping 
data can be further improved by label-free semi-quantitative analysis of proteolytic 
peptides in the mass spectrometer. Semi-quantitative analysis of phospho-peptides 
reduced false negative identification of phosphorylation sites in the Bub1b and WAPAL 
phospho-site analysis and thus improved the detection of mitosis-specific and inhibitor-
sensitive sites. In addition, analysis of the relative complex stoichiometry of Bub1b 
recapitulated the mitosis-specific formation of a mitotic checkpoint-kinetochore complex 
(Chan et al., 1999; Jablonski et al., 1998) including the recently identified CASC5. It is 
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thus conceivable that quantification of the entire cell cycle- and inhibitor-dependent 
data set would provide an informative data set about complex stoichiometry of the 
selected baits. 
 
A number of the identified substrates could play important role in processes regulated 
by PLK1 and or AURKB on the different cellular structure that we probed: the 
kinetochore/mitotic checkpoint complex, the spindle/centrosome and the mitotic 
chromosome. 
 
For example, it was initially shown that the mitosis-dependent phosphorylation shift of 
BUB1B is abolished when PLK1 or AURBK is inhibited or depleted before cells enter 
mitosis (Ditchfield et al., 2003; Matsumura et al., 2007) but not when PLK1 
(unpublished results) or AURBK (Ditchfield et al., 2003) are inhibited during mitosis. 
Whether this was a due to direct phosphorylation by either of the two kinases was not 
clear. It was later shown that mutation of the potential PBD binding motif of BUB1B 
inhibited the formation of proper kinetochore microtubule interactions and caused 
chromosome congression defects as well as a delay in prometaphase. Subsequent 
identification of a PLK1-dependent phosphorylation site on S676 showed that this site is 
selectively phosphorylated when kinetochores are attached but not under tension in 
prometaphase, indicating that PLK1 directly phosphorylates BUB1B and that this 
phosphorylation is necessary to mediate kinetochore microtubule interactions but not to 
fulfil its checkpoint function (Elowe et al., 2007). It was not shown whether S676 was 
the only PLK1 phosphorylation site on BUB1B or whether mutation of the PBD binding 
motif abolished the phosphorylation of BUB1B. We found a site adjacent to S676, S670, 
phosphorylated on BUB1B that copurified with CDC27 and Mad2l1. This site was 
mitosis-specific but not sensitive to inhibitor treatment. On Bub1b we do not find a 
peptide covering the sequence surrounding S676 but we find that T47 is sensitive to 
PLK1 inhibitor treatment, indicating that a number of sites on BUB1B might be 
phosphorylated by PLK1 in vivo.  
 
How AURBK might be involved in BUB1B phosphorylation on the kinetochore is not fully 
understood. Inhibition of AURKB using Hesperadin or ZM447439 inhibits localisation of 
BUB1B to the kinetochore in prometaphase (Ditchfield et al., 2003; Hauf et al., 2003) 
and AURKB inhibition leads to immediate override of a taxol induced arrest or a three h 
delayed override of a nocodazole induced arrest (Hauf et al., 2003). A study in yeast 
showed that phosphorylation of Mad3p (the yeast homolog of BUB1B) is required for 
checkpoint activation in response to loss of tension at the kinetochores but not in 
response to loss of attachment (King et al., 2007). This is consistent with the immediate 
override of a taxol arrest which mimics a loss of tension situation compared to the 
delayed override of nocodazole arrested cells. We have identified T354 on BUB1B to be 
Hesperadin-sensitive and S733 to be sensitive to the PLK1-inhibitor and Hesperadin. 
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Phospho-mutants of these sites together with the PLK1-dependent sites could be used 
to delineate whether the phosphorylation of BUB1B by PLK1 and AURKB is 
interdependent. Based on the recent finding that for AURKB to efficiently phosphorylate 
its centromeric substrate MCAK, MCAK needs to first be phosphorylated by PLK1 
(Rosasco-Nitcher et al., 2008), one could speculate that a similar temporal regulation of 
phosphorylation is also in place for BUB1B. This would explain why inhibition of PLK1 
and AURBK abolished the BUB1B mitotic phosphoshift and why we detect a 
phosphorylation site which perfectly matches the AURKB consensus sequence 
(Cheeseman et al., 2002) that is sensitive to treatment with the PLK1 inhibitor and 
Hesperadin. 
 
We have also detected three PLK1-dependent and six AURKB-dependent sites out of 49 
total phosphorylation sites on the NUP107-NUP160 complex. A previous phosphorylation 
mapping study has identified twelve sites in total, seven of which we could also detect 
(Glavy et al., 2007).The NUP107-NUP160 subcomplex of the NPC localises to the 
kinetochore during mitosis (Belgareh et al., 2001) and has been proposed to be 
involved in bipolar spindle formation (Orjalo et al., 2006). Detailed evidence of its 
mitotic function, however, is lacking. It is conceivable that components of the NUP107-
NUP160 complex need to be phosphorylated at the kinetochore to fulfil their functions. 
 
Analysis of the centrosomal γ-tubulin ring complex (γ-TuRC), which is required for 
microtubule nucleation and mitotic spindle organisation, has detected three BI-sensitive 
sites, three Hes-sensitive sites and one site sensitive to both inhibitors out of the 20 
total sites identified on the complex. It is particularly interesting to note that TUBG1 
contains one phosphorylation site that is dependent on PLK1. For a long time it has 
been known that depletion of PLK1 leads to a block in centrosome maturation, i.e. the 
accumulation of TUBG1 on centrosomes in mitosis (Lane and Nigg, 1996; Lenart et al., 
2007; Sumara et al., 2004). It is, however, not clear how this process is regulated on a 
molecular basis. Depletion of the p58 variant of CDK11 by RNAi blocks centrosome 
maturation but also leads to a loss of PLK1 and AURKA from the centrosome (Petretti et 
al., 2006). The ninein like protein Nlp localizes to centrosomes in interphase but is 
displaced from centrosomes by PLK1 phosphorylation at the onset of mitosis (Casenghi 
et al., 2005; Casenghi et al., 2003). A non-phosphorylatable mutant of Nlp remains at 
the centrosome in mitosis and prevents centrosome maturation. It was later shown that 
this failure in centrosomal dissociation is most likely due to the fact that PLK1 
phosphorylation of Nlp leads either to a defect of Nlp transport to the centrosome by 
dynein-dynactin or to inhibition of Nlp binding to the centrosome (Casenghi et al., 
2005). It is thus likely that additional activating events are necessary to recruit extra 
TUBG1 to the centrosome in mitosis. By generating an S131A mutant of TUBG1 we will 
test whether direct phosphorylation of TUBG1 is required for centrosome maturation. 
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Of the chromosomal proteins it was especially interesting to look at the cohesin complex 
members. We know from previous studies that phosphorylation of RAD21 by PLK1 is 
required for efficient cleavage by Separase and that phosphorylation of STAG2, 
presumably by PLK1 is required for cohesin’s efficient removal from chromosome arms 
in prophase (Hauf et al., 2005), the so-called prophase pathway (Waizenegger et al., 
2000). Even though the mitosis-specific phosphorylation sites of RAD21 and STAG2 
have been identified (Hauf et al., 2001), it was not clear which of these are dependent 
on PLK1. We could identify four PLK1 sites on RAD21 and two sites on STAG2, two of 
the RAD21 sites and one STAG2 site were further validated using phospho-specific 
antibodies. In addition to the previous phosphorylation analysis we could now also 
identify phosphorylation sites on STAG1, PDS5A, PDS5B and WAPAL. The most striking 
result was that WAPAL, which is essential for the prophase pathway, is highly 
phosphorylated in mitosis and that seven out of the nine mitosis-specific 
phosphorylation sites are dependent on PLK1. One speculative explanation of this 
finding is that PLK1 indeed functions upstream of WAPAL in the prophase pathway and 
that WAPAL needs PLK1 phosphorylation to be fully active in prophase when it is 
involved in the removal of cohesin from chromatin. This would be the simplest 
explanation why PLK1 inhibition leads to a mild defect in the prophase pathway and why 
phosphorylation of STAG2 alone is not sufficient to remove it from chromatin in 
prophase (Kueng et al., 2006). Mutational analysis of the identified phosphorylation 
sites on WAPAL should be able to test this speculative hypothesis. 
 
To conclude, the dataset we generated presents a basis for further research of the 
functions of PLK1 and AURKB at the centrosome, the centromere, the spindle and in 
chromosomal architecture. In addition, further application of this method to more 
candidate substrates in mitotic protein complexes will likely yield more detailed idea of 
which proteins are the key targets of PLK1 and AURKB and will ultimately lead to a 
better understanding of kinase substrate interactions in mitosis. 
 
2.2.5 Materials and methods 
2.2.5.1 Cell culture 
HeLa cells were grown on Nunc cell culture dishes in DMEM supplemented with 10% 
FCS, 0.2 mM L-glutamine, 100 U/ml penicillin, and 100 µg/ml streptomycin. For 
transfected cell lines the medium was supplemented with 500 µg/ml G418. Mitotic cells 
were arrested for a total of 18 h using 100 ng/µl nocodazole. Inhibition of PLK1 was 
achieved using either 250 nM of BI4834 or 100 nM of BI2536 (Lenart et al., 2007; 
Steegmaier et al., 2007) during the last two h of nocodazole arrest. AURKB was 
inhibited using 100 nM Hesperadin (Hauf et al., 2003) in combination with 10 µM 
MG132 during the last two h of nocodazole arrest. For BI4834 characterisation, RAD21-
9x MYC cells (Hauf et al., 2005) were induced by 2 µg/ml doxycycline for three days. 
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2.2.5.2 Protein extraction and purification 
Protein extracts for immunopurifications using antibodies against the endogenous 
proteins were prepared using IP-buffer (20 mM Tris-HCl, pH 7.5; 150 mM NaCl, 5 mM 
EDTA, 20 mM β-glycerophosphate, 10 mM NaF, 10% glycerol, 0.1% NP-40, 1 µM 
okadaic acid, 0.2 mM NaVO4, 1 mM DTT and protease inhibitor mix (PIM: leupeptin, 
chymostatin and pepstatin at 10 µg/ml). Extracts from cell treated with either BI2536, 
BI4834 or Hesperadin/MG132 also contained these components at the concentrations 
given. 
 
Endogenous proteins were immunopurified using antibodies described in the antibody 
section. After immunoprecipitation using antibodies crosslinked with DMP (Harlow and 
Lane, 1988) to affiprep beads (Bio-Rad, USA), purified complexes were washed 
extensively in 100x bead volume of IP buffer for a total of 1 h at 4°C. For mass 
spectrometric analysis the last three washing steps were carried out in IP-buffer without 
detergent. 
 
FLAG-purification was done from cells expressing either NCAPH-GFP-FLAG fusion or 
NCAPH2-GFP-FLAG fusion proteins (Hirota et al., 2004). Cells were extracted using IP-
buffer B (50 mM HEPES-KOH, pH 7.5; 5 mM EDTA, 150 mM KCl, 10% glycerol, 1% 
Triton X-100, 20 mM beta-glycerophosphate, 10 mM NaF, 10 mM Na-pyrophosphate, 
1 µM okadaic acid, 0.1 mM PMSF, 1 mM Na3VO4, 1 mM DTT and PIM). After 
immunoprecipitation using FLAG-M2 beads (Sigma-Aldrich), beads were washed 
extensively in IP-buffer B (Triton was substituted by 0.5% NP-40), then three times 
with 50 mM HEPES-KOH, pH 7.5, 5 mM EDTA, 150 mM KCl, 10% glycerol and finally 
three times with 150 mM KCl. 
 
LAP-purification was done as described (Poser et al., 2008). All buffers additionally 
contained 1 µM okadaic acid and either BI2536, BI4834 or Hesperadin/MG132 when 
proteins were purified from inhibitor-treated cells. Purified proteins were eluted from 
beads using 0.2 M glycine pH 2.0 and the eluate neutralised with 1/10 volume 1.5 M 
Tris pH 9.2. 
 
2.2.5.3 MS and data analysis 
Elution and in-solution digest 
Eluted and neutralised proteins were subjected to in-solution digest using trypsin, 
chymotrypsin, subtilisin or GluC as described previously (Kraft et al., 2003). 
Approximately equal amounts of digested peptide mixtures were analysed by MS. 
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MS analysis 
Equipment - All nano HPLC separations were performed using UltiMate 3000 Nano-LC 
system (Dionex Benelux, Amsterdam, The Netherlands) equipped with a  trap column 
(PepMap C18, 300 μm ID x 5mm length, 3 μm particle size, 100 Å pore size, Dionex 
Benelux) for sample desalting and concentration and an analytical column (PepMap C18, 
75 μm ID x 150 mm length, 3 μm particle size, 100 Å pore size, Dionex Benelux) for the 
chromatographic separation. Loading buffer used contains 0.1% trifluoroacetic acid 
(Pierce). For chromatographic separation mobile phase A contains 5% acetonitrile 
(Merck, Darmstadt, Germany) and 0.1% formic acid (Merck) and mobile phase B 80% 
acetonitrile and 0.08% formic acid. 
Mass spectrometric analyses were conducted on a hybrid linear ion trap/Fourier 
transform ion cyclotron resonance (FTICR) mass spectrometer (LTQ-FT Ultra, 
ThermoElectron, Bremen, Germany) with a 7-Tesla superconducting magnet. The mass 
spectrometer was equipped with a nano-electrospray ionization source (Proxeon 
Biosystems, Odense, Denmark). Metal coated nano ESI needles were used (New 
Objective, Woburn, MA, USA).  
 
LC separation - Samples were loaded onto the trap column at a flow rate of 20 µL/min 
loading buffer and were washed for ten minutes. Afterwards the sample was eluted from 
the trap column and separated on the separation column with a gradient from 20% to 
50% mobile phase B in 180 minutes at a flow rate of 300nL/min. 
 
MS detection – Eluting peptides were ionized with a spray voltage set to 1.5 kV. Fullscan 
(400-1800 m/z) was conducted in the ICR cell yielding a survey scan with resolution of 
100.000 and a typical mass accuracy < 2ppm. CAD fragmentation and spectra 
acquisition were carried out in the linear ion trap using a multi stage activation (MSA) 
method. The target values of the automatic gain control (AGC) were set to 10,000 for 
CAD in the ion trap, and to 500,000 for FT-ICR fullscan spectra. In the applied MS 
method fragmentation was performed on the five most intense signals of the survey 
scan using MSA of the neutral loss of phosphoric acid. Singly charged ions were 
excluded for precursor selection and precursors of MS² spectra acquired in previous 
scans were excluded for further fragmentation for a period of 3 min whereas the 
exclusion mass tolerance was set to 5 ppm.  
 
Data base search – Acquired data (Xcalibur RAW-file) were converted into Mascot 
generic files using Mascot Daemon (Matrix Science, London, UK).  For peptide 
identification a database search against a custom database containing the human KBMS 
database (5.0.20050304, 187752 sequence entries, Applied Biosystems) and all 
relevant mouse bait sequences was carried out using Mascot (Matrix Science, London, 
UK; version 2.2.0). The following parameters were used for the database search: 
carboxymethylation (+58.0055 u) of cysteine was set as fixed and oxidation (+ 15.9949 
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u) of methionine and phosphorylation (+79.966331 u) as variable modification; 
enzymatic cleavage was specified to either Trypsin, Chymotrypsin or no specificity (for 
Subtilisin digests). Mass tolerances of the parent ion and the fragments were set to 10 
ppm and 0.80 Da, respectively. Unphosphorylated peptides with a Mascot score greater 
than 20 were kept and used to calculate the sequence coverage of detected proteins 
after combining all parallel digests (usually trypsin, chymotrypsin and subtilisin). 
Detected phospho-peptides with a Mascot score greater than 15 were manually 
validated and rated with a score between 0 (lowest) and 3 (highest). Phosphorylation 
sites within peptides were assigned to, if possible, unambiguous positions. Peptides 
scored 1-3 were kept for further analysis. 
 
Phosphorylation sites from all four cell cycle conditions (interphase (L), mitosis (N), 
mitosis + PLK1 inhibition (NB), mitosis + AURKB inhibition (NHM)) were compared. For 
each cell cycle state the phosphorylation site could either be present (M), absent with 
an unmodified peptide covering the site (UM) or absent with no peptide covering the 
site (nd). We disregard the sites that are nd in one state or UM in all states, so that we 
are left with 15 possible combinations for a single site. The name of each combination is 
given in the table below. Most sites that were detected fall into the first six categories 
(Phosphorylated (M), unphosphorylated (UM) or no peptide (nd) present). 
 
Category Abbrev. L N NB NHM 
interphase I M UM UM UM 
interphase and mitosis I/M M M M M 
mitosis M UM M M M 
PLK1 inhibitor-sensitive BI-sens UM M UM M 
Hesperadin-sensitive Hes-sens UM M M UM 
PLK1 inhibitor- &  
Hesperadin-sensitive 
BI+Hes sens UM M M M 
I/M, PLK1 inhibitor- 
sensitive 
I/M, BI-sens M M UM M 
I/M, Hesperadin-
sensitive 
I/M, Hes-sens M M M UM 
I/M, PLK1 inhibitor- &  
Hesperadin-sensitive 
I/M, BI+Hes sens M M M M 
PLK1 inhibitor-induced hes-ind UM UM UM M 
Hesperadin-induced bi-ind UM UM M UM 
PLK1 inhibitor &  
Hesperadin-induced 
BI+Hes-ind UM UM M M 
I & PLK1 inhibitor- 
induced 
I, BI-ind M UM M UM 
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I, Hes-ind I & Hesperadin-induced M UM UM M 
I & PLK1 inhibitor- &  
Hesperadin-induced 
I/bi+hes-ind M UM M M 
 
The following categories were assigned to sites where sequence information could not 
be detected in all four states: 
 
Category Abbrev. I N NB NHM 
potentially mitosis m? nd M M M 
potentially in interphase 
and mitosis 
I/M? M M nd nd 
potentially in interphase I? M nd nd nd 
potentially Hesperadin-
induced 
hes-ind? nd nd nd M 
potentially PLK1 
inhibitor-induced 
bi-ind? nd nd M nd 
potentially PLK1 
inhibitor- &  Hesperadin- 
induced 
BI+Hes-ind? nd nd M M 
potentially I & PLK1 
inhibitor-induced 
I/BI-ind? M nd M nd 
 
 
 
Peptide quantification: We integrated the intensities for each charge state of a given 
peptide manually using QualBrowser (Thermo Fisher Scientific). To determine the level 
changes of a protein, at least six unmodified peptides that did not contain methionine 
and no mis-cleavage sites were were integrated. The intensity of each peptide was 
normalised to the nocodazole sample and the changes relative to nocodazole were 
averaged over all peptides of a single protein. The standard deviation of relative level 
changes was calculated and is indicated with the error bars in the graphs. To compare 
relative complex composition changes the relative level change of a given prey protein 
was normalised to the relative level changes of the bait. The standard deviation 
indicated is that of the different peptides of the prey protein. To asses relative changes 
of phospho-peptide the same method was used. Since only one peptide per digest was 
detected for a given phosphorylation site, no standard deviation could be computed. 
 
2.2.5.4 Antibodies 
Phospho-antibodies (listed Figure 2.2-3 C) were raised against 8mer to 13mer synthetic 
peptides in rabbits and affinity purified as described (Kraft et al., 2003). Further 
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antibodies used in immunopurification, western blotting and immunofluorescence were 
(antibodies are from rabbit if not stated otherwise): α-CDC27 (Gieffers et al., 1999), α-
PDS5A (521, (Sumara et al., 2000)), α-PDS5B (1531: QLKGLEDTKSPQFNRYFC and 
2230: VSTVNVRRRSAKRERR (Losada et al., 2005)), α-STAG1 (444 (Sumara et al., 
2000)), α-STAG2 (446 (Sumara et al., 2000)), α-WAPAL (986 and 987 (Kueng et al., 
2006)), α-NUP85 (Loiodice et al., 2004), α-NCAPH (Yeong et al., 2003), mouse α-
phospho-S10-H3 (05-499, Upstate), goat α-H3 (sc8654, Santa Cruz), mouse α-CCNB1 
(GNS1, Santa Cruz Biotechnology), α-CDC25C (Cell Signaling), α-BUB1B (gift from 
Gregor Kohlmaier), α-INCENP (Hauf et al., 2005), α-TUBG1 (T3559, Sigma), mouse α-
TUBA1B (clone B-5-1-2, Sigma), α-phospho CDC16 (Kraft et al., 2003), human CREST 
(Cortex Biochem), mouse α-MYC (4A6, 05-724, Upstate) and α-SMC2 (Yeong et al., 
2003). 
Secondary antibodies used for western blotting were α-mouse, α-rabbit or α-goat 
coupled to horse radish peroxidase (HRP); for immunofluorescence Alexa 488, Alexa 
568 and Alexa 633 labeled secondary antibodies were used (Molecular Probes 
(Invitrogen)). 
 
2.2.5.5 In vitro kinase assay 
WAPAL and STAG2 were immuno purified as described above. In vitro phosphorylation 
was performed as described (Kraft et al., 2003) using 10 mM ATP and recombinant 
6xHis-tagged PLK1. Recombinant human PLK1 was expressed as a 6xHis-tagged fusion 
protein using a baculoviral expression system and purified by affinity chromatography 
using Ni-NTA (QIAGEN). Where indicated, reactions were supplemented with 1 µM BI 
2536. 
 
2.2.5.6 Immunofluorescence microscopy 
Cells were grown on coverslips and fixed with 4% formaldehyde in PBS at RT or -20 °C 
methanol for 15 min. RAD21-9x MYC cells were cytospun (Shandon Brand), extracted 
with 0.5% Triton-X100 in PBS for 2 min and fixed with 4% formaldehyde in PBS (Hauf 
et al., 2005). After fixation samples were permeabilized with 0.5% Triton-X100 in PBS 
for 15 min and thereafter blocked with 10% FCS in PBS containing 0.01% Triton-X100. 
Coverslips were incubated for 1 h each at RT with primary and secondary antibodies (at 
2 µg/ml in 3% BSA in PBS containing 0.01% Triton-X100), DNA was counterstained 
with Hoechst 33342 coverslips and mounted with either ProLong Gold (Molecular 
Probes) or Vectashield Mounting Medium (H1000, Vector Laboratories) onto slides. 
Image acquisition was performed as described (Waizenegger et al., 2000) or (for 
BI4834 characterisation) images were taken on a Zeiss Axioplan 2 microscope using 
100x Plan-Apochromat objective lens (Carl Zeiss, Jena) equipped with CoolSnapHQ CCD 
camera (Photometrics). For signal intensity quantification, images were acquired as raw 
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12-bit images taken at identical exposure times within each experiment. Images were 
processed in ImageJ (http://rsb.info.nih.gov/ij/). Images shown in the same panel have 
been scaled identically. For quantification of TUBG1 intensities a circular region with 
fixed diameter was measured on the centrosome and a same-sized region was also 
measured in the cytoplasm. After subtracting the background outside the cells ratio of 
these values was calculated and average and standard deviation of these measurements 
were plotted. For each measurement at least 20 centrosomes were quantified. Mitotic 
phenotypes were classified based on the TUBA1B and DAPI staining; for each 
measurement 100 cells were counted.   
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2.2.6 Figure Legend 
2.2.6.1 Figure 2.2-1 
Summary of analysed baits and example of Bub1b purification from four cellular states. 
A) The baits (either LAP-tagged mouse (mm) baits, a single LAP-tagged human bait (hs 
SMC6) or endogenous baits purified via polyclonal antibodies (hs)) are sorted according 
to their subcellular localisation. 
B) LAP-tagged Bub1b was tandem purified and glycine eluted from log-phase cells (log), 
noc-arrested cells (N) and noc-arrested cells treated for two h with either BI4834 (NB) 
or Hesperadin and MG132 (NHM). 7% of the eluted complex was analysed by SDS-
PAGE/silver staining and the remaining sample was digested in solution using, in 
parallel, trypsin, chymotrypsin and subtilisin. The combined sequence coverage and the 
number of detected phosphorylation sites per protein are shown in C).  
 
 
2.2.6.2 Figure 2.2-2 
Relative quantification of Bub1b and WAPAL phosphorylation sites and determination of 
relative Bub1b complex stoichiometry. 
X-axes in all plots in this figure represent fold change while all y-axes give the source of 
the measured peptide as log-cells (L), noc-arrested cells (N) and noc-arrested cells 
treated for two h with either BI4834 (NB) or a combination of Hesperadin and MG132 
(NHM). 
A) Six unmodified peptides of Bub1b were quantified by integrating ion intensities over 
all charge states observed between 400 and 1800 m/z in the MS1 chromatogram of 
three different digests (trypsin, chymotrypsin, subtilisin). Integrated areas were 
normalised to the nocodazole sample (N) and the average fold change calculated.  
In B) fold changes for UBR5, BUB3, CASC5, CDC20, CDC27 and BUB1 over all four 
samples were derived from integrated intensities of six tryptic peptides. Values were 
normalised to N and their change relative to observed Bub1b level changes in the tryptic 
digest were plotted. Error bars indicate standard deviation calculated for each data point 
of each protein.  
C) Fold changes for CDC27 and BUB1B in a CDC27 immunopurification were calculated 
as in A. The fold change for BUB1 relative to CDC27 levels was calculated as in B. 
D) Based on the calculated fold changes for Bub1b given in A, relative phospho-peptide 
levels of each identified phosphorylation site in Bub1b were calculated for all digests 
(Supplemental figure 2.2-2 E for details). Phosphorylation sites were then categorised 
into sites present in interphase and mitosis (orange), sites present exclusively in mitosis 
(red) and sites that could not be clearly categorised (dark grey). See text for details on 
categorisation. * denotes sites sensitive to BI4834, # denotes sites sensitive to 
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Hesperadin, protein domains are shaded in grey and labelled according to Interpro 
names. 
E) Fold changes for WAPAL in WAPAL immunoprecipitations from L, N, NB and NHM 
were calculated as in A, relative phospho-peptide levels were determined and three 
examples are shown for phosphorylation sites S465, S528 and S1154. All sites were 
categorised and labelled as in D.  
 
2.2.6.3 Figure 2.2-3 
Phospho-specific antibodies generated against a subset of phosphorylation sites validate 
the MS results. 
A) Phospho-specific polyclonal antibodies raised against different phosphopeptides listed 
in C) were tested on protein immunopurified using the indicated antibodies from 
extracts obtained from log-phase cells (L), noc-arrested cells (N) and noc-arrested cells 
treated for two h with either BI4834 (NB) or a combination of Hesperadin and MG132 
(NHM). (B) The pSTAG2_S1224 antibody was tested on protein extracts from cells 
synchronised with a double thymidine arrest release and harvested either four h after 
release (G2), ten h after release by mitotic shake off (SO), ten h after release with the 
last three h in nocodazole (N), with last three h nocodazole and last two h either BI4834 
(NB) or Hesperadin/MG132 (NHM). The cell cycle stage was controlled using antibodies 
against CCNB1, H3S10ph, H3 and CDC27 as indicated. (C) Lists the phosphopeptides 
used to generate polyclonal rabbit phospho-specific antibodies against the listed 
proteins. # Refers to the antibody and antigenic peptide number. The phospho-site 
category as determinded by mass spectrometry (MS) and subsequent western blotting 
(WB) is indicated. D) STAG2 and WAPAL immunopurified from interphase cells and 
subsequently incubated with recombinant Plk1, ATP and 1 µM of BI2536 as indicated 
were separated by SDS-PAGE and transferred to a membrane for subsequent 
immunoblotting using two different phospho-specific antibodies (pSTAG2_S1224 and 
pWAPAL_S465). (E) Shows cells grown on coverslips and treated or not with 100 nM of 
BI2536 for 30 min prior to fixation and staining with the pSTAG2_S1224 phospho-
specific antibody (pSTAG2), STAG2 antibody, H3S10ph antibody and DAPI.  
 
2.2.6.4 Figure 2.2-4  
Summary of all analysed baits and prey, the number of detected phosphorylation sites 
and potential Plk1 and Aurora B kinase substrates:  
A) Summary table of all analysed baits and prey, number of phospho-sites per cell cycle 
stage (I – interphase, I/M – interphase and mitosis, M – only present in mitosis) and 
number of hesperadin-sensitive (H-sens) and Plk1 inhibitor-sensitive (B-sens) sites. 
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List of detected potential novel Plk1 (B) and Aurora B kinase (C) substrates. The 
number of inhibitor-sensitive sites (BI-site and Hes-sites), total sites in mitosis and 
mitosis-specific sites is given. 
 
2.2.6.5 Supplemental figure 2.2-1 
BI4834 is structurally and functionally related to BI2536 
A) BI4834 is an ATP analogue, very similar in structure to BI2536 (Lenart et al., 2007; 
Steegmaier et al., 2007). 
B) Addition of 250 nM BI4834 to cells released from a single (24h) thymidine arrest 
arrests cells in prometaphase with a monopolar spindle (DNA stained with DAPI (blue), 
Tubulin stained with α-TUBA1B antibody (red)).  
C) The same experiment as described in B) was performed with different concentrations 
of BI4834, the mitotic phases were scored and compared to treatment with 100 nM 
BI2536. 
D) Cells were treated as in C, fixed and stained with TUBG1 antibody and the ratio of 
centrosomal to cytoplasmic TUBG1 was calculated. A representative image of cells 
treated with 250 nM BI4834 is shown. 
E) Cells were treated as in B but fixed and stained with pAPC6 antibody (Kraft et al., 
2003). 
F) To test the effect of BI4834 on cohesin dissociation from chromosomes in early 
mitosis, cells stably expressing MYC-tagged cohesin were treated as in A, cytospun onto 
slides, fixed and stained with CREST serum, α-SMC2 and α-MYC antibodies. 
F) To monitor the effect of BI4834 and BI2536 on BUB1B phosphorylation, cells were 
treated as in A, harvested ten h after thymidin release, whole cell extracts were 
prepared and analysed by SDS-PAGE and western blotting with the indicated antibodies. 
Phosphorylated (P) and no-phosphorylated (NP) forms of BUB1B and CDC25C are 
marked. 
 
2.2.6.6 Supplemental figure 2.2-2  
Phospho-specific antibodies against various interphase, mitosis-specific and inhibitor-
sensitive phosphorylation sites. Quantification of all BUB1B phosphorylation sites. 
Phospho-specific polyclonal antibodies raised against different phosphopeptides listed in 
Figure 2.2-3 were tested on immunopurified protein (IP) using the indicated antibodies 
or directly on extracts (XT) obtained from log-phase cells (L), hydroxyurea-arrested S-
phase cells (HU), noc-arrested cells (N) and noc-arrested cells treated for two h with 
either BI4834 (NB) or a combination of Hesperadin and MG132 (NHM). Antibodies 
against sites determined by MS to be present in interphase and mitosis (A), to be 
mitosis-specific and sensitive to the PLK1 inhibitor (B) and to be mitosis-specific and 
sensitive to Hesperadin treatment (C) are shown. The pRAD21_S175 antibody was 
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tested on protein extracts from cells synchronised with a double thymidine arrest 
release and harvested either four h after release (G2), ten h after release by mitotic 
shake off (SO), ten h after release with the last three h in nocodazole (N), with last 
three h nocodazole and last two h either BI4834 (NB) or Hesperadin/MG132 (NHM). The 
cell cycle stage was controlled using antibodies against CCNB1, H3S10ph, H3 and 
CDC27 as indicated. 
D) Based on the calculated fold changes for Bub1b (Figure 2.2-2 A), relative phospho-
peptide levels of each identified phosphorylation site in Bub1b were calculated for all 
digests in which the phosphorylation site was detected (trypsin (yellow), chymotrypsin 
(orange) and subtilisin (brown)).  
 
2.2.6.7 Supplemental table 2.2-1 
List of detected potential known Plk1 (B) and Aurora B kinase (C) substrates. The 
number of inhibitor-sensitive sites (BI-site and Hes-sites, respectively) total sites in 
mitosis and mitosis-specific sites is given. 
 
 
 
2.2.6.8 Supplemental table 2.2-2  (see appendix 5.5) 
All identified annotated phosphorylation sites and their classification. Since this table is 
very long it is in the appendix. 
 
 
86 
                                                               2.2 Phosphorylation site mapping manuscript 
  
2.2.7 Figures 
Figure 2.2-1 
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Figure 2.2-2 
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Figure 2.2-3 
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Figure 2.2-4 
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Supplemental figure 2.2-1 
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Supplemental figure 2.2-2 
 
 
 
 
 
 
 
 
92 
                                                               2.2 Phosphorylation site mapping manuscript 
  
Supplemental table 2.2-1 
 
 
 
Supplemental table 2.2-2 
Since this table is very long it is in the appendix (5.5). 
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2.3 PDS5A/PDS5B cell lines 
 
2.3 Generation and characterisation of cell lines stably expressing MYC-
tagged versions of PDS5A and PDS5B 
The cohesin complex interaction with PDS5 proteins is conserved from yeast to 
mammals. Studies in yeast have placed PDS5 in the cohesion 
establishment/maintenance pathway (Hartman et al., 2000; Panizza et al., 2000) but 
their function in yeast as well as in human, which have two orthologs designated PDS5A 
and PDS5B, is not well understood (Losada et al., 2005). A recent study identifying 
another cohesin interactor and regulator called WAPAL has shown that PDS5A but not 
PDS5B interacts with WAPAL (Gandhi et al., 2006; Kueng et al., 2006), indicating that 
PDS5A and B might have distinct roles within the cohesin complex. To further 
investigate this question I wanted to generate MYC-tagged version of PDS5A and PDS5B 
inducibly expressed in HeLa cells. 
 
The vertebrate orthologs of yeast Pds5 (PDS5A, PDS5B) are very similar (Losada et al., 
2005). The 1140 amino acid N-terminal domain is 72% identical in sequence and 
contains a number of HEAT repeats just like the yeast Pds5b (Losada et al., 2005; 
Panizza et al., 2000). To better define the number of these repeats and their position 
within the sequence we used profile based searches employing hidden Markov models 
(HMMs) (HMMER, Eddy, S., unpublished data). The REP and Pfam databases provide 
specific repeat definitions, which can be used for the identification of HEAT elements in 
a query sequence (Andrade et al., 2000). 
 
The analysis showed that PDS5A contains 18 HEAT motifs within amino acids 69 to 756 
followed by two Armadillo repeats (ARM) from amino acids 829 to 1033 and an 
unstructured C-terminus (Table 5.2-1). PDS5B also contains 18 HEAT repeats from 
amino acid 58 to 779, a charged C-terminal region from amino acids 1084 to 1447 
including a potential DNA binding AT-hook domain (Table 5.2-2). HEAT and ARM repeats 
are a very common sequence motif present in many proteins and involved in mediating 
protein interactions (Andrade et al., 2001), suggesting that the role of PDS5A and 
PDS5B in the cohesin complex might be to mediate inter complex protein interactions. 
 
2.3.1 Cloning of PDS5A and PDS5B constructs into a MYC-Tet-On expression 
vector 
To generate a cDNA of PDS5A and PDS5B that contains a MYC array on the N- or C-
terminus, that is resistant to siRNA knockdown and whose expression is inducible with 
doxycyclin I pursued the following cloning strategy (Table 4.5-1: Primers used for 
amplification and Quickchange mutagenesis.). A sequence containing (from 5’ – 3’) start 
codon, kozak sequence, twelve repeats of the MYC-tag coding sequence followed by the 
coding sequence for a five glycine linker and the restriction site for NarI was cloned into 
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the pTRE2hyg vector (TetOn System, Clontech) via MluI and NheI resulting in plasmid 
1132. A sequence containing (from 5’ – 3’) restriction sites for MluI, NarI and NotI; the 
coding sequence for a five glycine linker, nine repeats of the MYC-tag coding sequence 
and a stop codon was cloned into the pTRE2hyg vector via MluI and SalI resulting in 
plasmid 1131. The coding sequence for PDS5A was previously cloned into the 
pBluescript expression vector (plasmid 124, gift from E. Roitinger). Plasmid 124 was 
used to generate an siRNA resistant construct by introducing six silent point mutation 
within the target site of siRNA 32 (Figure 2.3-1) with the Quickchange system. The 
resulting plasmid 1137 was used to amplify PDS5A for cloning it into plasmid 1131 via 
NarI and NotI resulting in plasmid 1136. The plasmid 124 coding sequence contained an 
insertion of two T after base 739 (as counted from start codon). The insertion was 
removed in plasmid 1136 using the Quickchange system (Stratagene). This plasmid 
thus contains the siRNA resistant sequence for expressing PDS5A with a C-terminal 9x 
MYC-tag in mammalian cells. The coding sequence of PDS5B is fully included in the 
KIAA0979 cDNA (Nagase et al., 1999) which was obtained from the Kazusa consortium 
and entered into the cDNA database as plasmid 1138. To generate an siRNA resistant 
cDNA six silent point mutations were introduced in the target sequence of siRNA 34 
(Figure 2.3-1) using the Quickchange system. The resulting plasmid 1139 was used to 
amplify the siRNA resistant cDNA of KIAA0979 for cloning into plasmid 1132 via NarI 
and NotI resulting in plasmid 1133. This plasmid thus contains the siRNA resistant 
sequence for expressing PDS5B with an N-terminal 12x MYC-tag in mammalian cells. 
 
Following a similar strategy plasmids with N-terminally tagged 12x MYC PDS5A (#1135) 
and C-terminally tagged PDS5B 9x MYC (#1134) were also generated.  
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Figure 2.3-1 
Scheme of PDS5A-MYC and MYC-PDS5B fusion protein including their siRNA resistant sites 
on the corresponding cDNA sequence. 
A) PDS5A contains 17 HEAT repeats, one HEAT or ARM repeat and two ARM repeats in the 
region from amino acid 69 to 1033. Some repeat boundaries could not be well defined (see 
supplement x for details). A 9x MYC array was fused with a linker to the C-terminus of 
PDS5A. At the target sequence of siRNA #32 (bp 554 – 571) six silent mutations were 
introduced to render the resulting mRNA siRNA resistant. 
B) PDS5B contains 17 HEAT repeats andoneHEAT or ARM repeat (amino acids 58 – 779) as 
well as a charged C-terminus (amino acids 1084 – 1447). A 12x MYC array was fused with 
a linker to the N-terminus of PDS5B. At the target sequence of siRNA #34 (bp 464 – 482) 
six silent mutations were introduced to render the resulting mRNA siRNA resistant. 
 
2.3.2 Generation of stable doxycyclin-induceable HeLa cell lines expressing 
PDS5A-MYC and MYC-PDS5B 
To obtain HeLa cell lines that stably express the inducible, MYC-tagged constructs of 
PDS5A and PDS5B generated in 2.3.1, I largely followed the protocol suggested by 
Clontech, the supplier of the TetOn system. The plasmids 1133, 1134, 1135 and 1136 
were amplified in E. Coli and purified using the Maxi Prep kit (Qiagen). HeLa cells were 
grown to about 40% confluency on a 10 cm dish (4 x 106 cells) and transfected with 4 
µg of DNA using the Lipofectamin PLUS reagent (Invitrogen). Two days after 
transfection cells were split 1:40 to 1:80 into selection medium containing 400 µg 
hygromycin/ml. Most of the cells died within one day after addition of selection medium, 
colonies started appearing eleven days after transfection. The colonies were picked two 
weeks after transfection when they were sufficiently dense and seeded onto a 12-well 
plate.  
 
To screen the single colonies for expression level and localisation, cells were split either 
on to 8-well Labtek chambers for immunofluorescence or into another 12-welll plate for 
western blot analysis. Expression was induced for two days using 1 µg/µl doxycycline 
and the hygromycin concentration was lowered to 100 µg/ml. Cells on Labtek chambers 
were PFA-fixed, stained for DNA,  MYC and the cohesin subunit STAG2. Cells on 12-well 
plates were washed, trypsinised, resuspended in 4x SDS-PAGE buffer, sonicated and 
analysed by SDS-PAGE separation and western blotting using MYC and STAG2 
antibodies. In total, 30 clonal cell lines were screened -/+ doxycyclin which yielded a 
number of cell lines with expression levels similar to the endogenous gene, little 
expression in the uninduced cells and with nuclear localisation during interphase but 
cytoplasmic, non-chromatin localisation during mitosis (see Table 2.3-1). No clones for 
C-terminally tagged PDS5B were obtained while there were some clones for N-
terminally tagged PDS5B. The N-terminally tagged PDS5A clones localised correctly but 
were not as homogenous as the C-terminally tagged PDS5A clones. Since the 
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expression level variation within each cell line was still quite high, some clones were 
split again onto selection medium for another round of selection, colony picking and 
screening. This resulted in four N-terminal 12x MYC PDS5B clones and three C-terminal 
9x MYC PDS5A clones. Clones 1133_6_13, 1133_6_22 for PDS5B and clone 1136_21_8 
showed the most homogenous expression and their expression levels were similar to 
endogenous expression (data not shown). These clones were then further characterised. 
 
 Table 2.3-1: PDS5A and PDS5B MYC-tagged cell lines 
 
Cell clone Gene Tag 
1st selection   
PDS5B Nterm 12x MYC 1133_4 
1133_6 PDS5B Nterm 12x MYC 
PDS5B Nterm 12x MYC 1133_10 
1135_18 PDS5A Nterm 12x MYC 
PDS5A Nterm 12x MYC 1135_8 
1136_4 PDS5A Cterm 9x MYC 
PDS5A Cterm 9x MYC 1136_16 
1136_20 PDS5A Cterm 9x MYC 
PDS5A Cterm 9x MYC 1136_21 
2nd selection   
PDS5B Nterm 12x MYC 1133_4_14 
1133_6_10 PDS5B Nterm 12x MYC 
PDS5B Nterm 12x MYC 1133_6_13 
1133_6_19 PDS5B Nterm 12x MYC 
PDS5B Nterm 12x MYC 1133_6_22 
1136_21_8 PDS5A Cterm 9x MYC 
1136_21_9 PDS5A Cterm 9x MYC 
1136_16_12 PDS5A Cterm 9x MYC 
  
 
2.3.3 Characterisation of one stable PDS5A-MYC cell line (1136_21_8) and 
two stable MYC-PDS5B cell lines (1133_6_13/1133_6_22) 
Initial experiments using different doxycyclin concentrations (0.2 µg/ml – 2 µg/ml) for 
48 or 72 h to induce PDS5A-MYC or MYC-PDS5B expression were carried out to 
determine the doxycyclin concentration that lead to a near to endogenous expression 
level. Using 1 µg/ml doxycyclin for 48 or 72 h gave the best results (data not shown) 
and was thus used in all subsequent experiments. 
 
To test whether the generated tagged proteins are resistant to siRNA depletion the cell 
lines 1136_21_8, 1133_6_13 and 1133_6_22 were transfected or not with siRNA 
specific for either PDS5A or PDS5B and also treated or not with doxycyclin to induce 
exogenous protein expression. Two days after transfection and induction, cells were 
harvested, extracted, separated on SDS-PAGE and transferred to a membrane. 
Membranes were probed with PDS5B or PDS5A antibodies to compare expression and 
extent of depletion between wild type and PDS5B cell lines (Figure 2.3-2). Myc-PDS5B 
expression in the line 1133_6_13 is very similar to endogenous levels when doxycline is 
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added but almost undetectable in untreated cells. Weak expression is detectable using 
the MYC antibody since the 12x MYC epitope strongly amplifies the signal. Importantly, 
the exogenous protein levels are not reduced upon siRNA transfection but rather slightly 
increased; indicating that the MYC-PDS5B construct is indeed resistant to the siRNA 
which reduces the endogenous protein levels to less than 50%. The MYC antibody 
detects a faster migrating band in the + doxycyclin sample which does not match the 
endogenous PDS5B band size and thus might be a truncated version of PDS5B that is 
being expressed. 
 
Myc-PDS5B expression in the 1133_6_22 line is less than half the level of wild type cells 
upon doxycyclin induction but not detectable in control cells. However, weak expression 
is detectable using the MYC antibody. The siRNA depletion of endogenous protein 
reduces endogenous protein levels to less than 50% but did not affect the levels of 
MYC-PDS5B. Similar to the 1133_6_13 cell line the MYC antibody detects a faster 
migrating band in the + doxycyclin sample which does not match the endogenous 
PDS5B band size. This might also be a truncated version of PDS5B that is being 
expressed. 
 
The 1136_21_8 cell line expresses PDS5A-MYC at much lower levels than the 
endogenous protein upon doxycyclin addition. The background expression level in 
uninduced cells is only about 50% lowever than the induced levels, indicating that the 
expression is quite leaky. Transfection of these cells with siRNA specific for PDS5A leads 
to a reduction of endogenous PDS5A levels while PDS5A-MYC levels do not change, 
confirming that the PDS5A-MYC construct is resistant to the PDS5A siRNA. 
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Figure 2.3-2 
PDS5A-MYC and MYC-PDS5B fusion proteins are expressed at near endogenous levels after 
doxycyclin addition and are resistant to siRNA silencing. 
A) Cell lines stably expressing MYC-PDS5B (1133_6_13 and 1133_6_22) were transfected 
with siRNA directed against endogenous PDS5B or water, 1 mg/ml doxycyclin was added 
or not and protein extracts were prepared 48 h later (-> check methods). Extract 
supernatants were separated by SDS-PAGE, transferred to membranes and probed with 
the indicated antibodies. Two different exposure times for the PDS5B signal are displayed. 
B) A Cell line stably expressing PDS5A-MYC (1136_21_8) was transfected with siRNA 
directed against endogenous PDS5A or water, 1 mg/ml doxycyclin was added or not and 
protein extracts were prepared 48 h later. Extract supernatants were separated by SDS-
PAGE, transferred to membranes and probed with the indicated antibodies. Two different 
exposure times for the PDS5A signal are displayed. 
 
To test the functionality of PDS5A and PDS5B I analysed whether exogenous PDS5A and 
PDS5B can integrate into the cohesin complex. Myc-PDS5B cell lines and PDS5A-MYC 
cell lines were grown for 48 h in the presence of absence of doxycyclin, protein extracts 
prepared and incubated with antibodies crosslinked to Affiprep beads directed against 
either the MYC-tag (MYC) or the cohesin subunits SMC3 or STAG2. Immunoprecipitated 
proteins were eluted with glycine, separated by SDS-PAGE, transferred to membranes 
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and probed with antibodies against PDS5A or PDS5B, the MYC-tag or RAD21 (Figure 
2.3-3). Myc-PDS5B can be immunoprecipitated from both cell lines (1133_6_13 and 
1133_6_2) using the MYC-antibody and also copurifies RAD21. SMC3 and STAG2 can 
both co-IP small amounts of PDS5B that were only detectable using the MYC antibody 
and, as expected, RAD21. SMC3 and STAG2 can however not IP detectable amounts of 
endogenous PDS5B which is not consistent with earlier findings (Losada et al., 2005). It 
is possible that only a small amount of PDS5B interacts with cohesin that, in this case, 
can only be detected using the MYC antibody against the exogenous MYC-PDS5B. 
Further characterisation of the MYC-PDS5B cell lines and their complex integration using 
sucrose gradients might give a clearer answer which fraction of the tagged PDS5B 
integrates into the cohesin complex as compared to the endogenous PDS5B. 
 
PDS5A-MYC can be immunoprecipitated from the 1136_21_8 cell line using the MYC-
antibody and also copurifies RAD21 (Figure 2.3-3). SMC3 and STAG2 can both co-IP 
endogenous and exogenous PDS5A at roughly equal levels from doxycyclin induced cells 
while no PDS5A-MYC is coimmunoprecipitated from uninduced cells. This indicates that 
MYC-tagged PDS5A associcates with the cohesin complex equally well as the 
endogenous protein. 
 
 
Figure 2.3-3 
PDS5A-MYC and MYC-PDS5B fusion proteins interact with SMC3, STAG2 and RAD21 
subunits of the cohesin complex. 
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A) Cell lines stably expressing MYC-PDS5B (1133_6_13 and 1133_6_22) were induced 
with 1 mg/ml doxycyclin or not and protein extracts were prepared 48 h later. Extracts 
were incubated with different antibodies (as indicated) crosslinked to Affiprep beads. 
Glycine eluates of the immunoprecipitate were separated by SDS-PAGE, transferred to a 
membrane and probed with the indicated antibodies. Two different exposure times for the 
RAD21 signal are displayed. 
 B) A Cell line stably expressing PDS5A-MYC (1136_21_8) was induced with 1 mg/ml 
doxycyclin or not and protein extracts were prepared 48 h later. Extracts were incubated 
with different antibodies (as indicated) crosslinked to Affiprep beads. Glycine eluates of the 
immunoprecipitate were separated by SDS-PAGE, transferred to a membrane and probed 
with the indicated antibodies. Two different exposure times for the RAD21 signal are 
displayed. 
 
 
Finally I wanted to test the expression level variation as well as the localisation of 
PDS5A-MYC and MYC-PDS5B within cells. Expression of tagged PDS5A and PDS5B was 
induced for 48 h using 1 µg/ml doxycyclin and the cells fixed and stained with antibody 
against the MYC-tag and RAD21. All cell lines show a very similar staining pattern. Only 
nuclei are stained with very few high expressing cells showing some cytoplasmic 
staining. The expression level varies from cell to cell in induced cells with the highest 
expressing cells showing the most intense staining in the nuclear membrane or 
associated structures (Figure 2.3-4). In high expressing cells it is difficult to discern 
nucleoli while in medium and low expressing cells the nucleoli are not stained. The 
nuclear localisation of PDS5A-MYC is consistents with earlier findings (Losada et al., 
2000; Sumara et al., 2000). PDS5B localisation has not been previously analysed by 
immunofluorescence microscopy. However, localisation of PDS5B to the nucleus is 
consistent with earlier findings that it is chromatin associated in biochemical 
fractionation experiments (Losada et al., 2005). Further experiments are needed to 
characterise the localisation of PDS5A and PDS5B during mitosis to answer the question 
whether these two cohesin interactors also localise to mitotic chromosome centromers 
as has been described for RAD21 and STAG2 (Hauf et al., 2005). 
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Figure 2.3-4 
PDS5A-MYC and MYC-PDS5B fusion proteins localise to the nucleus and expression levels 
vary from cell to cell. 
Cell lines stably expressing MYC-PDS5B (1133_6_13 and 1133_6_22) or PDS5A-MYC 
(1136_21_8) were grown on cover slips, induced with 1 µg/ml doxycyclin and fixed with 
PFA 48 h later. Antibodies against the MYC-tag (MYC, green channel) and RAD21 (red 
channel) were used and DAPI was applied to visualise the DNA. 
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2.4 Contributions 
2.1 Manuscript in preparation: Systematic analysis of mitotic protein complexes 
using tandem affinity purification and mass spectrometry discovers 71 novel potential 
mitotic protein complexes 
 
The LAP method adaption was initiated by me and continued by Martina Sykora and 
James R.A. Hutchins. Generation of LAP-tagged cells lines was performed by Ina Poser 
and colleagues in the laboratory of Anthony Hyman (Max-Planck-Institute of Cell Biology 
and Genetics, Dresden, Germany). LAP purifications were mainly done by Martina 
Sykora and James R.A. Hutchins, some were performed by me. MS-analysis and 
database searching was done by Ines Steinmacher, Christoph Stingl and Otto Hudecz 
(IMP/IMBA Protein Chemistry Facility). Primary data analysis was performed by Martina 
Sykora, James R.A. Hutchins and me. The interaction data analysis pipeline was set up 
by Jean-Karim Hériché in the group of Richard Durbin (Wellcome Trust Sanger Institute, 
Hinxton CB10 1HH, England) in collaboration with James R.A. Hutchins and me. Data 
interpretation was done by Martina Sykora, James R.A. Hutchins and me. The validation 
experiments for the γ-TuRC and the FAM29A complex were performed by Martina 
Sykora, the validation of the C10orf104/ANAPC16 interaction by LAP-MS was performed 
by James R.A. Hutchins, the remaining C10orf104/ANAPC16 characterisation was done 
by Bettina A. Buschhorn and me. The manuscript was written by me (except the main 
part of the introduction which was written by James R.A. Hutchins) in discussions with 
Jean-Karim Hériché, James R.A. Hutchins and Jan-Michael Peters. 
 
2.2 Manuscript in preparation: A systematic approach to discover new PLK1 and AURKB 
substrates finds 17 novel PLK1 and 18 novel AURKB substrates on 99 candidate proteins 
 
The characterisation of BI4834 was done by Peter Lenart. LAP method adaption was as 
above. LAP and antibody purifications were mainly done by James R.A. Hutchins and 
me, Aurkb purification was done by Martina Sykora. Data evaluation and analysis was 
done by Otto Hudecz, James R.A. Hutchins and me. Peptide quantification was done by 
me. Phospho-peptide antibody generation was initiated by me, peptides were 
synthesized by Mathias Madalinski and Gabrieal Krssakova (IMP/IMBA Protein Chemistry 
Facility), rabbit immunisation was done at Gramsch Laboratories, Schwabhausen, 
Germany, all further phospho-antibody experiments were done by me. The manuscript 
was written by me in discussions with James R.A. Hutchins and Jan-Michael Peters. 
 
2.3 Generation and characterisation of cell lines stably expressing MYC-tagged version 
of PDS5A and PDS5B 
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All experiments were performed by me. The bioinformatic analysis of PDS5A and PDS5B 
was performed by Maria Novatchkova.  
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3 Discussion 
The discussion sections 3.1 and 3.2 are in addition to the discussion within the 
manuscripts included in section 2.1 and 2.2, respectively. 
3.1 Protein interaction mapping 
We aimed to establish a method that would allow large scale analysis of human protein 
complex composition to systematically identify mitotic protein complexes. Further we 
wanted to use computational methods to analyse the data generated by this large scale 
analysis. 
 
We adapted the LAP-protocol (Cheeseman and Desai, 2005) into a fast, robust and 
clean tandem affinity purification procedure. In combination with very sensitive FT or OT 
MS we were able to successfully identify 91% of purified baits and a large number of 
specific interacting proteins. Further computational analysis of the data set identified 
75% of the members of a set of known complexes and predicted 70 novel complexes. 
Preliminary validation experiments confirmed one novel complex and three novel 
interaction partners of known complexes. The combination of LAP-MS purifications and 
computational analysis thus enabled us to systematically identify potential mitotic 
protein complexes. 
 
The main difficulties in protein complex analysis by AP-MS are 1) to separate true from 
spurious interactions and 2) to define the actual protein complex by separating 
substoichiometric components, that might be substrates or members of lower abundant 
complex isoforms, from near stoichiometric complex components (see definition of 
protein complexes, section 2.1.3.3).  
 
To address the first point it is essential to use a purification procedure that minimises 
unspecific interactions but conserves less stable interactions, i.e. increases the number 
of true positives and decreases the number of false negatives, respectively. The tandem 
affinity purification procedure, originally developed in yeast (Rigaut et al., 1999), has 
proven in many studies to be very successful in avoiding unspecific interactions. Even 
though some high abundant proteins still copurify in tandem procedures and some less 
stable interactions might be lost in tandem purifications in comparison to single step 
purifications, tandem affinity purification has become the method of choice for many 
large scale complex analysis projects (Gingras et al., 2007). Two approaches have been 
used to remove unspecific interactors from tandem affinity purifications. Proteins 
present above a certain percent threshold of all identified prey are removed based on 
the assumption that most proteins will only interact with a small number of other 
proteins (Krogan et al., 2006 and this study). Alternatively, the expected frequency of a 
protein in a dataset is calculated based on the number of prey it purifies when it is a 
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bait. Proteins present above their expected frequency are considered as contaminants 
(Gavin et al., 2006). The second method is only applicable to genome scale interaction 
studies since all potential contaminants need to be tagged to calculate their expected 
frequency. 
 
The second point is much more difficult to address. The definition of a protein complex 
is rather arbitrary; we have chosen a simple definition which can be fulfilled by AP-MS 
data alone (see section 2.1.3.3). With an AP-MS approach as taken in this study, a set 
of interacting proteins can be defined. The relationship between these proteins, 
however, remains unknown. It is likely that some or all of the proteins identified by 
reciprocal AP-MS experiments form a very stable complex which represents a structural 
and functional unit. This is the case for the APC/C which we purified with a number of its 
subunits used as baits and which has been characterised structurally and functionally in 
some detail (Peters, 2006). However, some of the interacting proteins identified by AP-
MS might also be substoichiometric interactors. This is exemplified by NEK2 which 
copurifies with the APC/C, but which has been identified as a substrate and not as a 
complex member of APC/C (Peters, 2006). At the same time we also find CDC20 and 
FZR1 (also known as Cdh1) in purifications of APC/C. However, CDC20 and FZR1 are 
APC/C coactivators that bind exclusive of each other to the complex. To resolve this 
problem and to separate stoichiometric interactors from substoichiometric interactors 
cell extracts can be analysed with density gradient centrifugation. All close to 
stoichiometric interactors should largely cosediment while substoichiometric interactors 
would only cosediment to a small fraction with the main peak.  
 
This established method and the data set of potential mitotic protein interactions opens 
two perspectives: the further extension of the dataset and more detailed 
characterisation of detected protein complexes as outlined below. 
 
The dataset generated within this study is focused on a relatively small number of 
proteins involved in mitosis. This concentrated approach was necessary to obtain a 
certain overlap between purified complexes that would allow the higher confidence 
prediction of novel complexes. Ultimately, to understand mitotic regulation, the aim 
should be to obtain a complete interaction map of all protein complexes involved in 
mitosis. To define a set of “mitotic protein complexes” the correlation of protein 
interaction data and functional data is necessary. As part of the MitoCheck project, the 
laboratory of Jan Ellenberg (EMBL, Heidelberg, Germany) has conducted a genome 
wide, live cell imaging based siRNA screen to identify genes required for mitosis 
(Neumann et al., in preparation). This screen has identified about 1200 genes by their 
specific mitotic phenotype. Ideally all of these hits should be analysed for their 
interaction partners. So far, only 67 of the ca. 1200 hits have been purified as baits and 
another 88 have been detected as prey. Since the analysis of the first 175 baits took 
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slightly less than two years, the analysis of the remaining screen hits (ca. 1100) might 
take quite a long time. It would thus be necessary to improve the throughput of the 
purification procedure considerably before extending the protein interaction mapping to 
the whole set of mitotic screen hits. As an alternative, a reiterative purification and 
tagging cycle might cover all siRNA screen hits with less than 1200 baits since it is likely 
that the 1200 screen hits are part of less than 1200 distinct protein complexes (in the 
current set 65% of siRNA screen hits hit predicted clusters and small connected 
components twice or more often). 
 
More detailed characterisation of predicted novel complexes and protein interaction 
partners has already been initiated. Two new potential interaction partners of the γ-
TuRC and five members of the predicted novel complex FAM29A were validated by 
reciprocal tagging and purification. The novel potential APCC/C subunit 
C10orf104/APC16 was validated by reciprocal LAP-purification as well as antibody 
purification of the endogenous protein. In addition, further biochemical characterisation 
confirmed ANAPC16 as an APC/C subunit and initial functional characterisation suggest 
ANAPC16 might be important for APC/C’s function in S- or G2-phase. 
 
Further validation and characterisation of other potential novel complexes and 
interaction partners can be carried out. Using the LAP-tagged cell lines, the localisation 
via the GFP moiety of the LAP-tag can be done in fixed cells or in live cells if the 
expression levels are high enough (Poser et al., 2008). The complex composition can be 
further analysed throughout the cell cycle by purifying candidate complexes from cells 
synchronised at different cell cycle stages. A cell cycle-dependent change of complex 
composition could be best analysed by using quantitative proteomic approaches as 
described in the phosphorylation mapping manuscript (section 2.2.3.5) or as outlined in 
a recent review (Bantscheff et al., 2007). 
 
The use of mouse genes offers the possibility to perform RNAi mediated depletion of the 
endogenous gene while the transgene remains unaffected by the RNAi reagent (Kittler 
et al., 2005b).  This offers a useful tool to test the functionality of each transgene and 
also allows testing the effect of mutations or deletions on the functionality. Especially 
those potential novel complexes that have one or more hits within the MitoCheck siRNA 
screen (Neumann et al., in preparation) can be tested by using the validated siRNA 
oligos used in the screen and following the detected phenotype.  
 
A further potential application of the BAC transgene rescue would be to remove the 
endogenous protein corresponding to the transgene in a large cell population followed 
by purification of the bait. This would avoid potential competition of transgene and the 
endogenous copy for interaction partners and thus create a situation closely resembling 
a knock in situation. The main obstacle for this experiment is the large number of cells 
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that need to be transfected and the high amount of RNAi reagent. The costly siRNA 
oligos coud be replaced by a self made endoribonuclease prepared so-called esiRNA pool 
(Kittler et al., 2005a; Yang et al., 2002). Whether efficient esiRNA transfection of large 
cell pools is possible remains to be seen. 
3.2 Phosphorylation site mapping 
We wanted to set up a method that would allow the identification of PLK1 and AURKB 
substrates in cells using small molecule inhibitors, protein purification and MS. 
 
We detected 470 phosphorylation sites on 99 unique proteins purified with 16 different 
baits. Out of those 99 proteins, 25 were identified as potential PLK1 substrates (17 were 
novel) and 18 were identified as potential AURKB substrates (18 were novel). The main 
improvement of the method we established is that we can map kinase-dependent 
phosphorylation sites directly in a cellular assay which avoids artefacts that might be 
introduced in in vitro kinase assays commonly used to find kinase substrates. In 
addition we mainly used the robust tandem affinity purification of LAP-tagged proteins 
as described in section 2.1 which allows a systematic analysis of a large number of 
protein complexes involved in mitosis. The drawback is, however, that some of the 
identified PLK1 or AURKB-dependent phosphorylation sites might not be direct targets of 
PLK1 or AURKB but rather caused by kinases downstream of PLK1 and AURKB. In 
addition, we also find a number of phosphorylation sites that are induced by addition of 
the PLK1 inhibitor or Hesperadin. This might also point to indirect effects which might 
be caused by blocking inhibitory functions of PLK1 or AURKB. 
 
A very short inhibitor treatment might minimise the extent of indirect effects on other 
phosphorylation sites. However, there also needs to be sufficient time after kinase 
inhibition for the phosphorylation sites generated by PLK1 or AURKB to be removed by 
phosphatases. Initial experiments in which we monitored the phosphorylation of Serine 
10 on histone H3 (H3S10ph) at different timepoints after Hesperadin addition indicated 
that two h of inhibition are required to fully abolish phosphorylation on Serine 10 of 
histone H3. Whether this rather slow turnover observed for H3S10ph is true for many 
mitotic phosphorylation sites is not clear. Previous experiments using the BI2536 PLK1 
inhibitor showed that addition of BI2536 to cells arrested in metaphase by the 
proteasome inhibitor MG132 converted from a bipolar spindle to a monopolar spindle 
within 60 to 120 minutes. This indicates that the activity of PLK1 is not just required for 
bipolar spindle formation but also for its maintenance. In addition, it indicates that to 
achieve a full PLK1 phenotype, i.e. monopolar spindles, it takes at least 60 minutes, 
suggesting that PLK1 phosphorylations presumably required for bipolar spindle 
maintenance are reversed rather slowly. Using the set of six phospho-specific antibodies 
detecting PLK1-dependent sites and two phospho-specific antibodies detecting AURKB 
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phosphorylation sites we can now test the turnover rate of a few phosphorylation sites 
in mitosis. 
 
We used mainly a qualitative analysis to detect mitosis-specific and kinase- dependent 
phosphorylation sites. As pointed out in section 2.2.3.4-5, upon inhibitor treatment or in 
interphase some phosphorylation sites are not diminished to an extent that they are not 
detectable by MS anymore. Using a semi-quantitative approach we could show that a 
relative change of phosphorylation levels by 5- to 20-fold can be within the dynamic 
range of the mass spectrometer (e.g. phosphorylation of S465 on WAPAL, Figure 2.2-2 
D) and is sufficient to identify a kinase-dependent phosphorylation site (compare Figure 
2.2-3 D). This suggests that we might miss phosphorylation sites in our qualitative 
analysis since their relative change is within the dynamic range of the mass 
spectrometer. It will be therefore essential to extend the quantitative analysis 
performed on the Bub1b and WAPAL phosphorylation sites to all phospho-proteins we 
detected.  
 
The quantitative analysis of unlabelled peptides in the mass spectrometer has become 
possible due to the high mass accuracy and sensitivity of the FT and OT mass 
spectrometers. Most quantitation of MS experiments, especially in large scale 
proteomics of whole cell extracts or similar complex samples, is often done using 
isotopic labels (Stable isotope labelling of amino acid in cell culture - SILAC) or isobaric 
labels (isobaric tag for relative and absolute quantitation - iTRAQ). This allows for 
several  samples being mixed and compared in a single MS run (reviewed in (Bantscheff 
et al., 2007)). These approaches are more difficult to apply for protein complex 
purification because of a number of reasons. SILAC allows direct labelling of proteins in 
the growing cells by supplementing the growth medium with heavy isotope amino acids, 
usually arginine and lysine (Ong et al., 2002). The advantage of SILAC is that cells can 
be mixed prior to extract preparation which avoids all possible quantification artefacts 
due to variable sample preparation. However, SILAC only allows the direct comparison 
of up to three samples since proteins are labelled with either two of a heavy or one light 
amino acid by supplementing the cell culture medium. In addition, the high price of 
SILAC media would make experiment with large amounts of cells very expensive. 
 
The iTRAQ label (Ross et al., 2004) is covalently bound to the proteolytic peptide at the 
amino-terminus of each peptide and allows comparison of up to eight different samples 
(Choe et al., 2007). However, the label is only detectable in the MS/MS chromatogram 
in the low mass range (m/z 113-121) which is not detectable using a standard ion trap 
instrument with a typical mass range of 400 to 1800 m/z. In addition, since the label is 
only added during the proteolytic digest of the sample differences in sample variation 
can not be avoided. Thus, using a label-free quantitation is the only method that allows 
for potentially unlimited amounts of samples to be compared and does not require the 
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use of other instrumentation. Differences in sample amounts due to variations during 
sample preparation as well as run to run variation need to be normalised and will lead 
to a relatively high standard deviation. The standard deviation can best be assessed by 
automated comparison and quantification of samples (Mueller et al., 2007). Automated 
comparison allows many more peptides to be compared and outliers to be identified by 
statistical methods to keep the standard deviation at a minimum.  
 
3.3 PDS5A and PDS5B cell lines 
To better understand the function of the cohesin interacting proteins PDS5A and PDS5B 
I wanted to generate cell lines inducibly expressing MYC-tagged PDS5A and PDS5B.  
 
Using the Tet-ON doxycyclin inducible expression system I generated stable cell lines 
inducibly expressing N-terminally tagged MYC-PDS5A and C-terminally tagged PDS5B-
MYC. The tagged exogenous proteins are resistant to siRNA mediated knockdown of the 
endogenous proteins, incorporate into the cohesin complex and localise to the nucleus 
just like cohesin. I decided to generate MYC-tagged inducible cDNA constructs instead of 
the LAP-tagged BAC versions for two reasons. First, we know from previous 
experiments that to visualise cohesin on centromeres in mitosis it is necessary to use at 
least an array of nine MYC tags (Waizenegger et al., 2000). This might thus also be the 
case for PDS5A and PDS5B. Second, stable expression of PDS5A has been tried in the 
lab previously and showed to be toxic to the cells, we thus needed an inducible system 
to avoid this problem.  
 
The two PDS5 cell lines thus allow to further study the function of PDS5A and PDS5B in 
cohesion. In a first experiment one could test the interactions partners of PDS5A and 
PDS5B by MS and compare them to earlier results obtained with antibodies directed 
against the endogenous proteins (data not shown). Since both proteins contain the 
same tag, unspecific interaction partners should be more easily identified.  
 
To further understand the interaction of WAPAL and PDS5A, deletion mutants of MYC-
PDS5A could be constructed, inducibly expressed in HeLa cells and purified to identify 
the binding region of PDS5A to WAPAL. Based on the phosphorylation sites identified on 
PDS5A (5.5 Phosphorylation manuscript table S2 (all phospho-peptides)) phospho-
mutants could also be constructed and the effect of phosphorylation on WAPAL binding 
could be tested. Once a mutant version of PDS5A has been identified that can not bind 
WAPAL anymore, the phenotype of this mutant can be tested by depleting the 
endogenous PDS5A in cell lines expressing the mutant PDS5A. To test whether PDS5A 
associates with centromeres in mitosis like described for RAD21 (Waizenegger et al., 
2000), mitotic cells could be analysed by cytospin and MYC staining. 
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The role of PDS5B in cohesion is even less understood than that of PDS5A. Sequence 
analysis showed that the only region that distinguishes PDS5A and PDS5B from each 
other is the C-terminal unstructured region which is highly charged and contains a 
potential AT-hook in PDS5B. The AT-hook is a DNA binding domain present in many 
high mobility group proteins (HMG) that preferentially bind the minor groove of DNA 
and often interact with transcription factors (Reeves, 2001). Since the AT-hook in 
PDS5B is the only known DNA binding domain within the cohesin complex one can 
speculate that PDS5B is needed to connect the cohesin complex to DNA. However, 
siRNA depletion of PDS5B does not lead to displacement of cohesin from DNA (Losada 
et al., 2005). By comparing the chromatin association of PDS5B-MYC with a truncated 
version lacking the AT-hook and the charged C-terminus, it could be tested whether 
PDS5B binding to chromatin is dependent on this region. In a rescue experiment using 
wild type or a truncated version of PDS5B-MYC in parallel to siRNA-mediated depletion, 
the function of the PDS5B C-terminus in cohesion could be tested. 
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4 Materials and methods 
4.1 Cell culture and siRNA depletion 
HeLa cells were grown on Nunc cell culture dishes in DMEM medium supplemented with 
10% FCS, 0.2 mM L-glutamine, 100 U/ml penicillin, and 100 µg/ml streptomycin. For 
TetOn cell lines the medium was supplemented with 100 µg/ml G418 and 200 or 400 
µg/ml hygromycin for maintenance or selection, respectively. RNAi depletions were 
performed as previously described (Hirota et al., 2004) using a preannealed siRNA oligo 
(Ambion) targeting PDS5A (5’- UGCACAUGCUAGAUUUGAUtt-3’ (database ID: 32) or 
PDS5B (5’-CCCAGCUAUACAGAACCUUtt-3’ (database ID: 34, Ambion ID: 203071)). 
 
4.2 Protein extract preparation and immunoprecipitation 
Protein extracts for immunopurifications were prepared using IP-buffer A (20 mM Tris-
HCl, pH 7.5; 150 mM NaCl, 5 mM EDTA, 20 mM β-glycerophosphate, 10 mM NaF, 10% 
glycerol, 0.1% NP-40, 1 mM DTT and protease inhibitor mix (PIM: leupeptin, 
chymostatin and pepstatin at 10 µg/ml). Equal volumes of cell pellet and buffer were 
used to resuspend the pellet using a 27G needle and corresponding syringe. Crude cell 
extracts were centrifuged at 13 200 rpm in a table top centrifuge at 4°C for 15 minutes 
and the supernatant kept. The concentration was determined using the BRADFORD 
reagent (Bio-Rad). 
 
Proteins were immunopurified using the following antibodies: α-SMC3 (725 (Sumara et 
al., 2002)) α-STAG2 (446 (Sumara et al., 2000)) and α-MYC 9E10 (Waizenegger et al., 
2000). After immunoprecipitation using antibodies crosslinked with DMP to affiprep 
beads (BIORAD, USA), purified complexes were washed in TBS Tween (0.01%) and 
eluted with 200 mM glycine pH 2.0. Eluates were neutralised with 1/10 volume 1.5 M 
Tris pH 9.2 and analysed by SDS-PAGE and western blotting. 
 
4.3 Antibodies 
To detect proteins on western blots (WB) or in immunofluorescence microscopy (IF), the 
following antibodies were used: α-RAD21 (Upstate, 05-908), α-PDS5B (Bethyl Labs, 
BL2352), α-MYC 9E10 (Waizenegger et al., 2000), α-PDS5A (521, (Sumara et al., 
2000)). 
 
4.4 Immunofluorescence microscopy 
see section 2.2.5.6
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4.5 Cloning 
DNA was amplified in DH5α E. Coli strains. For plasmid preparations the QIAGEN mini or 
maxi prep kits were used. Glycerol stock of strains carrying the final plasmids were 
generated using 0.5 ml of exponentially growing bacteria and 0.5 ml of 87% glycerol. 
PCR Primers were synthesized by MWG Biotech, Vienna, Austria (Table 2.3-1). PCR 
reactions were carried out using Pfu turbo Polymerase (Stratagene) according to 
manufacturers instructions with Tm adjusted according to primer length. Restriction 
enzymes as indicated were all from NEB and used according to manufacturers 
instructions. DNA fragments were ligated using the T4 ligase (Fermentas). Quickchange 
primers were designed according to manufacturers instructions (Stratagene) and PCR 
reactions performed with isopropanol precipitated mini prep DNA and Pfu Ultra II DNA 
polymerase (Stratagene). All final plasmids were sequenced with a set of sequencing 
primers designed either for PDS5A or PDS5B (Table 4.5-1). 
 
Table 4.5-1: Primers used for amplification and Quickchange mutagenesis. 
 
Name # Sequence RE-site /note 
  5’-addition/RE-sites/Kozak sequence/gly-linker  
pds5B_for_n-MYC  BJ35 GCGCTTGGCGCCGCTCATTCAAAGACTAGGACC NarI/KasI 
pds5B_rev_n-
MYC  BJ36 CGGCTTGCGGCCGCTCATCGCCGTTCCCTTTTAG  NotI 
pds5B_for_c-MYC  BJ39 GCGCTTGGCGCCGCCACCATGGCTCATTCAAAGACTAGG NarI/KasI 
pds5B_rev_c-
MYC  BJ40  CGGCTTGCGGCCGCTCGCCGTTCCCTTTTAGCAC NotI 
pds5A_for_n-MYC  BJ37  GCGCTTGGCGCCGACTTCACCGCGCAGCCCAAG NarI/KasI 
pds5A_rev_n-
MYC  BJ38  CGGCTTGCGGCCGCTTACCTTTGTAAGTCAATTTGTCTTTCTGC NotI 
pds5A_for_c-MYC  BJ41 GCGCTTGGCGCCGCCACCATGGACTTCACCGCGCAGCC NarI/KasI 
pds5A_rev_c-
MYC  BJ42 CGGCTTGCGGCCGCCCTTTGTAAGTCAATTTGTCTTTCTGC NotI 
9xMYCN-term_for BJ43 GCGCTTACGCGTGCCACCATGGCTAGTGGTGAACAAAAGTTG MluI 
9xMYCN-
term_rev4 BJ71 
GCGCTTGCTAGCGGCGCCACCACCACCACCTCTACTAGTGGATCCG
TTCAAGTC NheI, NarI/KasI 
9xMYCC-
term_for2 BJ63 
GCGCTTACGCGTGGCGCCGCGGCCGCTGGTGGTGGTGGTGGTCAA
AAGTTGATTTCTGAAGAAGATTTG 
MluI, NarI/KasI 
NotI 
9xMYCC-
term_rev BJ46 GCGCTTGTCGACTCAGCTAGTGGATCCGTTC SalI 
pds5B_siRNA1-
RES_6PM_for BJ50 
GCAATGAAATTTTCACG CAA TTG TAT CGA ACC 
TTATTTTCAGTTATAAACAATGGCC 6 mismatches 
pds5B_siRNA1-
RES_6PM_rev BJ51 
GGCCATTGTTTATAACTGAAAATAAGGTTCGATACAATTGCGTGAAA
ATTTCATTGC 6 mismatches 
pds5A_siRNA1-
RES_6PM_for BJ57 
CAATAAGAAGGTACAAATG CAT ATG TTG GAC CTA 
ATGAGTTCTATCATCATGG 6 mismatches 
pds5A_siRNA1-
RES_6PM_rev BJ58 
CCATGATGATAGAACTCATTAGGTCCAACATATGCATTTGTACCTTC
TTATTG 6 mismatches 
pds5A_siRNA1- BJ68 CAATAAGAAGGTACAAATG CAC ATG TTA GAT TTG 1 mismatch 
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RES_1-1PM_for ATGAGTTCTATCATCATGG 
pds5A_siRNA1-
RES_1-1PM_rev BJ69 
CCATGATGATAGAACTCATCAAATCTAACATGTGCATTTGTACCTTC
TTATTG 1 mismatch 
pds5A_TTdel_for BJ75 GCATGCATTGCTAATTTTTTCAATCAAGTCCTGGTGCTGG extra TT deletion 
pds5A_TTdel_rev BJ76 CCAGCACCAGGACTTGATTGAAAAAATTAGCAATGCATGC extra TT deletion 
pds5b_1  BJ08  GGATATGGACCAGGACTCTG  sequencing 
pds5b_2  BJ09  CAAGCAAGCATATGATTTGGC  sequencing 
pds5b_3  BJ10  GAGAGAGAACATTAGACAAAC  sequencing 
pds5b_4  BJ11  CTTGTTAGTCCAACATGCTC  sequencing 
pds5b_5  BJ12  CAAGCCAAATATGCCATTCATTG  sequencing 
pds5b_6  BJ13  CAAGTGTTTGCCCAGAAAC  sequencing 
pds5b_7  BJ14  CTCAACCTGACAAGAATTTCAG  sequencing 
pds5b_8  BJ15  GAAGATGAACAGAATAGTC  sequencing 
PDS5A BJ72 CTTCCCATGATAAACTTAAGGAC sequencing 
PDS5A BJ73 GCTGTTGTTCGACTTCTAGC sequencing 
PDS5A SEQ1 AGAACTCATCAAATCTAGCATGTGC sequencing 
PDS5A SEQ2 TATCTTGTCCCCCACAACCTGG sequencing 
PDS5A SEQ3 TGTTACAGTGCCTAAGAATGGAGG sequencing 
PDS5A SEQ4 TGGTAGTGCCATAATGAAGC sequencing 
PDS5A SEQ5 TGCAATGCAGATTCACCAAAGG sequencing 
PDS5A SEQ6  AGGGAAAGAACACTGGATAAACG sequencing 
PDS5A BJ74 GACAAGATCACCACGGACG sequencing 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
114 
                                                                                                               5 Appendix 
5 Appendix 
5.1 Plasmids generated for studying PDS5A and PDS5B 
Table 5.1-1 Plasmids generated 
Name db# 
C-term 9x MYC-tag pTRE2hyg 1131 
N-term 12x MYC-tag pTRE2hyg 1132 
N-term 12x MYC -PDS5B pTRE2hyg 1133 
PDS5B-9x MYC tag pTRE2hyg 1134 
N-term 12x MYC -PDS5A pTRE2hyg 1135 
PDS5A-9x MYC-tag pTRE2hyg 1136 
124_6pm_siRNA#32 1137 
KIAA0979  1138 
KIAA0979_6pm_siRNA#34 1139 
 
5.2 Sequence analysis of PDS5A and PDS5B 
Table 5.2-1: Detected conserved domains in PDS5A 
Protein Domain # Start End Length Remarks 
HEAT 1 69 107 38  PDSA 
PDSA HEAT/ARM 1 153 177 24  
HEAT 3-5 169 285 116 boundaries undefined PDSA 
PDSA HEAT 6 285 319 34  
HEAT 7 326 360 34  PDSA 
PDSA HEAT 8 363 397 34  
HEAT 9 401 435 34  PDSA 
PDSA HEAT 10-15 435 668 233 boundaries undefined 
HEAT 16 673 711 38  PDSA 
PDSA HEAT 17 722 756 34  
HEAT 18 756 793 37  PDSA 
PDSA ARM 1 829 870 41 HEAT also poss. 
PDSA ARM 2 995 1033 38  
 
Table 5.2-2: Detected conserved domains in PDS5B 
Protein Name # Start End Length Remarks 
HEAT 1 58 93 35  PDSB 
PDSB HEAT/ARM 1 124 152 28  
HEAT 3-5 155 271 116 boundaries undefined PDSB 
PDSB HEAT 6 271 305 34  
HEAT 7 312 346 34  PDSB 
PDSB HEAT 8 349 383 34  
HEAT 9 387 421 34  PDSB 
PDSB HEAT 10-15 421 659 238 boundaries undefined 
HEAT 16 659 697 38  PDSB 
PDSB HEAT 17 708 742 34  
HEAT 18 745 779 34  PDSB 
PDSB Charged  1084 1447 363 KR, ED enriched 
PDSB AT-hook  1372 1384 12  
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5.3 Interaction manuscript table S2 (all cleaned purifications) 
Table summarising all 175 unique bait purifications plus all Cdc2 purifications after 
contaminant removal annotated with bait species (sp), bait human orthologue (HGNC 
symbol, bait), prey (human orthologue of bait is marked with [Mm] if bait was a mouse 
protein or [Hs] if bait was a human protein), additive Mascot score (aM-Sc. (Mascot 
score of all unique identified peptides added up)) and percent sequence coverage 
(%SC). 
  
sp bait prey aM-Sc. %SC 
 Mm  ACTR1A  [Mm] ACTR1A 744 40.2 
 Mm  ACTR1A DCTN2 1160 50.5 
 Mm  ACTR1A DCTN1 1045 22.4 
 Mm  ACTR1A ACTR1A 566 33.2 
 Mm  ACTR1A DCTN3 303 44.3 
 Mm  AKAP12  [Mm] AKAP12 3295 51.5 
 Mm  AKAP12 LGALS7 352 55.1 
 Mm  AKAP12 PKM2 265 13 
 Mm  AKAP12 FABP5 222 61.4 
 Mm  AKAP12 ALDOA 144 9.1 
 Mm  AKAP12 PPIA 132 26.7 
 Mm  AKAP12 POF1B 128 6.8 
 Mm  AKAP12 PFN1 118 30 
 Mm  AKAP12 SBSN 96 11.3 
 Mm  AKAP12 TPI1 88 10 
 Mm  AKAP12 SPRR2E 79 36.1 
 Mm  AKAP12 TF 78 3.9 
 Mm  AKAP12 VCP 77 3.4 
 Mm  ANLN  [Mm] ANLN 2478 54.2 
 Mm  ARD1A  [Mm] ARD1A 657 53.6 
 Mm  ARD1A NARG1 1555 35.8 
 Mm  ARD1A NARG1L 1144 30.2 
 Mm  ARD1A NAT13 312 69.5 
 Mm  ARD1A SERF2 202 33.3 
 Mm  ARD1A ARRB2 72 5.3 
 Mm  ARD1A ARRB1 72 5.6 
 Mm  ATM  [Mm] ATM 2626 20 
 Mm  ATM DDB1 966 20 
 Mm  ATM CUL4A 634 21.7 
 Mm  ATM WDR42A 302 14.9 
 Mm  ATM LMNB1 143 11.6 
 Mm  ATM IQWD1 108 3.5 
 Hs  ATM  [Hs] ATM 401 4.6 
 Hs  ATM  [Hs] ATM 1447 11.6 
 Hs  AURKA  [Hs] AURKA 1168 62.3 
 Hs  AURKA AURKA 514 27.4 
 Hs  AURKA CEP192 400 5.4 
 Hs  AURKA TPX2 106 3.9 
 Hs  AURKA CALU 89 6.7 
 Mm  AZI1  [Mm] AZI1 4869 74.9 
 Mm  AZI1 AZI1 3601 60.7 
 Mm  AZI1 RANBP5 1783 60.9 
 Mm  AZI1 MIB1 729 18.8 
 Mm  AZI1 PCM1 438 8.8 
 Mm  BACH1  [Mm] BACH1 1020 29.4 
 Mm  BACH1 HMMR 607 23 
 Mm  BACH1 MAFK 243 34 
 Mm  BACH1 ENSG00000215622 193 19.3 
 Mm  BACH1 DYNLL1 177 49.4 
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 Mm  BACH1 FAM83D 115 5.9 
 Mm  BACH1 ARF1 104 13.8 
 Mm  BACH1 MAFF 83 15.2 
 Mm  BMPR1A  [Mm] BMPR1A 525 23.9 
 Mm  BUB1  [Mm] BUB1 3441 73.7 
 Mm  BUB1 CASC5 4310 46.9 
 Mm  BUB1 UBR5 3122 28.7 
 Mm  BUB1 BUB1B 1784 40.6 
 Mm  BUB1 NDC80 1336 42.1 
 Mm  BUB1 PMF1 762 77.6 
 Mm  BUB1 DSN1 713 48.6 
 Mm  BUB1 NUF2 489 29.7 
 Mm  BUB1 SPC25 486 37.1 
 Mm  BUB1 NSL1 479 35.9 
 Mm  BUB1 SPC24 419 50.3 
 Mm  BUB1 MIS12 337 31.7 
 Mm  BUB1 ZWINT 335 39.5 
 Mm  BUB1 PDE4D 163 4.8 
 Mm  BUB1 CDC20 78 5 
 Hs  BUB1  [Hs] BUB1 2781 49.4 
 Hs  BUB1 CASC5 3310 31.7 
 Hs  BUB1 UBR5 3133 24.8 
 Hs  BUB1 BUB1 2117 41.9 
 Hs  BUB1 BUB1B 1246 27 
 Hs  BUB1 NDC80 1112 34 
 Hs  BUB1 DSN1 680 43 
 Hs  BUB1 PMF1 547 55.6 
 Hs  BUB1 NSL1 504 51.2 
 Hs  BUB1 NUF2 467 19.4 
 Hs  BUB1 ZWINT 437 38.9 
 Hs  BUB1 MIS12 320 30.7 
 Hs  BUB1 SPC24 297 36 
 Hs  BUB1 SPC25 290 21.4 
 Mm  BUB1B  [Mm] BUB1B 3218 64.8 
 Mm  BUB1B UBR5 4197 35.6 
 Mm  BUB1B CASC5 4069 47 
 Mm  BUB1B ANAPC1 1785 23.9 
 Mm  BUB1B BUB1 1694 36.1 
 Mm  BUB1B ANAPC5 1132 33.6 
 Mm  BUB1B CDC23 1033 37.9 
 Mm  BUB1B CDC20 1003 55.7 
 Mm  BUB1B CDC27 928 33.3 
 Mm  BUB1B NDC80 894 28 
 Mm  BUB1B ASAH1 783 41.3 
 Mm  BUB1B CDC16 746 27.6 
 Mm  BUB1B DSN1 616 48.6 
 Mm  BUB1B PMF1 545 42.4 
 Mm  BUB1B NSL1 492 45.9 
 Mm  BUB1B NUF2 422 18.5 
 Mm  BUB1B SPC24 402 50.3 
 Mm  BUB1B MIS12 320 34.1 
 Mm  BUB1B ZWINT 312 24.9 
 Mm  BUB1B MAD2L1 273 32.2 
 Mm  BUB1B ANAPC10 215 32.4 
 Mm  BUB1B SPC25 210 18.8 
 Mm  BUB1B C10orf104 204 37.3 
 Mm  BUB1B ANAPC2 184 5.7 
 Mm  BUB1B CDC26 151 56.5 
 Mm  BUB1B XPNPEP3 131 7.7 
 Mm  BUB1B ANAPC13 92 37.8 
 Hs  BUB1B  [Hs] BUB1B 2017 50.5 
 Hs  BUB1B BUB1B 1542 39.8 
 Hs  BUB1B CDC20 227 14.4 
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 BUB1B CDC27 191 5.9  Hs 
 C11orf68  [Mm] C11orf68 334 27.9  Mm 
 C11orf68 PKM2 328 16.2  Mm 
 C11orf68 PHGDH 320 11.6  Mm 
 C11orf68 ALDOA 258  Mm 17.6 
 Mm  C11orf68 HNRPK 256 14 
 Mm  C11orf68 PA2G4 230 15.5 
 Mm  C11orf68 TRAP1 221 7.4 
 Mm  C11orf68 HNRNPA2B1 220 13.6 
 Mm  C11orf68 DDX5 213 6.8 
 Mm  C11orf68 PPIB 199 20.8 
 Mm  C11orf68 GNB2L1 191 14.2 
 Mm  C11orf68 EIF4A1 186 8.1 
 Mm  C11orf68 P4HB 183 7.5 
 Mm  C11orf68 NRAS 180 4.3 
 Mm  C11orf68 HNRNPU 178 4.9 
 Mm  C11orf68 PHB2 176 11.7 
 Mm  C11orf68 NME2 171 35.1 
 Mm  C11orf68 FASN 169 1.8 
 Mm  C11orf68 CALR 159 8.4 
 Mm  C11orf68 PHB 150 11.4 
 Mm  C11orf68 XRCC6 141 4.3 
 Mm  C11orf68 GPI 139 6.1 
 Mm  C11orf68 NACA 136 12.6 
 Mm  C11orf68 NP_001005472.1 135 10.5 
 Mm  C11orf68 or: ENSG00000215576 135 10.5 
 Mm  C11orf68 SERBP1 135 10.3 
 Mm  C11orf68 RAN 134 14.8 
 Mm  C11orf68 CSTA 134 28.6 
 Mm  C11orf68 AHNAK 133 1.1 
 Mm  C11orf68 NONO 127 6.2 
 Mm  C11orf68 PABPC1 121 5.5 
 Mm  C11orf68 SFPQ 118 4.8 
 Mm  C11orf68 VDAC4 115 12 
 Mm  C11orf68 EIF4A3 115 8.5 
 Mm  C11orf68 SET 112 12.8 
 Mm  C11orf68 PDIA3 111 7.1 
 Mm  C11orf68 TPI1 109 10 
 Mm  C11orf68 RCN1 107 7.9 
 Mm  C11orf68 PPIA 107 15.2 
 Mm  C11orf68 PDIA6 104 7.3 
 Mm  C11orf68 HNRPAB 103 9.5 
 Mm  C11orf68 ARF1 101 13.8 
 Mm  C11orf68 STRAP 101 9.7 
 Mm  C11orf68 PFN1 100 18.6 
 Mm  C11orf68 GOT2 99 6 
 Mm  C11orf68 CAPRIN1 97 3.5 
 Mm  C11orf68 ENSG00000177219 91 5.3 
 Mm  C11orf68 or: ENSG00000188174 91 6.9 
 Mm  C11orf68 or: HNRPA3 91 5.5 
 Mm  C11orf68 VCP 90 3.1 
 Mm  C11orf68 PGK1 89 5.8 
 Mm  C11orf68 TFRC 88 3.3 
 Mm  C11orf68 HNRNPR 87 3.2 
 Mm  C11orf68 CANX 87 7.1 
 Mm  C11orf68 EIF4H 87 9.6 
 Mm  C11orf68 ANXA5 84 5.6 
 Mm  C11orf68 SFRS5 84 7.7 
 Mm  C11orf68 TAGLN2 82 11.6 
 Mm  C11orf68 PDIA4 82 3.3 
 Mm  C11orf68 TKT 81 4.2 
 Mm  C11orf68 BAT1 79 5.6 
 Mm  C11orf68 or: DDX39 79 5.6 
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 Mm  C11orf68 or: UAP56_HUMAN 79 5.6 
 Mm  C11orf68 RBMX 78 6.6 
 Mm  C11orf68 SFRS6 76 5.2 
 Mm  C11orf68 DHX15 72 3 
 Mm  C11orf68 RUVBL2 70 4.3 
 Mm  C11orf68 ASS1 68 5 
 Mm  C13orf23  [Mm] C13orf23 30 5.6 
 Mm  C13orf23 ARF1 98 13.8 
 Mm  C9orf58  [Mm] C9orf58 243 32 
 Mm  C9orf58 THRAP3 75 2.6 
 Mm  C9orf58 PCBP1 74 8.7 
 Mm  C9orf58 or: PCBP3 74 9.9 
 Mm  CBX1  [Mm] CBX1 157 15.1 
 Mm  CBX1 GNAI3 633 43.5 
 Mm  CBX1 DSG2 619 17.4 
 Mm  CBX1 ALDH18A1 598 26.6 
 Mm  CBX1 GNAI1 537 40.7 
 Mm  CBX1 GNAI2 433 36.1 
 Mm  CBX1 GNB2 268 25.6 
 Mm  CBX1 RCN2 250 28.7 
 Mm  CBX1 ALPPL2 238 15.3 
 Mm  CBX1 RNH1 198 13.4 
 Mm  CBX1 FLOT1 182 14.3 
 Mm  CBX1 or: FLOT1 182 20 
 Mm  CBX1 FOLR1 181 21.4 
 Mm  CBX1 RPA2 180 18.5 
 Mm  CBX1 FLOT2 174 10.3 
 Mm  CBX1 RCN1 158 15.4 
 Mm  CBX1 CBX1 157 15.1 
 Mm  CBX1 GNAS 147 12.6 
 Mm  CBX1 FAM83B 144 3.7 
 Mm  CBX1 TMOD3 143 13.4 
 Mm  CBX1 STOM 122 10.8 
 Mm  CBX1 HNRPH1 119 7.6 
 Mm  CBX1 LGALS3BP 96 4.3 
 Mm  CBX1 FAM83H 88 3.8 
 Mm  CBX1 CSNK1A1L 82 6.5 
 Mm  CBX1 RBMX 81 6.6 
 Mm  CBX1 GNG12 75 41.7 
 Mm  CBX1 RTN4RL2 74 5.2 
 Mm  CCDC15  [Mm] CCDC15 118 3.2 
 Mm  CCDC15 HNRNPA2B1 228 19.7 
 Mm  CCDC15 NACA 208 26.5 
 Mm  CCDC15 FUS 173 24.5 
 Mm  CCDC15 TPM2 160 12.3 
 Mm  CCDC15 SERBP1 154 11.1 
 Mm  CCDC15 PYGM 145 4.1 
 Mm  CCDC15 C1QBP 135 19.1 
 Mm  CCDC15 PPIA 131 25.5 
 Mm  CCDC15 SET 130 13.2 
 Mm  CCDC15 HNRPK 115 12.4 
 Mm  CCDC15 SOD1 104 32.5 
 Mm  CCDC15 EIF4B 95 3.9 
 Mm  CCDC15 AHNAK 95 0.7 
 Mm  CCDC15 PTMS 81 22.5 
 Mm  CCDC15 Q9NYD7_HUMAN 77 18.4 
 Mm  CDC16  [Mm] CDC16 949 35.3 
 Mm  CDC16 ANAPC1 2650 38.1 
 Mm  CDC16 BUB1B 1791 46.2 
 Mm  CDC16 ANAPC5 1463 41.6 
 Mm  CDC16 CDC27 1208 43.3 
 Mm  CDC16 CDC23 1182 46.4 
 Mm  CDC16 ANAPC2 1062 28.3 
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 Mm  CDC16 CDC16 975 35.7 
 Mm  CDC16 CDC20 749 39.9 
 Mm  CDC16 HOMER3 412 34.5 
 Mm  CDC16 NEK2 310 20.9 
 Mm  CDC16 CDC26 304 54.1 
 Mm  CDC16 HOMER1 291 20.5 
 Mm  CDC16 ANAPC10 290 49.7 
 Mm  CDC16 C10orf104 244 51.8 
 Mm  CDC16 FBXO5 175 11 
 Mm  CDC16 ANAPC13 156 55.4 
 Mm  CDC16 FZR1 134 7.4 
 Mm  CDC16 ANAPC11 82 31 
 Mm  CDC16 MAD2L1 64 11.1 
 Hs  CDC16  [Hs] CDC16 50 3 
 Hs  CDC16 ANAPC1 198 3 
 Hs  CDC16 CDC20 134 7.4 
 Mm  CDC2  [Mm] CDC2 1158 69.7 
 Mm  CDC2 CCNB2 410 21.4 
 Mm  CDC2 CCNB1 300 17.3 
 Mm  CDC2 CCNA2 75 5.1 
 Mm  CDC2  [Mm] CDC2 648 34 
 Mm  CDC2 CCNB2 292 14.6 
 Mm  CDC2 CCNB1 263 13.9 
 Mm  CDC2 CKS2 74 24.1 
 Mm  CDC2  [Mm] CDC2 1438 78.8 
 Mm  CDC2 ESPL1 635 8.6 
 Mm  CDC2 CCNB2 564 34.4 
 Mm  CDC2 CCNB1 514 24.5 
 Mm  CDC2 SKP2 323 19.5 
 Mm  CDC2 CKS1B 162 38.8 
 Mm  CDC2 CCNA2 161 11.6 
 Mm  CDC2 SKP1A 160 20.9 
 Mm  CDC2 CKS2 88 24.1 
 Mm  CDC2 PKMYT1 80 4.4 
 Mm  CDC2  [Mm] CDC2 1561 83.5 
 Mm  CDC2 CCNB1 705 42.9 
 Mm  CDC2 CCNB2 703 49 
 Mm  CDC2 SKP2 477 22.9 
 Mm  CDC2 CCNA2 464 30.1 
 Mm  CDC2 ESPL1 335 4.6 
 Mm  CDC2 PKMYT1 264 11.2 
 Mm  CDC2 CKS1B 209 38.8 
 Mm  CDC2 SKP1A 196 25.8 
 Mm  CDC2 CCNO 163 10 
 Mm  CDC2 CKS2 161 44.3 
 Mm  CDC2 PHGDH 138 8.6 
 Mm  CDC2 CPS1 81 1.9 
 Mm  CDC2 AIFM1 81 4.6 
 Mm  CDC2 CDKN1C 72 8.4 
 Mm  CDC2  [Mm] CDC2 384 39.7 
 Mm  CDC2  [Mm] CDC2 1728 77.4 
 Mm  CDC2 CCNB2 929 50 
 Mm  CDC2 CCNB1 906 47.2 
 Mm  CDC2 CCNA2 341 21.5 
 Mm  CDC2 CKS1B 235 38.8 
 Mm  CDC2 CKS2 202 32.9 
 Mm  CDC2 NSUN2 155 8.3 
 Mm  CDC2 SKP2 137 6.3 
 Mm  CDC2 CDKN1B 104 7.1 
 Mm  CDC2  [Mm] CDC2 928 53.5 
 Mm  CDC2 CCNB1 310 18 
 Mm  CDC2 CCNB2 239 14.3 
 Mm  CDC2 CKS1B 105 28.4 
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 Mm  CDC2 CKS2 85 24.1 
 Mm  CDC2  [Mm] CDC2 1102 68.4 
 Mm  CDC2 CCNB2 387 26.6 
 Mm  CDC2 CCNB1 359 25.6 
 Mm  CDC2 CKS1B 173 38.8 
 Mm  CDC2  [Mm] CDC2 1736 85.2 
 Mm  CDC2 CCNB2 806 48.5 
 Mm  CDC2 ASCC3L1 692 9 
 Mm  CDC2 CCNB1 602 31.1 
 Mm  CDC2 EFTUD2 413 11.1 
 Mm  CDC2 CCNA2 359 21.8 
 Mm  CDC2 C20orf4 220 21.1 
 Mm  CDC2 SKP2 176 11.5 
 Mm  CDC2 CKS2 171 34.2 
 Mm  CDC2 CKS1B 170 38.8 
 Mm  CDC2 CCNO 128 8.3 
 Mm  CDC2 WDR57 76 22 
 Mm  CDC2  [Mm] CDC2 937 40.1 
 Mm  CDC2 CCNB2 348 21.4 
 Mm  CDC2 CCNB1 269 12 
 Mm  CDC2 SKP2 141 7.6 
 Mm  CDC2 SSBP1 106 15.5 
 Mm  CDC2 ESPL1 101 1.1 
 Mm  CDC2 CKS2 95 24.1 
 Mm  CDC2  [Mm] CDC2 914 53.9 
 Mm  CDC2 CCNB2 382 25.1 
 Mm  CDC2 CCNB1 351 22.9 
 Mm  CDC2 ANAPC1 314 4 
 Mm  CDC2 CDC27 200 5.5 
 Mm  CDC2 CCNA2 186 10.9 
 Mm  CDC2 SKP2 148 9 
 Mm  CDC2 PKMYT1 130 7.8 
 Mm  CDC2 CDC23 128 7.3 
 Mm  CDC2 CDC25C 92 4.8 
 Mm  CDC2 SKP1A 90 8 
 Mm  CDC2 ANAPC2 82 2.7 
 Mm  CDC2 CORO1C 79 3.6 
 Mm  CDC2 CKS2 78 24.1 
 Mm  CDC2  [Mm] CDC2 1302 71.7 
 Mm  CDC2 CCNB2 578 34.2 
 Mm  CDC2 CCNB1 465 28.6 
 Mm  CDC2 CKS1B 121 38.8 
 Mm  CDC2 CKS2 105 25.3 
 Mm  CDC2 SKP2 100 4.9 
 Mm  CDC2 C19orf21 85 3.8 
 Mm  CDC2  [Mm] CDC2 1701 85.5 
 Mm  CDC2 CCNB2 1165 61.6 
 Mm  CDC2 CCNB1 1096 51.3 
 Mm  CDC2 CCNA2 349 19 
 Mm  CDC2 CKS1B 245 47.8 
 Mm  CDC2 CKS2 204 46.8 
 Mm  CDC2 ESPL1 170 2.7 
 Mm  CDC2  [Mm] CDC2 1444 69 
 Mm  CDC2 CCNB1 492 24.7 
 Mm  CDC2 CCNB2 482 31.2 
 Mm  CDC2 WEE1 461 15.3 
 Mm  CDC2 CCNA2 202 14.1 
 Mm  CDC2 SKP2 186 10 
 Mm  CDC2 CKS1B 144 38.8 
 Mm  CDC2 PKMYT1 71 4.2 
 Mm  CDC2  [Mm] CDC2 988 65.7 
 Mm  CDC2 CCNB1 328 19.4 
 Mm  CDC2 CCNB2 199 12.6 
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 Mm  CDC2 CKS1B 147 38.8 
 Mm  CDC2 MAD1L1 107 3.3 
 Mm  CDC2 PDLIM7 101 5.7 
 Mm  CDC2 CCNA2 100 8.1 
 Mm  CDC2 SKP2 99 5.1 
 Mm  CDC2 BSG 78 15.3 
 Mm  CDC2 CKS2 75 24.1 
 Mm  CDC2  [Mm] CDC2 1987 88.9 
 Mm  CDC2 CCNB2 923 45.7 
 Mm  CDC2 CCNB1 772 40.9 
 Mm  CDC2 CCNA2 689 38.9 
 Mm  CDC2 SKP2 671 39.2 
 Mm  CDC2 SKP1A 519 55.2 
 Mm  CDC2 CKS2 234 45.6 
 Mm  CDC2 ESPL1 208 2.2 
 Mm  CDC2 CCNO 197 10.9 
 Mm  CDC2 CKS1B 191 38.8 
 Mm  CDC2 PKMYT1 109 6.2 
 Mm  CDC2  [Mm] CDC2 1058 70.7 
 Mm  CDC2 CCNB2 432 32.2 
 Mm  CDC2 CCNB1 271 23.1 
 Mm  CDC2 CKS2 134 32.9 
 Mm  CDC2 CKS1B 124 38.8 
 Mm  CDC2  [Mm] CDC2 0 0 
 Mm  CDC20  [Mm] CDC20 982 47.7 
 Mm  CDC20 BUB1B 2744 51.1 
 Mm  CDC20 ANAPC1 2072 27.5 
 Mm  CDC20 ANAPC5 1638 45.7 
 Mm  CDC20 CDC27 1265 35.2 
 Mm  CDC20 CDC16 949 29.8 
 Mm  CDC20 ANAPC2 929 21.7 
 Mm  CDC20 CDC23 870 36.5 
 Mm  CDC20 CDC20 829 40.9 
 Mm  CDC20 CASC5 559 7.5 
 Mm  CDC20 BUB1 546 13 
 Mm  CDC20 NUDC 497 39 
 Mm  CDC20 MAD2L1 479 39.5 
 Mm  CDC20 RNH1 475 23.4 
 Mm  CDC20 ANAPC10 323 48.1 
 Mm  CDC20 CDC26 299 65.9 
 Mm  CDC20 C10orf104 274 51.8 
 Mm  CDC20 ANAPC13 164 55.4 
 Mm  CDC23  [Mm] CDC23 1574 50.6 
 Mm  CDC23 ANAPC1 1780 23.4 
 Mm  CDC23 BUB1B 1400 29 
 Mm  CDC23 CDC27 1209 34.2 
 Mm  CDC23 ANAPC5 1150 27.4 
 Mm  CDC23 CDC16 931 29.4 
 Mm  CDC23 ANAPC2 925 23 
 Mm  CDC23 CDC23 875 28.6 
 Mm  CDC23 CDC20 758 36.3 
 Mm  CDC23 CDC26 379 67.1 
 Mm  CDC23 ANAPC10 224 24.9 
 Mm  CDC23 C10orf104 188 37.3 
 Mm  CDC23 ANAPC13 146 55.4 
 Mm  CDC23 MAD2L1 111 13.2 
 Mm  CDC23 FZR1 77 6.4 
 Mm  CDC26  [Mm] CDC26 421 63.5 
 Mm  CDC26 ANAPC1 2215 27.8 
 Mm  CDC26 ANAPC5 1479 30.1 
 Mm  CDC26 BUB1B 1329 31 
 Mm  CDC26 CDC27 1188 32.6 
 Mm  CDC26 CDC16 1043 26.9 
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 Mm  CDC26 CDC23 1039 37.7 
 Mm  CDC26 ANAPC2 985 23 
 Mm  CDC26 CDC20 721 34.9 
 Mm  CDC26 NEK2 422 24.7 
 Mm  CDC26 ANAPC10 255 40.5 
 Mm  CDC26 CDC26 234 65.9 
 Mm  CDC26 C10orf104 198 37.3 
 Mm  CDC26 ANAPC13 187 79.7 
 Mm  CDC26 FZR1 175 8.5 
 Mm  CDC26 FBXO5 146 9 
 Mm  CDC26 MAD2L1 136 13.2 
 Mm  CDC27  [Mm] CDC27 114 10.5 
 Mm  CDC27 CDC27 114 5.1 
 Hs  CDC27  [Hs] CDC27 0 0 
 Mm  CDC6  [Mm] CDC6 1071 35.2 
 Mm  CDC6 AIFM1 235 11.3 
 Mm  CDC6 THRAP3 219 6.7 
 Mm  CDC6 BCLAF1 74 2.2 
 Mm  CDCA5  [Mm] CDCA5 403 27.3 
 Mm  CDCA5 SMC1A 1143 32 
 Mm  CDCA5 SMC3 1006 20.4 
 Mm  CDCA5 RAD21 476 17.7 
 Mm  CDCA5 PDS5B 405 7.7 
 Mm  CDCA5 AURKB 97 9.3 
 Mm  CDCA5 LCN1 69 12.5 
 Hs  CDCA5  [Hs] CDCA5 331 35.7 
 Mm  CDCA8  [Mm] CDCA8 513 41.2 
 Mm  CDCA8 C1QBP 173 13.8 
 Mm  CDCA8 SIRT1 97 5 
 Mm  CDCA8 MRPS7 86 10.7 
 Mm  CDCA8 AURKB 84 6.4 
 Mm  CDCA8 CDCA8 79 10.7 
 Mm  CDCA8 EBNA1BP2 63 6.9 
 Mm  CENPE  [Mm] CENPE 7927 51.8 
 Mm  CENPE CLASP1 787 15.2 
 Mm  CENPE CLASP2 522 7.5 
 Mm  CEP110  [Mm] CEP110 6516 63.5 
 Mm  CEP110 SNAP29 238 18.2 
 Mm  CEP110 CEP110 227 10.3 
 Mm  CEP110 GOLGA3 158 2.2 
 Mm  CEP110 RAB14 133 14.9 
 Mm  CEP135  [Mm] CEP135 3824 59.6 
 Mm  CEP135 WDR8 670 33.6 
 Mm  CEP135 CEP135 139 2.1 
 Mm  CEP135 TTN 64 0 
 Mm  CEP152  [Mm] CEP152 3957 52.2 
 Mm  CEP152 CEP152 1823 29.3 
 Mm  CEP152 CEP63 387 17 
 Mm  CEP152 C15orf23 291 20.6 
 Mm  CEP152 DYNLL1 270 50.6 
 Mm  CEP152 SPAG5 259 8.6 
 Mm  CEP152 DYNLL2 250 50.6 
 Mm  CEP152 HNRPD 147 14.1 
 Mm  CEP152 CENPF 128 1.2 
 Mm  CEP152 SERBP1 93 7 
 Mm  CEP170  [Mm] CEP170 3332 46.3 
 Mm  CEP170 HERC2 2091 12.4 
 Mm  CEP170 KIFC3 1380 37.2 
 Mm  CEP170 CEP170 1298 21.6 
 Mm  CEP170 WDR62 625 10.1 
 Mm  CEP170 NP_115818.2 418 6.7 
 Mm  CEP170 KIAA1967 402 11.6 
 Mm  CEP170 SNAPAP 202 30.9 
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 CEP170 RALY 172 14.1  Mm 
 CEP170 SSBP1 169 23.6  Mm 
 CEP170 BEGAIN 149 8.8  Mm 
 CEP170 ZFP106 125 1.8  Mm 
 CEP170 PCM1 94 3  Mm 
 CEP170 PCYT1A 70 7.9  Mm 
 CEP192  [Mm] CEP192 1342 27.9  Mm 
 CEP192 LMO7 639 13.6  Mm 
 CEP192 AURKA 437 27.4  Mm 
 CEP192 C19orf21 227 10.2  Mm 
 CEP192 FOLR1 107 12.8  Mm 
 CEP27  [Mm] CEP27 258 32.2  Mm 
 CEP27 FAM29A 2211 47.6  Mm 
 CEP27 KIAA0841 1461 41.2  Mm 
 CEP27 C4orf15 1225 44.4  Mm 
 CEP27 CCDC5 871 57.9  Mm 
 CEP27 C14orf94 817 38.7  Mm 
 CEP27 UCHL5IP 682 50.4  Mm 
 CEP27 NP_219485.1 561 26.1  Mm 
 CEP290  [Mm] CEP290 1269 31.1  Mm 
 CEP290 TPM2 441 26.1  Mm 
 CEP290 TPM1 371 23.6  Mm 
 CEP290 RNH1 228 11.1  Mm 
 CEP290 CALD1 195 10  Mm 
 CEP290 NM_001014342.1 192 2.8  Mm 
 CEP290 PIP 169 29.5  Mm 
 CEP350  [Mm] CEP350 1578 20.3  Mm 
 CEP350 TLN2 3364 32.4  Mm 
 CEP350 TLN1 3226 36  Mm 
 CEP350 VCL 806 17.9  Mm 
 CEP350 C9orf140 605 39.3  Mm 
 CEP350 CTNNA1 566 16.3  Mm 
 CEP350 ENSG00000205476 288 19.6  Mm 
 CEP350 PPP2R1A 190 9  Mm 
 CEP350 PPP2R3C 98 5.7  Mm 
 CEP350 PAWR 95 8.5  Mm 
 CEP350 TES 93 8  Mm 
 CEP55  [Mm] CEP55 2013 65.7  Mm 
 CEP55 CEP55 1030 45.7  Mm 
 CEP55 TSG101 246 17.2  Mm 
 CEP55 PCBP1 238 18.8  Mm 
 CEP55 SPAG5 181 4  Mm 
 Mm  CEP55 PDCD6IP 147 4.1 
 Mm  CEP55 VPS37C 111 6.5 
 Mm  CEP55 C15orf23 108 7.3 
 Mm  CEP55 VPS28 104 11.8 
 Mm  CEP55 FBXO28 103 6.8 
 Mm  CEP55 NP_710154.1 97 5.8 
 Mm  CEP55 CEP170 88 1.5 
 Mm  CEP55 GNB2L1 79 7.3 
 Mm  CEP55 NP_001005472.1 77 7.1 
 Mm  CEP55 or: ENSG00000215576 77 7.1 
 Mm  CEP55 HNRNPA2B1 67 5.6 
 Mm  CEP55 SET 63 7.9 
 Mm  CEP72  [Mm] CEP72 457 18.6 
 Mm  CEP72 PPP1R12A 1748 31.1 
 Mm  CEP72 PPP1R12C 904 31.1 
 Mm  CEP72 SH2D4A 759 26.7 
 Mm  CEP72 PPP1CB 433 26.9 
 Mm  CEP72 PPP1R7 365 21.7 
 Mm  CEP72 PPP1R2 321 32.2 
 Mm  CEP72 PPP1R8 195 21.5 
 Mm  CEP72 YLPM1 191 3.4 
124 
                                                                                                               5 Appendix 
 Mm  CEP72 PPP1R12B 152 6.3 
 Mm  CEP72 PPP1R11 130 12.7 
 Mm  CEP72 PPP1R10 111 4.5 
 Mm  CEP76  [Mm] CEP76 1199 57.8 
 Mm  CEP76 DCTN2 593 40.1 
 Mm  CEP76 ACTR1A 397 31.4 
 Mm  CEP76 CORO1C 344 18.6 
 Mm  CEP76 GNAI2 318 23.3 
 Mm  CEP76 CEP76 303 22.6 
 Mm  CEP76 RAI14 290 6.9 
 Mm  CEP76 GNB2 253 18.5 
 Mm  CEP76 ANPEP 249 5.4 
 Mm  CEP76 CALD1 202 11.9 
 Mm  CEP76 C17orf84 188 5.9 
 Mm  CEP76 FOLR1 185 21.4 
 Mm  CEP76 CACNA2D1 181 6.8 
 Mm  CEP76 GNB1 179 14.1 
 Mm  CEP76 GNAI3 163 13 
 Mm  CEP76 ALPPL2 146 8.1 
 Mm  CEP76 DCTN1 134 3.3 
 Mm  CEP76 GNAI1 118 8.8 
 Mm  CEP78  [Mm] CEP78 2374 47.7 
 Mm  CEP78 CEP78 911 26.4 
 Mm  CEP78 UBR5 705 6.1 
 Mm  CEP78 SQSTM1 156 9.3 
 Mm  CEP78 NSUN2 137 5.5 
 Mm  CEP78 Q8TBD9_HUMAN 102 2.5 
 Mm  CEP78 NAP1L4 77 9.7 
 Mm  CETN2  [Mm] CETN2 427 65 
 Mm  CETN2 XPC 153 3.6 
 Mm  CETN2 CETN2 132 26.7 
 Mm  CETN2 CETN3 111 28.1 
 Mm  CETN2 RAD23B 101 7.8 
 Mm  CETN2 C5orf37 84 9 
 Hs  CHORDC1  [Hs] CHORDC1 1368 68.1 
 Mm  CKAP5  [Mm] CKAP5 1519 16.6 
 Mm  CKAP5 SET 71 9 
 Mm  CKAP5  [Mm] CKAP5 2804 31.3 
 Mm  CKAP5 TACC3 869 29.6 
 Mm  CKAP5 SLAIN2 292 11.1 
 Mm  CKAP5 APC 277 2.7 
 Mm  CKAP5 CKAP5 245 4.4 
 Hs  CKAP5  [Hs] CKAP5 4851 51.7 
 Hs  CKAP5 TACC3 1157 37 
 Hs  CKAP5 CKAP5 629 10 
 Hs  CKAP5 SLAIN2 232 12.3 
 Hs  CKAP5 TACC2 220 11.7 
 Hs  CKAP5 SNW1 70 4.3 
 Mm  CNOT3  [Mm] CNOT3 942 31 
 Mm  CNOT3 CNOT1 5472 53.2 
 Mm  CNOT3 TNKS1BP1 3852 63.8 
 Mm  CNOT3 CNOT10 1529 55.8 
 Mm  CNOT3 RAVER1 1444 65 
 Mm  CNOT3 CNOT2 1172 62.2 
 Mm  CNOT3 CNOT6L 1054 49.5 
 Mm  CNOT3 FHL2 882 64.2 
 Mm  CNOT3 RQCD1 752 50.5 
 Mm  CNOT3 CNOT8 619 55.1 
 Mm  CNOT3 CNOT6 593 28 
 Mm  CNOT3 C13orf7 549 17.6 
 Mm  CNOT3 CNOT7 498 50.9 
 Mm  CNOT3 C2orf29 463 24.1 
 Mm  CNOT3 TOB2 271 19.2 
125 
5 Appendix 
 
 Mm  CNOT3 BTG3 207 23.4 
 Mm  CNTROB  [Mm] CNTROB 0 0 
 Mm  CNTROB DYNLL1 176 49.4 
 Mm  CNTROB DYNLL2 159 49.4 
 Mm  CNTROB DYNLT3 136 23.3 
 Mm  CNTROB DYNLRB1 130 29.2 
 Mm  CNTROB NSUN2 98 5.5 
 Mm  COPA  [Mm] COPA 3145 51.5 
 Mm  COPA COPG 2468 57 
 Mm  COPA COPB1 1987 40.5 
 Mm  COPA COPB2 1731 45.5 
 Mm  COPA ARCN1 1193 51.5 
 Mm  COPA COPE 847 53.7 
 Mm  COPA ENSG00000214133 481 41.9 
 Mm  COPA BCAP31 351 26.4 
 Mm  COPA COPZ1 316 36.2 
 Mm  COPA ERGIC2 101 5.6 
 Mm  COPA SIPA1L3 92 1.4 
 Mm  COPA ARL6IP2 81 5.2 
 Mm  CSK  [Mm] CSK 1295 56.9 
 Mm  CSNK1E  [Mm] CSNK1E 974 50.2 
 Mm  CSNK1E GAPVD1 2070 44.9 
 Mm  CSNK1E PER1 1965 41.9 
 Mm  CSNK1E VPS13B 986 8.8 
 Mm  CSNK1E FAM83H 904 27.3 
 Mm  CSNK1E STOX2 892 32.1 
 Mm  CSNK1E PER3 878 26.5 
 Mm  CSNK1E CRY2 763 38.1 
 Mm  CSNK1E CRY1 654 37.9 
 Mm  CSNK1E FAM110B 424 33 
 Mm  CSNK1E RRP12 395 11.7 
 Mm  CSNK1E AP2A1 382 13.6 
 Mm  CSNK1E PER2 367 18.8 
 Mm  CSNK1E TSR1 304 9.6 
 Mm  CSNK1E PKM2 295 21.3 
 Mm  CSNK1E PPIA 267 55.8 
 Mm  CSNK1E AZI1 246 6.8 
 Mm  CSNK1E HNRNPA2B1 241 22.3 
 Mm  CSNK1E CPS1 234 4.9 
 Mm  CSNK1E AP2M1 224 19.2 
 Mm  CSNK1E SNX24 183 31.4 
 Mm  CSNK1E TKT 173 10 
 Mm  CSNK1E FAM110A 172 20 
 Mm  CSNK1E MCC 161 4.1 
 Mm  CSNK1E LTV1 157 8.6 
 Mm  CSNK1E GPI 146 6.6 
 Mm  CSNK1E TAGLN2 143 18.6 
 Mm  CSNK1E RPSAP15 140 18.6 
 Mm  CSNK1E ALDOA 139 9.1 
 Mm  CSNK1E TPI1 123 19.3 
 Mm  CSNK1E PFN1 115 21.4 
 Mm  CSNK1E SFRS2 112 12.4 
 Mm  CSNK1E NME2P1 107 19 
 Mm  CSNK1E MIF 97 17.4 
 Mm  CSNK1E EIF4A1 92 7.4 
 Mm  CSNK1E C1QBP 92 12.1 
 Mm  CSNK1E HNRPK 89 9.8 
 Mm  CSNK1E RAN 87 11.1 
 Mm  CSNK1E AHNAK 87 0.7 
 Mm  CSNK1E PCBP1 86 9.3 
 Mm  CSNK1E EIF5AP1 86 15.6 
 Mm  CSNK1E PGK1 82 6.7 
 Mm  CSNK1E NACA 82 13 
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 Mm  CUL3  [Mm] CUL3 211 8.9 
 Mm  CUL3 GOLGA2 1421 29.3 
 Mm  CUL3 KLHDC5 83 5 
 Mm  CUL3 LGALS3BP 79 3.2 
 Mm  DCTN1  [Mm] DCTN1 3031 42.3 
 Mm  DCTN1 DCTN2 1091 71.9 
 Mm  DCTN1 DCTN1 959 18.5 
 Mm  DCTN1 ACTR1A 954 63.6 
 Mm  DCTN1 DCTN3 305 52.7 
 Mm  DCTN2  [Mm] DCTN2 709 35.1 
 Mm  DCTN2 DCTN2 1441 62.6 
 Mm  DCTN2 DCTN1 1072 22.5 
 Mm  DCTN2 ACTR1A 828 45.7 
 Mm  DCTN2 DCTN3 369 50 
 Mm  DCTN2 SHCBP1 339 15.6 
 Mm  DCTN2 KIF23 128 4.1 
 Mm  DCTN3  [Mm] DCTN3 34 4.8 
 Mm  DCTN3 DCTN2 1035 63.3 
 Mm  DCTN3 DCTN1 945 23.6 
 Mm  DCTN3 ACTR1A 891 66 
 Mm  DCTN3 SNAP29 279 27.9 
 Mm  DCTN3 DCTN3 274 40.3 
 Mm  DDX41  [Mm] DDX41 833 27 
 Mm  DDX41 NKAP 213 6.3 
 Mm  DDX41 CSTA 82 21.4 
 Mm  DDX41 APOD 78 9.5 
 Mm  DTL  [Mm] DTL 1072 39.9 
 Mm  DTL DDB1 2349 45.3 
 Mm  DTL CUL4A 1352 37.4 
 Mm  DTL CUL4B 609 17.7 
 Mm  DTL COPS4 135 8.4 
 Mm  DTL COPS6 83 8 
 Mm  DTL COPS2 71 5.6 
 Mm  DYNC1H1  [Mm] DYNC1H1 7533 32.6 
 Mm  DYNC1H1 FOLR1 133 12.8 
 Mm  DYNC1H1 DYNLRB1 125 29.2 
 Mm  DYNC1H1 NSUN2 124 8.3 
 Mm  DYNC1H1 DYNLT3 124 23.3 
 Mm  DYNC1I2  [Mm] DYNC1I2 1522 53.4 
 Mm  DYNLL1  [Mm] DYNLL1 484 69.7 
 Mm  DYNLL1 HMMR 2394 60.4 
 Mm  DYNLL1 ANKRD15 2297 42.4 
 Mm  DYNLL1 C20orf117 1859 31.8 
 Mm  DYNLL1 ZMYM4 1825 31.3 
 Mm  DYNLL1 KIAA0802 1772 26.2 
 Mm  DYNLL1 NP_001006948.1 1396 21.9 
 Mm  DYNLL1 EML3 1367 35.4 
 Mm  DYNLL1 CTTNBP2NL 1229 33.8 
 Mm  DYNLL1 FAM83D 1206 37.9 
 Mm  DYNLL1 TLK2 1194 33 
 Mm  DYNLL1 SPAG5 1110 21.5 
 Mm  DYNLL1 TLK1 1033 29 
 Mm  DYNLL1 ZMYM2 996 18.9 
 Mm  DYNLL1 ANKRD25 977 28.9 
 Mm  DYNLL1 MORC3 828 26.7 
 Mm  DYNLL1 STRN3 786 25.8 
 Mm  DYNLL1 TP53BP1 763 11.5 
 Mm  DYNLL1 ZNF609 737 13.9 
 Mm  DYNLL1 FBXO30 603 25.9 
 Mm  DYNLL1 STRN4 574 21.1 
 Mm  DYNLL1 C15orf23 563 40.8 
 Mm  DYNLL1 STRN 546 19.2 
 Mm  DYNLL1 DYNLL1 408 68.5 
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 Mm  DYNLL1 MOBKL3 376 35.8 
 Mm  DYNLL1 FBXO38 355 7.2 
 Mm  DYNLL1 AOF2 337 9.6 
 Mm  DYNLL1 C5orf21 335 22.8 
 Mm  DYNLL1 DYNLL2 330 55.1 
 Mm  DYNLL1 ZMYM3 307 6.6 
 Mm  DYNLL1 FAM40A 290 12.7 
 Mm  DYNLL1 SKP1A 290 52.1 
 Mm  DYNLL1 PAPD1 276 9.8 
 Mm  DYNLL1 RCOR1 270 16 
 Mm  DYNLL1 NEK9 265 7.2 
 Mm  DYNLL1 GLCCI1 247 9 
 Mm  DYNLL1 GPHN 239 6.9 
 Mm  DYNLL1 DYNLRB1 218 74 
 Mm  DYNLL1 TRPS1 214 4.5 
 Mm  DYNLL1 AGGF1 165 6 
 Mm  DYNLL1 PPP2R1A 158 6.8 
 Mm  DYNLL1 CREB3L2 145 7.7 
 Mm  DYNLL1 NP_057626.2 137 7.9 
 Mm  DYNLL1 RCOR3 137 9.6 
 Mm  DYNLL1 PPP2CA 128 11 
 Mm  DYNLL1 PRKAR2A 127 10.2 
 Mm  DYNLL1 Q9H7K0_HUMAN 126 11 
 Mm  DYNLL1 HDAC2 124 8.6 
 Mm  DYNLL1 PDCD10 117 16 
 Mm  DYNLL1 NP_060219.2 113 3.5 
 Mm  DYNLL1 CIZ1 102 6 
 Mm  DYNLL1 WDR60 77 2.5 
 Mm  DYNLL1 MASTL 67 1.8 
 Mm  ECT2  [Mm] ECT2 1984 58.7 
 Mm  ECT2  [Mm] ECT2 1622 45.4 
 Mm  EDA2R  [Mm] EDA2R 267 25.9 
 Mm  EDC4  [Mm] EDC4 3245 63.7 
 Mm  EDC4 HADHA 994 38.7 
 Mm  EDC4 EDC4 934 21.6 
 Mm  EDC4 HADHB 610 35.7 
 Mm  EDC4 CCDC101 442 37.2 
 Mm  EDC4 DCP2 273 14 
 Mm  EDC4 EDC3 164 8.5 
 Mm  EDC4 NP_689929.1 129 6 
 Mm  EDC4 AP2B1 127 7 
 Mm  EDC4 AP2A1 110 5 
 Mm  EDC4 AP2M1 108 5.8 
 Mm  EEA1  [Mm] EEA1 4364 59.9 
 Mm  EEA1 EEA1 1281 22.9 
 Mm  EIF4A3  [Mm] EIF4A3 1251 46.4 
 Mm  EIF4A3 EIF4A3 481 18.7 
 Mm  ERH  [Mm] ERH 194 34.6 
 Mm  ERH THRAP3 1949 39.4 
 Mm  ERH CLTC 1719 27.8 
 Mm  ERH BCLAF1 1532 36.6 
 Mm  ERH PRMT1 968 51.3 
 Mm  ERH POLDIP3 967 54.6 
 Mm  ERH SAMM50 471 20.9 
 Mm  ERH TMOD3 424 28.1 
 Mm  ERH C1QBP 386 40.8 
 Mm  ERH SPECC1 342 9.6 
 Mm  ERH CHCHD3 337 25.6 
 Mm  ERH C19orf21 330 20 
 Mm  ERH PPP1R12A 292 7.1 
 Mm  ERH C1orf77 219 25.7 
 Mm  ERH FANCE 134 4.5 
 Mm  ERH C10orf18 130 1.4 
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 Mm  ERH CHCHD6 121 13.6 
 Mm  ERH CXorf23 108 2.8 
 Mm  ERH RBMX 96 5.4 
 Mm  ERH C14orf173 93 8.2 
 Mm  ERH ALPPL2 91 6.6 
 Mm  ERH BAT1 88 5.6 
 Mm  ERH or: DDX39 88 5.6 
 Mm  ERH or: UAP56_HUMAN 88 5.6 
 Mm  ERH THOC4 85 11.3 
 Mm  ERH FLOT1 68 7 
 Mm  ERH or: FLOT1 68 9.8 
 Mm  ESCO1  [Mm] ESCO1 859 23.5 
 Mm  ESPL1  [Mm] ESPL1 2773 31.1 
 Mm  ESPL1 C1QBP 195 14.9 
 Mm  ESPL1 ESPL1 133 1.4 
 Mm  ESPL1 CDC2 90 8.3 
 Mm  ESPL1 CCNB1 76 4.8 
 Mm  FAM107B  [Mm] FAM107B 516 58.8 
 Mm  FAM107B PLOD1 485 25.4 
 Mm  FAM107B RNH1 401 24.7 
 Mm  FAM107B PLOD2 343 17 
 Mm  FAM107B DYNLL1 202 49.4 
 Mm  FAM107B CTSD 171 9 
 Mm  FAM107B NM_001014342.1 89 1.3 
 Mm  FAM107B RPA2 73 8.1 
 Mm  FAM29A  [Mm] FAM29A 1658 38.3 
 Mm  FAM29A KIAA0841 1124 34.8 
 Mm  FAM29A C4orf15 857 34.2 
 Mm  FAM29A C14orf94 768 42.4 
 Mm  FAM29A CCDC5 571 37.1 
 Mm  FAM29A CEP27 486 35.3 
 Mm  FAM29A NP_219485.1 483 25.6 
 Mm  FAM29A UCHL5IP 470 42.5 
 Mm  FAM29A PTMS 71 22.5 
 Mm  FANCC  [Mm] FANCC 479 25 
 Mm  FANCC FANCE 885 40.3 
 Mm  FANCC C17orf70 367 13.4 
 Mm  FANCC FANCB 263 7.5 
 Mm  FANCC LASP1 215 17.6 
 Mm  FBXO5  [Mm] FBXO5 281 16.9 
 Mm  FGFR1OP  [Mm] FGFR1OP 1127 51.5 
 Mm  FGFR1OP PPP2R3C 260 12.8 
 Mm  FGFR1OP SHCBP1 185 5.2 
 Mm  FGFR1OP PPP2CA 93 6.1 
 Hs  FGFR1OP  [Hs] FGFR1OP 0 0 
 Mm  GORASP1  [Mm] GORASP1 209 13.9 
 Mm  GORASP1 GOLGA2 2875 55.4 
 Mm  GORASP1 KIF14 1094 19.1 
 Mm  GORASP1 LGALS3BP 374 13.5 
 Mm  GORASP1 SBSN 151 17 
 Mm  GORASP1 CLIP1 132 3.9 
 Mm  GORASP1 TMED7 129 13.8 
 Mm  GORASP1 LGALS7 109 16.9 
 Mm  GORASP1 FABP5 102 24.8 
 Mm  GORASP1 TMED2 89 10.4 
 Mm  GORASP1 LRRFIP2 85 14.1 
 Mm  GORASP1 CSTA 67 27.6 
 Mm  GORASP1 TMED4 66 8.8 
 Mm  GTF3C6  [Mm] GTF3C6 163 17.2 
 Mm  GTF3C6 GTF3C1 3352 38.3 
 Mm  GTF3C6 GTF3C3 1410 36.6 
 Mm  GTF3C6 GTF3C5 1207 59.8 
 Mm  GTF3C6 GTF3C2 1068 34.5 
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 Mm  GTF3C6 GTF3C4 945 53.7 
 Mm  GTF3C6 GTF2F1 214 11 
 Mm  HDAC6  [Mm] HDAC6 1097 24.5 
 Mm  HDAC6 PLAA 348 14.5 
 Mm  HDAC6 USP47 260 24.5 
 Mm  HDAC6 GARS 80 3.2 
 Mm  HSD17B7  [Mm] HSD17B7 251 15.6 
 Mm  HSD17B7 AHSG 98 3.5 
 Mm  HSP90AA1  [Mm] HSP90AA1 3549 73.5 
 Mm  ITSN2  [Mm] ITSN2 737 8.2 
 Mm  ITSN2 EIF4A3 132 3.4 
 Mm  KCTD5  [Mm] KCTD5 459 55.1 
 Mm  KCTD5 KCTD2 221 27 
 Mm  KCTD5 KCTD5 76 13.2 
 Mm  KIAA0892  [Mm] KIAA0892 42 1.5 
 Mm  KIAA0892 NIPBL 1435 13.9 
 Mm  KIAA0892 GNAI3 146 10.7 
 Mm  KIAA0892 RPA2 134 12.6 
 Mm  KIAA0892 LMO7 123 3.4 
 Mm  KIAA0892 GNG12 97 34.7 
 Mm  KIAA0892 SPECC1 79 2.7 
 Mm  KIAA0892 CHCHD3 77 11.5 
 Mm  KIAA0892 C19orf21 70 3.5 
 Mm  KIAA0892 GNB2 62 6.2 
 Mm  KIAA0892 or: GNB1 62 6.4 
 Mm  KIF1C  [Mm] KIF1C 1492 28.4 
 Mm  KIF1C THRAP3 179 5.3 
 Mm  KIF1C EIF4A3 167 9.2 
 Mm  KIF1C SSBP1 138 20.9 
 Mm  KIF1C C1orf77 135 20.8 
 Mm  KIF1C THOC4 116 10.9 
 Mm  KIF1C ARF1 115 13.8 
 Mm  KIF1C CCDC9 114 5.3 
 Mm  KIF1C HNRPD 82 7.8 
 Mm  KIF1C SUB1 81 15.7 
 Mm  KIF20A  [Mm] KIF20A 2463 56.8 
 Mm  KIF20A KIF20A 1692 43.7 
 Mm  KIF23  [Mm] KIF23 2276 56.2 
 Mm  KIF23 SHCBP1 1255 42.6 
 Mm  KIF23 CCAR1 1240 22.7 
 Mm  KIF23 RACGAP1 903 39.6 
 Mm  KIF23 KIF23 864 22.9 
 Mm  KIF23 MICAL3 492 24.2 
 Mm  KIF23 MICAL3 308 9.2 
 Mm  KIF23 PAWR 297 28.5 
 Mm  KIF23 CD2AP 276 13.1 
 Mm  KIF23 TRAF3IP1 192 9.4 
 Mm  KIF4A  [Mm] KIF4A 2844 41.8 
 Mm  KIF4A KIF4A 1008 16.8 
 Mm  KIF4A PRC1 210 9.7 
 Mm  KIF4A CEP170 81 2.7 
 Mm  KIF4A TUBGCP2 72 7.9 
 Mm  KIFC1  [Mm] KIFC1 1647 39.1 
 Mm  KIFC1 NUP153 1576 26.2 
 Mm  KIFC1 KIFC1 1411 41.5 
 Mm  KIFC1 NUP50 1065 49.3 
 Mm  KIFC1 KPNB1 914 25.6 
 Mm  KIFC1 IMA2_HUMAN 567 26.8 
 Mm  KIFC1 RANBP2 500 4.1 
 Mm  KIFC1 RANGAP1 392 16 
 Mm  KIFC1 TPR 144 8.7 
 Mm  LCK  [Mm] LCK 655 30.6 
 Mm  LCK CSTA 96 30.6 
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 MAD2L1  [Mm] MAD2L1 436 48.8  Mm 
 MAD2L1 MAD1L1 1127 34.4  Mm 
 MAD2L1 BUB1B 746 18.7  Mm 
 MAD2L1 KIF20A 731 21.3  Mm 
 MAD2L1 TPR 457 5.5  Mm 
 MAD2L1 CDC27 287 8.3  Mm 
 MAD2L1 NUDT5 276 24.2  Mm 
 MAD2L1 CDC20 239 13.4  Mm 
 MAD2L1 MAD2L1 237 25.9  Mm 
 MAD2L1 ANAPC1 235 3.1  Mm 
 MAD2L1 TOR1AIP1 219 12.2  Mm 
 MAD2L1 CDC16 191 7.2  Mm 
 MAD2L1 DNAJA1 149 9.3  Mm 
 MAD2L1 CDC23 135 4.4  Mm 
 MAD2L1 CDC26 129 14.1  Mm 
 MAD2L1 C1orf52 128 24  Mm 
 MAD2L1 THRAP3 123 4  Mm 
 MAD2L1 INSR 121 2.7  Mm 
 MAD2L1 TPX2 113  Mm 2.8 
 Mm  MAD2L1 C15orf23 101 7.3 
 Mm  MAD2L1 RCN1 97 7.9 
 Mm  MAD2L1 ANAPC5 95 5.5 
 Mm  MAD2L1 AHSG 87 3.5 
 Mm  MAD2L1 BCLAF1 74 3.2 
 Mm  MAD2L1 ANTXR1 73 6.6 
 Mm  MAD2L1 MAD2L1BP 65 7.7 
 Hs  MAD2L1  [Hs] MAD2L1 0 0 
 Mm  MAD2L1BP  [Mm] MAD2L1BP 306 21 
 Mm  MAD2L1BP MAD1L1 1814 46 
 Mm  MAD2L1BP LMO7 377 6.7 
 Mm  MAD2L1BP MAD2L1 172 15.1 
 Mm  MAD2L1BP PPIA 73 12.1 
 Mm  MAD2L2  [Mm] MAD2L2 248 40 
 Mm  MAD2L2 C13orf8 1716 43.3 
 Mm  MAD2L2 POGZ 974 18.8 
 Mm  MAD2L2 FAM35A 737 21.8 
 Mm  MAD2L2 GTF2I 613 16.4 
 Mm  MAD2L2 ZMYM4 462 10.3 
 Mm  MAD2L2 CBX3 421 36.6 
 Mm  MAD2L2 EHMT2 236 4.8 
 Mm  MAD2L2 or: BAT8_HUMAN 236 4.8 
 Mm  MAD2L2 EHMT1 218 6.8 
 Mm  MAD2L2 CALU 187 12.1 
 Mm  MAD2L2 RCN1 172 12.4 
 Mm  MAD2L2 ZNF644 159 21 
 Mm  MAD2L2 CBX1 120 15.1 
 Mm  MAD2L2 C20orf196 111 24.9 
 Mm  MAD2L2 SBSN 105 17 
 Mm  MAD2L2 ALDH3A2 90 5.2 
 Mm  MAD2L2 RCN2 73 9.8 
 Mm  MAD2L2 PGAM5 60 8.2 
 Hs  MARK2  [Hs] MARK2 1265 34.6 
 Hs  MARK2 KIAA0802 821 14.9 
 Mm  MIS12  [Mm] MIS12 799 69.9 
 Mm  MIS12 CASC5 5935 61.7 
 Mm  MIS12 NDC80 2164 63.2 
 Mm  MIS12 BUB1 1622 34.2 
 Mm  MIS12 BUB1B 1300 28.5 
 Mm  MIS12 PMF1 1286 84.4 
 Mm  MIS12 DSN1 1242 69.9 
 Mm  MIS12 SPC25 1022 63.8 
 Mm  MIS12 NUF2 953 46.3 
 Mm  MIS12 NSL1 834 60.5 
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 Mm  MIS12 ZWINT 814 62.4 
 Mm  MIS12 SPC24 583 74.6 
 Mm  MIS12 CNBP 269 34.7 
 Mm  MIS12 TRIM28 209 8.6 
 Mm  MIS12 CBX3 199 23 
 Mm  MIS12 AKAP8 159 9.8 
 Mm  MIS12 CYR61 113 7.1 
 Mm  MIS12 TRIM29 89 3.7 
 Mm  MIS12 CALU 77 7.6 
 Mm  MIS12 AKAP8L 67 3.7 
 Mm  MIS12 MYPN 67 2.4 
 Mm  MIS12 HNRPF 66 8 
 Hs  MIS12  [Hs] MIS12 511 43.9 
 Hs  MIS12 CASC5 4581 50.7 
 Hs  MIS12 NDC80 1823 55.6 
 Hs  MIS12 BUB1 1337 30.6 
 Hs  MIS12 DSN1 1200 68.5 
 Hs  MIS12 PMF1 1033 76.1 
 Hs  MIS12 NUF2 944 44.8 
 Hs  MIS12 SPC25 842 51.8 
 Hs  MIS12 ZWINT 754 70.7 
 Hs  MIS12 BUB1B 705 20 
 Hs  MIS12 NSL1 697 54.4 
 Hs  MIS12 SPC24 499 64 
 Hs  MIS12 MIS12 434 39.5 
 Hs  MIS12 CENPC1 199 6.8 
 Mm  MKI67  [Mm] MKI67 6608 47.3 
 Mm  MKI67 KPNB1 1958 49.5 
 Mm  MKI67 NUP153 1778 38.6 
 Mm  MKI67 IMA2_HUMAN 1401 68.8 
 Mm  MKI67 NUP50 782 49.1 
 Mm  MKI67 KPNA6 610 35.5 
 Mm  MKI67 KPNA3 525 33.6 
 Mm  MKI67 KPNA4 425 29.6 
 Mm  MKI67 PPP1CC 378 31.9 
 Mm  MKI67 KPNA1 375 18.2 
 Mm  MKI67 MKI67IP 310 23.5 
 Mm  MKI67 SFPQ 127 5.2 
 Mm  MKI67 MRTO4 114 12.1 
 Mm  MKI67 NONO 78 5.7 
 Mm  NARG1  [Mm] NARG1 2092 44 
 Mm  NARG1 NARG1 1307 25.9 
 Mm  NARG1 NAT13 551 74.4 
 Mm  NARG1 SERF2 326 50.4 
 Mm  NARG1 ARD1A 288 29.5 
 Mm  NAT13  [Mm] NAT13 340 61.2 
 Mm  NAT13 NAT13 263 56.1 
 Hs  NDC80  [Hs] NDC80 1033 35.2 
 Hs  NDC80 NDC80 951 32.4 
 Hs  NDC80 NUF2 321 20.5 
 Hs  NDC80 SPC24 311 57.4 
 Hs  NDC80 SPC25 262 25.4 
 Mm  NDC80  [Mm] NDC80 2044 53 
 Mm  NDC80 CASC5 2318 22.9 
 Mm  NDC80 HMMR 818 28.5 
 Mm  NDC80 NUF2 735 30 
 Mm  NDC80 DSN1 703 43.8 
 Mm  NDC80 SPC25 686 39.7 
 Mm  NDC80 C13orf24 597 18.1 
 Mm  NDC80 IQGAP3 463 6.3 
 Mm  NDC80 PCM1 462 6.2 
 Mm  NDC80 CCDC101 447 24.2 
 Mm  NDC80 ZWINT 444 31.8 
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 Mm  NDC80 BUB1 440 11.2 
 Mm  NDC80 NDC80 403 12.1 
 Mm  NDC80 PMF1 395 36.6 
 Mm  NDC80 CALCOCO1 371 12.8 
 Mm  NDC80 EPS15L1 332 10.3 
 Mm  NDC80 RRBP1 307 7.6 
 Mm  NDC80 THRAP3 279 8.5 
 Mm  NDC80 MLF1IP 248 16.5 
 Mm  NDC80 NSL1 213 17.1 
 Mm  NDC80 SPC24 212 37.6 
 Mm  NDC80 BUB1B 196 3.3 
 Mm  NDC80 KIFC1 191 7.1 
 Mm  NDC80 BICD2 191 5.5 
 Mm  NDC80 MIS12 148 16.1 
 Mm  NDC80 ODF2L 147 4.4 
 Mm  NDC80 NPR1 145 4.3 
 Mm  NDC80 SNAP29 116 12.8 
 Mm  NDC80 PHKA2 112 3 
 Mm  NDC80 HNRNPU 96 2.7 
 Mm  NDC80 ASPM 91 1.3 
 Mm  NDC80 RCN1 83 7.9 
 Mm  NDC80 SNAPAP 74 17.6 
 Mm  NDC80 PHKB 68 1.9 
 Mm  NDC80 BEGAIN 62 4.7 
 Mm  NDE1  [Mm] NDE1 1532 79.9 
 Mm  NDE1 SYNE1 2032 14.4 
 Mm  NDE1 KIAA1128 857 30.5 
 Mm  NDE1 NDE1 659 47.4 
 Mm  NDE1 NDEL1 579 41.5 
 Mm  NDE1 DIXDC1 411 26.5 
 Mm  NDE1 RNH1 148 8.9 
 Mm  NDE1 LGALS7 121 18.4 
 Mm  NDE1 RPA2 81 9.6 
 Mm  NEDD1  [Mm] NEDD1 1284 44.4 
 Mm  NEDD1 NEDD1 1062 34.2 
 Mm  NEDD1 SET 69 8.6 
 Mm  NEK2  [Mm] NEK2 747 40.9 
 Mm  NEK2 NEK2 428 28.4 
 Mm  NEK2 ACAD8 83 6 
 Mm  NEK9  [Mm] NEK9 1973 37.6 
 Mm  NEK9 NEK9 455 12.3 
 Mm  NEK9 NP_060219.2 424 10.3 
 Mm  NEK9 COG7 400 10.1 
 Mm  NEK9 DYNLL1 292 64 
 Mm  NEK9 COG5 271 7.9 
 Mm  NEK9 DDB1 241 5.8 
 Mm  NEK9 DYNLL2 222 59.6 
 Mm  NEK9 TCEB1 97 23.2 
 Mm  NEK9 C19orf58 96 27.5 
 Mm  NEK9 RPA2 70 8.1 
 Mm  NEK9 AURKA 70 6.9 
 Mm  NHP2L1  [Mm] NHP2L1 479 78.1 
 Mm  NHP2L1 NOL5A 1701 64.8 
 Mm  NHP2L1 NOP5_HUMAN 1528 54.6 
 Mm  NHP2L1 TGS1 1338 43.6 
 Mm  NHP2L1 RRP9 1284 64.8 
 Mm  NHP2L1 KPNB1 989 29 
 Mm  NHP2L1 SSB 950 48.5 
 Mm  NHP2L1 IMA2_HUMAN 919 49.5 
 Mm  NHP2L1 FBL 871 59.2 
 Mm  NHP2L1 DHX15 760 20.6 
 Mm  NHP2L1 KPNA1 717 30.3 
 Mm  NHP2L1 KPNA6 649 31.2 
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 Mm  NHP2L1 DHX9 570 12.3 
 Mm  NHP2L1 RUVBL2 556 27.6 
 Mm  NHP2L1 COIL 524 20 
 Mm  NHP2L1 NOLC1 519 21.7 
 Mm  NHP2L1 DHX30 518 12.3 
 Mm  NHP2L1 DKC1 509 25.2 
 Mm  NHP2L1 NUFIP1 472 23.8 
 Mm  NHP2L1 RUVBL1 443 30 
 Mm  NHP2L1 HNRPUL1 413 11.6 
 Mm  NHP2L1 SART3 401 13.8 
 Mm  NHP2L1 MOV10 328 11 
 Mm  NHP2L1 PINX1_HUMAN 256 19 
 Mm  NHP2L1 C1QBP 251 26.2 
 Mm  NHP2L1 NOLA2 232 42.2 
 Mm  NHP2L1 HNRPCL1 219 17.1 
 Mm  NHP2L1 ZNHIT3 200 32.3 
 Mm  NHP2L1 TARDBP 187 10.1 
 Mm  NHP2L1 SNRPD3 170 40.5 
 Mm  NHP2L1 C1orf181 160 10.2 
 Mm  NHP2L1 RANBP5 158 3.9 
 Mm  NHP2L1 LARP7 146 13.6 
 Mm  NHP2L1 PABPC1 144 6 
 Mm  NHP2L1 SNRPB 133 16 
 Mm  NHP2L1 NOLA3 127 45.3 
 Mm  NHP2L1 SNRPD1 117 45.4 
 Mm  NHP2L1 WDR43 117 2.9 
 Mm  NHP2L1 NHP2L1 116 18.8 
 Mm  NHP2L1 URB1 110 1.4 
 Mm  NHP2L1 SNRPE 101 25 
 Mm  NHP2L1 WDR79 96 6.6 
 Mm  NHP2L1 HNRPF 92 8.2 
 Mm  NHP2L1 SNRPD2 82 16.1 
 Mm  NHP2L1 GPATCH4 64 8.5 
 Mm  NIPBL  [Mm] NIPBL 1599 13.8 
 Mm  NIPBL NIPBL 631 5.9 
 Mm  NIPBL KPNA6 88 3.5 
 Mm  NIPBL KPNA1 85 3.7 
 Mm  NP_710154.1  [Mm] NP_710154.1 1041 45 
 Mm  NP_710154.1 LTF 971 35.1 
 Mm  NP_710154.1 NP_710154.1 643 30.8 
 Mm  NP_710154.1 AZGP1 206 15.7 
 Mm  NP_710154.1 WFDC2 147 43.8 
 Mm  NP_710154.1 TCN1 115 5.3 
 Mm  NP_710154.1 C20orf114 112 6.7 
 Mm  NP_710154.1 PLUNC 102 13.3 
 Mm  NRIP3  [Mm] NRIP3 31 5.4 
 Mm  NRIP3 SERPINB12 77 8.6 
 Mm  NUP107  [Mm] NUP107 1906 36.5 
 Mm  NUP107 NUP133 2165 40.9 
 Mm  NUP107 NUP160 1910 28.8 
 Mm  NUP107 NUP98 1457 18 
 Mm  NUP107 NUP85 1285 35.4 
 Mm  NUP107 SEH1L 822 41.9 
 Mm  NUP107 NUP107 574 13.3 
 Mm  NUP107 NUP37 473 33.7 
 Mm  NUP107 NUP43 447 27.6 
 Mm  NUP107 SEC13 442 34.4 
 Mm  NUP107 LGALS3BP 262 11.6 
 Mm  NUP155  [Mm] NUP155 4220 61.7 
 Mm  NUP188  [Mm] NUP188 1338 19 
 Mm  NUP188 NUP214 2059 26.5 
 Mm  NUP188 NUP93 2008 50.2 
 Mm  NUP188 NUP88 1012 31.2 
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 Mm  NUP188 OGT 907 18.1 
 Mm  NUP188 RAE1 855 42.9 
 Mm  NUP188 NUP98 614 17.3 
 Mm  NUP188 NUP62 446 12.6 
 Mm  NUP188 XPO1 123 3.4 
 Mm  NUP188 PKM2 111 5.3 
 Mm  NUP188 RAN 74 10.2 
 Mm  NUP214  [Mm] NUP214 1704 23.8 
 Mm  NUP214 NUP93 745 19.8 
 Mm  NUP214 NUP88 683 24.3 
 Mm  NUP214 NUP188 382 6.9 
 Mm  NUP214 NUP62 360 12.5 
 Mm  NUP214 OGT 357 8.6 
 Mm  NUP214 NUP214 269 2.8 
 Mm  NUP214 RAE1 179 16.3 
 Mm  NUP88  [Mm] NUP88 1489 38.8 
 Mm  NUP88 NUP214 1918 25.2 
 Mm  NUP88 NUP62 440 12.6 
 Mm  NUP88 RAN 98 11.1 
 Mm  NUP88 XPO1 87 2.1 
 Mm  NUP98  [Mm] NUP98 1002 15.3 
 Mm  NUP98 NUP160 2686 34.1 
 Mm  NUP98 NUP133 2615 42.5 
 Mm  NUP98 NUP107 1915 42.6 
 Mm  NUP98 NUP85 1579 40.9 
 Mm  NUP98 AHCTF1 1370 15.6 
 Mm  NUP98 SEH1L 982 60 
 Mm  NUP98 NUP43 589 37.9 
 Mm  NUP98 SEC13 577 37.3 
 Mm  NUP98 NUP37 517 33.7 
 Mm  OGG1  [Mm] OGG1 582 47 
 Mm  OGG1 LAMB1 100 3.5 
 Mm  ORC1L  [Mm] ORC1L 548 13.3 
 Mm  ORC1L ORC2L 287 10.1 
 Mm  ORC1L ORC3L 181 3.9 
 Mm  ORC1L ORC5L 166 7.8 
 Mm  ORC1L NP_690852.1 129 4.9 
 Mm  PAFAH1B1  [Mm] PAFAH1B1 1516 66.8 
 Mm  PAFAH1B1 CALD1 977 39.8 
 Mm  PAFAH1B1 PLS3 646 23.6 
 Mm  PAFAH1B1 FSCN1 468 22.5 
 Mm  PAFAH1B1 PAFAH1B2 255 27.1 
 Mm  PAFAH1B1 PAFAH1B3 231 23.8 
 Mm  PAFAH1B1 NDEL1 182 11.9 
 Mm  PAFAH1B1 NDE1 167 11.9 
 Mm  PAFAH1B1 TMOD3 159 9.7 
 Mm  PAFAH1B1 TPM2 146 11.8 
 Mm  PAFAH1B1 PAFAH1B1 122 3.4 
 Mm  PAFAH1B1 KIAA1949 114 5.4 
 Mm  PAFAH1B1 or: KIAA1949 114 7.2 
 Mm  PAFAH1B1 PPP1CA 110 8.8 
 Mm  PAFAH1B1 EDIL3 78 6 
 Mm  PAFAH1B1 LMO7 72 1.5 
 Mm  PAPSS1  [Mm] PAPSS1 701 34.3 
 Mm  PAPSS1 PAPSS2 268 19.7 
 Mm  PCNA  [Mm] PCNA 293 35.2 
 Mm  PDS5A  [Mm] PDS5A 2242 39.6 
 Mm  PDS5A PDS5A 1378 22.5 
 Mm  PDS5A EDC4 307 7 
 Mm  PDS5A LGALS7 304 39 
 Mm  PDS5A FABP5 213 61.4 
 Mm  PDS5A NACA 169 19.5 
 Mm  PDS5A C1QBP 163 26.2 
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 Mm  PDS5A SERPINB12 130 8.6 
 Mm  PDS5A FUS 128 16.6 
 Mm  PDS5A HNRPK 120 12.4 
 Mm  PDS5A PTMS 109 22.5 
 Mm  PDS5A SERBP1 103 7 
 Mm  PDS5A SOD1 100 32.5 
 Mm  PDS5A SET 99 9 
 Mm  PDS5A HNRNPA2B1 96 7.3 
 Mm  PDS5A ANXA5 94 7.8 
 Mm  PDS5A EIF5AP1 90 15.6 
 Mm  PLK1  [Mm] PLK1 1369 43.6 
 Mm  PLK1 BICD2 540 13.7 
 Mm  PLK1 ERCC6L 287 8.4 
 Mm  PLK1 FABP5 137 33.7 
 Mm  PLK1 NSUN2 106 5.5 
 Mm  PLK1 RAI14 69 2.3 
 Mm  PLK2  [Mm] PLK2 547 16.4 
 Mm  PLK4  [Mm] PLK4 266 8.1 
 Mm  PLK4 SET 121 12.8 
 Mm  PLK4 NACA 113 12.6 
 Mm  PLK4 PTMS 84 22.5 
 Mm  PPP1R10  [Mm] PPP1R10 1405 36.3 
 Mm  PPP1R10 WDR82 338 21.1 
 Mm  PPP1R10 TOX4 329 12.9 
 Mm  PPP1R10 PPP1CA 327 21.8 
 Mm  PPP1R10 PPP1CC 327 21.4 
 Mm  PPP1R10 PPP1CB 298 20.2 
 Mm  PPP1R10 TERF2 208 11.6 
 Mm  PPP1R10 PPP1R2 138 17.6 
 Mm  PPP1R10 C19orf7 87 1.8 
 Mm  PPP2R1A  [Mm] PPP2R1A 1906 59.6 
 Mm  PPP2R1A PPP2R5D 1519 53.2 
 Mm  PPP2R1A PPP2R2A 1163 49.4 
 Mm  PPP2R1A PPP2CA 1029 68 
 Mm  PPP2R1A PPP2CB 984 65.4 
 Mm  PPP2R1A PPME1 945 50.8 
 Mm  PPP2R1A PPP2R2D 567 31.2 
 Mm  PPP2R1A PPP2R5E 565 24 
 Mm  PPP2R1A PPP2R5C 497 29.3 
 Mm  PPP2R1A PPP2R1A 443 12.4 
 Mm  PPP2R1A FECH 196 13 
 Mm  PPP2R1A SGOL1 159 11 
 Mm  PPP2R1A PPP2R5A 157 8.2 
 Mm  PREB  [Mm] PREB 354 25.4 
 Mm  PRPF8  [Mm] PRPF8 4068 39.2 
 Mm  PRPF8 ASCC3L1 4498 41.9 
 Mm  PRPF8 EFTUD2 2214 50.8 
 Mm  PRPF8 DDX23 2016 48.5 
 Mm  PRPF8 PRPF6 1924 40.3 
 Mm  PRPF8 SART1 1514 45.2 
 Mm  PRPF8 PRPF3 1056 32.4 
 Mm  PRPF8 AQR 861 11.2 
 Mm  PRPF8 CDC5L 840 25.9 
 Mm  PRPF8 PRPF4 806 35.9 
 Mm  PRPF8 TFIP11 742 23.1 
 Mm  PRPF8 XAB2 719 24.2 
 Mm  PRPF8 USP39 687 30.3 
 Mm  PRPF8 C21orf66 656 20.5 
 Mm  PRPF8 RUVBL2 639 32.4 
 Mm  PRPF8 ECD 606 20.8 
 Mm  PRPF8 WDR57 591 46.5 
 Mm  PRPF8 C20orf4 574 33.9 
 Mm  PRPF8 NCDN 558 19.3 
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 PRPF8 SNW1 554 22.9  Mm 
 PRPF8 CRNKL1 521 12.8  Mm 
 PRPF8 PRPF31 515 24.6  Mm 
 PRPF8 PLRG1 494 30.7  Mm 
 PRPF8 SNRPB 470 31.2  Mm 
 PRPF8 CD2BP2 465 26.7  Mm 
 PRPF8 RUVBL1 448 19.7  Mm 
 PRPF8 DHX15 403 11.2  Mm 
 PRPF8 EAPP 383 19.3  Mm 
 PRPF8 TSSC4 339 41.7  Mm 
 PRPF8 SNRPD2 312 49.2  Mm 
 PRPF8 PRPF19 306 16.1  Mm 
 PRPF8 SNRPD3 290 47.6  Mm 
 PRPF8 NP_006848.1 243 23.9  Mm 
 PRPF8 RAB43 238 17.9  Mm 
 PRPF8 SYF2 210 23  Mm 
 PRPF8 SNRPD1 202 37.8  Mm 
 PRPF8 ZNHIT2 186 12.7  Mm 
 PRPF8 DHX38 182 3.3  Mm 
 PRPF8 RSRC1 166 14.9  Mm 
 PRPF8 C9orf78 164 12.8  Mm 
 PRPF8 BCAS2 143 21.8  Mm 
 PRPF8 TTC27 135 3.4  Mm 
 PRPF8 LSM4 133 25.2  Mm 
 PRPF8 SNRPE 132 30.8  Mm 
 PRPF8 PPIE 130 9.6  Mm 
 PRPF8 LSM8 123 27.1  Mm 
 PRPF8 CWC15 123 14  Mm 
 PRPF8 PPIH 123 17.2  Mm 
 PRPF8 NHP2L1 120 18.8  Mm 
 PRPF8 SNRPG 111 17.1  Mm 
 PRPF8 CCDC12 108 7.8  Mm 
 PRPF8 DHX35 104 3.1  Mm 
 PRPF8 PPIL1 81 16.9  Mm 
 PTTG1  [Hs] PTTG1 85 12.4  Hs 
 PTTG1 ESPL1 2778 32  Hs 
 PTTG1 DECR1 72 7.8  Hs 
 PTTG1  [Mm] PTTG1 56 9  Mm 
 PTTG1 CLTC 87 1.4  Mm 
 RAB4A  [Mm] RAB4A 0 0  Mm 
 RAB4A EIF4A3 132 3.4  Mm 
 RAB5C  [Mm] RAB5C 1078 85.6  Mm 
 RAB5C GDI2 987 50.2  Mm 
 RAB5C APOD 285 28  Mm 
 RAB5C FABP5 176 51.5  Mm 
 RAB5C PIP 159 28.8  Mm 
 RAB5C LGALS7 124 16.9  Mm 
 RAB5C NM_001014342.1 96 0.8  Mm 
 RAB5C CTSD 64 4.1  Mm 
 RAB8A  [Mm] RAB8A 159 15.9  Mm 
 RAB8A MICALL2 245 9.2  Mm 
 RAB8A SYTL4 148 6.3  Mm 
 RACGAP1  [Mm] RACGAP1 1304 55.4  Mm 
 RACGAP1 SHCBP1 1589 54.3  Mm 
 RACGAP1 KIF23 1233 33.3  Mm 
 RACGAP1 RACGAP1 1214 48.6  Mm 
 RACGAP1 CD2AP 589 26.3  Mm 
 RACGAP1 MICAL3 406  Mm 22.4 
 Mm  RACGAP1 MICAL3 359 9.7 
 Mm  RAD21  [Mm] RAD21 1239 37.3 
 Mm  RAD21 SMC1A 3724 52.1 
 Mm  RAD21 SMC3 3485 49.1 
 Mm  RAD21 PDS5B 1024 15.8 
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 Mm  RAD21 STAG1 1023 17.4 
 Mm  RAD21 RAD21 741 22.5 
 Mm  RAD21 WAPAL 563 13.2 
 Mm  RAD21 STAG2 338 4.8 
 Mm  RAD21 PDS5A 251 4.6 
 Mm  RAE1  [Mm] RAE1 0 0 
 Mm  RANBP2  [Mm] RANBP2 8731 57.6 
 Mm  RANBP2 RANBP2 2686 19 
 Mm  RANBP2 RANGAP1 2144 56.2 
 Mm  RANBP2 KPNB1 1328 33.1 
 Mm  RANBP2 RCC1 609 40.6 
 Mm  RANBP2 NUSAP1 527 29.5 
 Mm  RANBP2 NXF1 505 17.1 
 Mm  RANBP2 RAN 472 40.7 
 Mm  RANBP2 UBE2I 429 34.8 
 Mm  RANBP2 KIFC1 418 14.6 
 Mm  RANBP2 IMA2_HUMAN 296 15.7 
 Mm  RANBP2 KPNA4 198 8.8 
 Mm  RANBP2 RANBP1 197 44.3 
 Mm  RANBP2 SUMO1P3 179 29.7 
 Mm  RANBP2 BICD2 142 3.9 
 Mm  RANBP2 NUMA1 142 1.8 
 Mm  RANBP2 KPNA3 91 5.4 
 Mm  RANBP2 SUMO3 82 20.4 
 Mm  RANBP2 SUMO2 77 31 
 Mm  RASSF1  [Mm] RASSF1 633 41.5 
 Mm  RASSF1 STK4 1403 55 
 Mm  RASSF1 STK3 1149 53 
 Mm  RASSF1 VAPA 326 29.8 
 Mm  RASSF1 VAPB 171 26.3 
 Mm  RASSF1 TMEM109 128 12.8 
 Mm  RASSF1 MAP1S 85 2.5 
 Mm  RASSF1 KIAA1754 77 4.6 
 Mm  RECQL4  [Mm] RECQL4 918 19.5 
 Mm  RECQL4 GNAI2 162 12.7 
 Mm  RECQL4 or: GNAI3 162 12.7 
 Mm  RECQL4 STOM 159 10.8 
 Mm  RECQL4 ATAD3C 128 7.6 
 Mm  RECQL4 CHCHD3 108 11.5 
 Mm  RECQL4 HNRNPU 97 3.1 
 Mm  RECQL4 HNRNPA2B1 71 7.6 
 Mm  RHOA  [Mm] RHOA 367 35.2 
 Mm  RHOA NM_001014342.1 86 0.9 
 Mm  SASS6  [Mm] SASS6 1284 52.6 
 Mm  SASS6 FSCN1 537 31 
 Mm  SASS6 TPM2 528 27.8 
 Mm  SASS6 TPM1 515 28.9 
 Mm  SASS6 PPP1R12A 495 10 
 Mm  SASS6 TMOD3 385 34.7 
 Mm  SASS6 CALD1 302 18 
 Mm  SASS6 CORO1C 212 13.5 
 Mm  SASS6 PPP1CC 171 21.1 
 Mm  SASS6 or: PPP1CB 171 20.8 
 Mm  SASS6 C17orf84 150 3.8 
 Mm  SASS6 C19orf21 84 4.6 
 Mm  SASS6 PLS3 79 6.4 
 Mm  SASS6 SASS6 74 5.6 
 Mm  SF3A1  [Mm] SF3A1 2092 57.3 
 Mm  SF3A1 SF3B1 3253 56.1 
 Mm  SF3A1 SF3B3 2550 47.2 
 Mm  SF3A1 DDX46 2494 45.1 
 Mm  SF3A1 SF3B2 1539 38.8 
 Mm  SF3A1 HTATSF1 1430 38.8 
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 Mm  SF3A1 SF3A3 1319 51.5 
 Mm  SF3A1 DHX15 1148 32.8 
 Mm  SF3A1 O15042_HUMAN 645 16.3 
 Mm  SF3A1 DDX42 590 16.2 
 Mm  SF3A1 SNRPA1 575 89.7 
 Mm  SF3A1 SF3A2 509 21.1 
 Mm  SF3A1 CCDC97 416 41.1 
 Mm  SF3A1 SF3B4 374 25.7 
 Mm  SF3A1 SNRPD2 344 49.2 
 Mm  SF3A1 LEPRE1 337 10.5 
 Mm  SF3A1 CHERP 305 8.8 
 Mm  SF3A1 WDR61 286 29.5 
 Mm  SF3A1 RBM39 285 12.9 
 Mm  SF3A1 SNRPB 268 19.5 
 Mm  SF3A1 PM14_HUMAN 267 40.8 
 Mm  SF3A1 PHF5A 245 40.9 
 Mm  SF3A1 SNRPD3 241 47.6 
 Mm  SF3A1 SNRPB2 240 24.4 
 Mm  SF3A1 CRTAP 222 14 
 Mm  SF3A1 RBM17 203 14.5 
 Mm  SF3A1 SF3B5 201 55.8 
 Mm  SF3A1 SNRPD1 174 45.4 
 Mm  SF3A1 SNRPE 155 30.8 
 Mm  SF3A1 DNAJC8 136 17.4 
 Mm  SF3A1 TTC33 125 13 
 Mm  SF3A1 CCDC75 116 12.3 
 Mm  SF3A1 SNRPG 78 17.1 
 Mm  SF3A1 SNRPF 73 24.4 
 Mm  SGOL1  [Mm] SGOL1 372 19.1 
 Mm  SGOL1 LGALS7 177 27.2 
 Mm  SGOL2  [Mm] SGOL2 2471 47.3 
 Mm  SGOL2 SGOL2 1016 20.2 
 Mm  SGOL2 PPP2R5E 544 19.9 
 Mm  SGOL2 PPP2R5A 478 19.8 
 Mm  SGOL2 PPP2R1B 288 10.5 
 Mm  SGOL2 PPP2CA 215 16.2 
 Mm  SGOL2 SET 207 19.1 
 Mm  SGOL2 PPP2R1A 204 7.1 
 Mm  SGOL2 DHX30 85 1.7 
 Mm  SGOL2 GNL3 78 3.9 
 Mm  SGOL2 MYBBP1A 71 1.4 
 Mm  SHOC2  [Mm] SHOC2 858 25.9 
 Mm  SHOC2 SUGT1 457 29.4 
 Mm  SHOC2 SCRIB 206 2.6 
 Mm  SHOC2 NACA 198 19.5 
 Mm  SHOC2 RBMX 130 9.2 
 Mm  SHOC2 HNRNPA2B1 101 7.6 
 Mm  SHOC2 NP_001005472.1 100 7.8 
 Mm  SHOC2 or: ENSG00000215576 100 7.8 
 Mm  SHOC2 or: XP_371273.1 100 7.9 
 Mm  SHOC2 HNRPAB 97 8.4 
 Mm  SHOC2 SERBP1 84 7 
 Mm  SHOC2 FUS 81 16.6 
 Mm  SHOC2 HNRPD 81 7.8 
 Mm  SHOC2 SUB1 72 15.7 
 Mm  SHOC2 TMPO 71 9.3 
 Mm  SLC25A4  [Mm] SLC25A4 86 7 
 Mm  SLC25A4 BCLAF1 66 2 
 Mm  SMAD3  [Mm] SMAD3 643 41.5 
 Mm  SMAD3 LEMD3 544 18.3 
 Mm  SMAD3 AHSG 95 3.5 
 Mm  SMC6  [Mm] SMC6 976 16.2 
 Mm  SMC6 SMC5 2814 40.4 
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 Mm  SMC6 SMC6 1683 30 
 Mm  SMC6 NSMCE4A 552 22.1 
 Mm  SMC6 NSMCE2 536 36.4 
 Mm  SMC6 NDNL2 493 38.8 
 Mm  SMC6 TUFT1 460 25.4 
 Mm  SMC6 NSMCE1 367 21.4 
 Mm  SMC6 RAD18 150 8.5 
 Mm  SNW1  [Mm] SNW1 1146 50.4 
 Mm  SNW1 ASCC3L1 1213 18.1 
 Mm  SNW1 EFTUD2 1078 24.3 
 Mm  SNW1 CDC5L 905 32.4 
 Mm  SNW1 SAAL1 778 33.1 
 Mm  SNW1 PRPF19 469 37.5 
 Mm  SNW1 XAB2 422 12.9 
 Mm  SNW1 SNW1 422 20.3 
 Mm  SNW1 AQR 405 6.8 
 Mm  SNW1 HOMER3 402 33.8 
 Mm  SNW1 SYF2 375 23 
 Mm  SNW1 PLRG1 356 26.1 
 Mm  SNW1 WDR57 334 38.6 
 Mm  SNW1 HOMER1 263 21.2 
 Mm  SNW1 CCDC12 219 33.1 
 Mm  SNW1 CRNKL1 214 6 
 Mm  SNW1 RAB43 206 17.5 
 Mm  SNW1 PPIL1 205 26.5 
 Mm  SNW1 PPIE 200 15.6 
 Mm  SNW1 C20orf4 198 18.2 
 Mm  SNW1 RSRC1 179 18.8 
 Mm  SNW1 CDC40 178 8.2 
 Mm  SNW1 DHX15 132 4.2 
 Mm  SNW1 SNRPD3 124 24.6 
 Mm  SNW1 C21orf66 115 5.5 
 Mm  SNW1 CWC15 106 15.4 
 Mm  SNW1 SNRPD2 72 16.1 
 Mm  SNW1 SNRPD1 72 20.2 
 Mm  SNW1 SNRPE 71 25 
 Mm  SPAG5  [Mm] SPAG5 2328 45.9 
 Mm  SPAG5 SPAG5 2118 45.5 
 Mm  SPAG5 C15orf23 973 52.5 
 Mm  SPAG5 CDK5RAP2 682 15.1 
 Mm  SPAG5 SNAP29 613 62 
 Mm  SPAG5 DYNLL1 284 64 
 Mm  SPAG5 DYNLL2 193 50.6 
 Mm  SPAG5 ATAD3B 178 16.4 
 Mm  SPAG5 or: ENSG00000215733 178 8.7 
 Mm  SPAG5 WDR68 124 8.2 
 Mm  SPAG5 TROAP 122 6.6 
 Mm  SPC24  [Mm] SPC24 145 18.1 
 Mm  SPC24 LMO7 195 3.7 
 Mm  STAG2  [Mm] STAG2 2361 40.8 
 Mm  STAG2 SMC1A 4143 56.5 
 Mm  STAG2 SMC3 3948 54.3 
 Mm  STAG2 PDS5B 1843 29.4 
 Mm  STAG2 RAD21 1444 44.2 
 Mm  STAG2 WAPAL 1259 28.2 
 Mm  STAG2 RNH1 472 22.8 
 Mm  STAG2 ALDH3A2 468 20.4 
 Mm  STAG2 PDS5A 371 7.2 
 Mm  TACC3  [Mm] TACC3 1264 28.3 
 Mm  TACC3 CKAP5 453 8 
 Mm  TACC3 TACC3 217 15.9 
 Mm  TIMELESS  [Mm] TIMELESS 1307 26.9 
 Mm  TIMELESS TIPIN 368 25.6 
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 Mm  TIMELESS CRY1 289 17.1 
 Mm  TIMELESS RPA2 83 7.4 
 Mm  TIPIN  [Mm] TIPIN 272 21.9 
 Mm  TIPIN TIMELESS 2071 35.9 
 Mm  TIPIN THRAP3 403 11.9 
 Mm  TIPIN RPA2 212 26.7 
 Mm  TIPIN TIPIN 155 11.3 
 Mm  TIPIN RPA3 138 38.8 
 Mm  TIPIN BCLAF1 120 4.3 
 Mm  TIPIN PCMTD1 84 6.7 
 Mm  TMEM48  [Mm] TMEM48 1164 41.9 
 Mm  TOP2B  [Mm] TOP2B 3423 36.7 
 Mm  TOP2B Q71UN1_HUMAN 1609 20.5 
 Mm  TOP2B ZNF451 1092 23.5 
 Mm  TOP2B TOP2B 463 4.9 
 Mm  TOP2B LMO7 349 7.2 
 Mm  TOP2B ITPR1 112 0.6 
 Mm  TOR1AIP1  [Mm] TOR1AIP1 1311 53.7 
 Mm  TOR1AIP1 CANX 78 3.5 
 Mm  TPR  [Mm] TPR 7351 52.4 
 Mm  TPR TPR 1090 11 
 Mm  TPR LGALS7 383 46.3 
 Mm  TPR PPIA 166 23 
 Mm  TPR FABP5 130 24.8 
 Mm  TPR POF1B 114 4.9 
 Mm  TPR AHNAK 98 0.9 
 Mm  TPR TRIM29 86 3.7 
 Mm  TPR PKM2 85 4.5 
 Mm  TRIM69  [Mm] TRIM69 129 7.4 
 Mm  TRIM69 DSG2 1355 40 
 Mm  TRIM69 FLOT1 1122 60.7 
 Mm  TRIM69 GNAI2 782 49.9 
 Mm  TRIM69 GNAI3 766 44.4 
 Mm  TRIM69 ALPPL2 765 37.8 
 Mm  TRIM69 LMO7 729 15.9 
 Mm  TRIM69 FLOT2 659 41.7 
 Mm  TRIM69 GNB2 646 41.2 
 Mm  TRIM69 GNAI1 635 39.3 
 Mm  TRIM69 GNB4 593 44.7 
 Mm  TRIM69 GNB1 591 46.8 
 Mm  TRIM69 C19orf21 574 23.6 
 Mm  TRIM69 GNAS 551 40 
 Mm  TRIM69 SPECC1 516 16.4 
 Mm  TRIM69 C17orf84 468 12.8 
 Mm  TRIM69 YES1 447 25.2 
 Mm  TRIM69 STOM 433 48.8 
 Mm  TRIM69 FYN 395 24.3 
 Mm  TRIM69 LYN 379 25.8 
 Mm  TRIM69 CPM 350 21.7 
 Mm  TRIM69 PACSIN3 304 19.1 
 Mm  TRIM69 PPP1R12A 304 7.6 
 Mm  TRIM69 FABP5 208 62.4 
 Mm  TRIM69 FOLR1 206 21.4 
 Mm  TRIM69 LYPD3 200 20.4 
 Mm  TRIM69 HNRPCL1 199 17.7 
 Mm  TRIM69 LGALS1 185 31.9 
 Mm  TRIM69 TMOD3 182 12.5 
 Mm  TRIM69 RRAS2 171 19.1 
 Mm  TRIM69 ABCG2 168 4.9 
 Mm  TRIM69 RTN4RL2 161 10 
 Mm  TRIM69 GPRC5A 160 18.8 
 Mm  TRIM69 HNRNPU 159 5.3 
 Mm  TRIM69 GNG12 150 56.9 
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 Mm  TRIM69 SVIL 138 2.6 
 Mm  TRIM69 PKM2 129 9.8 
 Mm  TRIM69 ALDH18A1 125 4.7 
 Mm  TRIM69 NEXN 79 4.6 
 Mm  TRIM69 RBMX 67 6.6 
 Mm  TTK  [Mm] TTK 1101 36.6 
 Mm  TTK NM_001014342.1 112 1.3 
 Mm  TTK CTSD 88 4.6 
 Mm  TTK TGM1 77 3.4 
 Hs  TTK  [Hs] TTK 1822 49.6 
 Mm  TUBA1B  [Mm] TUBA1B 1200 58.1 
 Mm  TUBA1B DNAJA1 126 6.3 
 Mm  TUBA3D  [Mm] TUBA3D 714 45.3 
 Mm  TUBA3D ACTR1A 325 27.7 
 Mm  TUBA3D DCTN1 308 7.4 
 Mm  TUBA3D PFDN2 177 29.9 
 Mm  TUBA3D PFDN4 114 20.1 
 Mm  TUBA3D VBP1 107 11.7 
 Mm  TUBA3D DCTN2 105 11.6 
 Mm  TUBA3D AIFM1 100 6.4 
 Mm  TUBB  [Mm] TUBB 1912 73.2 
 Mm  TUBB TBCD 866 22.9 
 Mm  TUBB DNAJA1 721 46.7 
 Mm  TUBB TCP11L1 363 13 
 Mm  TUBB AIFM1 346 12.8 
 Mm  TUBB DNAJA2 179 11.7 
 Mm  TUBB PNKD 148 30.3 
 Mm  TUBB THBS1 120 3.5 
 Mm  TUBB NME2 100 33.8 
 Mm  TUBB CDKN2A 72 15.6 
 Mm  TUBB DNAJA4 61 5 
 Mm  TUBB2C  [Mm] TUBB2C 2102 75.7 
 Mm  TUBB2C TBCD 1338 28 
 Mm  TUBB2C AIFM1 909 42.6 
 Mm  TUBB2C MAP7D1 689 18.9 
 Mm  TUBB2C DNAJA1 570 38.8 
 Mm  TUBB2C DNAJA2 370 17.2 
 Mm  TUBB2C VBP1 242 25.4 
 Mm  TUBB2C RRAS2 235 23 
 Mm  TUBB2C MGST3 224 18.4 
 Mm  TUBB2C PFDN2 207 30.5 
 Mm  TUBB2C CYC1 178 14.8 
 Mm  TUBB2C PFDN6 156 28.7 
 Mm  TUBB2C ICAM1 147 7.3 
 Mm  TUBB2C CHCHD4 146 33.1 
 Mm  TUBB2C PFDN5 138 19.5 
 Mm  TUBB2C PFDN1 111 21.3 
 Mm  TUBB2C PHGDH 105 3.8 
 Mm  TUBB2C FBLN1 99 3.5 
 Mm  TUBB2C BSG 97 14.2 
 Mm  TUBB2C TIMM50 86 4.8 
 Mm  TUBB2C C2orf47 76 6.5 
 Mm  TUBB2C NME2P1 64 13.9 
 Mm  TUBG1  [Mm] TUBG1 1012 41 
 Mm  TUBG1 TUBGCP2 931 23.1 
 Mm  TUBG1 TUBGCP4 819 33.8 
 Mm  TUBG1 TUBGCP3 794 20.1 
 Mm  TUBG1 TUBGCP5 405 8.9 
 Mm  TUBG1 TUBGCP6 281 5.1 
 Mm  TUBG1 TUBG1 177 8.4 
 Mm  TUBG1 AIFM1 172 12 
 Mm  TUBG1 FAM128B 168 31 
 Mm  TUBG1 NSUN2 99 5.5 
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 Mm  TUBGCP2  [Mm] TUBGCP2 460 11.3 
 Mm  TUBGCP2 TUBGCP3 168 5.9 
 Mm  TUBGCP2 TUBGCP2 138 3.4 
 Mm  TUBGCP2 FAM128B 118 22.8 
 Mm  TUBGCP2 TUBG2 99 6.7 
 Mm  TUBGCP3  [Mm] TUBGCP3 2672 55.4 
 Mm  TUBGCP3 TUBGCP2 2614 56.9 
 Mm  TUBGCP3 TUBGCP3 976 21.6 
 Mm  TUBGCP3 TUBGCP5 955 20.8 
 Mm  TUBGCP3 NEDD1 916 32.9 
 Mm  TUBGCP3 TUBGCP4 901 31.1 
 Mm  TUBGCP3 TUBG1 849 57.6 
 Mm  TUBGCP3 TUBGCP6 482 7 
 Mm  TUBGCP3 FAM128B 348 51.9 
 Mm  TUBGCP3 NEXN 345 14 
 Mm  TUBGCP3 TMOD3 304 21.9 
 Mm  TUBGCP3 C19orf21 202 8.7 
 Mm  TUBGCP3 Q5VXS7_HUMAN 193 52.4 
 Mm  UBE1  [Mm] UBE1 3994 73.9 
 Mm  UBE1 NM_001014342.1 173 2 
 Mm  UBE1 PIP 130 19.2 
 Mm  UBE2C  [Mm] UBE2C 514 46.9 
 Mm  WAPAL  [Mm] WAPAL 0 0 
 Hs  WAPAL  [Hs] WAPAL 4724 71.7 
 Hs  WAPAL SMC1A 3879 59.6 
 Hs  WAPAL SMC3 3138 48.9 
 Hs  WAPAL PDS5A 3025 43.8 
 Hs  WAPAL PDS5B 2367 31.9 
 Hs  WAPAL RAD21 1487 44.7 
 Hs  WAPAL WAPAL 1419 26.7 
 Hs  WAPAL STAG1 767 12.9 
 Hs  WAPAL STAG2 346 6.2 
 Mm  WDR38  [Mm] WDR38 0 0 
 Mm  WDR51B  [Mm] WDR51B 641 32.8 
 Mm  WDR51B CALD1 659 33.6 
 Mm  WDR51B WDR51A 319 25.6 
 Mm  WDR51B TPM1 316 19 
 Mm  WDR51B EXOC4 311 9.4 
 Mm  WDR51B C17orf84 310 9.7 
 Mm  WDR51B CORO1C 284 14.3 
 Mm  WDR51B TMOD3 249 24.1 
 Mm  WDR51B EXOC3 248 7.5 
 Mm  WDR51B TPM2 223 15.8 
 Mm  WDR51B RAI14 212 6.7 
 Mm  WDR51B PKM2 180 7.5 
 Mm  WDR51B LMO7 173 4.2 
 Mm  WDR51B GNAI2 173 13.3 
 Mm  WDR51B WDR51B 161 13 
 Mm  WDR51B C19orf21 158 7.7 
 Mm  WDR51B PPP1R12A 153 4.9 
 Mm  WDR51B EIF4A1 151 11.1 
 Mm  WDR51B FOLR1 134 21.4 
 Mm  WDR51B STOM 123 19.5 
 Mm  WDR51B HNRPK 121 11.9 
 Mm  WDR51B SQSTM1 109 7 
 Mm  WDR51B HSBP1 94 39 
 Mm  WDR51B SPECC1 80 3.1 
 Mm  WDR51B COG7 77 5.5 
 Mm  WDR51B GNG12 76 37.5 
 Mm  WDR51B COG5 64 6.2 
 Mm  ZW10  [Mm] ZW10 714 17.3 
 Mm  ZW10 KNTC1 2710 29.7 
 Mm  ZW10 RINT1 851 28.2 
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 Mm  ZW10 ZWILCH 836 35 
 Mm  ZW10 ZW10 744 27.7 
 Mm  ZW10 APOD 253 23.3 
 Mm  ZW10 C19orf25 207 41.6 
 Mm  ZW10 SCFD2 186 7.3 
 Mm  ZW10 NP_056993.2 66 0.9 
 Mm  ZWINT  [Mm] ZWINT 666 58.7 
 Mm  ZWINT TACC3 936 28.9 
 Mm  ZWINT OGT 716 14.8 
 Mm  ZWINT EPS15 656 17.9 
 Mm  ZWINT NUP62 506 19.2 
 Mm  ZWINT CASC5 358 3.7 
 Mm  ZWINT EPS15L1 232 8.3 
 Mm  ZWINT HSF1 197 8.1 
 Mm  ZWINT KIFC3 156 5.4 
 Mm  ZWINT TPM2 143 10.6 
 Mm  ZWINT NDC80 139 5 
 Mm  ZWINT PRKCSH 132 6.8 
 Mm  ZWINT DSN1 126 10.4 
 Mm  ZWINT PMF1 112 17.1 
 Mm  ZWINT GOLGA2 97 2.3 
 Mm  ZWINT HSF2 89 3.7 
 Mm  ZWINT NUP62CL 81 15.8 
 Mm  ZWINT SPC24 81 9.1 
 Mm  ZWINT EDEM3 78 2.5 
 Mm  ZWINT THAP11 72 5.4 
 Mm  ZWINT GANAB 69 2 
 Mm  ZWINT NUF2 64 4.1 
 Hs  ZWINT  [Hs] ZWINT 874 62.6 
 Hs  ZWINT CASC5 5882 58.8 
 Hs  ZWINT RRBP1 2893 53.2 
 Hs  ZWINT NDC80 2045 62 
 Hs  ZWINT BUB1 1383 34.1 
 Hs  ZWINT DSN1 1269 72.8 
 Hs  ZWINT NUF2 1093 52.4 
 Hs  ZWINT BUB1B 936 21.4 
 Hs  ZWINT PMF1 846 72.2 
 Hs  ZWINT ZWINT 795 62.4 
 Hs  ZWINT SPC25 739 60.7 
 Hs  ZWINT NSL1 662 57.3 
 Hs  ZWINT MIS12 523 44.9 
 Hs  ZWINT SPC24 520 74.6 
 Hs  ZWINT LMNB1 256 17.6 
 Hs  ZWINT DDX5 254 8.6 
 Hs  ZWINT CNBP 178 20.6 
 Hs  ZWINT DDX17 172 6.6 
 Hs  ZWINT SMTN 157 4.8 
 Hs  ZWINT HNRPF 157 12 
 Hs  ZWINT CENPC1 156 5.1 
 Hs  ZWINT HNRPH1 133 10.5 
 Hs  ZWINT RCN1 125 8.5 
 Hs  ZWINT TRIM28 114 4.2 
 Hs  ZWINT CYR61 87 7.1 
 Hs  ZWINT SNAP29 74 7.8 
 Hs  ZWINT TRIM5 70 6.6 
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5.4 Interaction manuscript table S3 (all annotated complexes) 
Table summarising all identified clusters, annotated with complex number, baits within 
these clusters, known interactions of the bait within the cluster, total known interactions 
within the cluster, probability of observing the given number of interactions with each 
cluster at random, summary of mitotic screen hits per cluster, screen hits (fly: Goshima 
et al., 2007; human esiRNA: Kittler et al., 2007; human siRNA: Neumann et al., in 
preparation; worm: Sonnichsen et al., 2005).  
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0 X TTK 0     1         
0   TGM1 0     1         
1   THBS1 0 1 6.47E-02 4         
1   PNKD 0 1 6.47E-02 4   X     
1   NME2 0 1 6.47E-02 4         
1   TUBB 0 1 6.47E-02 4   X     
1   TBCD 1 1 6.47E-02 4       X 
1   DNAJA2 0 1 6.47E-02 4         
1   TCP11L1 0 1 6.47E-02 4         
1   CDKN2A 0 1 6.47E-02 4 X       
1   DNAJA4 0 1 6.47E-02 4         
2   TPM1 1 1 5.40E-03           
2   TPM2 1 1 5.40E-03           
2   CALD1 0 1 5.40E-03           
3   LTF 0               
3   WFDC2 0               
3   C20orf114 0               
3   TCN1 0               
3   PLUNC 0               
3   AZGP1 0               
4   NXF1 0 4 4.60E-06 6   X     
4   SUMO2 2 4 4.60E-06 6         
4   NUSAP1 0 4 4.60E-06 6 X       
4   SUMO3 1 4 4.60E-06 6     X   
4   SUMO1P3 1 4 4.60E-06 6 X       
4   RANBP1 1 4 4.60E-06 6         
4   NUMA1 0 4 4.60E-06 6         
4   UBE2I 4 4 4.60E-06 6         
4   RCC1 1 4 4.60E-06 6 X     X 
5   FANCE 0 3 3.62E-03 2 X       
5   CXorf23 0 3 3.62E-03 2         
5   CHCHD6 0 3 3.62E-03 2         
5   BAT1/UAP56_HUMAN/DDX39 4 3 3.62E-03 2         
5   C1orf77 1 3 3.62E-03 2         
5   C14orf173 0 3 3.62E-03 2         
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5   SAMM50 0 3 3.62E-03 2         
5   POLDIP3 0 3 3.62E-03 2         
5   PRMT1 0 3 3.62E-03 2 X       
5   C10orf18 0 3 3.62E-03 2         
5   THOC4/ENSG00000215640 1 3 3.62E-03 2         
5 X ERH 0 3 3.62E-03 2   X     
6   SIRT1 0     5   X     
6   MRPS7 0     5   X     
6 X CDCA8 0     5 X X X   
6   EBNA1BP2 0     5         
7   FANCB 1 1 1.08E-02 2         
7   LASP1 0 1 1.08E-02 2         
7 X FANCC 0 1 1.08E-02 2 X X     
7   C17orf70 1 1 1.08E-02 2         
8 X DDX41 0     4 X X     
8   NKAP 0     4 X X     
9   PFN1 0     1         
9   ALDOA 0     1 X       
9   TPI1 0     1         
10 X RAB5C 0     1         
10   GDI2 0     1   X     
10   APOD 0     1         
11 X ZW10 3 4 4.83E-07 4 X       
11   NP_056993.2 0 4 4.83E-07 4       X 
11   ZWILCH 2 4 4.83E-07 4 X       
11   SCFD2 0 4 4.83E-07 4         
11   RINT1 1 4 4.83E-07 4   X     
11   KNTC1 2 4 4.83E-07 4         
11   C19orf25 0 4 4.83E-07 4         
12 X MARK2 0     1         
12   KIAA0802 0     1         
13   Q8TBD9_HUMAN 0               
13 X CEP78 0               
13   NAP1L4 0               
14   CBX3 0     2   X     
14   AKAP8 0     2   X     
14   TRIM29 0     2         
14   AKAP8L 0     2         
14   CALU 0     2         
14   MYPN 0     2         
15 X FAM107B 0     1   X     
15   PLOD2 0     1         
15   PLOD1 0     1         
16   VPS13B 0 14 1.39E-13 2         
16   NME2P1/NME2 0 14 1.39E-13 2         
16   LTV1 0 14 1.39E-13 2   X     
16   SNX24 0 14 1.39E-13 2         
16   PER3 5 14 1.39E-13 2         
16   TSR1 0 14 1.39E-13 2         
16 X CSNK1E 0 14 1.39E-13 2         
16   RPSAP15 0 14 1.39E-13 2         
16   MIF 0 14 1.39E-13 2         
16   FAM110B 0 14 1.39E-13 2         
16   CRY2 3 14 1.39E-13 2 X       
16   PER2 5 14 1.39E-13 2         
16   RRP12 0 14 1.39E-13 2         
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16   MCC 1 14 1.39E-13 2         
16   SFRS2 0 14 1.39E-13 2         
16   STOX2 0 14 1.39E-13 2         
16   FAM110A 0 14 1.39E-13 2         
16   FAM83H 0 14 1.39E-13 2         
16   PER1 5 14 1.39E-13 2         
16   GAPVD1 0 14 1.39E-13 2         
16   CRY1 4 14 1.39E-13 2         
17   DNAJA1 0     3         
17 X TUBA1B 0     3 X X   X 
18   HNRPD 0     2         
18 X CEP152 0     2         
18   CEP63 0     2   X     
18   CENPF 0     2 X       
19 X ESPL1 0     4 X X   X 
19   CLTC 0     4       X 
19 X PTTG1 0     4         
19   DECR1 0     4         
20   CCNO 0 26 9.71E-31 13         
20   BSG 2 26 9.71E-31 13         
20   SKP2 9 26 9.71E-31 13         
20   CPS1 0 26 9.71E-31 13         
20   CCNB1 5 26 9.71E-31 13 X     X 
20   CDKN1B 5 26 9.71E-31 13         
20   PHGDH 0 26 9.71E-31 13         
20   WDR57 2 26 9.71E-31 13         
20 X CDC2 11 26 9.71E-31 13 X X     
20   CCNA2 6 26 9.71E-31 13 X X     
20   PKMYT1 2 26 9.71E-31 13         
20   CKS1B 5 26 9.71E-31 13       X 
20   CCNB2 2 26 9.71E-31 13         
20   EFTUD2 2 26 9.71E-31 13 X X     
20   PDLIM7 2 26 9.71E-31 13         
20   CDC25C 4 26 9.71E-31 13         
20   ASCC3L1 2 26 9.71E-31 13 X       
20   WEE1 2 26 9.71E-31 13 X X     
20   CKS2 2 26 9.71E-31 13         
20   CDKN1C 1 26 9.71E-31 13         
20   SKP1A 4 26 9.71E-31 13         
20   C20orf4 0 26 9.71E-31 13   X     
21 X CBX1 0     1 X       
21   RCN2 0     1         
22   GNAI1/GNAI3/GNAI2 0     1         
22 X RECQL4 0     1         
22   STOM 0     1         
22   ATAD3C 0     1         
22   HNRNPU 0     1   X     
23 X SMAD3 0     1 X       
23   LEMD3 0     1         
24   DYNLL2 1 1 1.80E-03 2         
24 X DYNLL1 1 1 1.80E-03 2   X   X 
25   MAFF 0 1 3.78E-02 1         
25   FAM83D 0 1 3.78E-02 1         
25 X BACH1 1 1 3.78E-02 1         
25   HMMR 0 1 3.78E-02 1 X       
25   MAFK 1 1 3.78E-02 1         
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  MAFG/ENSG00000215622 0 1 3.78E-02 1         25 
X CDC16 6 32 6.85E-55 14 X       26 
  ANAPC7 9 32 6.85E-55 14         26 
  ANAPC10 9 32 6.85E-55 14 X X     26 
X CDC27 8 32 6.85E-55 14 X X     26 
X CDC20 3 32 6.85E-55 14 X X   X 26 
X MAD2L1 3 32 6.85E-55 14 X       26 
X CDC23 4 32 6.85E-55 14 X       26 
  ANAPC1 3 32 6.85E-55 14       X 26 
  ANAPC13 0 32 6.85E-55 14         26 
  C10orf104 0 32 6.85E-55 14         26 
  ANAPC4 9 32 6.85E-55 14 X       26 
  CDC26 0 32 6.85E-55 14         26 
  ANAPC2 4 32 6.85E-55 14 X       26 
  ANAPC5 3 32 6.85E-55 14 X       26 
  MRTO4 0 2 3.91E-03           27 
X MKI67 1 2 3.91E-03           27 
  SFPQ 1 2 3.91E-03           27 
  KPNA4 0 2 3.91E-03           27 
  KPNA1 0 2 3.91E-03           27 
  KPNA6 0 2 3.91E-03           27 
  MKI67IP 1 2 3.91E-03           27 
  NONO 1 2 3.91E-03           27 
  KPNA3 0 2 3.91E-03           27 
  NP_689929.1 0 5 2.79E-08           28 
  HADHB 1 5 2.79E-08           28 
  AP2B1 3 5 2.79E-08           28 
  AP2M1 3 5 2.79E-08           28 
  EDC3 1 5 2.79E-08           28 
  HADHA 1 5 2.79E-08           28 
  AP2A1 2 5 2.79E-08           28 
  DCP2 1 5 2.79E-08           28 
  TTC33 0 41 3.87E-48 23         29 
  CRTAP 0 41 3.87E-48 23 X       29 
  PM14_HUMAN 6 41 3.87E-48 23   X X   29 
  SF3B4 6 41 3.87E-48 23   X X   29 
  SF3A2 18 41 3.87E-48 23     X   29 
  CCDC75 0 41 3.87E-48 23         29 
  O15042_HUMAN 0 41 3.87E-48 23         29 
X SF3A1 2 41 3.87E-48 23 X X X   29 
  DDX42 1 41 3.87E-48 23         29 
  LEPRE1 0 41 3.87E-48 23         29 
  SF3B3 5 41 3.87E-48 23   X X   29 
  HTATSF1 2 41 3.87E-48 23         29 
  SNRPF 1 41 3.87E-48 23 X X X   29 
  SF3A3 2 41 3.87E-48 23   X X   29 
  SNRPA1 5 41 3.87E-48 23   X     29 
  PHF5A 5 41 3.87E-48 23         29 
29   CHERP 0 41 3.87E-48 23         
29   SNRPB2 6 41 3.87E-48 23   X     
29   CCDC97 0 41 3.87E-48 23         
29   DNAJC8 1 41 3.87E-48 23         
29   RBM17 1 41 3.87E-48 23         
29   SF3B5 9 41 3.87E-48 23 X   X   
29   DDX46 1 41 3.87E-48 23         
29   SF3B2 6 41 3.87E-48 23         
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29   WDR61 0 41 3.87E-48 23 X       
29   SF3B1 6 41 3.87E-48 23 X X     
29   RBM39 1 41 3.87E-48 23         
30 X LCK 0     1 X       
30   CSTA 0               
31   Q71UN1_HUMAN 0     4     X X 
31   ZNF451 0     4         
31 X TOP2B 0     4       X 
31   ITPR1 0     4 X       
32   FABP5 0     4         
32   PKM2 0     4         
32   TF 0     4   X     
32   PPIA 0     4         
32   VCP 0     4       X 
32   POF1B 0     4 X       
32   LGALS7 0     4         
32 X AKAP12 0     4   X     
32   SPRR2E 0     4         
32   SBSN 0     4         
33   ZMYM4 0     1         
33   PGAM5 0     1         
33 X MAD2L2 0     1         
33   GTF2I 0     1 X       
33   ALDH3A2 0     1         
33   C13orf8 0     1         
33   POGZ 0     1         
33   BAT8_HUMAN/EHMT2 0     1         
33   ZNF644 0     1         
33   FAM35A 0     1         
33   EHMT1 0     1         
33   C20orf196 0     1         
34 X ATM 0               
34   WDR42A 0               
34   LMNB1 0               
34   IQWD1 0               
34   CUL4A 0               
35   BICD2 0     3         
35 X PLK1 0     3 X X X   
35   ERCC6L 0     3         
36 X TOR1AIP1 0     6 X       
36   INSR 0     6         
36 X KIF20A 0     6 X X     
36 X MAD2L1BP 0     6         
36   NUDT5 0     6         
36   TPX2 0     6 X X     
36   ANTXR1 0     6         
36   MAD1L1 0     6 X       
36   C1orf52 0     6         
37   TLN2 0 3 1.57E-04           
37   C9orf140 0 3 1.57E-04           
37   VCL 2 3 1.57E-04           
37   TLN1 2 3 1.57E-04           
37   ENSG00000205476 0 3 1.57E-04           
37   CTNNA1 1 3 1.57E-04           
37 X CEP350 0 3 1.57E-04           
37   TES 1 3 1.57E-04           
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37   PAWR 0 3 1.57E-04           
38   PTMS 0               
38   NACA 0               
39   TUBGCP6 0 1 2.70E-02 7 X   X   
39 X TUBG1 1 1 2.70E-02 7     X X 
39   TUBGCP4 1 1 2.70E-02 7     X   
39   Q5VXS7_HUMAN 0 1 2.70E-02 7         
39 X NEDD1 0 1 2.70E-02 7   X X   
39   TUBGCP5 0 1 2.70E-02 7         
40 X BUB1B 0     4 X X X   
40   XPNPEP3 0     4 X       
40   PDE4D 0     4         
40   UBR5 0     4         
40   ASAH1 0     4         
41   SMC1A 7 27 1.15E-65 5 X       
41   STAG1 7 27 1.15E-65 5   X   X 
41   PDS5B 6 27 1.15E-65 5         
41   SMC3 7 27 1.15E-65 5 X       
41 X WAPAL 7 27 1.15E-65 5         
41 X PDS5A 6 27 1.15E-65 5         
41 X RAD21 7 27 1.15E-65 5 X       
41 X STAG2 7 27 1.15E-65 5         
42 X SGOL2 3 8 3.88E-13 3 X       
42   PPP2R5A 4 8 3.88E-13 3         
42 X PPP2R1A 1 8 3.88E-13 3 X     X 
42   MYBBP1A 1 8 3.88E-13 3         
42   XP_496190.1 0 8 3.88E-13 3         
42   DHX30 1 8 3.88E-13 3         
42   PPP2R1B 3 8 3.88E-13 3         
42   GNL3 1 8 3.88E-13 3         
42   PPP2R5E 2 8 3.88E-13 3         
43   SNRPB/SNURF 4 11 2.11E-07 4         
43   GPATCH4 0 11 2.11E-07 4         
43   DKC1 0 11 2.11E-07 4         
43   NOLC1 1 11 2.11E-07 4         
43   LARP7 0 11 2.11E-07 4         
43   RRP9 0 11 2.11E-07 4         
43   ZNHIT3 0 11 2.11E-07 4         
43   NOLA2 0 11 2.11E-07 4   X     
43   URB1 0 11 2.11E-07 4         
43   WDR43 0 11 2.11E-07 4   X     
43   NUFIP1 0 11 2.11E-07 4         
43   PINX1_HUMAN 3 11 2.11E-07 4         
43   NOP5_HUMAN 0 11 2.11E-07 4         
43   TGS1 1 11 2.11E-07 4         
43   PABPC4/PABPC1 2 11 2.11E-07 4         
43   COIL 4 11 2.11E-07 4         
43   NOL5A 0 11 2.11E-07 4         
43   HNRPUL1 1 11 2.11E-07 4         
43   WDR79 0 11 2.11E-07 4         
43   C1orf181 0 11 2.11E-07 4         
43   NOLA3 0 11 2.11E-07 4         
43   SSB 0 11 2.11E-07 4         
43   DHX9 3 11 2.11E-07 4         
43   FBL 1 11 2.11E-07 4 X       
43   TARDBP 0 11 2.11E-07 4         
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43   SART3 2 11 2.11E-07 4 X       
43   MOV10 0 11 2.11E-07 4         
44   KIAA1967 0 1 5.03E-02 2         
44   ZFP106 0 1 5.03E-02 2         
44   HERC2 0 1 5.03E-02 2         
44   PCYT1A 0 1 5.03E-02 2   X     
44   NP_115818.2 0 1 5.03E-02 2         
44   RALY 1 1 5.03E-02 2         
44   KIFC3 0 1 5.03E-02 2 X       
44   WDR62 1 1 5.03E-02 2         
45   GPRC5A 0     2         
45 X TRIM69 0     2         
45   LYN 0     2         
45   LYPD3 0     2         
45   YES1 0     2         
45   PACSIN3 0     2         
45   CPM 0     2 X       
45   FYN 0     2         
45   RRAS2 0     2         
45   LGALS1 0     2         
45   SVIL 0     2         
45   NEXN 0     2         
45   ABCG2 0     2         
45   HNRPCL1 0     2         
45   GNB4 0     2 X       
46 X WDR51B 0     2         
46   EXOC3 0     2 X       
46   HSBP1 0     2 X       
46   EXOC4 0     2         
46   WDR51A 0     2         
47   CSNK1A1L/CSNK1A1 0     2       X 
47   FAM83B 0     2   X     
48 X CKAP5 0     7 X X X X 
48   SLAIN2 0     7         
48 X SNW1 0     7 X X     
48 X TACC3 0     7 X       
48   TACC2 0     7         
48   APC 0     7         
49   PFDN4 1 2 9.67E-05 1         
49   PFDN2 2 2 9.67E-05 1         
49   VBP1 1 2 9.67E-05 1       X 
49 X TUBA3D 0 2 9.67E-05 1         
50   PCM1 0               
50   MIB1 0               
50   RANBP5 0               
50 X AZI1 0               
51   SEC13 1 16 2.16E-28 4         
51 X NUP107 4 16 2.16E-28 4   X     
51 X NUP98 5 16 2.16E-28 4         
51   NUP37 3 16 2.16E-28 4         
51   NUP160 4 16 2.16E-28 4         
51   SEH1L 2 16 2.16E-28 4         
51   NUP133 6 16 2.16E-28 4 X X     
51   AHCTF1 4 16 2.16E-28 4         
51   NUP43 3 16 2.16E-28 4         
51   NUP85 2 16 2.16E-28 4       X 
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  AIFM1 0     3         52 
X CDC6 0     3 X X   X 52 
  RAB14 0               53 
  GOLGA3 0               53 
X CEP110 0               53 
X AURKA 0     4 X X     54 
X CEP192 0     4 X X     54 
  PRPF31 0 15 8.78E-12 15         55 
  LSM8 1 15 8.78E-12 15         55 
  C9orf78 0 15 8.78E-12 15         55 
  SART1 0 15 8.78E-12 15 X       55 
  BCAS2 0 15 8.78E-12 15 X       55 
  TSSC4 0 15 8.78E-12 15         55 
  DHX35 0 15 8.78E-12 15         55 
  PRPF3 0 15 8.78E-12 15         55 
  PRPF6 4 15 8.78E-12 15 X       55 
  SNRPB 4 15 8.78E-12 15     X X 55 
  NP_006848.1 0 15 8.78E-12 15         55 
  TFIP11 0 15 8.78E-12 15         55 
  RUVBL1 0 15 8.78E-12 15         55 
  PRPF4 2 15 8.78E-12 15       X 55 
  DHX38 1 15 8.78E-12 15         55 
  EAPP 0 15 8.78E-12 15         55 
X PRPF8 1 15 8.78E-12 15 X X     55 
X NHP2L1 3 15 8.78E-12 15 X X     55 
  CD2BP2 8 15 8.78E-12 15         55 
  ZNHIT2 0 15 8.78E-12 15         55 
  DDX23 3 15 8.78E-12 15         55 
  NCDN 0 15 8.78E-12 15         55 
  ECD 0 15 8.78E-12 15         55 
  PPIH 1 15 8.78E-12 15   X     55 
  LSM4 1 15 8.78E-12 15         55 
  SNRPG 2 15 8.78E-12 15 X X X X 55 
  TTC27 0 55 15 8.78E-12 15         
55   USP39 1 15 8.78E-12 15         
56 X KIF4A 0     6 X X X X 
56   PRC1 0     6 X X     
56 X CEP170 0     6         
57   DCTN6 0     3   X     
57   CAPZA2 0     3         
57   DCTN4 0     3       X 
57   DCTN5 0     3       X 
57 X DCTN3 0     3         
58   RPA2 0     1   X     
58   KIAA1128 0     1         
58   RNH1 0     1         
58   SYNE1 0     1         
58   DIXDC1 0     1         
59   RANGAP1 1 1 1.80E-03           
59 X RANBP2 1 1 1.80E-03           
60   SHCBP1 0     3         
60   PPP2R3C 0     3       X 
60 X FGFR1OP 0     3         
60   PPP2CB/PPP2CA 0     3 X     X 
61   NDEL1 0     2 X       
61 X NDE1 0     2   X     
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62 X CDCA5 0     5 X X     
62   LCN1L1/LCN1 0     5         
62   AURKB 0     5 X X   X 
63   PPP1CB 0     2 X X     
63   PPP1R2 0     2         
63   PPP1R10 0     2         
64   NUP153 2 5 7.48E-11 3         
64   IMA2_HUMAN/KPNA2 2 5 7.48E-11 3       X 
64   NUP50 3 5 7.48E-11 3         
64   KPNB1 3 5 7.48E-11 3   X   X 
65   C13orf24 0 1 1.61E-01 2         
65   RRBP1 0 1 1.61E-01 2         
65   SNAPAP 0 1 1.61E-01 2         
65   EPS15L1 0 1 1.61E-01 2         
65   IQGAP3 0 1 1.61E-01 2         
65   MLF1IP 0 1 1.61E-01 2         
65   BEGAIN 0 1 1.61E-01 2         
65   PHKB 1 1 1.61E-01 2         
65   NPR1 0 1 1.61E-01 2         
65   PHKA2 1 1 1.61E-01 2         
65   ODF2L 0 1 1.61E-01 2         
65   CCDC101 0 1 1.61E-01 2         
65   CALCOCO1 0 1 1.61E-01 2         
65   ASPM 0 1 1.61E-01 2 X   X   
66   BTG3 2 12 3.26E-13 7   X     
66   NUDC 0 12 3.26E-13 7 X     X 
66   CNOT10 0 12 3.26E-13 7         
66 X CNOT3 3 12 3.26E-13 7   X   X 
66   RAVER1 0 12 3.26E-13 7         
66   CNOT6L 0 12 3.26E-13 7         
66   FHL2 0 12 3.26E-13 7         
66   CNOT6 2 12 3.26E-13 7         
66   CNOT1 5 12 3.26E-13 7       X 
66   CNOT8 7 12 3.26E-13 7         
66   CNOT2 4 12 3.26E-13 7         
66   C13orf7 0 12 3.26E-13 7         
66   RQCD1 0 12 3.26E-13 7         
66   C2orf29 0 12 3.26E-13 7         
66   CNOT7 3 12 3.26E-13 7       X 
66   TOB2 2 12 3.26E-13 7         
66   TNKS1BP1 0 12 3.26E-13 7         
66   KLHL2 0 12 3.26E-13 7         
67 X ZWINT 6 18 5.95E-31 12 X       
67   CASC5 3 18 5.95E-31 12   X     
67 X BUB1 0 18 5.95E-31 12 X       
67   DSN1 5 18 5.95E-31 12   X     
67   PMF1 3 18 5.95E-31 12         
67   SPC25 2 18 5.95E-31 12   X     
67   NUF2 1 18 5.95E-31 12 X X X   
67 X NDC80 5 18 5.95E-31 12   X X   
67 X SPC24 3 18 5.95E-31 12 X       
67   NSL1 2 18 5.95E-31 12         
67 X MIS12 6 18 5.95E-31 12     X   
68   SNAP29 0     2       X 
68   CDK5RAP2 0     2 X       
68   WDR68 0     2         
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68   TROAP 0     2         
68   ENSG00000215733/ATAD3B/ATAD3C 0     2         
69 X TIPIN 1 1 1.08E-02 2   X     
69   PCMTD1 0 1 1.08E-02 2         
69 X TIMELESS 1 1 1.08E-02 2   X     
69   RPA3 0 1 1.08E-02 2         
70   EML3 0 4 2.05E-01 7 X       
70   C5orf21 0 4 2.05E-01 7         
70   TLK2 1 4 2.05E-01 7         
70   FBXO30 0 4 2.05E-01 7         
70   CIZ1 0 4 2.05E-01 7         
70   ANKRD15 0 4 2.05E-01 7         
70   STRN3 0 4 2.05E-01 7         
70   WDR60 0 4 2.05E-01 7         
70   GPHN 0 4 2.05E-01 7         
70   RCOR1 2 4 2.05E-01 7         
70   FBXO38 0 4 2.05E-01 7         
70   TP53BP1 0 4 2.05E-01 7         
70   FAM40A 0 4 2.05E-01 7         
70   PRKAR2A 0 4 2.05E-01 7   X     
70   PAPD1 0 4 2.05E-01 7         
70   ZMYM2 0 4 2.05E-01 7         
70   TRPS1 0 4 2.05E-01 7         
70   CREB3L2 0 4 2.05E-01 7         
70   ANKRD25 0 4 2.05E-01 7         
70   STK25/NP_057626.2 1 4 2.05E-01 7 X       
70   Q9H7K0_HUMAN 0 4 2.05E-01 7         
70   TLK1 1 4 2.05E-01 7     X   
70   AOF2 1 4 2.05E-01 7         
70   ZMYM3 0 4 2.05E-01 7         
70   CTTNBP2NL 0 4 2.05E-01 7         
70   NP_001006948.1 0 4 2.05E-01 7         
70   MOBKL3 0 4 2.05E-01 7         
70   STRN 0 4 2.05E-01 7 X       
70   AGGF1 0 4 2.05E-01 7         
70   GLCCI1 0 4 2.05E-01 7         
70   PDCD10 1 4 2.05E-01 7         
70   RCOR3 0 4 2.05E-01 7   X     
70   MASTL 0 4 2.05E-01 7 X       
70   ZNF609 0 4 2.05E-01 7         
70   HDAC2 1 4 2.05E-01 7         
70   MORC3 0 4 2.05E-01 7         
70   C20orf117 0 4 2.05E-01 7   X     
70   STRN4 0 4 2.05E-01 7         
71   FAM128B 0 2 2.89E-04 3         
71   TUBG1/TUBG2 2 2 2.89E-04 3 X       
71 X TUBGCP3 2 2 2.89E-04 3     X   
71 X TUBGCP2 0 2 2.89E-04 3     X   
72   LGALS3BP 0     2         
72 X CUL3 0     2 X     X 
72   GOLGA2 0     2         
72   KLHDC5 0     2         
   73 
  RPSAP15/NP_001005472.1/ENSG0000
0215576 
0 5 2.32E-06 4 
        
73   PDCD6IP 2 5 2.32E-06 4         
73 X NP_710154.1 0 5 2.32E-06 4   X     
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73   TSG101 5 5 2.32E-06 4   X     
73 X CEP55 1 5 2.32E-06 4 X       
73   FBXO28 0 5 2.32E-06 4         
73   GNB2L1 0 5 2.32E-06 4       X 
73   VPS37C 1 5 2.32E-06 4         
73   PCBP1 0 5 2.32E-06 4         
73   VPS28 3 5 2.32E-06 4         
74 X DCTN2 0 2 2.89E-04 6     X X 
74 X ACTR1A 1 2 2.89E-04 6       X 
74   ACTR10 0 2 2.89E-04 6       X 
74   ACTR1B 1 2 2.89E-04 6         
74 X DCTN1 2 2 2.89E-04 6     X X 
75 X HSD17B7 0     1 X       
75   AHSG 0     1         
76   CCDC9 0     1 X       
76 X KIF1C 0     1         
76   THOC4 0     1         
76   AHCY 0     1         
76   SSBP1 0     1         
77 X DTL 1 4 1.73E-08 5 X X     
77   COPS6 2 4 1.73E-08 5       X 
77   COPS4 2 4 1.73E-08 5       X 
77   COPS2 2 4 1.73E-08 5       X 
77   CUL4B 1 4 1.73E-08 5         
78 X KIAA0892 0 3 7.29E-05 1         
78   LMO7 0 3 7.29E-05 1         
78 X NIPBL 0 3 7.29E-05 1         
78   GNB1/GNB2/GNB4 3 3 7.29E-05 1 X       
78   SPECC1 0 3 7.29E-05 1         
78   GNG12 3 3 7.29E-05 1         
79   NP_219485.1 0     7         
79 X FAM29A 0     7     X   
79   UCHL5IP 0     7         
79   C14orf94 0     7 X       
79   CCDC5 0     7 X       
79 X CEP27 0     7   X     
79   C4orf15 0     7 X   X   
79   KIAA0841 0     7   X     
80   SET/ENSG00000203911 0               
80   SERPINB12 0               
81   CENPC1 0 4 1.33E-03 2       X 
81   HNRPH1 1 4 1.33E-03 2   X     
81   DDX5 1 4 1.33E-03 2         
81   GANAB 1 4 1.33E-03 2         
81   EDEM3 0 4 1.33E-03 2         
81   HSF1 1 4 1.33E-03 2         
81   EPS15 0 4 1.33E-03 2         
81   THAP11 0 4 1.33E-03 2         
81   CNBP 0 4 1.33E-03 2         
81   TRIM5 0 4 1.33E-03 2         
81   CYR61 0 4 1.33E-03 2         
81   PRKCSH 1 4 1.33E-03 2         
81   HSF2 1 4 1.33E-03 2         
81   DDX17 1 4 1.33E-03 2         
81   SMTN 0 4 1.33E-03 2         
81   HNRPF 1 4 1.33E-03 2         
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  TRIM28 0 4 1.33E-03 2         81 
  NUP62CL 0 4 1.33E-03 2         81 
X FBXO5 2 1 1.08E-02 3   X X   82 
  ANAPC11/ENSG00000215639 0 1 1.08E-02 3       X 82 
  FZR1 2 1 1.08E-02 3         82 
  ARF1/ARF3 0     1         83 
X C13orf23 0     1 X       83 
  THRAP3 0 1 1.80E-02 1         84 
X C9orf58 0 1 1.80E-02 1   X     84 
  PCBP3/PCBP1/PCBP2 2 1 1.80E-02 1         84 
  KIF14 0 1 3.78E-02 3 X X     85 
  LRRFIP2 0 1 3.78E-02 3         85 
  TMED2 1 1 3.78E-02 3         85 
  TMED4 0 1 3.78E-02 3         85 
  CLIP1 0 1 3.78E-02 3         85 
X GORASP1 1 1 3.78E-02 3 X       85 
  TMED7 0 1 3.78E-02 3         85 
X SASS6 0     3 X   X   86 
86   PPP1CB/PPP1CC/PPP1CA 0     3     X   
86   FSCN1 0     3         
86   PLS3 0     3         
87   PPP2R5D 1 4 4.60E-06 4         
87   PPP2CB 0 4 4.60E-06 4         
87   FECH 0 4 4.60E-06 4         
87 X SGOL1 2 4 4.60E-06 4 X X     
87   PPP2CA 3 4 4.60E-06 4 X     X 
87   PPP2R2D 0 4 4.60E-06 4         
87   PPME1 0 4 4.60E-06 4         
87   PPP2R5C 1 4 4.60E-06 4         
87   PPP2R2A 0 4 4.60E-06 4         
88   SERPINB12 0     1         
88 X NRIP3 0     1   X     
89 X DYNC1H1 0     3 X   X X 
89   FOLR1 0     3         
90   NUP93 2 6 3.84E-10 2         
90 X NUP88 3 6 3.84E-10 2         
90 X NUP188 0 6 3.84E-10 2         
90 X NUP214 2 6 3.84E-10 2 X       
90   XPO1 2 6 3.84E-10 2   X     
90 X RAE1 2 6 3.84E-10 2         
90   NUP62 0 6 3.84E-10 2         
90   OGT 0 6 3.84E-10 2         
91 X SLC25A4 0               
92   PFDN5 1 1 1.18E-01 5       X 
92   MGST3 0 1 1.18E-01 5         
92   PFDN6 1 1 1.18E-01 5         
92   PFDN1 0 1 1.18E-01 5       X 
92 X TUBB2C 0 1 1.18E-01 5 X X     
92   TIMM50 0 1 1.18E-01 5         
92   C2orf47 0 1 1.18E-01 5         
92   ICAM1 0 1 1.18E-01 5         
92   CYC1 0 1 1.18E-01 5 X       
92   FBLN1 0 1 1.18E-01 5         
92   MAP7D1 0 1 1.18E-01 5         
92   CHCHD4 0 1 1.18E-01 5         
93   CCAR1 0 1 2.70E-02 9 X       
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93 X RACGAP1 1 1 2.70E-02 9 X X X X 
93   CD2AP 0 1 2.70E-02 9         
93   MICAL3 0 1 2.70E-02 9 X       
93 X KIF23 1 1 2.70E-02 9 X X X   
93   TRAF3IP1 0 1 2.70E-02 9         
94 X CEP76 0               
94   ANPEP 0               
94   CACNA2D1 0               
95   EDIL3 0 3 1.04E-05 3         
95   PAFAH1B3 2 3 1.04E-05 3         
95 X PAFAH1B1 2 3 1.04E-05 3 X X   X 
95   PAFAH1B2 2 3 1.04E-05 3         
95   XP_941179.1/KIAA1949 0 3 1.04E-05 3         
96   TMOD3 0     1         
96   PPP1R12A 0     1   X     
96   C19orf21 0     1         
97   C15orf23 0     1 X       
97 X SPAG5 0     1         
98   FLOT2 0     1         
98   DSG2 0     1         
98   ALDH18A1 0     1         
98   GNAS 0     1 X       
98   RTN4RL2 0     1         
99 X CEP72 0     4         
99   PPP1R12B 0     4         
99   SH2D4A 0     4 X       
99   PPP1R7 0     4   X   X 
99   PPP1R8 0     4   X     
99   PPP1R11 0     4         
99   PPP1R12C 0     4         
99   YLPM1 0     4         
100   RAN 0     3   X   X 
100   GPI 0     3         
100   TAGLN2 0     3 X       
100   PGK1 0     3         
100   TKT 0     3         
101 X NEK2 0     2 X X     
101   ACAD8 0     2         
102   SNRPD3 3 6 5.27E-12 8   X X X 
102   SNRPD2 3 6 5.27E-12 8   X X X 
102   SNRPD1 3 6 5.27E-12 8   X     
102   DHX15 0 6 5.27E-12 8         
102   SNRPE/SNRPEL1 0 6 5.27E-12 8       X 
103   PPIE 3 5 1.38E-04 10 X       
103   RSRC1 0 5 1.38E-04 10         
103   SAAL1 0 5 1.38E-04 10         
103   CDC5L 2 5 1.38E-04 10 X X     
103   PLRG1 2 5 1.38E-04 10 X X     
103   CDC40 0 5 1.38E-04 10 X       
103   HOMER1 1 5 1.38E-04 10         
103   PRPF19 1 5 1.38E-04 10 X       
103   AQR 0 5 1.38E-04 10         
103   PPIL1 0 5 1.38E-04 10         
103   CCDC12 0 5 1.38E-04 10         
103   SYF2 0 5 1.38E-04 10         
103   HOMER3 1 5 1.38E-04 10         
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103   RAB43 0 5 1.38E-04 10   X     
103   C21orf66 0 5 1.38E-04 10         
103   CRNKL1 1 5 1.38E-04 10         
103   CWC15 0 5 1.38E-04 10   X X   
103   XAB2 3 5 1.38E-04 10         
104 X HSD17B7 0     9 X       
104 X EIF4A3 0     9   X     
104 X CEP192 0     9 X X     
104   NUDC 0     9 X     X 
104 X CEP290 0     9         
104 X RAB4A 0     9   X     
104 X NRIP3 0     9   X     
104 X ITSN2 0     9   X     
104 X UBE1 0     9         
104   KLHL2 0     9         
105 X CCDC15 0 1 6.47E-02 3         
105   SOD1 0 1 6.47E-02 3 X X     
105   HMGB1/Q9NYD7_HUMAN 1 1 6.47E-02 3         
105   EIF4B 0 1 6.47E-02 3         
105   C1QBP 0 1 6.47E-02 3         
105   HNRPK 1 1 6.47E-02 3   X     
105   PYGM 0 1 6.47E-02 3         
105   AHNAK 0 1 6.47E-02 3         
106   SET 0     2         
106 X PLK4 0     2 X   X   
107   TERF2 0     1         
107   TOX4 0     1         
107   C19orf7 0     1 X       
107   PPP1CC 0     1         
107   WDR82 0     1         
108   GNB2 0               
108   ALPPL2 0               
108   GNAI2 0               
108   GNAI3 0               
108   GNAI1 0               
109   RPA2 0 1 5.03E-02 5   X     
109   DDB1 0 1 5.03E-02 5   X     
109   NP_060219.2 0 1 5.03E-02 5         
109   C19orf58 0 1 5.03E-02 5         
109   COG7 2 1 5.03E-02 5 X       
109   COG5 2 1 5.03E-02 5         
109   TCEB1 0 1 5.03E-02 5       X 
109 X NEK9 0 1 5.03E-02 5 X       
110   DDX5 0 14 3.27E-08 7         
110   CAPRIN1 0 14 3.27E-08 7         
110   EIF4H 3 14 3.27E-08 7         
110   SFRS5 3 14 3.27E-08 7         
110   NRAS 2 14 3.27E-08 7         
110   SFRS6 3 14 3.27E-08 7         
110   ASS1 0 14 3.27E-08 7         
110   PHGDH 0 14 3.27E-08 7         
110   GOT2 0 14 3.27E-08 7         
110   P4HB 1 14 3.27E-08 7   X     
110   CANX 1 14 3.27E-08 7   X     
110   VDAC1/VDAC4 0 14 3.27E-08 7         
110   PA2G4 0 14 3.27E-08 7         
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110   PHB 0 14 3.27E-08 7   X     
110   PDIA3 3 14 3.27E-08 7         
110 X C11orf68 2 14 3.27E-08 7   X     
110   PDIA6 0 14 3.27E-08 7 X       
110   CALR 1 14 3.27E-08 7         
110   TFRC 0 14 3.27E-08 7         
110   RUVBL2 0 14 3.27E-08 7         
110   PDIA4 0 14 3.27E-08 7         
110   SYNCRIP/HNRNPR 5 14 3.27E-08 7         
110   PPIB 0 14 3.27E-08 7   X     
110   STRAP 0 14 3.27E-08 7         
110   PHB2 0 14 3.27E-08 7         
110   FASN 0 14 3.27E-08 7         
110   TRAP1 0 14 3.27E-08 7   X     
110   XRCC6 0 14 3.27E-08 7         
110   HNRPA3/ENSG00000176825/ENSG000
00177219/ENSG00000188174 
3 14 3.27E-08 7     
110   PABPC1 3 14 3.27E-08 7         
111   CORO1C 0               
111   C17orf84 0               
112   DYNLT3 0     1         
112 X CNTROB 0     1         
112   NSUN2 0     1         
112   DYNLRB1 0     1       X 
113 X RHOA 0     8         
113 X HSD17B7 0     8 X       
113 X CEP192 0     8 X X     
113   NUDC 0     8 X     X 
113 X CEP290 0     8         
113 X RAB4A 0     8   X     
113 X NRIP3 0     8   X     
113 X ITSN2 0     8   X     
113 X UBE1 0     8         
113   KLHL2 0     8         
114   SUGT1 0     1         
114   TMPO 0     1         
114   SCRIB 0     1         
114   SUB1 0     1         
114 X SHOC2 0     1 X       
114 
  RPSAP15/XP_371273.1/NP_001005472
.1/ENSG00000215576 0     1 
        
114   HNRPAB 0     1         
114   RBMX 0     1         
115   THRAP3 0               
115   BCLAF1 0               
116   PAPSS2 0     1         
116 X PAPSS1 0     1 X       
117 X KCTD5 0     1   X     
117   KCTD2 0     1         
118   CLASP2 0     5         
118 X CENPE 0     5 X X     
118   CLASP1 0     5 X   X X 
119 X TMEM48 0               
120 X UBE2C 0               
121   NARG1L 0 1 3.78E-02 1         
121 X NAT13 0 1 3.78E-02 1         
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121 X NARG1 0 1 3.78E-02 1   X     
  SERF2 0 1 3.78E-02 1       121   
121   ARRB2 1 1 3.78E-02 1         
121 X ARD1A 0 1 3.78E-02 1         
  ARRB1 1 1 3.78E-02 1         121 
122   SYTL4 1 1 5.40E-03 2         
122   MICALL2 0 1 5.40E-03 2 X       
122 X RAB8A 1 1 5.40E-03 2 X       
123   ARL6IP2 0 18 2.73E-29 7         
123   ENSG00000214133 0 18 2.73E-29 7         
123   ERGIC2 0 18 2.73E-29 7   X     
123   COPE 7 18 2.73E-29 7         
123   COPB1 5 18 2.73E-29 7   X     
123   SIPA1L3 0 18 2.73E-29 7         
123   ARCN1 6 18 2.73E-29 7   X     
123   BCAP31 0 18 2.73E-29 7         
123   COPZ1 5 18 2.73E-29 7   X     
123   COPB2 6 18 2.73E-29 7   X     
123   COPG 5 18 2.73E-29 7   X     
123 X COPA 4 18 2.73E-29 7   X     
124   GTF2F1 0 10 6.06E-20 1         
124 X GTF3C6 0 10 6.06E-20 1   X     
124   GTF3C2 4 10 6.06E-20 1         
124   GTF3C5 4 10 6.06E-20 1         
124   GTF3C3 4 10 6.06E-20 1         
124   GTF3C1 5 10 6.06E-20 1         
124   GTF3C4 5 10 6.06E-20 1         
125 X HSP90AA1 0               
126 X CSK 0     1   X     
127   XPC 2 2 2.89E-04 1   X     
127   C5orf37 0 2 2.89E-04 1         
127 X CETN2 1 2 2.89E-04 1         
127   RAD23B 1 2 2.89E-04 1         
127   CETN3 0 2 2.89E-04 1         
128 X OGG1 0     1 X       
128   LAMB1 0     1         
129 X EEA1 0     1   X     
130 X WDR38 0               
131 X EDA2R 0     1   X     
132 X HDAC6 1 1 1.08E-02 1   X     
132   USP47 0 1 1.08E-02 1         
132   GARS 0 1 1.08E-02 1         
132   PLAA 1 1 1.08E-02 1         
133 X DYNC1I2 0               
134 X NUP155 0               
135 X CEP135 1 1 5.40E-03 1 X       
135   TTN 0 1 5.40E-03 1         
135   WDR8 1 1 5.40E-03 1         
136 X BMPR1A 0     2 X X     
137   STK4 1 1 5.03E-02 1         
137 X RASSF1 1 1 5.03E-02 1         
137   TMEM109 0 1 5.03E-02 1         
137   KIAA1754 0 1 5.03E-02 1         
137   STK3 0 1 5.03E-02 1   X     
137   VAPB 0 1 5.03E-02 1         
137   MAP1S 0 1 5.03E-02 1         
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137   VAPA 0 1 5.03E-02 1         
138 X ANLN 0     3 X X   X 
139 X PREB 0               
140 X ORC1L 3 6 2.24E-13 1   X     
140   NP_690852.1 0 6 2.24E-13 1         
140   ORC5L 4 6 2.24E-13 1         
140   ORC3L 5 6 2.24E-13 1         
140   ORC2L 4 6 2.24E-13 1         
141 X CHORDC1 0               
142 X PCNA 0     2   X   X 
143 X ESCO1 0     1     X   
144 X PLK2 0     2 X X     
145 X ECT2 0     2 X X     
146   NSMCE4A 0               
146   TUFT1 0               
146   NSMCE1 0               
146   NDNL2 0               
146 X SMC6 0               
146   NSMCE2 0               
146   SMC5 0               
146   RAD18 0               
 
5.5 Phosphorylation manuscript table S2 (all phospho-peptides) 
List of all determined phospho-peptides annotated with bait species (sp), bait, 
purification method used (Pur., either LAP or immunoaffinity purification using 
polyclonal antibodies (IP), the protein, the phospho-peptide (# indicates 
phosphorylation-site, % indicates ambigous phosphorylation sites), the phosphorylated 
residue, the cell cycle phase specificity (phase, see material and methods of phospho-
site manuscript for details (2.2.5.3)) and the inhibitor sensitivity (Inh sens). 
sp Bait Pur. Protein peptide site phase Inh sens 
mm Aurkb LAP AURKB TSQSGLNTLS#QR S25 M 
BI+Hes-
sens 
mm Aurkb LAP AURKB 
NKSQGSTASQGS#QNKQPFTIDN
FE 
S71 M 
BI+Hes-
sens 
mm Aurkb LAP AURKB IADFGWSVHAPS#LR S232 I Hes-sens 
mm Aurkb LAP AURKB RKT#MCGTLDYLPPEMIEGR T237 M Hes-sens 
mm Aurkb LAP AURKB FPS#SVPSGAQDLISK S299 M   
mm Aurkb LAP Borealin LTAEAIQT#PLK T106 M 
BI+Hes-
sens 
mm Aurkb LAP Borealin LEVSMVKPT#PGLTPR T185 M 
BI+Hes-
sens 
mm Aurkb LAP Borealin IYNISGNGS#PLADSK S219 M   
mm Aurkb LAP CBX5 RKS#NFSNSADDIK S92 M? 
BI+Hes-
sens 
mm Aurkb LAP Cdc37 TGDEKDVS#V S377 M BI-sens 
mm Aurkb LAP 
HSP90 
alpha 
ESEDKPEIEDVGS#DEEEEKK S263 I/M   
mm Aurkb LAP INCENP RIS#YVQDENRDPIR  S72 I/M Hes-sens 
mm Aurkb LAP INCENP ALAAPSS#PTPESPTML  S143 M?   
mm Aurkb LAP INCENP ALAAPSSPT#PESPTML  T145 M?   
mm Aurkb LAP INCENP ALAAPSSPTPES#PTML  S148 M?   
mm Aurkb LAP INCENP 
T#LSPTPASATAPTSQGIPTSDEES
TPKK 
T195 M?   
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mm Aurkb LAP INCENP 
TLSPTPASATAPTS#QGIPTSDEES
TPKK 
S208 M? Hes-sens 
mm Aurkb LAP INCENP 
TLSPTPASATAPTSQGIPT#SDEES
TPKK 
T213 M? Hes-sens 
mm Aurkb LAP INCENP 
TLSPTPASATAPTSQGIPTS#DEES
TPKK 
S214 M?   
mm Aurkb LAP INCENP 
TLSPTPASATAPTSQGIPTSDEES#
TPKK 
S218 M?   
mm Aurkb LAP INCENP 
TLSPTPASATAPTSQGIPTSDEEST
#PKK 
T219 M?   
mm Aurkb LAP INCENP ILESITVSSLMAT#PQDPK T239 M   
mm Aurkb LAP INCENP MATPQDPKGQGVGTGRSAS#KL S255 M?   
mm Aurkb LAP INCENP IAQVS#PGPRDSPAFPDSPWRER S263 I/M   
mm Aurkb LAP INCENP IAQVSPGPRDS#PAFPDSPWRER S269 M?   
mm Aurkb LAP INCENP IAQVSPGPRDSPAFPDS#PWRER S275 M?   
mm Aurkb LAP INCENP 
T#DSQSVRHSPIAPSSPSPQVLAQ
K 
T298 M   
mm Aurkb LAP INCENP 
TDS#QSVRHSPIAPSSPSPQVLAQ
K 
S300 M   
mm Aurkb LAP INCENP 
TDSQSVRHS#PIAPSSPSPQVLAQ
K 
S306 I/M   
mm Aurkb LAP INCENP 
TDSQSVRHSPIAPSS#PSPQVLAQ
K 
S312 M   
mm Aurkb LAP INCENP 
TDSQSVRHSPIAPSSPS#PQVLAQ
K 
S314 M   
mm Aurkb LAP INCENP NNGNNS#WPHNDTE S400 M?   
mm Aurkb LAP INCENP 
IANSTPNPKPAASS#PETPSAGQQ
E 
S421 M   
mm Aurkb LAP INCENP 
IANSTPNPKPAASSPET#PSAGQQ
E 
T424 M   
mm Aurkb LAP INCENP TDQADGPREPPQS#AR S446 M Hes-sens 
mm Aurkb LAP INCENP SKTPSS#PCPASK S481 M   
mm Aurkb LAP INCENP NQMLMT#PTSAPR T507 M 
BI+Hes-
sens 
mm Aurkb LAP INCENP 
INPDNYGMDLNS#DDSTDDEAHP
R 
S828 M BI-sens 
mm Aurkb LAP INCENP 
INPDNYGMDLNSDDS#TDDEAHP
R 
S831 M BI-sens 
mm Aurkb LAP INCENP 
INPDNYGMDLNSDDST#DDEAHP
R 
T832 M BI-sens 
mm Aurkb LAP INCENP RTS#SAVWNSPPLQGAR S893 M 
BI+Hes-
sens 
mm Aurkb LAP INCENP RTSS#AVWNSPPLQGAR S894 M 
BI+Hes-
sens 
mm Aurkb LAP INCENP RTSSAVWNS#PPLQGAR S899 M   
mm Aurkb LAP INCENP VPSSLAYS#LK S914 M 
BI+Hes-
sens 
mm Aurkb LAP INCENP VLAPILPDNFS%T%PTGSR 
S291 or 
T292 
M   
mm Aurkb LAP INCENP RT%S%S%AVWNSPPLQGAR 
T892 or 
S893 or 
S894 
M 
BI+Hes-
sens 
mm Bub1 LAP Bub1   QVMMTNSS#PEK S177 M?   
mm Bub1 LAP Bub1   DLPASENRPDVS#LVCVGQ S320 M  BI-sens 
mm Bub1 LAP Bub1   SESSGEKPQEEPS#VPLMVN S359 BI-ind   
mm Bub1 LAP Bub1   ANLPALPVPVS#GQSLTDSR S386 M 
 BI+Hes-
sens 
mm Bub1 LAP Bub1   CVNQS#VHEFMPQCGPETK S399 M  BI-sens 
mm Bub1 LAP Bub1   DFHTT#PNTSL T429 M   
mm Bub1 LAP Bub1   VASINDFHTTPNTS#LGMVQG S433 M   
mm Bub1 LAP Bub1   
VASINDFHTTPNTSLGMVQGT#PC
K 
T440 I/M   
mm Bub1 LAP Bub1   KVQPS#PTVHTK S447 I/M   
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mm Bub1 LAP Bub1   QAPTLPDIS#DDKDE S472 M  BI-sens 
mm Bub1 LAP Bub1   AVSS#GDWGVK S499 I/M   
mm Bub1 LAP Bub1   APS#PKSIGDF S579 M   
mm Bub1 LAP Bub1   TGKCETS#GFQCPEML S942 I/M   
mm Bub1 LAP Bub1   
TGIHLPAQAT%T%S%EPLHSAQI
L 
T157/58/
S159 
M 
 BI+Hes-
sens 
mm Bub1 LAP Bub1   S%QGS%ECSGVASSTCDEK S188/92 I/M  BI-sens 
mm Bub1 LAP Bub3 VAVEYLDPS#PEVQK S211 M  BI-sens 
mm Bub1 LAP Bub3 IRQVTDAETKPKS%PCT% 
S325/T3
28 
M   
mm Bub1 LAP BubR1 KNKS#PPADPPRVL S543 M   
mm Bub1 LAP BubR1 KLS#PIIEDSR S670 M   
mm Bub1 LAP BubR1 LT%S%PGALLFQ 
T1042/S
1043 
M  Bi-sens? 
mm Bub1 LAP CASC5 HSSILKPPRS#PLQDL S32 M?  Hes-sens? 
mm Bub1 LAP CASC5 TIYSGEENMDIT#K T487 M  Hes-sens 
mm Bub1 LAP CASC5 SHT#VAIDNQIFK T491 M 
 BI+Hes-
sens 
mm Bub1 LAP CASC5 AAPT#PEKEMMLQ T513 M   
mm Bub1 LAP CASC5 TVS#PDEITTRPMDK S930 M   
mm Bub1 LAP CASC5 NIKDVQS#PGFLNEPLSSK S1050 I/M   
mm Bub1 LAP CASC5 S%LS%NPTPDYCHDK S739/41 M 
 BI+Hes-
sens 
mm Bub1 LAP Cdc20 VQTT#PSKPGGDR T70 BI-ind   
mm Bub1 LAP NSL1 
KPDAKPENFITQIET%T%PTETAS
R 
T241/42 M  BI-sens? 
mm Bub1 LAP Nuf2 IVDS#PEKLK S247 I/M   
mm Bub1 LAP PMF1 THDHQLESS#L S28 M?   
mm Bub1 LAP PMF1 LS#PVEVFAK S30 M?   
mm Bub1 LAP PMF1 SLHLS#PQEQSASYQDR S81 M?   
mm Bub1 LAP PMF1 SMQQLDPS#PAR S331 M   
mm Bub1 LAP UBR5 RIS#QSQPVR S1549 I/M   
mm Bub1 LAP UBR5 RISQS#QPVR S1551 I/M   
mm Bub1 LAP UBR5 GQHDEHDEDGS#DMELDLL S1610 I?   
mm Bub1b LAP ANANAPC7 
VRPSTGNSAST#PQSQCLPSEIEV
K 
T92 M?   
mm Bub1b LAP ANANAPC7 
VRPSTGNSAST#PQSQCLPSEIEV
K 
T126 M?   
mm Bub1b LAP ANANAPC8 QLRNQGET#PTTEVPAPF T556 Hes-ind   
mm Bub1b LAP ANANAPC8 RVS#PLNLSSVT#P   
S582+T5
90 
M? Hes-sens? 
mm Bub1b LAP ANAPC1 KFSEQGGT#PQNVATSSSL T291 
BI+Hes-
ind? 
  
mm Bub1b LAP ANAPC1 AHS#PALGVHSFSGVQR S355 M?   
mm Bub1b LAP ANAPC1 NFDFEGSLS#PVIAPK S688 M?   
mm Bub1b LAP ANAPC1 S%PS%ISNMAALSR 
S341/34
3 
M Hes-sens? 
mm Bub1b LAP ANAPC1 AHS#PALGVHS%FS%GVQR   
S355+S3
62/364 
M?   
mm Bub1b LAP ANAPC1 SNTMPRPST#PLDGVST#PKPL 
T530+T5
37 
M?   
mm Bub1b LAP ANAPC2 LLQS#PLCAGCSSDK S218 M?   
mm Bub1b LAP ANAPC2 LQDGPARPAS#PEAGNTL S314 M   
mm Bub1b LAP BUB1 
VANTSSFHTTPNTSLGMVQAT#PS
K 
T452 M? Hes-sens 
mm Bub1b LAP BUB1 TAKCETS#GFQCVEML S969 I/M   
mm Bub1b LAP BUB1 
GIRCNKTLAPS#PKS#PGDFTSAA
QL   
S593+S5
96 
M? Hes-sens? 
mm Bub1b LAP Bub1b AEAS#EAMCLEGAEWELSK S5 M?   
  Bub1b LAP Bub1b STLQGALAKQESAGHT#AL T47 M BI-sens 
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mm Bub1b LAP Bub1b AKENELQPGPWS#TDRPAGR S307 
Bi+Hes-
ind 
  
mm Bub1b LAP Bub1b VEESAQQTVMT#PCKIEPSINH T347 M   
mm Bub1b LAP Bub1b IEPSINHVLS#TR S360 M   
mm Bub1b LAP Bub1b 
LQIASGPQEMSGVPLSCSICPLSS
#NPR 
S496 Hes-ind   
mm Bub1b LAP Bub1b 
SSNPREIS#PAENILQEQPDSKGS
SMPF 
S502 I/M   
mm Bub1b LAP Bub1b KDKS#PATGGPQVLNAQR S535 I/M   
hs BUB1B LAP BUB1B FLLS#EK S537 M   
mm Bub1b LAP Bub1b NVTLCPNPEDT#CDFAR T601 M   
mm Bub1b LAP Bub1b LAST#PFHEILSSK T613 Bi-ind   
mm Bub1b LAP Bub1b SRSSSSAPSTSS#IKGF S686 I   
mm Bub1b LAP Bub1b LELT#NDGAENAIQSPWCSQYR T699 M   
mm Bub1b LAP Bub1b TIS#PEALLTQQDK 1033 M   
mm Bub1b LAP Bub1b VMS%T%LQGALAK S33/T34 M   
mm Bub1b LAP Bub1b GS%S%MPFSIFDESLSDK 
S517/S5
18 
Bi-ind   
mm Bub1b LAP Bub1b GSSMPFSIFDES%LS%DKK 
S527/S5
29 
I/M   
mm Bub1b LAP Bub1b LASTPFHEILS%S%K 
S620/S6
21 
I/M   
mm Bub1b LAP BUB3 IRQVTDAETKPKS#PCT S325 M BI-sens 
mm Bub1b LAP CASC5 SHT#VAIDNQIFK T517 BI-ind   
mm Bub1b LAP CASC5 TVS#PDEITTRPMDK S956 Hes-ind?   
mm Bub1b LAP CASC5 DVQS#PGFLNEPLSSK S1076 M?   
mm Bub1b LAP CDC16 LKDES#GFKDPSSDW S111 M 
BI+Hes-
sens 
mm Bub1b LAP CDC16 NIIS#PPWDFR S559 M   
mm Bub1b LAP CDC16 QTAEETGLT#PLETSR T580 BI-ind?   
mm Bub1b LAP CDC20 QRKAKEAAGPAPS#PMRAAN S41 Hes-Ind?   
mm Bub1b LAP CDC20 
LLSKENQPENSQT#PTKKEHQKA
W 
T106 M?   
mm Bub1b LAP CDC26 
QKEDVEVVGGSDGEGAIGLSS#D
PK 
S52 M?   
mm Bub1b LAP CDC26 SSQFGS#LEF S82 M?   
mm Bub1b LAP CDC26 
QKEDVEVVGGS#DGEGAIGLSS#
DPK   
S42+S52 M? Hes-sens 
mm Bub1b LAP CDC27 QPETVLTET#PQDTIELNR T205 M?   
mm Bub1b LAP CDC27 GGITQPNINDS#LEITK S432 M   
mm Bub1b LAP CDC27 ISTIT#PQIQAFNLQK T452 M   
mm Bub1b LAP CDC27 IDSAVIS%PDT%VPLGTGTSIL 
S241/T2
44 
M? Bi-sens? 
mm Bub1b LAP DSN1 S%LHLS%PQEQSASYQDR S77/S81 BI-ind?   
mm Bub1b LAP EDD AMNQQTTLDT#PQLER T1969 BI-ind?   
mm Bub1b LAP EDD RRQLS#IDTRPF S2369 I?   
mm Bub1b LAP UBR5 TSDS#PWFLSGSETLGR S110 M Hes-sens 
mm Bub1b LAP UBR5 WLDGAS#FDNER S327 M 
BI-Hes-
sens 
mm Bub1b LAP UBR5 FRRSDS#MTFL S2028 I/M 
Bi+Hes-
sens? 
hs CDC27 IP ANAPC1 VGS#LQEV S60 Hes-ind   
hs CDC27 IP ANAPC1 VPPGS#PREPLPTMF S202 I/M   
hs CDC27 IP ANAPC1 KFS#EQGG S286 BI-ind   
hs CDC27 IP ANAPC1 KFSEQGGT#PQNVA T291 I/M   
hs CDC27 IP ANAPC1 SLSKGDS#PV S313 BI-ind   
hs CDC27 IP ANAPC1 PVTS#PFQNY S317 
BI+Hes-
ind 
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hs CDC27 IP ANAPC1 STSSPSLHS#R S339 I   
hs CDC27 IP ANAPC1 SPS#ISNMAALSR S343 I/M   
hs CDC27 IP ANAPC1 AALS#RAH S351 M Bi-sens 
hs CDC27 IP ANAPC1 AHS#PALGVHSFSGVQR S355 I/M   
hs CDC27 IP ANAPC1 FNISSHNQS#PK S377 I/M   
hs CDC27 IP ANAPC1 HSISHS#PNSNSNGSFL S386 I/M?   
hs CDC27 IP ANAPC1 KVFIPGLPAPS#LTMS S518 Hes-ind   
hs CDC27 IP ANAPC1 PSLTMS#NTMPRPSTPL S522 I/M?   
hs CDC27 IP ANAPC1 PSLTMSNT#MPRPS T524 I?   
hs CDC27 IP ANAPC1 TMPRPS#TPLDG S529 I?   
hs CDC27 IP ANAPC1 NTMPRPST#PLDGV T530 I/M?   
hs CDC27 IP ANAPC1 DGVS#TPKPL S536 M   
hs CDC27 IP ANAPC1 DGVST#PKPL T537 M   
hs CDC27 IP ANAPC1 LLGS#LDEVV S547 I/M   
hs CDC27 IP ANAPC1 LLGSLDEVVLLS#PVPELR S555 I/M   
hs CDC27 IP ANAPC1 LHDS#LYNEDCTF S569 I/M   
hs CDC27 IP ANAPC1 NFDFEGS#LS S686 I/M   
hs CDC27 IP ANAPC1 NFDFEGSLS#PVIAPK S688 I/M   
hs CDC27 IP ANAPC1 SLCLS#PSEASQMK S731 I   
hs CDC27 IP ANAPC1 LQVEQEENRFS#FR S916 M   
hs CDC27 IP ANAPC1 KHKS#PSYQIK S1347 Hes-ind   
hs CDC27 IP ANAPC1 STS%S%PSLHSR S333/34 M   
hs CDC27 IP ANAPC1 SELWS%S%DGAA S50/51 I/M   
hs CDC27 IP ANAPC1 VVLLSPVPELRDS%S%K S563/64 I/M   
hs CDC27 IP ANAPC1 ARPS%ET%GS%DDDWE 
S699/T7
01/S703 
I/M   
hs CDC27 IP ANAPC2 RLLQS#PL S218 I/M   
hs CDC27 IP ANAPC2 RPAS#PEAGNTL S314 I/M   
hs CDC27 IP ANAPC2 GQDS#EDDSGEP S470 I/M   
hs CDC27 IP ANAPC2 DNMVLIDS#DDES S732 Hes-ind?   
hs CDC27 IP ANAPC2 DDES#DSGMASQ S736 Hes-ind?   
hs CDC27 IP ANAPC2 LLHQFSFS#PER S532/34 I/M   
hs CDC27 IP ANAPC4 IKEEVLS#ESEAEN S777 I/M   
hs CDC27 IP ANAPC4 ES#EAENQQA S779 I/M   
hs CDC27 IP ANAPC5 TVEDADMELT#SR T178 M 
BI+Hes-
sens 
hs CDC27 IP ANAPC5 S#RDEGER S179 M 
BI+Hes-
sens 
hs CDC27 IP ANAPC5 KMEKEELDVS#VR S195 M 
BI+Hes-
sens 
hs CDC27 IP ANAPC5 QAEFFLSQQAS#LLK S221 M Bi-sens 
hs CDC27 IP ANAPC5 KNDETKALT#PASL T232 I/M   
hs CDC27 IP ANAPC6 YLKDES#GFKDPSS S112 M Bi-sens 
hs CDC27 IP ANAPC6 KNIIS#PPWDFREF S560 I/M   
hs CDC27 IP ANAPC6 QTAEETGLT#PLETSR T581 I/M   
hs CDC27 IP ANAPC6 RKT#PDSRPSLEETFEIE T589 Hes-ind?   
hs CDC27 IP ANAPC6 MNES#DMMLET S607 Hes-ind?   
hs CDC27 IP ANAPC6 MNESDMMLETS#MSDHST S614 Hes-ind?   
hs CDC27 IP ANAPC7 GNSAST#PQSQ T126 I/M   
hs CDC27 IP ANAPC8 RNQGET#PTTEVPAPF T556 I/M   
hs CDC27 IP ANAPC8 EVPAPFFLPAS#LS S570 I/M   
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hs CDC27 IP ANAPC8 LS#ANNTPTRR S572 I/M   
hs CDC27 IP ANAPC8 PASLSANNT#PT T576 I/M   
hs CDC27 IP ANAPC8 NNTPT#RR T578 M   
hs CDC27 IP ANAPC8 PTRRVS#PL S582 I/M   
hs CDC27 IP ANAPC8 PLNLS#SVT S587 M   
hs CDC27 IP ANAPC8 PLNLSS#VT S588 I/M   
hs CDC27 IP ANAPC8 VSPLNLSSVT#P T590 I/M   
hs CDC27 IP BUB1B IEPSINHILS#TR S367 M?   
hs CDC27 IP BUB1B KNKS#PPADPPR S543 M?   
hs CDC27 IP BUB1B KLS#PIIEDSR S670 M   
hs CDC27 IP BUB1B LT%S%PGALLFQ 
T1042/S
1043 
M   
hs CDC27 IP  C10orf104  FLCES#VFSYQVASTLK S57 Hes-ind   
hs CDC27 IP CDC20 EAAGPAPS#PMR S41 I/M   
hs CDC27 IP CDC20 VQTT#PSKPGGDR T70 
I, Hes-
ind 
  
hs CDC27 IP CDC20 VQTTPS#KPGGDR S72 BI-ind   
hs CDC27 IP CDC20 PENSQT#PTKKEHQKAW T106 I/M   
hs CDC27 IP CDC26 VVGGS#DGEGAIGLSSDPK S42 M   
hs CDC27 IP CDC26 KPQPKPNNRSS#QFG S78 I/M   
hs CDC27 IP CDC26 SSQFGS#LEF S82 I/M   
hs CDC27 IP CDC26 VVGGSDGEGAIGLS%S%DPK S52/53 M Bi-sens 
hs CDC27 IP CDC27 FSNCLPNS#CTTQVPNH S183 BI-ind   
hs CDC27 IP CDC27 QPETVLTET#PQDTIELNR T205 M   
hs CDC27 IP CDC27 NRLNLESS#NSKY S220 M   
hs CDC27 IP CDC27 NLESSNS#KY S222 I/M   
hs CDC27 IP CDC27 IDSAVIS#PDTVPL S241 M   
hs CDC27 IP CDC27 GTGTS#ILSK S252 Hes-ind?   
hs CDC27 IP CDC27 GGPAALS#PLTPSF S276 
BI+Hes-
ind 
  
hs CDC27 IP CDC27 PLT#PSFGILPL T279 
BI+Hes-
ind 
  
hs CDC27 IP CDC27 TNT#PPVIDV T304 Hes-ind?   
hs CDC27 IP CDC27 TNTPPVIDVPS#TGAPSKK S312 Hes-ind?   
hs CDC27 IP CDC27 VPST#GAPSKK T313 Hes-ind?   
hs CDC27 IP CDC27 SVFSQSGNS#R S345 M   
hs CDC27 IP CDC27 SSGPQTSTT#PQVL T365 BI-ind   
hs CDC27 IP CDC27 TTPQVLS#PTIT S370 M   
hs CDC27 IP CDC27 TSTTPQVLSPT#IT T372 M Bi-sens 
hs CDC27 IP CDC27 IT#SPPNALPR T374 M   
hs CDC27 IP CDC27 PQTSTTPQVLSPTITS#PPNALPR S375 I/M   
hs CDC27 IP CDC27 LFTSDS#STTK S392 M   
hs CDC27 IP CDC27 LFTSDSS#TTK S393 M   
hs CDC27 IP CDC27 T#TKENSK T394 M   
hs CDC27 IP CDC27 LFTSDSSTT#KENSK T395 M   
hs CDC27 IP CDC27 TSDSSTTKENS#KKL S399 I/M   
hs CDC27 IP CDC27 GGITQPNINDS#LEITK S432 I/M   
hs CDC27 IP CDC27 IIS#EGKIS S444 M   
hs CDC27 IP CDC27 ISTIT#PQIQAFNLQK T452 M?   
hs CDC27 IP CDC27 KLDS%S%IISEGK S440/41 M   
hs CDC27 IP FZR1 INENEKS#PSQNRK S70 I/M   
hs CDC27 IP FZR1 SLSTKRS%S%PDDGNDVSPY 
S137/13
8 
I?   
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hs CDC27 IP NEK2 TFVGTPYYMS#PEQMNR S184 Hes-ind?   
hs CDC27 IP NEK2 KFLSLASNPELLNLPS%S%VIK S378/79 Hes-ind?   
mm Dctn1 LAP DCTN1 VLTS#PGA S203 I/M   
mm Dctn1 LAP DCTN1 QEAS#VER S541 Hes-ind   
mm Dctn1 LAP DCTN1 SPET#PDS 
T105/10
8 
I/M   
mm Dctn1 LAP DCTN1 PLPS%PSK 
S212/21
4 
I/M   
mm Kif23 LAP Kif23 
S%VS%PSPLPLSSNNIAQISNGQ
QLMSQPQLHR 
S683/S6
85 
M BI-sens 
mm Kif23 LAP RACGAP1 PVKKTRS#IGSAVDQGNESIVAK S203 M BI-sens 
mm Mad2L1 LAP BUB1B VEETAQQPVMT#PC T354 M Hes-sens 
mm Mad2L1 LAP BUB1B REAELLTS#AEKR S435 M?   
mm Mad2L1 LAP BUB1B SIFDEFLLS#EK S537 M   
mm Mad2L1 LAP BUB1B SEKKNKS#PPADPPRVL S543 M?   
mm Mad2L1 LAP BUB1B EDVS#PDVCDEFTGIEPL S574 M   
mm Mad2L1 LAP BUB1B KLS#PIIEDSR S670 M   
mm Mad2L1 LAP BUB1B LELTNETSENPTQS#PWCSQYR S720 M?   
mm Mad2L1 LAP BUB1B 
WCSQYRRQLLKS#LPELSASAELC
IED 
S733 M? 
BI+Hes-
sens 
mm Mad2L1 LAP BUB1B GKLTS#PGAL S1043 M?   
mm Mad2L1 LAP CDC20 EAAGPAPS#PMR S41 I/M   
mm Mad2L1 LAP CDC20 SKVQTT#PSKPGGD T70 I/M   
mm Mad2L1 LAP CDC20 LSKENQPENSQT#PTKK T106 I/M   
mm Mad2L1 LAP MAD1L1 MQMELS#HKR S77 M   
mm Mad2L1 LAP MAD1L1 AILGSYDSELTPAEYS#PQLTR S428 I/M   
mm Mad2L1 LAP MAD1L1 SQSSSAEQS#FLFSR S490 M BI-sens 
mm Mad2L1 LAP MAD1L1 SSSAEQS#FLFSR S490 M   
mm Mad2L1 LAP MAD1L1 LNPTS#VARQR S547 M Hes-sens 
mm Mad2L1 LAP MAD1L1 LNPTS#VARQR S551 M   
mm Mad2L1 LAP MAD1L1 
QPLRQGRIMS%T%LQGALAQES
ACN 
S12/T13 M?   
mm Mad2L1 LAP MAD1L1 ERAAS%T%S%ARNY 
S91/92/
93 
M?   
mm Mad2L1 LAP Mad2l1 VQTTPS#KPGGDRYIPH S72 M BI-sens 
mm Mad2L1 LAP Mad2l1 AIQDEIRS#VIR S130 I   
mm Mad2L1 LAP Mad2l1 LRS#FTTTIHK S185 BI-ind   
mm Mad2L1 LAP Mad2l1 VNS#MVAYK S195 I/M   
mm Mad2L1 LAP Mad2l1 LEVS%CS%FDLL 
S148 OR 
S150 
M BI-sens 
mm Mad2L1 LAP MAD2L1BP STQEPLNAS#EAFCPR S78 M BI-sens 
mm Mad2L1 LAP MAD2L1BP KPS#PQAEEMLK S134 I/M   
mm Mad2L1 LAP MAD2L1BP IELLET%S%S%T%QEPLN 
T68/S69
/S70/T7
1 
I/M   
mm Mis12 LAP BUB1 S#PGDFTSAAQLASTPFHK S596 Hes-ind?   
mm Mis12 LAP BUB1B nd       
mm Mis12 LAP BUB3 nd       
mm Mis12 LAP CASC5 RVS#FADTIK S60 I, BI-ind   
mm Mis12 LAP CASC5 TVS#PDEITTRPMDK S930 
BI+Hes-
ind? 
  
mm Mis12 LAP CASC5 LVANDSQLT#PLEEWSNNR T1016 
BI+Hes-
ind 
  
mm Mis12 LAP CASC5 DVQS#PGFLNEPLSSK S1050 I/M   
mm Mis12 LAP CASC5 RCS#LGIFLPR S1675 M?   
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mm Mis12 LAP CASC5 TPS#SCSSSLDSIK S1819 I?   
mm Mis12 LAP CASC5 
NCS%VT%GIDDLEQIPADTTDIN
HLETQPVSSK 
S1664/T
1666 
I   
mm Mis12 LAP CASC5 T%VNT%PPT%PEDLMLSQY 
T1922/2
5/28 
Hes-ind   
mm Mis12 LAP CASC5 nd       
mm Mis12 LAP CBX5 
SLSDS#ESDDSKSKKKRDAADKP
RGF 
S97 I?   
mm Mis12 LAP CBX5 LT%WHS%CPEDEAQ 
T173/S1
76 
I, BI-ind   
mm Mis12 LAP CBX5 nd       
mm Mis12 LAP DSN1 SKTHDHQLESSLS#PVEVF S14 
I, Hes-
ind 
  
mm Mis12 LAP DSN1 THDHQLESSLS#PVEVF S30 I/M   
mm Mis12 LAP DSN1 LS#PVEVF S30 I/M   
mm Mis12 LAP DSN1 TSASLEMNQGVS#EER S49 Hes-ind   
mm Mis12 LAP DSN1 S#LHL S71 I/M   
mm Mis12 LAP DSN1 SLHLS#PQEQSASY S81 I/M   
mm Mis12 LAP DSN1 RKS#LHPIHQGITELSR S109 BI-ind   
mm Mis12 LAP DSN1 SIS#VDLAESK S125 I/M   
mm Mis12 LAP DSN1 SRSISVDLAES#KRL S131 
I, Hes-
ind 
  
mm Mis12 LAP DSN1 MQQLDPS#PARKL S331 I/M   
mm Mis12 LAP DSN1 THDHQLES%S%L S27/28 I/M   
mm Mis12 LAP DSN1 THDHQLES%S%LSPVEVF S27/28 I/M   
mm Mis12 LAP DSN1 KLQLQNPPAIHGS%GS%GSCQ 
S350/52
/54 
BI+Hes-
ind 
  
mm Mis12 LAP DSN1 T%S%AS%LEMNQGVSEER 
T38/S39
/S41 
I/M  Hes-sens 
mm Mis12 LAP DSN1 RIHLGS%S%PKKG S57/58 I/M   
mm Mis12 LAP HEC1 nd       
mm Mis12 LAP Mis12 nd       
mm Mis12 LAP NSL1 
KPDAKPENFITQIET%T%PTETAS
R 
T241/42/
44 
I/bi+hes-
ind 
  
mm Mis12 LAP NSL1 nd       
mm Mis12 LAP NUF2 IVDS#PEKLKNY S247 I/M   
mm Mis12 LAP NUF2 DLY#PNPKPEVL Y37 Hes-ind   
mm Mis12 LAP PMF1 nd       
mm Mis12 LAP SPBC24 DIEEVS#QGLLSLLGANR S11 I   
mm Mis12 LAP SPBC25 nd       
mm Mis12 LAP ZWINT nd       
mm Nup107 LAP Nup107  S#GFGGM S4 M 
BI+Hes-
sens 
mm Nup107 LAP Nup107  KHS#AHKR S27 M Hes-sens 
mm Nup107 LAP Nup107  VLIQANQEDNFGTAT#PR T46 M   
mm Nup107 LAP Nup107  SQIIPRT#PSSF T55 M   
mm Nup107 LAP Nup107  
LGLYTNTEHHS#MTEDVNLSTVML
R 
S130 I/M   
mm Nup107 LAP Nup107  MTEDVNLS#TVMLR S138 M 
BI+Hes-
sens 
mm Nup107 LAP Nup107  TSVMTQDDS#EELPR S476 M   
mm Nup107 LAP Nup107  
DNGEFS#HHDLAPSLDTGTTEED
RLK 
S653 M 
BI+Hes-
sens 
mm Nup107 LAP Nup107  HMNSAPQKPTLLSQATFT#EK T784 M 
BI+Hes-
sens 
mm Nup107 LAP Nup107  SGFGGMS%S%PVIR S10/11 I/M   
mm Nup107 LAP Nup107  SQIIPRTPS%S%FRQPFVTPS S57/58 M?   
mm Nup107 LAP Nup107  QPFVT%PS%SR T65/S67 M   
mm Nup107 LAP Nup107  HPDIS%YILGTEGRS%PR S78/87 M?   
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mm Nup107 LAP Nup107  
HT%QS%S%GY%LGNLS%MVT
NLDDSNWAAAFSSQR 
T91/S93
/S94/Y96
/S101 
M Hes-sens 
mm Nup107 LAP NUP133 APSPRT#PGTGSRR S10 Hes-ind   
mm Nup107 LAP NUP133 GPLAGLGPGS# S27 M   
mm Nup107 LAP NUP133 RGPLAGLGPGST#PR T28 M   
mm Nup107 LAP NUP133 RT#ASR T31 M   
mm Nup107 LAP NUP133 GLPLGS#AVS S41 M   
mm Nup107 LAP NUP133 AVSS#PVLF S45 I/M?   
mm Nup107 LAP NUP133 PVLFS#PVGR S50 I/M?   
mm Nup107 LAP NUP133 GT#PTRMFPH T63 M? Hes-sens 
mm Nup107 LAP NUP133 MFPHHS#ITESVNYDVK S72 I/M   
mm Nup107 LAP NUP133 GILS#PSSDLTLS S267 M   
mm Nup107 LAP NUP133 
ENVSILAEDLEGSLASSVAGPNS#
ESMIFETTTK 
S499 BI-ind   
mm Nup107 LAP NUP133 
DLGHAQMVVDELFSSHSDLDS#D
SELDR 
S553 BI-ind   
mm Nup107 LAP NUP133 KGLPLGSAVSS%PVLFS%PVGR S45/50 I/M   
mm Nup107 LAP NUP160 
LIRPEYAWIVQPVSGAVYDRPGAS
#PK 
S1157 I/M   
mm Nup107 LAP NUP37 nd       
mm Nup107 LAP NUP43 SIGDFGNLDS#DGGFEGDHQLL S57 BI-ind   
mm Nup107 LAP NUP43 
S%S%T%FLSHSISNQANVHQSV
ISSWLSTDPAKDR 
S369/S3
70/T371 
I   
mm Nup107 LAP NUP85 IDEELT#GK T91 M Hes-sens 
mm Nup107 LAP NUP85 EADAS#PASAGICR S224 M BI-sens 
mm Nup107 LAP NUP98 YGLQDS#DEEEEEHPSK S871 I/M   
mm Nup107 LAP NUP98 KLKTAPLPPASQTT#PLQM T899 M   
mm Nup107 LAP NUP98 GKPAPPPQSQS#PEVEQL S917 I/M   
mm Nup107 LAP NUP98 LEES#MPEDQEPVSAS S949 M BI-sens 
mm Nup107 LAP NUP98 ASLLT#DEEDVDMALDQR T983 M BI-sens 
mm Nup107 LAP NUP98 LPS#KADTSQEICSPR S1001 I/M Hes-sens 
mm Nup107 LAP NUP98 LPIS#ASHSSK S1017 M   
mm Nup107 LAP NUP98 TRS#LVGGLLQSK S1026 M   
mm Nup107 LAP NUP98 FTSGAFLS#PSVSVQECR S1043 I/M   
mm Nup107 LAP NUP98 VSVQECRT#PR T1053 M?   
mm Nup107 LAP NUP98 VFTMPS#PAPEVPLKTV S1082 I/M   
mm Nup107 LAP NUP98 QIADS#MEFGFLPNPVAVKPL S1157 BI-ind   
mm Nup107 LAP NUP98 
YACS#PLPSYLEGSGCVIAEEQNS
QTPLR 
S1448 M Hes-sens 
mm Nup107 LAP NUP98 LPMPEDYAMDELRS#LTQSYLR S1786 BI-ind   
mm Nup107 LAP NUP98 LPSKADT%S%QEICS 
T1005/S
1006 
M   
mm Nup107 LAP NUP98 FT%S%GAFLSPS 
T1037/S
1038 
M? 
BI+Hes-
sens 
mm Nup107 LAP NUP98 VVLSLHHPPDRT%S%DSTPDPQR 
T1751/S
1752 
M   
mm Nup107 LAP NUP98 EEEEEHPSKT%S%T%K 
T882/S8
83/T884 
M   
mm Nup107 LAP SEH1L nd       
hs PDS5A IP PDS5A LKMVVKT#FMDMDQDSEDEK T55 M   
hs PDS5A IP PDS5A KDLTEYLKVRS# S373 M   
hs PDS5A IP PDS5A NENNS#HAFMKK S1051 M   
hs PDS5A IP PDS5A SALCNADS#PKDPVLPMK S1057 M   
hs PDS5A IP PDS5A NSKS#ALCN S1098 M BI-sens? 
hs PDS5A IP PDS5A SREQSSEAAETGVS#ENEENPVR S1155 M   
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hs PDS5A IP PDS5A IISVT#PVK T1212 M   
hs PDS5A IP PDS5A AAVGQES#PGGL S1309 I/M   
hs PDS5A IP PDS5A SYIS%EET%R 
S1127/T
1130 
M   
hs PDS5A IP PDS5A EINSDQATQGNIS#SDR 
S1236/S
1237 
M   
hs PDS5A IP RAD21 nd       
hs PDS5A IP SMC1 nd       
hs PDS5A IP SMC3 nd       
hs PDS5A IP STAG2 nd       
hs PDS5A IP WAPAL nd       
hs PDS5B IP PDS5B KFT#QVLEDDEK 550 M?   
hs PDS5B IP PDS5B SFFT#PGKPK S1121 Hes-ind?   
hs PDS5B IP PDS5B SNPSS#PGRIK S1166 M   
hs PDS5B IP PDS5B LDS#SEMDHSENEDYTMS S1176 I/M   
hs PDS5B IP PDS5B LDSSEMDHS#ENEDYTMS S1182 I/M   
hs PDS5B IP PDS5B DHSENEDYT#MSSPLPG T1188 M?   
hs PDS5B IP PDS5B KKT#PVTEQEEKLGMDDLTKL S1220 I/M Hes-sens 
hs PDS5B IP PDS5B GHTAS#ESDEQQWPEEK S1257 I/M   
hs PDS5B IP PDS5B EDILENEDEQNS#PPK S1283 I/M   
hs PDS5B IP PDS5B GGGT#PKEEPTMK T1301 M Bi-sens 
hs PDS5B IP PDS5B AES#PESSAIESTQSTPQK S1358 I/M   
hs PDS5B IP PDS5B AESPESSAIESTQST#PQK T1370 M   
hs PDS5B IP PDS5B GRPSKT#P T1381 I/M   
hs PDS5B IP PDS5B GRPSKT#P T1382 I/M   
hs PDS5B IP PDS5B TPS#PSQPKK S1384 I/M   
hs PDS5B IP PDS5B TTNVLGAVNKPLS%S%AGK 1139/40 bi-ind?   
hs PDS5B IP PDS5B 
SGPPAPEEEEEEERQS%GNT%EQ
K 
S1334/T
1337 
S   
hs PDS5B IP PDS5B ENDS%S%EEVDVF 
S1406/0
7 
I/M   
hs PDS5B IP PDS5B 
QGS%S%PVDDIPQEETEEEEVST
V 
S1416/1
7 
I/M Hes-sens 
mm Plk1 LAP CDC25C YLGS#PITTVP S168 BI-ind   
mm Plk1 LAP NCAPG2 KEITGS%S%LIQ S935/36 I/BI-ind?   
mm Plk1 LAP Plk1 PSS#LDP S331 M BI-sens 
mm Plk1 LAP Plk1 KKT%LCGT%PNY 
T210/21
4 
I/M   
mm Plk1 LAP TP53BP1 VPSS#PTE S380 BI-ind   
mm Plk1 LAP TP53BP1 GKLS#PR S1362 BI-ind   
mm Smc6 LAP NDNL2 RGPGGSQGSQGPS#PQGA S64 I/M   
mm Smc6 LAP NDNL2 CEALADEENRARPQPSGPAPSS# S304 I/M   
mm Smc6 LAP NSMCE4A REAPERPSLEDT#EP T58 I/M Bi-sens 
mm Smc6 LAP NSMCE4A EPS#DS S61 I/M   
mm Smc6 LAP NSMCE4A DS#GDEMMDPA S63 I/M   
hs SMC6 LAP NSMCE4A LPVIEPVSINEENEGFEHNT#QVR T345 I?   
hs SMC6 LAP NSMCE4A TFEISEPVIT#PSQR T375 M   
hs SMC6 LAP NSMCE4A EISEPVITPS#QRQQKPSA S377 I?   
hs SMC6 LAP NSMCE4A EISEPVITPSQRQQKPS#A S384 BI-ind?   
hs SMC6 LAP SMC5 TSTPS#PQPSKR S12 M  Hes-sens 
hs SMC6 LAP SMC5 ALPRDPS#SEVPSK S25 I/M   
hs SMC6 LAP SMC5 KNS#APQLPLLQSSGPFVEGSIVR S35 I/M   
hs SMC6 LAP SMC5 NKLESDYMAASS#QLR S793 I/M   
hs SMC6 LAP SMC5 LHELT#PHHQSGGER T987 
BI+hes-
ind 
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hs SMC6 LAP SMC5 FRS%S%TQLHEL S979/80 M  Hes-sens 
hs SMC6 LAP SMC6 FQSIAGLS#TMK S265 Bi-ind   
hs SMC6 LAP SMC6 DVDSEIS#DLENEVENK S669 I   
hs SMC6 LAP SMC6 RMS#DPERGQTTLPFRPV S1068 M 
 BI+Hes-
sens 
hs SMC6 LAP TUFT1 ISKPPS#PKPMPVIR S378 
BI+hes-
ind? 
  
hs STAG1 IP RAD21 
SLNQSRVEEITMREEVGNIS#ILQ
ENDFGDF 
S153 M   
hs STAG1 IP RAD21 
EGS#AFEDDDMLVSTTTSNLLLES
EQSTSNLNEK 
S175 M   
hs STAG1 IP RAD21 S%LNQS%RVEEIT%MREEV 
S134/38
/T144+S
153 
M   
hs STAG1 IP SMC1 nd       
hs STAG1 IP SMC3 nd       
hs STAG1 IP STAG1 
SFVMDHVFIDQDEENQS#MEGDE
EDEANKIEAL 
S847 I/M   
hs STAG1 IP STAG1 ARRFALT#FGLDQIK T963 M   
hs STAG1 IP STAG1 STNET%T%AHS%DAGSELEETE 
T16/T17/
S20 
M   
hs STAG1 IP STAG1 LVKIT%DGS%PS%KEDLLVLRK 
T753/S7
56/58 
M   
hs STAG2 IP PDS5A NEENPVRIISVT#PVKNIDPVKNKE T1168 M   
hs STAG2 IP PDS5A AAVGQES#PGGLEAGNAK S1265 M   
hs STAG2 IP PDS5A INSDQATQGNIS%S%DRGKKR 
S1192/9
3 
M   
hs STAG2 IP PDS5B GRPPKPLGGGT#PKEEPTMK S1301 M   
hs STAG2 IP RAD21 AHVFECNLESSVESIIS#PK S46 M   
hs STAG2 IP RAD21 EEVGNIS#ILQENDFGDFGMDDR S153 M   
hs STAG2 IP RAD21 
GMDDREIMREGS#AFEDDDMLVS
TTTSNL 
S175 M BI-sens 
hs STAG2 IP RAD21 DDMDEDDNVS#MGGPDS S271 M   
hs STAG2 IP RAD21 EDAS#GGD S545 M BI-sens 
hs STAG2 IP RAD21 TQEEPYSDIIAT#PGPR T623 M   
hs STAG2 IP RAD21 QQFS%LNQS%R 
S134/S1
38 
M BI-sens 
hs STAG2 IP RAD21 GGPDS%PDS%VDPVEPMPT 
S277/28
0 
M?   
hs STAG2 IP SMC1 EQT#VKKDENEIEKL T841 I/M   
hs STAG2 IP SMC1 
SKGTMDDISQEEGS%S%QGEDS
VSGSQRISSIY 
S956/57 M   
hs STAG2 IP SMC3 
KGDVEGS%QS%QDEGEGSGESE
R 
S1065/6
7 
I/M   
hs STAG2 IP STAG2 ILDHVFIEQDDDNNS#ADGQQED 912 I/M   
hs STAG2 IP STAG2 GMQLS#LTEE S1091 M BI-sens 
hs STAG2 IP STAG2 
LRPEDSFMSVYPMQTEHHQT#PL
DYNR 
1151 M   
hs STAG2 IP STAG2 EQT%LHT%PVMMQTPQLTSTIMR 1109/12 M   
hs STAG2 IP STAG2 
RGT%S%LMEDDEEPIVEDVMMS
SEGR 
1160/61 M   
hs STAG2 IP STAG2 
GTSLMEDDEEPIVEDVMMS%S%
EGR 
1177/78 M   
hs STAG2 IP STAG2 SIMDES#VLGVS S1224  M BI-sens 
hs STAG2 IP STAG2 VYPMQTEHHQT#PLDYNR   M   
hs STAG2 IP WAPAL 
VEEESTGDPFGFDS#DDESLPVSS
K 
S162 M   
hs STAG2 IP WAPAL RPES#PSEI S306 M   
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hs STAG2 IP WAPAL PSEIS#PIK S311 M   
hs STAG2 IP WAPAL S#MDEFTASTPADLGEAGR S465 M BI-sens 
hs STAG2 IP WAPAL 
LEFFGFEDHETGGDEGGS#GSSN
YK 
S528 M BI-sens 
hs STAG2 IP WAPAL 
AEDS#ICLADSKPLPHQNVTNHVG
K 
S989 M   
hs STAG2 IP WAPAL 
DAPTTQHDKS#GEWQETSGEIQ
WVSTEK 
S1154 M BI-sens 
hs STAG2 IP WAPAL KNSHHIHKNADDS%T%KKPNAE  
S275/T2
76 
M   
hs STAG2 IP WAPAL S%GPKRS%PTKAVY S581/86 M   
mm Tubg1 LAP Tubg1 CAEHGIS#PEGIVEEF S32 M 
 BI+Hes-
sens 
mm Tubg1 LAP Tubg1 
SQGEKIHEDIFDIIDREADGSDS#
LEGF 
S131 I/M  BI-sens 
mm Tubg1 LAP Tubg1 TTDQSVAS#VR S284 M?  Hes-sens 
mm Tubg1 LAP Tubg1 KS#PYLPSAHR S364 
BI+Hes-
ind 
  
mm Tubg1 LAP Tubg1 NFDEMDT%S%REIVQQL 
T423/S4
24 
Hes-ind   
mm Tubg1 LAP Tubg1 ILNS%S%YAKLY S80/81 Hes-ind   
mm Tubg1 LAP TUBGCP3 
S%AES%PQDAADLFTDLENAFQG
K 
S512/S5
15 
I/M   
mm Tubg1 LAP TUBGCP4 REGPSRETS#PREAPASGW S441 M   
mm Tubg1 LAP TUBGCP5 MSDNASASS%GS%DQGPSSR 
S535/S5
37 
I/M   
mm Tubg1 LAP TUBGCP5 HGEDS%T%PQVLTEQQATK 
S610/T6
11 
M  Hes-sens 
mm Tubg1 LAP TUBGCP6 LGLPPVPDNADLS#GLAIK S242 M  BI-sens 
mm Tubg1 LAP TUBGCP6 VHPQVTS#PGPEHPEGGQGC S831 I/M   
mm Tubg1 LAP TUBGCP6 QHS#PAWDGW S852 I/M   
mm Tubg1 LAP TUBGCP6 NRPGLLT#PQPLKPL T865 M   
mm Tubg1 LAP TUBGCP6 GALS#PEAEPN S1283 
BI+Hes-
ind? 
  
mm Tubg1 LAP TUBGCP6 TPRPQQS#PPGHTSQ S1296 I/M   
mm Tubg1 LAP TUBGCP6 WNIHGHVS%NAS%IR 
S1111/S
1114 
BI-ind   
mm Tubg1 LAP TUBGCP6 EDT%AAQS%S%PGRGEEAEAS 
T1392/S
1396/S1
397 
BI-ind?   
mm Tubg1 LAP TUBGCP6 RHSS%VS%KEEKELRME 
S655/S5
7 
M  Hes-sens 
mm Tubg1 LAP TUBGCP6 RPAVAT%S%PAPGPL 
T963/T9
64 
M  BI-sens 
hs WAPAL IP PDS5A IISVT#PVKNIDPVK T1211 I/M   
hs WAPAL IP PDS5A AAVGQES#PGGLEAGNAK S1305 M Hes-sens 
hs WAPAL IP RAD21 AHVFECNLESSVESIIS#PK S46 M Hes-sens 
hs WAPAL IP RAD21 SLNQS#RVEEITMR S142 M? Bi-sens? 
hs WAPAL IP RAD21 EEVGNIS#ILQENDFGDFGMDDR S153 I/M BI-sens 
hs WAPAL IP RAD21 GMDDREIMREGS#AFEDDDMLVS S175 I/M BI-sens? 
hs WAPAL IP SMC1 nd       
hs WAPAL IP SMC3 nd       
hs WAPAL IP STAG1 nd       
hs WAPAL IP STAG2 nd       
hs WAPAL IP WAPAL 
VEEESTGDPFGFDS#DDESLPVSS
K 
S162 I/M   
hs WAPAL IP WAPAL 
CSSYS#ESSEAAQLEEVTSVLEAN
SK 
S183 I/M   
hs WAPAL IP WAPAL NADDS#TKKPNAETTVASEIK S275 M   
hs WAPAL IP WAPAL FGKRPES#PSEI S306 I/M?   
hs WAPAL IP WAPAL PSEIS#PIKGS S311 I/M   
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hs WAPAL IP WAPAL SEDCILS#LDSDPLLEMK S339 M BI-sens 
hs WAPAL IP WAPAL SEDCILSLDS#DPLLEMK S342 M?   
hs WAPAL IP WAPAL NEAIEEDIVQS#VLRPT S371 M 
BI+Hes-
sens 
hs WAPAL IP WAPAL GGVSCGTS#FR S432 I/M   
hs WAPAL IP WAPAL S#MDEFTASTPADLGEAGR S465 M BI-sens 
hs WAPAL IP WAPAL TAST#PADLGEAGRL T473 M BI-sens 
hs WAPAL IP WAPAL 
TKTAPSPS#LQPPPESNDNSQDS
QSGTN 
S487 bi-ind?   
hs WAPAL IP WAPAL GFEDHETGGDEGGS#GSSNY S528 M BI-sens 
hs WAPAL IP WAPAL YFGFDDLS#E S544 I/M   
hs WAPAL IP WAPAL ES#EDDEDDDCQVERK S546 I/M   
hs WAPAL IP WAPAL KIFSGPKRS#PTKA S586 I/M   
hs WAPAL IP WAPAL DFTEDLPGVPES#VKKPINKQ S608 M   
hs WAPAL IP WAPAL 
AEDS#ICLADSKPLPHQNVTNHVG
K 
S989 M BI-sens 
hs WAPAL IP WAPAL HDKS#GEWQET S1154 M BI-sens 
hs WAPAL IP WAPAL GEWQETS#GEIQ S1161 M BI-sens 
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6 Abbreviations 
Human gene symbols from HGNC (www.genenames.org) were used for genes and their 
respective gene products within the text and in all tables and figures. The following 
table lists symbols frequently used in the text: 
 
HGNC symbol Name Ensembl ID 
Aurora kinase B ENSG00000178999 AURKB 
Baculoviral IAP repeat-containing protein 5, 
Survivin ENSG00000089685 BIRC5 
Mitotic checkpoint serine/threonine-protein 
kinase BUB1  ENSG00000169679 BUB1 
Mitotic checkpoint S/T-protein kinase BUB1 
beta (BubR1) ENSG00000156970 BUB1B 
Mitotic checkpoint protein BUB3 ENSG00000154473 BUB3 
C10orf104 Uncharacterized protein C10orf104 ENSG00000166295 
Uncharacterized protein C14orf94 ENSG00000092036 C14orf94 
C4orf15 Uncharacterized protein C4orf15  ENSG00000214367 
Protein CASC5, Blinkin  ENSG00000137812 CASC5 
CCDC5 Coiled-coil domain-containing protein 5  ENSG00000152240 
Cyclin-A1 ENSG00000133101 CCNA1 
CCNB1 G2/mitotic-specific cyclin-B1 ENSG00000134057 
G1/S-specific cyclin-D1  ENSG00000110092 CCND1 
CCNE1 G1/S-specific cyclin-E1 ENSG00000105173 
Cell division cycle protein 20 homolog  ENSG00000117399 CDC20 
CDC25A M-phase inducer phosphatase 1  ENSG00000164045 
M-phase inducer phosphatase 2  ENSG00000101224 CDC25B 
CDC25C M-phase inducer phosphatase 3  ENSG00000158402 
Cell division cycle protein 27 homolog  ENSG00000004897 CDC27 
CDCA8 Borealin  ENSG00000134690 
Cyclin-dependent kinase 1 ENSG00000170312 CDK1 
CDK2 Cyclin-dependent kinase 2 ENSG00000123374 
Cyclin-dependent kinase 4 ENSG00000135446 CDK4 
CDK6 Cyclin-dependent kinase 6 ENSG00000105810 
Cyclin-dependent kinase inhibitor 1B  ENSG00000111276 CDKN1B 
CEP27 Centrosomal protein of 27 kDa  ENSG00000137814 
CHK1 ENSG00000149554 CHEK1 
CHEK2 CHK2 ENSG00000183765 
Family with sequence similarity 128, member 
B ENSG00000152082 FAM128B 
FAM29A Protein FAM29A ENSG00000147874 
hCDH1, Fizzy-related protein homolog ENSG00000105325 FZR1 
KIF23 Kinesin-like protein KIF23  ENSG00000137807 
Mitotic spindle assembly checkpoint protein 
MAD2A  ENSG00000164109 MAD2L1 
MIS12 Protein MIS12 homolog ENSG00000167842 
Condensin complex subunit 1  ENSG00000010292 NCAPD2 
NCAPH Condensin complex subunit 2  ENSG00000121152 
Kinetochore protein Hec1  ENSG00000080986 NDC80 
NEDD1 Protein NEDD1 ENSG00000139350 
PDS5, homolog A isoform 1  ENSG00000121892 PDS5A 
PDS5B Androgen-induced proliferation inhibitor  ENSG00000083642 
Serine/threonine-protein kinase PLK1  ENSG00000166851 PLK1 
RACGAP1 Rac GTPase-activating protein 1  ENSG00000161800 
174 
                                                                                                         6 Abbreviations 
Double-strand-break repair protein rad21 
homolog  ENSG00000164754 RAD21 
SGOL1 Shugoshin-like 1  ENSG00000129810 
Structural maintenance of chromosomes 
protein 1A  ENSG00000072501 SMC1A 
SMC3 Structural maintenance of chromosomes 3 ENSG00000108055 
Structural maintenance of chromosomes 
protein 6  ENSG00000163029 SMC6 
STAG1 Cohesin subunit SA-1  ENSG00000118007 
Cohesin subunit SA-2  ENSG00000101972 STAG2 
TUBG1 Tubulin gamma-1 chain  ENSG00000131462 
Gamma-tubulin complex component 2  ENSG00000130640 TUBGCP2 
TUBGCP3 Gamma-tubulin complex component 3  ENSG00000126216 
Gamma-tubulin complex component 4  ENSG00000137822 TUBGCP4 
TUBGCP5 Gamma-tubulin complex component 5  ENSG00000153575 
Gamma-tubulin complex component 6  ENSG00000128159 TUBGCP6 
UBR5 E3 ubiquitin-protein ligase EDD1  ENSG00000104517 
UCHL5IP UCHL5-interacting protein  ENSG00000213397 
WAPAL Wings apart-like protein homolog  ENSG00000062650 
 
Other abbreviations used in this work: 
Abbreviation Explanation 
Å Ångstrom 
aa amino acid 
AGC automatic gain control 
APC/C anaphase-promoting complex 
AP-MS affinity purification followed by MS 
as-kinase analogue-sensitive kinase 
BAC bacterial artifical chromosomes 
BI-ind induced after BI4834 treatment 
BI-sens sensitive to BI4834 treatment 
CAD collision activated dissociation 
ChT chymotrypsin protease 
CPC chromosomal passenger complex 
D. melanogaster/Dm Drosophila. melanogaster 
DAPI 4',6-Diamidino-2-phenylindol 
DMEM Dulbecco's Modified Eagle Medium 
dox  doxycyclin 
E. Coli Escherichia coli 
ESI electrospray ionisation 
FCS fetal calf serum 
FT-ICR fourier transform – ion cyclontron resonance 
G1 gap-phase 1 
G2 gap-phase 2 
G418 geneticin 
H. sapiens/Hs Homo sapiens 
Hes-ind induced after Hesperadin treatment 
Hes-sens sensitive to Hesperadin treatment 
HGNC humane genome project genome nomenclature committee 
HMM hidden Markov model 
HPLC high pressure liquid chromatography 
hyg hygromycin 
I interphase-specific 
I/M interphase- and mitosis-specific 
IF immunofluorescence microscopy 
L log-phase cells 
LAP localisation and affinity purification tag 
LC liquid chromatography 
M mitosis-specific 
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MCC mitotic checkpoint complex 
MGI mouse genome informatics 
M-phase mitosis 
MS mass spectrometry 
N noc arrest 18 h 
NB noc18 h, incl 2 h BI4834 treatment 
NHM noc 18 h, incl 2 h Hesperadin and MG132 treatment 
OT orbital trap 
PBD polo box domain 
PIM protease inhibitor mix 
preRC prereplication complex  
RNAi RNA interference 
S serine 
S. cerevisiae/Sc Saccharomyces cerevisiae 
S. pombe/Sp Schizosaccharomyces pombe 
SAC spindle assembly checkpoint 
SCF Skip1, Cullin, F-box ubiquitin ligase 
SDS-PAGE Sodium dodecyl sulfate polyacrylamid electrophoresis 
SFCM spectral fuzzy c-means 
siRNA small interfering RNA 
sN synchronised cells, 3 h noc treatment 
sNB synchronised cells, 3 h noc treatment incl 2 h BI4834 
treatment 
sNHM synchronised cells, 3 h noc treatment incl 2 h Hesperadin 
and MG132 treatment 
SO mitotic shake off 
S-phase synthesis-phase 
Sub subtilisin protease 
T threonine 
Try trypsin protease 
WB western blot 
X. laevis/Xl Xenopus laevis 
Y tyrosine 
Y2H yeast two hybrid assay 
γ-TuRC γ-tubulin ring complex 
176 
                                                                                                            7 References 
 
7 References 
 
Adams, R. R., Wheatley, S. P., Gouldsworthy, A. M., Kandels-Lewis, S. E., Carmena, M., 
Smythe, C., Gerloff, D. L., and Earnshaw, W. C. (2000). INCENP binds the Aurora-related 
kinase AIRK2 and is required to target it to chromosomes, the central spindle and cleavage 
furrow. Curr Biol 10, 1075-1078. 
Ahonen, L. J., Kallio, M. J., Daum, J. R., Bolton, M., Manke, I. A., Yaffe, M. B., Stukenberg, P. 
T., and Gorbsky, G. J. (2005). Polo-like kinase 1 creates the tension-sensing 3F3/2 
phosphoepitope and modulates the association of spindle-checkpoint proteins at 
kinetochores. Curr Biol 15, 1078-1089. 
Alberts, B. (1998). The cell as a collection of protein machines: preparing the next 
generation of molecular biologists. Cell 92, 291-294. 
Allen, J. J., Lazerwith, S. E., and Shokat, K. M. (2005). Bio-orthogonal affinity purification of 
direct kinase substrates. J Am Chem Soc 127, 5288-5289. 
Andersen, J. S., Wilkinson, C. J., Mayor, T., Mortensen, P., Nigg, E. A., and Mann, M. (2003). 
Proteomic characterization of the human centrosome by protein correlation profiling. Nature 
426, 570-574. 
Andrade, M. A., Petosa, C., O'Donoghue, S. I., Muller, C. W., and Bork, P. (2001). 
Comparison of ARM and HEAT protein repeats. J Mol Biol 309, 1-18. 
Andrade, M. A., Ponting, C. P., Gibson, T. J., and Bork, P. (2000). Homology-based method 
for identification of protein repeats using statistical significance estimates. J Mol Biol 298, 
521-537. 
Andrews, P. D., Knatko, E., Moore, W. J., and Swedlow, J. R. (2003). Mitotic mechanics: the 
auroras come into view. Curr Opin Cell Biol 15, 672-683. 
Arnaud, L., Pines, J., and Nigg, E. A. (1998). GFP tagging reveals human Polo-like kinase 1 
at the kinetochore/centromere region of mitotic chromosomes. Chromosoma 107, 424-429. 
Asano, S., Park, J. E., Sakchaisri, K., Yu, L. R., Song, S., Supavilai, P., Veenstra, T. D., and 
Lee, K. S. (2005). Concerted mechanism of Swe1/Wee1 regulation by multiple kinases in 
budding yeast. Embo J 24, 2194-2204. 
Ashburner, M., Ball, C. A., Blake, J. A., Botstein, D., Butler, H., Cherry, J. M., Davis, A. P., 
Dolinski, K., Dwight, S. S., Eppig, J. T., et al. (2000). Gene ontology: tool for the unification 
of biology. The Gene Ontology Consortium. Nat Genet 25, 25-29. 
Bantscheff, M., Schirle, M., Sweetman, G., Rick, J., and Kuster, B. (2007). Quantitative mass 
spectrometry in proteomics: a critical review. Anal Bioanal Chem 389, 1017-1031. 
Barr, F. A., Sillje, H. H., and Nigg, E. A. (2004). Polo-like kinases and the orchestration of 
cell division. Nat Rev Mol Cell Biol 5, 429-440. 
Baumann, C., Korner, R., Hofmann, K., and Nigg, E. A. (2007). PICH, a centromere-
associated SNF2 family ATPase, is regulated by Plk1 and required for the spindle checkpoint. 
Cell 128, 101-114. 
Beausoleil, S. A., Jedrychowski, M., Schwartz, D., Elias, J. E., Villen, J., Li, J., Cohn, M. A., 
Cantley, L. C., and Gygi, S. P. (2004). Large-scale characterization of HeLa cell nuclear 
phosphoproteins. Proc Natl Acad Sci U S A 101, 12130-12135. 
Belgareh, N., Rabut, G., Bai, S. W., van Overbeek, M., Beaudouin, J., Daigle, N., Zatsepina, 
O. V., Pasteau, F., Labas, V., Fromont-Racine, M., et al. (2001). An evolutionarily conserved 
177 
7 References 
 
NPC subcomplex, which redistributes in part to kinetochores in mammalian cells. J Cell Biol 
154, 1147-1160. 
Bishop, J. D., and Schumacher, J. M. (2002). Phosphorylation of the carboxyl terminus of 
inner centromere protein (INCENP) by the Aurora B Kinase stimulates Aurora B kinase 
activity. J Biol Chem 277, 27577-27580. 
Blethrow, J. D., Glavy, J. S., Morgan, D. O., and Shokat, K. M. (2008). Covalent capture of 
kinase-specific phosphopeptides reveals Cdk1-cyclin B substrates. Proc Natl Acad Sci U S A 
105, 1442-1447. 
Brohee, S., and van Helden, J. (2006). Evaluation of clustering algorithms for protein-protein 
interaction networks. BMC Bioinformatics 7, 488. 
Burkard, M. E., Randall, C. L., Larochelle, S., Zhang, C., Shokat, K. M., Fisher, R. P., and 
Jallepalli, P. V. (2007). Chemical genetics reveals the requirement for Polo-like kinase 1 
activity in positioning RhoA and triggering cytokinesis in human cells. Proc Natl Acad Sci U S 
A 104, 4383-4388. 
Casenghi, M., Barr, F. A., and Nigg, E. A. (2005). Phosphorylation of Nlp by Plk1 negatively 
regulates its dynein-dynactin-dependent targeting to the centrosome. J Cell Sci 118, 5101-
5108. 
Casenghi, M., Meraldi, P., Weinhart, U., Duncan, P. I., Korner, R., and Nigg, E. A. (2003). 
Polo-like kinase 1 regulates Nlp, a centrosome protein involved in microtubule nucleation. 
Dev Cell 5, 113-125. 
Chan, C. S., and Botstein, D. (1993). Isolation and characterization of chromosome-gain and 
increase-in-ploidy mutants in yeast. Genetics 135, 677-691. 
Chan, G. K., Jablonski, S. A., Sudakin, V., Hittle, J. C., and Yen, T. J. (1999). Human BUBR1 
is a mitotic checkpoint kinase that monitors CENP-E functions at kinetochores and binds the 
cyclosome/APC. J Cell Biol 146, 941-954. 
Chatr-aryamontri, A., Ceol, A., Palazzi, L. M., Nardelli, G., Schneider, M. V., Castagnoli, L., 
and Cesareni, G. (2007). MINT: the Molecular INTeraction database. Nucleic Acids Res 35, 
D572-574. 
Cheeseman, I. M., Anderson, S., Jwa, M., Green, E. M., Kang, J., Yates, J. R., 3rd, Chan, C. 
S., Drubin, D. G., and Barnes, G. (2002). Phospho-regulation of kinetochore-microtubule 
attachments by the Aurora kinase Ipl1p. Cell 111, 163-172. 
Cheeseman, I. M., Chappie, J. S., Wilson-Kubalek, E. M., and Desai, A. (2006). The 
conserved KMN network constitutes the core microtubule-binding site of the kinetochore. Cell 
127, 983-997. 
Cheeseman, I. M., and Desai, A. (2005). A combined approach for the localization and 
tandem affinity purification of protein complexes from metazoans. Sci STKE 2005, pl1. 
Cheeseman, I. M., and Desai, A. (2008). Molecular architecture of the kinetochore-
microtubule interface. Nat Rev Mol Cell Biol 9, 33-46. 
Cheeseman, I. M., Hori, T., Fukagawa, T., and Desai, A. (2008). KNL1 and the CENP-H/I/K 
Complex Coordinately Direct Kinetochore Assembly in Vertebrates. Mol Biol Cell 19, 587-594. 
Cheeseman, I. M., Niessen, S., Anderson, S., Hyndman, F., Yates, J. R., 3rd, Oegema, K., 
and Desai, A. (2004). A conserved protein network controls assembly of the outer 
kinetochore and its ability to sustain tension. Genes Dev 18, 2255-2268. 
Choe, L., D'Ascenzo, M., Relkin, N. R., Pappin, D., Ross, P., Williamson, B., Guertin, S., 
Pribil, P., and Lee, K. H. (2007). 8-plex quantitation of changes in cerebrospinal fluid protein 
expression in subjects undergoing intravenous immunoglobulin treatment for Alzheimer's 
disease. Proteomics 7, 3651-3660. 
178 
                                                                                                            7 References 
Collins, S. R., Kemmeren, P., Zhao, X. C., Greenblatt, J. F., Spencer, F., Holstege, F. C., 
Weissman, J. S., and Krogan, N. J. (2007). Toward a comprehensive atlas of the physical 
interactome of Saccharomyces cerevisiae. Mol Cell Proteomics 6, 439-450. 
Crosio, C., Fimia, G. M., Loury, R., Kimura, M., Okano, Y., Zhou, H., Sen, S., Allis, C. D., and 
Sassone-Corsi, P. (2002). Mitotic phosphorylation of histone H3: spatio-temporal regulation 
by mammalian Aurora kinases. Mol Cell Biol 22, 874-885. 
Dai, J., Sullivan, B. A., and Higgins, J. M. (2006). Regulation of mitotic chromosome cohesion 
by Haspin and Aurora B. Dev Cell 11, 741-750. 
D'Avino, P. P., Savoian, M. S., and Glover, D. M. (2005). Cleavage furrow formation and 
ingression during animal cytokinesis: a microtubule legacy. J Cell Sci 118, 1549-1558. 
DeLuca, J. G., Gall, W. E., Ciferri, C., Cimini, D., Musacchio, A., and Salmon, E. D. (2006). 
Kinetochore microtubule dynamics and attachment stability are regulated by Hec1. Cell 127, 
969-982. 
Di Fiore, B., and Pines, J. (2007). Emi1 is needed to couple DNA replication with mitosis but 
does not regulate activation of the mitotic APC/C. J Cell Biol 177, 425-437. 
Ditchfield, C., Johnson, V. L., Tighe, A., Ellston, R., Haworth, C., Johnson, T., Mortlock, A., 
Keen, N., and Taylor, S. S. (2003). Aurora B couples chromosome alignment with anaphase 
by targeting BubR1, Mad2, and Cenp-E to kinetochores. J Cell Biol 161, 267-280. 
Einarson, M. B., Cukierman, E., Compton, D. A., and Golemis, E. A. (2004). Human enhancer 
of invasion-cluster, a coiled-coil protein required for passage through mitosis. Mol Cell Biol 
24, 3957-3971. 
Elia, A. E., Cantley, L. C., and Yaffe, M. B. (2003a). Proteomic screen finds pSer/pThr-
binding domain localizing Plk1 to mitotic substrates. Science 299, 1228-1231. 
Elia, A. E., Rellos, P., Haire, L. F., Chao, J. W., Ivins, F. J., Hoepker, K., Mohammad, D., 
Cantley, L. C., Smerdon, S. J., and Yaffe, M. B. (2003b). The molecular basis for 
phosphodependent substrate targeting and regulation of Plks by the Polo-box domain. Cell 
115, 83-95. 
Elowe, S., Hummer, S., Uldschmid, A., Li, X., and Nigg, E. A. (2007). Tension-sensitive Plk1 
phosphorylation on BubR1 regulates the stability of kinetochore microtubule interactions. 
Genes Dev 21, 2205-2219. 
Ewing, R. M., Chu, P., Elisma, F., Li, H., Taylor, P., Climie, S., McBroom-Cerajewski, L., 
Robinson, M. D., O'Connor, L., Li, M., et al. (2007). Large-scale mapping of human protein-
protein interactions by mass spectrometry. Mol Syst Biol 3, 89. 
Felix, M. A., Pines, J., Hunt, T., and Karsenti, E. (1989). A post-ribosomal supernatant from 
activated Xenopus eggs that displays post-translationally regulated oscillation of its cdc2+ 
mitotic kinase activity. Embo J 8, 3059-3069. 
Fischle, W., Tseng, B. S., Dormann, H. L., Ueberheide, B. M., Garcia, B. A., Shabanowitz, J., 
Hunt, D. F., Funabiki, H., and Allis, C. D. (2005). Regulation of HP1-chromatin binding by 
histone H3 methylation and phosphorylation. Nature 438, 1116-1122. 
Francisco, L., and Chan, C. S. (1994). Regulation of yeast chromosome segregation by Ipl1 
protein kinase and type 1 protein phosphatase. Cell Mol Biol Res 40, 207-213. 
Fukunaga, R., and Hunter, T. (1997). MNK1, a new MAP kinase-activated protein kinase, 
isolated by a novel expression screening method for identifying protein kinase substrates. 
Embo J 16, 1921-1933. 
Gandhi, R., Gillespie, P. J., and Hirano, T. (2006). Human Wapl is a cohesin-binding protein 
that promotes sister-chromatid resolution in mitotic prophase. Curr Biol 16, 2406-2417. 
179 
7 References 
 
Gavin, A. C., Aloy, P., Grandi, P., Krause, R., Boesche, M., Marzioch, M., Rau, C., Jensen, L. 
J., Bastuck, S., Dumpelfeld, B., et al. (2006). Proteome survey reveals modularity of the 
yeast cell machinery. Nature 440, 631-636. 
Gieffers, C., Peters, B. H., Kramer, E. R., Dotti, C. G., and Peters, J. M. (1999). Expression of 
the CDH1-associated form of the anaphase-promoting complex in postmitotic neurons. Proc 
Natl Acad Sci U S A 96, 11317-11322. 
Gingras, A. C., Gstaiger, M., Raught, B., and Aebersold, R. (2007). Analysis of protein 
complexes using mass spectrometry. Nat Rev Mol Cell Biol 8, 645-654. 
Glavy, J. S., Krutchinsky, A. N., Cristea, I. M., Berke, I. C., Boehmer, T., Blobel, G., and 
Chait, B. T. (2007). Cell-cycle-dependent phosphorylation of the nuclear pore Nup107-160 
subcomplex. Proc Natl Acad Sci U S A 104, 3811-3816. 
Glotzer, M., Murray, A. W., and Kirschner, M. W. (1991). Cyclin is degraded by the ubiquitin 
pathway. Nature 349, 132-138. 
Glover, D. M., Leibowitz, M. H., McLean, D. A., and Parry, H. (1995). Mutations in aurora 
prevent centrosome separation leading to the formation of monopolar spindles. Cell 81, 95-
105. 
Golsteyn, R. M., Schultz, S. J., Bartek, J., Ziemiecki, A., Ried, T., and Nigg, E. A. (1994). Cell 
cycle analysis and chromosomal localization of human Plk1, a putative homologue of the 
mitotic kinases Drosophila polo and Saccharomyces cerevisiae Cdc5. J Cell Sci 107 ( Pt 6), 
1509-1517. 
Goshima, G., Wollman, R., Goodwin, S. S., Zhang, N., Scholey, J. M., Vale, R. D., and 
Stuurman, N. (2007). Genes required for mitotic spindle assembly in Drosophila S2 cells. 
Science 316, 417-421. 
Guse, A., Mishima, M., and Glotzer, M. (2005). Phosphorylation of ZEN-4/MKLP1 by aurora B 
regulates completion of cytokinesis. Curr Biol 15, 778-786. 
Hanisch, A., Wehner, A., Nigg, E. A., and Sillje, H. H. (2006). Different Plk1 functions show 
distinct dependencies on Polo-Box domain-mediated targeting. Mol Biol Cell 17, 448-459. 
Harlow, E., and Lane, D. (1988). Antibodies: A Laboratory Manual, 1st end. edn (Cold Spring 
Harbor, Cold Spring Harbor Laboratory). 
Hartman, T., Stead, K., Koshland, D., and Guacci, V. (2000). Pds5p is an essential 
chromosomal protein required for both sister chromatid cohesion and condensation in 
Saccharomyces cerevisiae. J Cell Biol 151, 613-626. 
Hauf, S., Cole, R. W., LaTerra, S., Zimmer, C., Schnapp, G., Walter, R., Heckel, A., van Meel, 
J., Rieder, C. L., and Peters, J. M. (2003). The small molecule Hesperadin reveals a role for 
Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle 
assembly checkpoint. J Cell Biol 161, 281-294. 
Hauf, S., Roitinger, E., Koch, B., Dittrich, C. M., Mechtler, K., and Peters, J. M. (2005). 
Dissociation of cohesin from chromosome arms and loss of arm cohesion during early mitosis 
depends on phosphorylation of SA2. PLoS Biol 3, e69. 
Hauf, S., Waizenegger, I. C., and Peters, J. M. (2001). Cohesin cleavage by separase 
required for anaphase and cytokinesis in human cells. Science 293, 1320-1323. 
Heald, R., and McKeon, F. (1990). Mutations of phosphorylation sites in lamin A that prevent 
nuclear lamina disassembly in mitosis. Cell 61, 579-589. 
Henderson, M. J., Munoz, M. A., Saunders, D. N., Clancy, J. L., Russell, A. J., Williams, B., 
Pappin, D., Khanna, K. K., Jackson, S. P., Sutherland, R. L., and Watts, C. K. (2006). EDD 
mediates DNA damage-induced activation of CHK2. J Biol Chem 281, 39990-40000. 
180 
                                                                                                            7 References 
Herzog, F., Dube, P., Primorac, I., Stark, H., and Peters, J. M. (in preparation). 
Hirano, T. (2005). SMC proteins and chromosome mechanics: from bacteria to humans. 
Philos Trans R Soc Lond B Biol Sci 360, 507-514. 
Hirano, T. (2006). At the heart of the chromosome: SMC proteins in action. Nat Rev Mol Cell 
Biol 7, 311-322. 
Hirota, T., Gerlich, D., Koch, B., Ellenberg, J., and Peters, J. M. (2004). Distinct functions of 
condensin I and II in mitotic chromosome assembly. J Cell Sci 117, 6435-6445. 
Hirota, T., Lipp, J. J., Toh, B. H., and Peters, J. M. (2005). Histone H3 serine 10 
phosphorylation by Aurora B causes HP1 dissociation from heterochromatin. Nature 438, 
1176-1180. 
Honda, R., Korner, R., and Nigg, E. A. (2003). Exploring the functional interactions between 
Aurora B, INCENP, and survivin in mitosis. Mol Biol Cell 14, 3325-3341. 
Jablonski, S. A., Chan, G. K., Cooke, C. A., Earnshaw, W. C., and Yen, T. J. (1998). The 
hBUB1 and hBUBR1 kinases sequentially assemble onto kinetochores during prophase with 
hBUBR1 concentrating at the kinetochore plates in mitosis. Chromosoma 107, 386-396. 
Jackman, M., Lindon, C., Nigg, E. A., and Pines, J. (2003). Active cyclin B1-Cdk1 first 
appears on centrosomes in prophase. Nat Cell Biol 5, 143-148. 
Janssens, V., Goris, J., and Van Hoof, C. (2005). PP2A: the expected tumor suppressor. Curr 
Opin Genet Dev 15, 34-41. 
Jeyaprakash, A. A., Klein, U. R., Lindner, D., Ebert, J., Nigg, E. A., and Conti, E. (2007). 
Structure of a Survivin-Borealin-INCENP core complex reveals how chromosomal passengers 
travel together. Cell 131, 271-285. 
Kang, Y. H., Park, J. E., Yu, L. R., Soung, N. K., Yun, S. M., Bang, J. K., Seong, Y. S., Yu, H., 
Garfield, S., Veenstra, T. D., and Lee, K. S. (2006). Self-regulated Plk1 recruitment to 
kinetochores by the Plk1-PBIP1 interaction is critical for proper chromosome segregation. Mol 
Cell 24, 409-422. 
Karsenti, E., Bravo, R., and Kirschner, M. (1987). Phosphorylation changes associated with 
the early cell cycle in Xenopus eggs. Dev Biol 119, 442-453. 
Kelm, O., Wind, M., Lehmann, W. D., and Nigg, E. A. (2002). Cell cycle-regulated 
phosphorylation of the Xenopus polo-like kinase Plx1. J Biol Chem 277, 25247-25256. 
Kerrien, S., Alam-Faruque, Y., Aranda, B., Bancarz, I., Bridge, A., Derow, C., Dimmer, E., 
Feuermann, M., Friedrichsen, A., Huntley, R., et al. (2007). IntAct--open source resource for 
molecular interaction data. Nucleic Acids Res 35, D561-565. 
King, E. M., Rachidi, N., Morrice, N., Hardwick, K. G., and Stark, M. J. (2007). Ipl1p-
dependent phosphorylation of Mad3p is required for the spindle checkpoint response to lack 
of tension at kinetochores. Genes Dev 21, 1163-1168. 
Kitajima, T. S., Hauf, S., Ohsugi, M., Yamamoto, T., and Watanabe, Y. (2005). Human Bub1 
defines the persistent cohesion site along the mitotic chromosome by affecting Shugoshin 
localization. Curr Biol 15, 353-359. 
Kittler, R., Heninger, A. K., Franke, K., Habermann, B., and Buchholz, F. (2005a). Production 
of endoribonuclease-prepared short interfering RNAs for gene silencing in mammalian cells. 
Nat Methods 2, 779-784. 
Kittler, R., Pelletier, L., Heninger, A. K., Slabicki, M., Theis, M., Miroslaw, L., Poser, I., Lawo, 
S., Grabner, H., Kozak, K., et al. (2007). Genome-scale RNAi profiling of cell division in 
human tissue culture cells. Nat Cell Biol 9, 1401-1412. 
181 
7 References 
 
Kittler, R., Pelletier, L., Ma, C., Poser, I., Fischer, S., Hyman, A. A., and Buchholz, F. 
(2005b). RNA interference rescue by bacterial artificial chromosome transgenesis in 
mammalian tissue culture cells. Proc Natl Acad Sci U S A 102, 2396-2401. 
Kiyomitsu, T., Obuse, C., and Yanagida, M. (2007). Human Blinkin/AF15q14 is required for 
chromosome alignment and the mitotic checkpoint through direct interaction with Bub1 and 
BubR1. Dev Cell 13, 663-676. 
Koch, C. A., Anderson, D., Moran, M. F., Ellis, C., and Pawson, T. (1991). SH2 and SH3 
domains: elements that control interactions of cytoplasmic signaling proteins. Science 252, 
668-674. 
Kocher, T., and Superti-Furga, G. (2007). Mass spectrometry-based functional proteomics: 
from molecular machines to protein networks. Nat Methods 4, 807-815. 
Kraft, C., Herzog, F., Gieffers, C., Mechtler, K., Hagting, A., Pines, J., and Peters, J. M. 
(2003). Mitotic regulation of the human anaphase-promoting complex by phosphorylation. 
Embo J 22, 6598-6609. 
Krogan, N. J., Cagney, G., Yu, H., Zhong, G., Guo, X., Ignatchenko, A., Li, J., Pu, S., Datta, 
N., Tikuisis, A. P., et al. (2006). Global landscape of protein complexes in the yeast 
Saccharomyces cerevisiae. Nature 440, 637-643. 
Kueng, S., Hegemann, B., Peters, B. H., Lipp, J. J., Schleiffer, A., Mechtler, K., and Peters, J. 
M. (2006). Wapl controls the dynamic association of cohesin with chromatin. Cell 127, 955-
967. 
Labbe, J. C., Capony, J. P., Caput, D., Cavadore, J. C., Derancourt, J., Kaghad, M., Lelias, J. 
M., Picard, A., and Doree, M. (1989). MPF from starfish oocytes at first meiotic metaphase is 
a heterodimer containing one molecule of cdc2 and one molecule of cyclin B. Embo J 8, 
3053-3058. 
Lane, H. A., and Nigg, E. A. (1996). Antibody microinjection reveals an essential role for 
human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes. J Cell 
Biol 135, 1701-1713. 
Lenart, P., Petronczki, M., Steegmaier, M., Di Fiore, B., Lipp, J. J., Hoffmann, M., Rettig, W. 
J., Kraut, N., and Peters, J. M. (2007). The small-molecule inhibitor BI 2536 reveals novel 
insights into mitotic roles of polo-like kinase 1. Curr Biol 17, 304-315. 
Li, H., Coghlan, A., Ruan, J., Coin, L. J., Heriche, J. K., Osmotherly, L., Li, R., Liu, T., Zhang, 
Z., Bolund, L., et al. (2006). TreeFam: a curated database of phylogenetic trees of animal 
gene families. Nucleic Acids Res 34, D572-580. 
Lindon, C., and Pines, J. (2004). Ordered proteolysis in anaphase inactivates Plk1 to 
contribute to proper mitotic exit in human cells. J Cell Biol 164, 233-241. 
Lipp, J. J., Hirota, T., Poser, I., and Peters, J. M. (2007). Aurora B controls the association of 
condensin I but not condensin II with mitotic chromosomes. J Cell Sci 120, 1245-1255. 
Liu, X., Zhou, T., Kuriyama, R., and Erikson, R. L. (2004). Molecular interactions of Polo-like-
kinase 1 with the mitotic kinesin-like protein CHO1/MKLP-1. J Cell Sci 117, 3233-3246. 
Llamazares, S., Moreira, A., Tavares, A., Girdham, C., Spruce, B. A., Gonzalez, C., Karess, R. 
E., Glover, D. M., and Sunkel, C. E. (1991). polo encodes a protein kinase homolog required 
for mitosis in Drosophila. Genes Dev 5, 2153-2165. 
Loiodice, I., Alves, A., Rabut, G., Van Overbeek, M., Ellenberg, J., Sibarita, J. B., and Doye, 
V. (2004). The entire Nup107-160 complex, including three new members, is targeted as 
one entity to kinetochores in mitosis. Mol Biol Cell 15, 3333-3344. 
182 
                                                                                                            7 References 
Losada, A., Hirano, M., and Hirano, T. (2002). Cohesin release is required for sister 
chromatid resolution, but not for condensin-mediated compaction, at the onset of mitosis. 
Genes Dev 16, 3004-3016. 
Losada, A., Yokochi, T., and Hirano, T. (2005). Functional contribution of Pds5 to cohesin-
mediated cohesion in human cells and Xenopus egg extracts. J Cell Sci 118, 2133-2141. 
Losada, A., Yokochi, T., Kobayashi, R., and Hirano, T. (2000). Identification and 
characterization of SA/Scc3p subunits in the Xenopus and human cohesin complexes. J Cell 
Biol 150, 405-416. 
Lowery, D. M., Clauser, K. R., Hjerrild, M., Lim, D., Alexander, J., Kishi, K., Ong, S. E., 
Gammeltoft, S., Carr, S. A., and Yaffe, M. B. (2007). Proteomic screen defines the Polo-box 
domain interactome and identifies Rock2 as a Plk1 substrate. Embo J 26, 2262-2273. 
Luders, J., Patel, U. K., and Stearns, T. (2006). GCP-WD is a gamma-tubulin targeting factor 
required for centrosomal and chromatin-mediated microtubule nucleation. Nat Cell Biol 8, 
137-147. 
Mailand, N., Podtelejnikov, A. V., Groth, A., Mann, M., Bartek, J., and Lukas, J. (2002). 
Regulation of G(2)/M events by Cdc25A through phosphorylation-dependent modulation of 
its stability. Embo J 21, 5911-5920. 
Maller, J., Wu, M., and Gerhart, J. C. (1977). Changes in protein phosphorylation 
accompanying maturation of Xenopus laevis oocytes. Dev Biol 58, 295-312. 
Matsumura, S., Toyoshima, F., and Nishida, E. (2007). Polo-like kinase 1 facilitates 
chromosome alignment during prometaphase through BubR1. J Biol Chem 282, 15217-
15227. 
Meila, M., and Shi, J. (2001). A Random Walks View of Spectral Segmentation. Paper 
presented at: Interna-  
tional Conference on AI and Statistics (AISTAT). 
Mewes, H. W., Frishman, D., Guldener, U., Mannhaupt, G., Mayer, K., Mokrejs, M., 
Morgenstern, B., Munsterkotter, M., Rudd, S., and Weil, B. (2002). MIPS: a database for 
genomes and protein sequences. Nucleic Acids Res 30, 31-34. 
Morgan, D. O. (1997). Cyclin-dependent kinases: engines, clocks, and microprocessors. 
Annu Rev Cell Dev Biol 13, 261-291. 
Morgan, D. O. (2007). The Cell Cycle - Principles of Control, 1 edn (London, New Science 
Press). 
Morgan, D. O., Kaplan, J. M., Bishop, J. M., and Varmus, H. E. (1989). Mitosis-specific 
phosphorylation of p60c-src by p34cdc2-associated protein kinase. Cell 57, 775-786. 
Morla, A. O., Draetta, G., Beach, D., and Wang, J. Y. (1989). Reversible tyrosine 
phosphorylation of cdc2: dephosphorylation accompanies activation during entry into mitosis. 
Cell 58, 193-203. 
Morrow, C. J., Tighe, A., Johnson, V. L., Scott, M. I., Ditchfield, C., and Taylor, S. S. (2005). 
Bub1 and aurora B cooperate to maintain BubR1-mediated inhibition of APC/CCdc20. J Cell 
Sci 118, 3639-3652. 
Mueller, L. N., Rinner, O., Schmidt, A., Letarte, S., Bodenmiller, B., Brusniak, M. Y., Vitek, 
O., Aebersold, R., and Muller, M. (2007). SuperHirn - a novel tool for high resolution LC-MS-
based peptide/protein profiling. Proteomics 7, 3470-3480. 
Mueller, P. R., Coleman, T. R., Kumagai, A., and Dunphy, W. G. (1995). Myt1: a membrane-
associated inhibitory kinase that phosphorylates Cdc2 on both threonine-14 and tyrosine-15. 
Science 270, 86-90. 
183 
7 References 
 
Munoz, M. A., Saunders, D. N., Henderson, M. J., Clancy, J. L., Russell, A. J., Lehrbach, G., 
Musgrove, E. A., Watts, C. K., and Sutherland, R. L. (2007). The E3 ubiquitin ligase EDD 
regulates S-phase and G(2)/M DNA damage checkpoints. Cell Cycle 6, 3070-3077. 
Musacchio, A., and Salmon, E. D. (2007). The spindle-assembly checkpoint in space and 
time. Nat Rev Mol Cell Biol 8, 379-393. 
Nagase, T., Ishikawa, K., Suyama, M., Kikuno, R., Hirosawa, M., Miyajima, N., Tanaka, A., 
Kotani, H., Nomura, N., and Ohara, O. (1999). Prediction of the coding sequences of 
unidentified human genes. XIII. The complete sequences of 100 new cDNA clones from brain 
which code for large proteins in vitro. DNA Res 6, 63-70. 
Nakajima, H., Toyoshima-Morimoto, F., Taniguchi, E., and Nishida, E. (2003). Identification 
of a consensus motif for Plk (Polo-like kinase) phosphorylation reveals Myt1 as a Plk1 
substrate. J Biol Chem 278, 25277-25280. 
Nasmyth, K., and Haering, C. H. (2005). The structure and function of smc and kleisin 
complexes. Annu Rev Biochem 74, 595-648. 
Neef, R., Gruneberg, U., Kopajtich, R., Li, X., Nigg, E. A., Sillje, H., and Barr, F. A. (2007). 
Choice of Plk1 docking partners during mitosis and cytokinesis is controlled by the activation 
state of Cdk1. Nat Cell Biol 9, 436-444. 
Nesvizhskii, A. I., and Aebersold, R. (2005). Interpretation of shotgun proteomic data: the 
protein inference problem. Mol Cell Proteomics 4, 1419-1440. 
Neumann, B., Erfle, H., Heriche, J. K., others, a., and Ellenberg, J. (in preparation). 
Ohshima, R., Ohta, T., Wu, W., Koike, A., Iwatani, T., Henderson, M., Watts, C. K., and 
Otsubo, T. (2007). Putative tumor suppressor EDD interacts with and up-regulates APC. 
Genes Cells 12, 1339-1345. 
Olsen, J. V., Blagoev, B., Gnad, F., Macek, B., Kumar, C., Mortensen, P., and Mann, M. 
(2006). Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. 
Cell 127, 635-648. 
Ong, S. E., Blagoev, B., Kratchmarova, I., Kristensen, D. B., Steen, H., Pandey, A., and 
Mann, M. (2002). Stable isotope labeling by amino acids in cell culture, SILAC, as a simple 
and accurate approach to expression proteomics. Mol Cell Proteomics 1, 376-386. 
Orjalo, A. V., Arnaoutov, A., Shen, Z., Boyarchuk, Y., Zeitlin, S. G., Fontoura, B., Briggs, S., 
Dasso, M., and Forbes, D. J. (2006). The Nup107-160 nucleoporin complex is required for 
correct bipolar spindle assembly. Mol Biol Cell 17, 3806-3818. 
Osmani, A. H., O'Donnell, K., Pu, R. T., and Osmani, S. A. (1991). Activation of the nimA 
protein kinase plays a unique role during mitosis that cannot be bypassed by absence of the 
bimE checkpoint. Embo J 10, 2669-2679. 
Panizza, S., Tanaka, T., Hochwagen, A., Eisenhaber, F., and Nasmyth, K. (2000). Pds5 
cooperates with cohesin in maintaining sister chromatid cohesion. Curr Biol 10, 1557-1564. 
Parrish, J. R., Gulyas, K. D., and Finley, R. L., Jr. (2006). Yeast two-hybrid contributions to 
interactome mapping. Curr Opin Biotechnol 17, 387-393. 
Peri, S., Navarro, J. D., Amanchy, R., Kristiansen, T. Z., Jonnalagadda, C. K., Surendranath, 
V., Niranjan, V., Muthusamy, B., Gandhi, T. K., Gronborg, M., et al. (2003). Development of 
human protein reference database as an initial platform for approaching systems biology in 
humans. Genome Res 13, 2363-2371. 
Peter, M., Heitlinger, E., Haner, M., Aebi, U., and Nigg, E. A. (1991). Disassembly of in vitro 
formed lamin head-to-tail polymers by CDC2 kinase. Embo J 10, 1535-1544. 
184 
                                                                                                            7 References 
Peter, M., Nakagawa, J., Doree, M., Labbe, J. C., and Nigg, E. A. (1990). In vitro 
disassembly of the nuclear lamina and M phase-specific phosphorylation of lamins by cdc2 
kinase. Cell 61, 591-602. 
Peters, J. M. (2006). The anaphase promoting complex/cyclosome: a machine designed to 
destroy. Nat Rev Mol Cell Biol 7, 644-656. 
Peters, J. M., King, R. W., Hoog, C., and Kirschner, M. W. (1996). Identification of BIME as a 
subunit of the anaphase-promoting complex. Science 274, 1199-1201. 
Petretti, C., Savoian, M., Montembault, E., Glover, D. M., Prigent, C., and Giet, R. (2006). 
The PITSLRE/CDK11p58 protein kinase promotes centrosome maturation and bipolar spindle 
formation. EMBO Rep 7, 418-424. 
Petronczki, M., Glotzer, M., Kraut, N., and Peters, J. M. (2007). Polo-like kinase 1 triggers 
the initiation of cytokinesis in human cells by promoting recruitment of the RhoGEF Ect2 to 
the central spindle. Dev Cell 12, 713-725. 
Piwnica-Worms, H., Atherton-Fessler, S., Lee, M. S., Ogg, S., Swenson, K. I., and Parker, L. 
L. (1991). p107wee1 is a serine/threonine and tyrosine kinase that promotes the tyrosine 
phosphorylation of the cyclin/p34cdc2 complex. Cold Spring Harb Symp Quant Biol 56, 567-
576. 
Poser, I., Sarov, M., Hutchins, J. R., Heriche, J. K., Toyoda, Y., Pozniakovsky, A., Weigl, D., 
Nitzsche, A., Hegemann, B., Bird, A. W., et al. (2008). BAC TransgeneOmics: a high-
throughput method for exploration of protein function in mammals. Nat Methods 5, 409-415. 
Potapova, T. A., Daum, J. R., Pittman, B. D., Hudson, J. R., Jones, T. N., Satinover, D. L., 
Stukenberg, P. T., and Gorbsky, G. J. (2006). The reversibility of mitotic exit in vertebrate 
cells. Nature 440, 954-958. 
Qi, W., Tang, Z., and Yu, H. (2006). Phosphorylation- and polo-box-dependent binding of 
Plk1 to Bub1 is required for the kinetochore localization of Plk1. Mol Biol Cell 17, 3705-3716. 
Raynaud-Messina, B., and Merdes, A. (2007). Gamma-tubulin complexes and microtubule 
organization. Curr Opin Cell Biol 19, 24-30. 
Reeves, R. (2001). Molecular biology of HMGA proteins: hubs of nuclear function. Gene 277, 
63-81. 
Rigaut, G., Shevchenko, A., Rutz, B., Wilm, M., Mann, M., and Seraphin, B. (1999). A generic 
protein purification method for protein complex characterization and proteome exploration. 
Nat Biotechnol 17, 1030-1032. 
Rines, D. R., Gomez-Ferreria, M. A., Zhou, Y., Dejesus, P., Grob, S., Batalov, S., Labow, M., 
Huesken, D., Mickanin, C., Hall, J., et al. (2008). Whole genome functional analysis identifies 
novel components required for mitotic spindle integrity in human cells. Genome Biol 9, R44. 
Rinner, O., Mueller, L. N., Hubalek, M., Muller, M., Gstaiger, M., and Aebersold, R. (2007). 
An integrated mass spectrometric and computational framework for the analysis of protein 
interaction networks. Nat Biotechnol 25, 345-352. 
Roessner-Tunali, U., Hegemann, B., Lytovchenko, A., Carrari, F., Bruedigam, C., Granot, D., 
and Fernie, A. R. (2003). Metabolic profiling of transgenic tomato plants overexpressing 
hexokinase reveals that the influence of hexose phosphorylation diminishes during fruit 
development. Plant Physiol 133, 84-99. 
Rosasco-Nitcher, S. E., Lan, W., Khorasanizadeh, S., and Stukenberg, P. T. (2008). 
Centromeric Aurora-B activation requires TD-60, microtubules, and substrate priming 
phosphorylation. Science 319, 469-472. 
Ross, P. L., Huang, Y. N., Marchese, J. N., Williamson, B., Parker, K., Hattan, S., Khainovski, 
N., Pillai, S., Dey, S., Daniels, S., et al. (2004). Multiplexed protein quantitation in 
185 
7 References 
 
Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol Cell 
Proteomics 3, 1154-1169. 
Ruchaud, S., Carmena, M., and Earnshaw, W. C. (2007). Chromosomal passengers: 
conducting cell division. Nat Rev Mol Cell Biol 8, 798-812. 
Sandall, S., Severin, F., McLeod, I. X., Yates, J. R., 3rd, Oegema, K., Hyman, A., and Desai, 
A. (2006). A Bir1-Sli15 complex connects centromeres to microtubules and is required to 
sense kinetochore tension. Cell 127, 1179-1191. 
Santamaria, A., Neef, R., Eberspacher, U., Eis, K., Husemann, M., Mumberg, D., Prechtl, S., 
Schulze, V., Siemeister, G., Wortmann, L., et al. (2007). Use of the novel Plk1 inhibitor ZK-
thiazolidinone to elucidate functions of Plk1 in early and late stages of mitosis. Mol Biol Cell 
18, 4024-4036. 
Schleiffer, A., Kaitna, S., Maurer-Stroh, S., Glotzer, M., Nasmyth, K., and Eisenhaber, F. 
(2003). Kleisins: a superfamily of bacterial and eukaryotic SMC protein partners. Mol Cell 11, 
571-575. 
Sessa, F., Mapelli, M., Ciferri, C., Tarricone, C., Areces, L. B., Schneider, T. R., Stukenberg, 
P. T., and Musacchio, A. (2005). Mechanism of Aurora B activation by INCENP and inhibition 
by hesperadin. Mol Cell 18, 379-391. 
Shah, K., and Shokat, K. M. (2002). A chemical genetic screen for direct v-Src substrates 
reveals ordered assembly of a retrograde signaling pathway. Chem Biol 9, 35-47. 
Shenoy, S., Choi, J. K., Bagrodia, S., Copeland, T. D., Maller, J. L., and Shalloway, D. 
(1989). Purified maturation promoting factor phosphorylates pp60c-src at the sites 
phosphorylated during fibroblast mitosis. Cell 57, 763-774. 
Shi, J., and Malik, J. (2000). Normalized Cuts and Image Segmentation. IEEE Transactions 
on Pattern Analysis and Machine Intelligence 22, 888-905. 
Simanis, V., and Nurse, P. (1986). The cell cycle control gene cdc2+ of fission yeast encodes 
a protein kinase potentially regulated by phosphorylation. Cell 45, 261-268. 
Skibbens, R. V. (2005). Unzipped and loaded: the role of DNA helicases and RFC clamp-
loading complexes in sister chromatid cohesion. J Cell Biol 169, 841-846. 
Skoufias, D. A., Indorato, R. L., Lacroix, F., Panopoulos, A., and Margolis, R. L. (2007). 
Mitosis persists in the absence of Cdk1 activity when proteolysis or protein phosphatase 
activity is suppressed. J Cell Biol 179, 671-685. 
Snead, J. L., Sullivan, M., Lowery, D. M., Cohen, M. S., Zhang, C., Randle, D. H., Taunton, 
J., Yaffe, M. B., Morgan, D. O., and Shokat, K. M. (2007). A coupled chemical-genetic and 
bioinformatic approach to Polo-like kinase pathway exploration. Chem Biol 14, 1261-1272. 
Sonnichsen, B., Koski, L. B., Walsh, A., Marschall, P., Neumann, B., Brehm, M., Alleaume, A. 
M., Artelt, J., Bettencourt, P., Cassin, E., et al. (2005). Full-genome RNAi profiling of early 
embryogenesis in Caenorhabditis elegans. Nature 434, 462-469. 
Steegmaier, M., Hoffmann, M., Baum, A., Lenart, P., Petronczki, M., Krssak, M., Gurtler, U., 
Garin-Chesa, P., Lieb, S., Quant, J., et al. (2007). BI 2536, a potent and selective inhibitor of 
polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol 17, 316-322. 
Steen, H., and Mann, M. (2004). The ABC's (and XYZ's) of peptide sequencing. Nat Rev Mol 
Cell Biol 5, 699-711. 
Stelzl, U., Worm, U., Lalowski, M., Haenig, C., Brembeck, F. H., Goehler, H., Stroedicke, M., 
Zenkner, M., Schoenherr, A., Koeppen, S., et al. (2005). A human protein-protein interaction 
network: a resource for annotating the proteome. Cell 122, 957-968. 
186 
                                                                                                            7 References 
Strom, L., and Sjogren, C. (2007). Chromosome segregation and double-strand break repair 
- a complex connection. Curr Opin Cell Biol 19, 344-349. 
Sudakin, V., Chan, G. K., and Yen, T. J. (2001). Checkpoint inhibition of the APC/C in HeLa 
cells is mediated by a complex of BUBR1, BUB3, CDC20, and MAD2. J Cell Biol 154, 925-936. 
Sumara, I., Gimenez-Abian, J. F., Gerlich, D., Hirota, T., Kraft, C., de la Torre, C., Ellenberg, 
J., and Peters, J. M. (2004). Roles of polo-like kinase 1 in the assembly of functional mitotic 
spindles. Curr Biol 14, 1712-1722. 
Sumara, I., Vorlaufer, E., Gieffers, C., Peters, B. H., and Peters, J. M. (2000). 
Characterization of vertebrate cohesin complexes and their regulation in prophase. J Cell Biol 
151, 749-762. 
Sumara, I., Vorlaufer, E., Stukenberg, P. T., Kelm, O., Redemann, N., Nigg, E. A., and 
Peters, J. M. (2002). The dissociation of cohesin from chromosomes in prophase is regulated 
by Polo-like kinase. Mol Cell 9, 515-525. 
Takemoto, A., Murayama, A., Katano, M., Urano, T., Furukawa, K., Yokoyama, S., 
Yanagisawa, J., Hanaoka, F., and Kimura, K. (2007). Analysis of the role of Aurora B on the 
chromosomal targeting of condensin I. Nucleic Acids Res 35, 2403-2412. 
Tanaka, T. U., Rachidi, N., Janke, C., Pereira, G., Galova, M., Schiebel, E., Stark, M. J., and 
Nasmyth, K. (2002). Evidence that the Ipl1-Sli15 (Aurora kinase-INCENP) complex promotes 
chromosome bi-orientation by altering kinetochore-spindle pole connections. Cell 108, 317-
329. 
Taylor, S., and Peters, J. M. (2008). Polo and Aurora kinases: lessons derived from chemical 
biology. Curr Opin Cell Biol 20, 77-84. 
Terada, Y., Tatsuka, M., Suzuki, F., Yasuda, Y., Fujita, S., and Otsu, M. (1998). AIM-1: a 
mammalian midbody-associated protein required for cytokinesis. Embo J 17, 667-676. 
Toyoda, Y., and Hyman, A. (in preparation). 
Toyoshima-Morimoto, F., Taniguchi, E., Shinya, N., Iwamatsu, A., and Nishida, E. (2001). 
Polo-like kinase 1 phosphorylates cyclin B1 and targets it to the nucleus during prophase. 
Nature 410, 215-220. 
Ubersax, J. A., Woodbury, E. L., Quang, P. N., Paraz, M., Blethrow, J. D., Shah, K., Shokat, 
K. M., and Morgan, D. O. (2003). Targets of the cyclin-dependent kinase Cdk1. Nature 425, 
859-864. 
Vagnarelli, P. B., and Earnshaw, W. C. (2001). INCENP loss from an inactive centromere 
correlates with the loss of sister chromatid cohesion. Chromosoma 110, 393-401. 
van Vugt, M. A., van de Weerdt, B. C., Vader, G., Janssen, H., Calafat, J., Klompmaker, R., 
Wolthuis, R. M., and Medema, R. H. (2004). Polo-like kinase-1 is required for bipolar spindle 
formation but is dispensable for anaphase promoting complex/Cdc20 activation and initiation 
of cytokinesis. J Biol Chem 279, 36841-36854. 
Waizenegger, I. C., Hauf, S., Meinke, A., and Peters, J. M. (2000). Two distinct pathways 
remove mammalian cohesin from chromosome arms in prophase and from centromeres in 
anaphase. Cell 103, 399-410. 
Ward, G. E., and Kirschner, M. W. (1990). Identification of cell cycle-regulated 
phosphorylation sites on nuclear lamin C. Cell 61, 561-577. 
Wasserman, W. J., and Masui, Y. (1975). Effects of cyclohexamide on a cytoplasmic factor 
initiating meiotic naturation in Xenopus oocytes. Exp Cell Res 91, 381-388. 
187 
7 References 
 
Watanabe, N., Arai, H., Iwasaki, J., Shiina, M., Ogata, K., Hunter, T., and Osada, H. (2005). 
Cyclin-dependent kinase (CDK) phosphorylation destabilizes somatic Wee1 via multiple 
pathways. Proc Natl Acad Sci U S A 102, 11663-11668. 
Watanabe, N., Arai, H., Nishihara, Y., Taniguchi, M., Hunter, T., and Osada, H. (2004). M-
phase kinases induce phospho-dependent ubiquitination of somatic Wee1 by SCFbeta-TrCP. 
Proc Natl Acad Sci U S A 101, 4419-4424. 
Watrin, E., Schleiffer, A., Tanaka, K., Eisenhaber, F., Nasmyth, K., and Peters, J. M. (2006). 
Human Scc4 is required for cohesin binding to chromatin, sister-chromatid cohesion, and 
mitotic progression. Curr Biol 16, 863-874. 
Wiese, C., and Zheng, Y. (2006). Microtubule nucleation: gamma-tubulin and beyond. J Cell 
Sci 119, 4143-4153. 
Wirth, K. G., Ricci, R., Gimenez-Abian, J. F., Taghybeeglu, S., Kudo, N. R., Jochum, W., 
Vasseur-Cognet, M., and Nasmyth, K. (2004). Loss of the anaphase-promoting complex in 
quiescent cells causes unscheduled hepatocyte proliferation. Genes Dev 18, 88-98. 
Witucki, L. A., Huang, X., Shah, K., Liu, Y., Kyin, S., Eck, M. J., and Shokat, K. M. (2002). 
Mutant tyrosine kinases with unnatural nucleotide specificity retain the structure and 
phospho-acceptor specificity of the wild-type enzyme. Chem Biol 9, 25-33. 
Wong, J., Nakajima, Y., Westermann, S., Shang, C., Kang, J. S., Goodner, C., Houshmand, 
P., Fields, S., Chan, C. S., Drubin, D., et al. (2007). A protein interaction map of the mitotic 
spindle. Mol Biol Cell 18, 3800-3809. 
Wong, O. K., and Fang, G. (2005). Plx1 is the 3F3/2 kinase responsible for targeting spindle 
checkpoint proteins to kinetochores. J Cell Biol 170, 709-719. 
Yang, D., Buchholz, F., Huang, Z., Goga, A., Chen, C. Y., Brodsky, F. M., and Bishop, J. M. 
(2002). Short RNA duplexes produced by hydrolysis with Escherichia coli RNase III mediate 
effective RNA interference in mammalian cells. Proc Natl Acad Sci U S A 99, 9942-9947. 
Yasui, Y., Urano, T., Kawajiri, A., Nagata, K., Tatsuka, M., Saya, H., Furukawa, K., 
Takahashi, T., Izawa, I., and Inagaki, M. (2004). Autophosphorylation of a newly identified 
site of Aurora-B is indispensable for cytokinesis. J Biol Chem 279, 12997-13003. 
Yeong, F. M., Hombauer, H., Wendt, K. S., Hirota, T., Mudrak, I., Mechtler, K., Loregger, T., 
Marchler-Bauer, A., Tanaka, K., Peters, J. M., and Ogris, E. (2003). Identification of a 
subunit of a novel Kleisin-beta/SMC complex as a potential substrate of protein phosphatase 
2A. Curr Biol 13, 2058-2064. 
Yu, T. S., Zeeman, S. C., Thorneycroft, D., Fulton, D. C., Dunstan, H., Lue, W. L., 
Hegemann, B., Tung, S. Y., Umemoto, T., Chapple, A., et al. (2005). alpha-Amylase is not 
required for breakdown of transitory starch in Arabidopsis leaves. J Biol Chem 280, 9773-
9779. 
188 
                                                                                          8 Acknowledgements 
8 Acknowledgements 
I would like to thank Jan for giving me the chance to work in his lab and for his support 
during my PhD project. 
 
Further I would like to thank the past and present members of my PhD committee Kim 
Nasmyth, Gustav Ammerer and Franz Klein for helpful discussions of the diverse 
problems associated with carrying out a PhD project within a large research consortium. 
I am especially grateful to Franz Klein and Anthony Hyman for reviewing this thesis. 
 
I very much enjoyed the great collaborations within the MitoCheck project. I would like 
to especially thank Ina Poser, Laurence Pelletier and Anthony Hyman at the Max-Planck-
Institute for Molecular Cell Biology in Dresden, Germany and Jose Luis Jimenez and 
Jean-Karim Hériché at the Sanger Institute, Hinxton, UK. I am very grateful to Jean-
Karim for critical reading of the interaction mapping manuscript and endless attempts to 
explain graph theory and clustering algorithms to me. Within the IMP I am indebted to 
the great expertise, patience and helpfulness of the IMP/IMBA protein chemistry facility, 
especially Karl, Lisi, Otto, Michi S, Michi M, Mathias, Gabi, Christoph and Ines. 
 
Life at the IMP was only fun because of all the nice members of the Peters lab, past and 
present. I would like to especially thank Jim, Martina and Kristina for lots of fun in the 
second floor lab. All the time outside of the lab and inside the fourth floor office was 
especially joyful thanks to Jim, Julia, Peter, Erwan and Kerstin who proved to me that 
total crazyness and serious science are not mutually exclusive. For more serious science 
I want to thank Stephie (but also for great skiing and concerts), Antonio and Bettina.  
Apart from science, Bettina deserves exceptional thanks for pretty much everything. 
 
Finally, for always supporting me I sincerely thank my parents, my sister and my 
grandparents; and for sharing my life I am grateful to Michèle. 
 
189 
9 Curriculum Vitae 
9 Curriculum Vitae 
Personal Details:                
 
Name:  Björn Hegemann 
Date of birth:  08.12.1978 
Place of birth: Giessen, Germany 
Nationality: German 
Gender:  Male 
 
Education: 
Since 2004/05  PhD thesis work with Jan-Michael Peters, Research Institute of 
Molecular Pathology, Vienna, Austria  
2004/03 Diploma degreee in biochemistry, University of Potsdam, 
Germany 
2003/05 - 12  Diploma thesis work with Jan Hofsteenge, Friedrich Miescher 
Institute, Basel, Switzerland 
1999/10 –  Programme in biochemistry, University of Potsdam, Germany 
2004/03 
 
Research experience:  
Since 2004/05 Ph D student in the group of Jan-Michael Peters at the Research 
Institute of Molecular Pathology, Vienna, Austria 
Thesis project title: Understanding human mitotic protein 
complex organisation and phospho-regulation using a combined 
proteomics and chemical biology approach 
2003/05 -  Diploma student in the group of Jan Hofsteenge at the 
2003/12  Friedrich Miescher Institute, Basel, Switzerland 
Thesis title: Structural determinants of C-mannosylation of the 
fourth thrombospondin type 1 repeat of F-Spondin 
2002/10 - Student worker in the group of Regina Brigelius-Flohé at the 
2003/04 German Institute for Nutrition, Potsdam, Germany 
 Contribution to a project for identifying downstream targets of 
Toll like receptors  
2002/07 - 09 Internship in the group of Alison Smith at the John Innes Centre 
in Norwich, UK 
 Contribution to a study on the role of alpha amylase in starch 
metabolism in arabidobsis thaliana (Yu et al., 2005)  
2000/10 - Student worker at the Max-Planck-Institute for Molecular Plant  
2002/06 Physiology in Golm, Germany, Group of Lothar Willmitzer/Alisdair 
Fernie 
190 
                                                                                                    9 Curriculum Vitae 
 Contribution to a metabolomic profiling study on tomato plants 
overexpressing hexokinase (Roessner-Tunali et al., 2003) 
2000/08 - 09:  Internship at the Max-Planck-Institute for Molecular Plant 
Physiology in Golm, Group of Lothar Willmitzer/Alisdair Fernie 
 
Publications: 
 
Poser, I., Sarov, M., Hutchins, J. R., Heriche, J. K., Toyoda, Y., Pozniakovsky, A., Weigl, 
D., Nitzsche, A., Hegemann, B., Bird, A. W., et al. (2008). BAC TransgeneOmics: a 
high-throughput method for exploration of protein function in mammals. Nat Methods 5, 
409-415. 
 
Jiménez, J.L., Hegemann, B., Hutchins, J.R.A., Peters, J.M., Durbin, R. (2007). A 
systematic comparative and structural analysis of protein phosphorylation sites based 
on the mtcPTM database. Genome Biol 8, R90.  
 
Kozma, K., Keusch, J.J., Hegemann, B., Luther, K.B., Klein, D., Hess, D., Haltiwanger, 
R.S., Hofsteenge, J. (2008). Identification and characterization of abeta1,3-
glucosyltransferase that synthesizes the Glc-beta1,3-Fuc disaccharide on 
thrombospondin type 1 repeats. J Biol Chem 281, 36742-36751. 
 
Kueng, S., Hegemann, B., Peters, B. H., Lipp, J. J., Schleiffer, A., Mechtler, K., and 
Peters, J. M. (2006). Wapl controls the dynamic association of cohesin with chromatin. 
Cell 127, 955-967. 
 
Yu, T.S., Zeeman, S.C., Thorneycroft, D., Fulton, D.C., Dunstan, H., Lue W.L., 
Hegemann, B., Tung, S.Y., Umemoto, T., Chapple, A., Tsai, D.L., Wang, S.M., Smith, 
A.M., Chen, J., Smith, S.M. (2005). alpha-Amylase is not required for breakdown of 
transitory starch in Arabidopsis leaves. J Biol Chem 280, 9773-9779. 
 
Roessner-Tunali, U., Hegemann, B., Lytovchenko, A., Carrari, F., Bruedigam, C., 
Granot, D., Fernie, A.R. (2003). Metabolic profiling of transgenic tomato plants 
overexpressing hexokinase reveals that the influence of hexose phosphorylation 
diminishes during fruit development. Plant Physiol 133, 84-99. 
 
191 
